---
document_datetime: 2023-09-21 21:13:45
document_pages: 151
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/nexpovio-h-c-005127-ii-0001-g-epar-assessment-report_en.pdf
document_name: nexpovio-h-c-005127-ii-0001-g-epar-assessment-report_en.pdf
version: success
processing_time: 246.7423378
conversion_datetime: 2026-01-02 08:37:44.24373
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

19 May 2022 EMA/620277/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Nexpovio

International non-proprietary name: selinexor

Procedure No. EMEA/H/C/005127/II/0001/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................6                                  |                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ....................................................................................6      |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                          |
| 2. Scientific discussion                                                                                                    | ................................................................................8                        |
| 2.1. Introduction.........................................................................................................8 |                                                                                                          |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................8            |
| 2.1.2. About the product............................................................................................10      |                                                                                                          |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                   | advice ......11                                                                                          |
| 2.1.4. General comments on compliance with                                                                                  | GCP........................................................11                                            |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11           |
| 2.2.1. Introduction....................................................................................................11   |                                                                                                          |
| 2.2.2. Pharmacology                                                                                                         | .................................................................................................11      |
| 2.2.3. Pharmacokinetics.............................................................................................11      |                                                                                                          |
| 2.2.4. Toxicology                                                                                                           | ......................................................................................................12 |
| 2.2.5. Ecotoxicity/environmental risk assessment                                                                            | .........................................................12                                              |
| 2.2.6. Discussion on non-clinical aspects......................................................................12           |                                                                                                          |
| 2.2.7. Conclusion on the non-clinical aspects................................................................12             |                                                                                                          |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................12     |
| 2.3.1. Introduction....................................................................................................12   |                                                                                                          |
| 2.3.2. Pharmacokinetics.............................................................................................15      |                                                                                                          |
| 2.3.3. Pharmacodynamics..........................................................................................35         |                                                                                                          |
| 2.3.4. PK/PD modelling..............................................................................................35      |                                                                                                          |
| 2.3.5. Discussion on clinical pharmacology...................................................................36             |                                                                                                          |
| 2.3.6. Conclusions on clinical pharmacology.................................................................37              |                                                                                                          |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................37     |
| 2.4.1. Dose response study........................................................................................39        |                                                                                                          |
| 2.4.2. Main study: KCP-330-023/BOSTON study...........................................................39                    |                                                                                                          |
| 2.4.3. Discussion on clinical efficacy............................................................................85        |                                                                                                          |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................92          |                                                                                                          |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................93   |
| 2.5.1. Post marketing experience..............................................................................              | 136                                                                                                      |
| 2.5.2. Discussion on clinical safety                                                                                        | ............................................................................ 137                         |
| 2.5.3. Conclusions on clinical safety ..........................................................................            | 142                                                                                                      |
| 2.5.4. PSUR cycle                                                                                                           | ................................................................................................... 142  |
| 2.6. Significance of paediatric studies........................................................................             | 143                                                                                                      |
| 3. Risk management plan                                                                                                     | ........................................................................143                              |
| 3.1. Overall conclusion on the RMP                                                                                          | ........................................................................... 144                          |
| 4. Changes to the Product Information....................................................144                                |                                                                                                          |
| 4.1.1. User consultation...........................................................................................         | 145                                                                                                      |
| 5. Benefit-Risk Balance............................................................................145                      |                                                                                                          |
| 5.1. Therapeutic Context                                                                                                    | ......................................................................................... 145            |
| 5.1.1. Disease or condition.......................................................................................          | 145                                                                                                      |
| 5.1.2. Available therapies and unmet medical need.....................................................                      | 145                                                                                                      |

<div style=\"page-break-after: always\"></div>

5.1.3. Main clinical studies .......................................................................................  146

5.2. Favourable effects ............................................................................................  146

5.3. Uncertainties and limitations about favourable effects  ........................................... 146

5.4. Unfavourable effects  .........................................................................................  147

5.5. Uncertainties and limitations about unfavourable effects ....................................... 147

5.6. Effects Table  ....................................................................................................  147

5.7. Benefit-risk assessment and discussion  ............................................................... 149

5.7.1. Importance of favourable and unfavourable effects  ............................................ 149

5.7.2. Balance of benefits and risks  ...........................................................................  149

5.7.3. Additional considerations on the benefit-risk balance ......................................... 149

5.8. Conclusions .....................................................................................................  149

4.

Recommendations .............................................................................  149

5.

EPAR changes ....................................................................................  151

<div style=\"page-break-after: always\"></div>

## List of abbreviations

<!-- image -->

| Abbreviation   | Definition                                                            |
|----------------|-----------------------------------------------------------------------|
| 5-HT3          | 5-hydrosytryptamine                                                   |
| ADR            | adverse drug reaction                                                 |
| AE             | adverse event                                                         |
| AUC            | area under the concentration versus time curve                        |
| AUCo-x         | area under the curve from the time of dosing extrapolated to infinity |
| BIW            | twice weekly                                                          |
| CBR            | clinical benefit rate                                                 |
| 10             | confidence interval                                                   |
| CHMP           | Committee for Medicinal Products for Human Use                        |
| CID1           | Cycle 1 Day 1                                                         |
| CL/F           | clearance                                                             |
| CMA            | conditional marketing authorization                                   |
| CMQ            | custom MedDRA query analysis                                          |
| C mix          | maximum plasma concentration                                          |
| CR             | complete response                                                     |
| CrCl           | creatinine clearance                                                  |
| CSR            | clinical study report                                                 |
| CYP            | cytochrome P450                                                       |
| DDI            | drug-drug interaction                                                 |
| DOR            | duration of response                                                  |
| DSMB           | Data Safety Monitoring Board                                          |
| ECOG           | Eastern Cooperative Oncology Group                                    |
| elF4E          | eukaryotic translation initiation factor 4E                           |
| EMA            | European Medicines Agency                                             |
| FDA            | Food and Drug Administration                                          |
| GSH            | glutathione                                                           |
| GST            | glutathione S transferase                                             |
| HLM            | human liver microsomes                                                |
| HR             | hazard ratio                                                          |
| HR-QoL         | Health Related- Quality of Life                                       |
| IC50           | half maximal inhibitory concentration                                 |
| IkB            | inhibitor of NF-kB                                                    |
| IMWG           | Intemational Myeloma Working Group                                    |
| IRC            | Independent Review Committee                                          |
| ISS            | Intermational Staging System                                          |
| ITT            | intent to treat                                                       |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                                             |
|----------------|------------------------------------------------------------------------|
| IV             | intravenously                                                          |
| MedDRA         | Medical Dictionary for Regulatory Activities                           |
| MM             | multiple myeloma                                                       |
| MRD            | minimal residual disease                                               |
| mRNA           | messenger ribonucleic acid                                             |
| NCCN           | National Comprehensive Cancer Network                                  |
| NF-rB          | nuclear factor kB                                                      |
| OE             | ophthalmological examination                                           |
| NHL            | non-Hodgkin's lymphoma                                                 |
| OR             |                                                                        |
| ORR            | overall response rate                                                  |
| OS             | overall survival                                                       |
| PD             | progressive disease                                                    |
| PFS            | progression-free survival                                              |
| PI             | proteasome inhibitors                                                  |
| PK             | pharmacokinetic(s)                                                     |
| PN             | peripheral neuropathy                                                  |
| PO             | oral                                                                   |
| PR             | partial response                                                       |
| PT             | preferred term                                                         |
| QoL            | quality of life                                                        |
| QW             | once weekly                                                            |
| R-ISS          | Revised Intermational Staging System for myeloma                       |
| RP2D           | recommended Phase 2 dose                                               |
| RR             | relapsed or refractory                                                 |
| SAE            | serious adverse event                                                  |
| SC             | subcutaneously                                                         |
| sCR            | stringent complete response                                            |
| SCT            | stem cell transplant/'transplantation                                  |
| Sd             | selinexor plus dexamethasone                                           |
| SdX            | patients originally randomized to Vd who crossed over to Sd treatment  |
| SINE           | selective inhibitor of nuclear export                                  |
| SmPC           | Summary of product characteristics                                     |
| SOC            | system organ class                                                     |
| SVd            | selinexor-bortezomib-low dose dexamethasone                            |
| SVdX           | patients originally randomized to Vd who crossed over to SVd treatment |
| tin            | time to peak plasma concentration                                      |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Karyopharm Europe GmbH submitted to the European Medicines Agency on 7 April 2021 an application for a group of variations.

The following changes were proposed:

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |
| B.II.z                 | B.II.z - Quality change - Finished product - Other variation                                                                   | Type IB | I, IIIA and IIIB   |

Group of variations including an extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and a quality variation for the addition of a new pack size (8 tablets) to align with the dose modification guidance for the new indication. Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 6.5 of the SmPC are updated to reflect the new indication and the new pack size. In addition, the Type II variation is intended to fulfil the Specific Obligation agreed in the context of the Conditional Marketing Authorisation (CMA) of Nexpovio via the submission of results from the confirmatory Phase 3 study, KCP-330-023. Annex II is updated to reflect the completion of this Specific Obligation. The Labelling and Package Leaflet are amended accordingly. The RMP (v 1.1) is amended consequently.

The requested group of variations proposed amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0384/2018 on the granting of a (product-specific) waiver.

The  Paediatric  Committee,  having  assessed  the  waiver  application  in  accordance  with  Article  13  of Regulation (EC) No 1901/2006 as amended, recommended to grant a product-specific waiver for all subsets of the paediatric population in accordance with Article ll(l)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients. The paediatric investigation plan waiver was granted for selinexor as a treatment of MM as of 6 December 2020.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Scientific advice

The MAH sought scientific advice from the CHMP in September 2016 regarding the design of the global

<div style=\"page-break-after: always\"></div>

phase 3 BOSTON study. Questions pertained to (key) study design features including the proposed patient population, selected dose regimens for the experimental and control arms, primary and secondary endpoints, PROs and statistical aspects (including sample size assumptions and planned interim analyses). A question regarding the safety database expected at the time of submission was also included as well as a question regarding regulatory options for approval. According to the MAH the protocol was modified to incorporate the feedback received from the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur:                                                                          | Blanca Garcia-Ochoa                                                                  |                   |
|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------|
| Timetable                                                                            | Timetable                                                                            | Actual dates      |
| Submission date                                                                      | Submission date                                                                      | 7 April 2021      |
| Start of procedure                                                                   | Start of procedure                                                                   | 24 April 2021     |
| CHMP Rapporteur's preliminary assessment report circulated on                        | CHMP Rapporteur's preliminary assessment report circulated on                        | 9 July 2021       |
| PRAC Rapporteur's preliminary assessment report circulated on                        | PRAC Rapporteur's preliminary assessment report circulated on                        | 29 June 2021      |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | PRAC RMP advice and assessment overview adopted by PRAC on                           | 8 July 2021       |
| Updated CHMP Rapporteur's assessment report circulated on                            | Updated CHMP Rapporteur's assessment report circulated on                            | 17 July 2021      |
| Request for supplementary information (RSI) adopted by the CHMP on                   | Request for supplementary information (RSI) adopted by the CHMP on                   | 22 July 2021      |
| MAH's responses submitted to the CHMP on                                             | MAH's responses submitted to the CHMP on                                             | 10 September 2021 |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses               | CHMP Rapporteur's preliminary assessment report on the MAH's responses               | 26 November 2021  |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on | PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on | 26 November 2021  |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | PRAC RMP advice and assessment overview adopted by PRAC on                           | 2 December 2021   |
| Updated CHMP Rapporteur's assessment report on the MAH's responses circulated on     | Updated CHMP Rapporteur's assessment report on the MAH's responses circulated on     | 10 December 2021  |
| 2 nd Request for supplementary information (RSI) adopted by the CHMP on              | 2 nd Request for supplementary information (RSI) adopted by the CHMP on              | 16 December 2021  |
| MAH's responses submitted to the CHMP on:                                            | MAH's responses submitted to the CHMP on:                                            | 22 December 2021  |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | 3 March 2022      |
| Updated CHMP Rapporteur's assessment report on the MAH's responses circulated on     | Updated CHMP Rapporteur's assessment report on the MAH's responses circulated on     | 21 March 2022     |
| 3 rd Request for supplementary information (RSI) adopted by the CHMP on              | 3 rd Request for supplementary information (RSI) adopted by the CHMP on              | 24 March 2022     |
| MAH's responses submitted to the CHMP on:                                            | MAH's responses submitted to the CHMP on:                                            | 4 April 2022      |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | 8 May 2022        |
| Updated CHMP Rapporteur's assessment report on the MAH's responses circulated on     | Updated CHMP Rapporteur's assessment report on the MAH's responses circulated on     | 13 May 2022       |
| CHMP Opinion                                                                         | CHMP Opinion                                                                         | 19 May 2022       |
| The CHMP adopted a report on similarity of Nexpovio with Imnovid,                    | The CHMP adopted a report on similarity of Nexpovio with Imnovid,                    | 19 May 2022       |

<div style=\"page-break-after: always\"></div>

| Timetable                                                             | Actual dates   |
|-----------------------------------------------------------------------|----------------|
| Farydak, Ninlaro, Darzalex, Kyprolis, Blenrep, Abecma and CARVYKTI on |                |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Multiple myeloma is a malignant plasma cell disorder that is characterized by the production of monoclonal immunoglobulin in a majority of patients and that invades adjacent bone tissue. Common manifestations include bone pain, renal insufficiency, hypercalcemia, anaemia, and recurrent infections.

Multiple myeloma is characterized by osteolytic lesions, usually in the pelvis, spine, ribs, and skull. Lesions are caused by expanding plasmacytomas or by cytokines secreted by myeloma cells that activate osteoclasts and suppress osteoblasts. Increased bone loss may also lead to hypercalcemia. Solitary extraosseous plasmacytomas are unusual but may occur in any tissue, especially in the upper respiratory tract. In many patients, renal failure is present at diagnosis or develops during the course of the disorder and is caused by the deposition of light chains in the distal tubules or by hypercalcemia. Patients also often develop anaemia due to kidney disease or suppression of erythropoiesis by cancer cells, but sometimes also due to iron deficiency. These signs and symptoms are commonly denoted as CRAB.

## Claimed therapeutic indication

NEXPOVIO (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

## Epidemiology and risk factors, screening tools/prevention

MM is a rare and incurable plasma cell neoplasm which typically affects adults mostly over 60 years of age. The median age at diagnosis is 65-70 years; only 2% of patients are younger than 40 years (Raab 2009).

Multiple myeloma (MM) accounts for 1%-1.8% of all cancers and is the second most common haematological malignancy (after non-Hodgkin's lymphoma [NHL]) with an estimated incidence in Europe of 4.5-6.0/100 000/year, with approximately 176.404 new MM cases and 117,077 deaths due to MM anticipated in 2020 worldwide (The Global Cancer Observatory 2020).

The treatment of MM has notably progressed with the availability of new drugs and its combinations, such way that survival of patients with newly diagnosed multiple myeloma has increased from approximately 3 years in the years 1985 to 1998 (Kyle 2003) to 6 to 10 years (Moreau 2015) along the last 15 years. Despite the significant improvement in patients' survival over the past 20 years, only 10%-15% of patients achieve or exceed expected survival compared with the matched general population.

<div style=\"page-break-after: always\"></div>

## Biologic features, aetiology and pathogenesis

As previously described, MM is characterized by the increased proliferation of malignant monoclonal plasma cells in the bone marrow, with the subsequent bone marrow failure due to replacement of normal bone marrow haematopoiesis, the over-production of monoclonal immunoglobulins (M-protein, either intact immunoglobulins and/or free light chains [FLC]) which could be detected in the serum or urine, and finally  the  presence of  systemic  symptoms named as CRAB (hyperCalcemia, Renal impairment, Anaemia  and  Bone  lesions).  Increased  susceptibility  to  infections  (immunoparesis)  and  neurological complications are also present (Palumbo 2011).

Based on karyotype, MM is classified as non-hyperdiploid and hyperdiploid, with the latter accounting for 50% to 60% of cases and characterized by trisomies in odd-numbered chromosomes. MM has a heterogeneous  progression  pathway,  with  multiple  relapses  over  time,  whereby  several  MM  cell subclones coexist at baseline and compete for dominance over time, leading to the evolution of drugresistance clones [Laubach, 2014].

Drug resistance to prior regimens in patients with relapsed/refractory (RR) MM is due to continuous changes in the disease biology, in which a higher proportion of malignant cells are expressing a more aggressive, highly proliferative phenotype over time (Anderson, 2008).

## Clinical presentation, diagnosis and stage/prognosis

The most common symptoms in MM patients include persistent skeletal pain, pathological fractures and vertebral  collapse,  anaemia,  renal  impairment,  hypercalcaemia  and  recurrent  or  persistent  bacterial infections. Approximately 20% of patients are asymptomatic at the time of diagnosis.

The most common criteria used in diagnosis of symptomatic MM is the presence of neoplastic plasma cells  comprising  more  than  10%  of  BM  cells  or  the  presence  of  plasmacytomas,  together  with  a monoclonal paraprotein (M-protein) in the serum and/or urine and the evidence of related organ or tissue impairment due to clonal plasma cell hyper-proliferation.

The International Staging System (ISS) is used for prognosis and it was revised by The International Myeloma Working Group (IMWG) including cytogenetics by fluorescence in situ hybridization (FISH) and lactate dehydrogenase (LDH, Revised International Staging System for Multiple Myeloma, R-ISS), and is now widely accepted (Palumbo, 2015). At the time of diagnosis, patients are categorized according to R-ISS, their age, comorbidity and their suitability for intensive treatment.

Despite  advance  in  therapy,  MM  remains  incurable.  All  patients  eventually  relapse  and  with  each successive relapse, the chance of response and duration of response typically decreases and ultimately the disease becomes refractory and results in cumulative end organ damage (e.g., renal, cytopenias, infections and bone complications).

## Management

Current treatment of MM includes glucocorticoids (dexamethasone, prednisolone, methylprednisolone), chemotherapy, primarily alkylating agents, including high dose chemotherapy followed by autologous stem  cell  transplantation  (ASCT),  proteasome  inhibitors  (PIs,  such  as  bortezomib,  carfilzomib  and ixazomib), immunomodulatory  agents (such as thalidomide, lenalidomide and pomalidomide), monoclonal  antibodies  (mAbs,  such  as  daratumumab,  isatuximab  and  elotuzumab)  and  the  histone deacetylase inhibitor panobinostat.

The choice of therapy in the relapse setting depends on several parameters such as age, performance status, comorbidities, the type, efficacy and tolerance of the previous treatment, the number of prior treatment lines, the available remaining treatment options, the interval since the last therapy and the

<div style=\"page-break-after: always\"></div>

type of relapse (i.e. clinical versus biochemical relapse; in the case of biochemical relapse, treatment can be delayed).

At  the  time  of  first  relapse  and  beyond,  lenalidomide  in  combination  with  dexamethasone  and bortezomib, either alone as single-agent or in combination with PEGylated doxorubicin were the available approved options until 2015. Bortezomib is mostly  used in combination with dexamethasone in the relapse setting.

Panobinostat in combination with bortezomib and dexamethasone, is now indicated for the treatment of patients  with  RR  MM  who  have  received  at  least  two  prior  regimens  including  bortezomib  and  an immunomodulatory agent. Carfilzomib has also been approved in combination with lenalidomide and dexamethasone and also in combination with dexamethasone alone in patients with at least one line of prior therapy. That is also the case of elotuzumab in combination with lenalidomide and dexamethasone and ixazomib in combination with lenalidomide and dexamethasone, all in patients who have received at least one prior line of therapy.

In  very  advanced-stage  disease,  pomalidomide  in  combination  with  low-dose  dexamethasone,  is approved in patients who have received at least two prior therapies, including both lenalidomide and bortezomib, and whose disease progressed after treatment with these medicines.

In young patients, a second ASCT may be considered, provided that the patient responded well to the previous ASCT and had a PFS of more than 24 months. In the relapse setting, allogeneic SCT should only be carried out in the context of a clinical trial. Therapies with a multimodal MoA, which target MM cells and elicit an immunogenic response, as well as drugs with new mechanisms of action, are expected to minimize the development of drug resistance in MM and/or increase disease response to therapy.

## 2.1.2. About the product

Selinexor (KPT-330) is an oral, slowly reversible covalent, selective inhibitor of nuclear export (SINE) compound that specifically  blocks  the  nuclear  export  protein  1  (XPO1.)  XPO1  is  responsible  for  the unidirectional export of ~220 different cargo proteins from the nucleus to the cytoplasm (Garg 2017, Xu 2010, Xu 2012). The anti-neoplastic activity of SINE compounds is mediated through at least 3 distinct pathways involving tumour suppressor proteins (TSPs), oncoproteins, and the glucocorticoid receptor.

Selinexor synergizes with PIs such as bortezomib (Turner 2013, Turner 2016, Tai 2014, Wu 2016) and carfilzomib (Kandarpa 2013, Rosebeck 2016) leading to inhibition of cell proliferation and induction of MM cell death.

The  European  Medicines  Agency's  (EMA)  Committee  for  Medicinal  Products  for  Human  Use  (CHMP) adopted a positive opinion for the conditional marketing authorization (CMA) for NEXPOVIO (selinexor) in combination with dexamethasone for the treatment of MM in adult patients who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents and an anti-CD38 MoA, and who have demonstrated disease progression on the last therapy (EPAR EMA/CHMP/95252/2021; 27/052021).

Nexpovio received a conditional marketing authorisation valid throughout the EU on 26 March 2021.

Selinexor  was  originally  designated  as  an  Orphan  Medicinal  Product  in  the  European  Union  on  19 November  2014  -  EU/3/14/1355.  This  product  was  withdrawn  from  the  Union  Register  of  orphan medicinal  products  by  the  European  Commission  in  February  2021  upon  request  of  the  marketing authorisation holder at the time of the granting of a marketing authorisation. This product is no longer an orphan medicine.

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The Applicant sought scientific advice from the CHMP in September 2016 regarding the design of the global phase 3 BOSTON study, see section 1.

## 2.1.4. General comments on compliance with GCP

The MAH states that study KCP-330-023 (BOSTON) was designed, implemented, and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice (GCP), with the applicable local regulations (including European Directive 2001/20/EC and United States [US] Code of Federal Regulations Title 21), and with the ethical principles laid down in the Declaration of Helsinki.

At the time of initial MAA, a routine GCP inspection was requested by the CHMP. Two investigator sites in Greece and USA and the sponsor site in USA were inspected in March 2019. Several critical and major findings were detected which were system and process related.

'A GCP system inspection of the sponsor is necessary to confirm that those critical aspects found during this inspection are not repeated in other trials where Karyopharm is the sponsor.'

Taking the above into account, it was considered justified to request a GCP inspection. One investigator site (in Barcelona, Spain) and the sponsor site (in Boston, US) were inspected on December 2021 and January 2022, respectively. The final Integrated Inspection Report (IIR) was made available on 17 th  March 2022. During this second GCP inspection it was concluded that even though significant improvements had been implemented since the previous EMA inspection there was still room for improvement in the quality management system of the Sponsor. Several critical findings were identified during the inspection. These aspects were satisfactorily addressed by the MAH during the procedure (see efficacy discussion).

## 2.2. Non-clinical aspects

The MAH submitted only new data related to the environmental risk assessment (ERA) for selinexor. No additional non-clinical information (pharmacology, pharmacokinetics or toxicology) was submited.

## 2.2.1. Introduction

The MAH submitted information for ERA of selinexor in accordance with EMEA/CHMP/SWP/4447/00 Corr 2 guidance. This information would not modify the current SmPC.

## 2.2.2. Pharmacology

N/A

## 2.2.3. Pharmacokinetics

N/A

<div style=\"page-break-after: always\"></div>

## 2.2.4. Toxicology

N/A

## 2.2.5. Ecotoxicity/environmental risk assessment

The MAH has presented data for the phase I assessment of ERA (log Kow and PECsw).

## Persistence, bioaccumulation and toxicity

LogKow (LogP at neutral Ph 7.0) of selinexor was measured by the shake-flask method (OECD 107). Prediction of Log P value was made using ACD/Labs software v12.5.

The experimental LogP of selinexor at neutral pH was 3.73 (predicted: 2.9).

Both  predicted  and  measured  LogKow  of  selinexor  is  &lt;  4.5  so  that  screening  for  persistence, bioaccumulation and toxicity is not required.

## Calculation of the Predicted Environmental Concentration (PEC)

PEC value was estimated in line with the formula provided in the ERA guideline. For selinexor, the following assumptions were made:

DOSEai = 100 mg /7 = 14.3 mg/day (calculated from the dose of 100 mg to be administered once weekly)

Fpen = 1.8/10,000 (=prevalence of plasma cell myeloma in the EU),

WASTEWinhab = 200 l/(inhabitant x day), the default value recommended in the guideline,

DILUTION = 10, the default value recommended in the guideline.

The PECsurfacewater of selinexor is 0.00129 μg/L and thus below the action limit of 0.01 μ g/L. A phase II for selinexor would not be required.

## 2.2.6. Discussion on non-clinical aspects

Selinexor PEC surfacewater value is below the action limit of 0.01 µ g/L and is not a PBT substance as log Kow does not exceed 4.5. Therefore, selinexor is not expected to pose a risk for environment.

## 2.2.7. Conclusion on the non-clinical aspects

Considering the above data, selinexor is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Summary of studies supporting the clinical pharmacology of selinexor

| Study No. Acronym Phase   | Study Design/ Key Objectives                                                                                                                                                                                                         | Population / N (treated)                                                                                   | Treatment                                                                                                                                                                        | Status    |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| KCP-330-001 Phase 1       | Multicenter, open- label, dose escalation study Evaluate PK, PDn, antitumor fesponse, OS, and tolerability of selinexor Determine the RP2D                                                                                           | Pts with advanced HM N=285                                                                                 | Selinexor: Doses range from 3 mg/m² to 80 mg/m² or a fixed dose up to 80 mg Regimens: 3-week and 4-week cycles, with QW or BIW, or QoDx3 (Weeks 1 and 3) and BIW (Weeks 2 and 4) | Completed |
| KCP-330-002 Phase 1       | Multicenter, open- label, dose escalation study Evaluate safety and tolerability. fecommend RP2D Determine PK and PDn Describe antitumor response                                                                                    | Pts with advanced or metastatic solid tumor malignancies N=189                                             | Selinexor ranging from 3 to 85 mg/m² dosing QW, BIW or QoDx3 (Weeks 1 and 3) and BIW (Weeks 2 and 4) 21- or 28-day cycles                                                        | Completed |
| Study No. Acronym Phase   | Study Design/ Key Objectives                                                                                                                                                                                                         | Population / N (treated)                                                                                   | Treatment                                                                                                                                                                        | Status    |
| KCP-330-003 Phase 1b      | Multicenter, randomized, open- label, 2-phase study Determine effects of high- and low-fat food on PK of selinexor tablet vs. capsules Compare PK of 3 selinexor formulations Evaluate tumor response Assess safety and tolerability | Pts with metastatic, locally advanced, unresectable, or locally recurrent soft tissue or bone safcoma N=54 | Selinexor 30 or 50 mg/m² or 60 mg BIW 3 different formulations: capsules, tablets (both 1\" and 2nd generation), and a liquid suspension (3 mg/mL) 4-week cycles                  | Completed |

<div style=\"page-break-after: always\"></div>

| Study No. Acronym Phase                              | Study Design/ Key Objectives                                                                                                                                                                                                                                                                                 | Population / N (treated)                                                                                    | Treatment                                                                                                                                                                                                                                | Status    |
|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| KCP-330-008 SOPRA Phase 2                            | A Randomized, Open-Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years O1d with Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation | Pts with RR AML ≥60 years of age who are ineligible for intensive chemotherapy and/or transplantation N=213 | Selinexor Dose Regimen: 60 mg fixed dose or 55 mg/m² BIW, 4- week cycle Control arm: One of the following: ·BSC including blood product transfusions, antimicrobials, and growth factors ·BSC+low dose AraC ·BSC + hypomethylating agent | Completed |
| KCP-330-009 SADAL Phase 2b                           | Open-label. multicenter, low- vs. high-dose study Evaluate efficacy (ORR, DOR, DCR) of study treatment Assess safety profile of study treatment                                                                                                                                                              | Pts with RR DLBCL N=267                                                                                     | Low dose: Selinexor 60 mg, BIW, 4- week cycle High dose: Selinexor 100 mg BIW, 4-week cycle                                                                                                                                              | Completed |
| Study No. Acronym Phase                              | Study Design/ Key Objectives                                                                                                                                                                                                                                                                                 | Population / N (treated)                                                                                    | Treatment                                                                                                                                                                                                                                | Status    |
| KCP-330-010 SIRRT Phase 2                            | Single-arm, open- label study Determine ORR DOR,DCR,PFS, OS.QoL Evaluate toxicity of selinexor                                                                                                                                                                                                               | Pts with initial or RR RT N=26                                                                              | Selinexor 60 mg BIW, 4-week cycle                                                                                                                                                                                                        | Completed |
| KCP-330-012 STORM Phase 2b Part 2 (Pivotal analysis) | Open-label, single- arm study Primary: Evaluate ORR Secondary:Evaluate DOR, CBR, DCR, PFS, TTP, TTNT, OS, and QoL Evaluate safety and tolerability                                                                                                                                                           | Pts with penta- reffractory MM N=123                                                                        | Selinexor 80 mg + dexamethasone 20 mg BIW (Days 1 and 3 for Weeks 1 to 4), 4-week cycles                                                                                                                                                 | Completed |

<div style=\"page-break-after: always\"></div>

| Study No. Acronym Phase                                 | Study Design/ Key Objectives                                                                                                                                                         | Population / N (treated)                      | Treatment                                                                                | Status    |
|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|------------------------------------------------------------------------------------------|-----------|
| KCP-330-012 STORM Phase 2b Part l (Supportive analysis) | Secondary:Evaluate efficacy (ORR DOR, CBR, DCR PFS, TTP, TTNT, OS; analyzed separately for patients with quad- or penta-refractory MM), QoL, and PK Evaluate safety and tolerability | Pts with quad- or penta- refractory MM N = 79 | Selinexor 80 mg + dexamethasone 20 mg BIW (Days 1 and 3 for Weeks 1 to 3), 4-week cycles | Completed |

## 2.3.2. Pharmacokinetics

## Analytical methods

Bortezomib Matrix Lot-Dependent Stability Investigation

## Covance Study Number 8413-691

To analyze bortezomib plasma samples from clinical study KPT-330-023, development and validation of a method to analyze bortezeomib in human plasma (K2EDTA) was performed under Covance study number 8413-691. During method development, it was determined that bortezomib is not stable when stored at -70 ºC or -20 ºC in selected lots of K2EDTA human plasma or Na-Heparin human plasma. Based on the method development data, it was determined that pretreatment of samples with formic acid (2%) is essential to stabilize bortezomib. Details of the stability experiments and results are summarized in this report.

The bortezomib instability was observed in accuracy and precision tests. When a previously qualified QC batch was re-tested (with curves prepared on the day of extraction in a later run) after having been stored at -20 ºC, the result failed to meet acceptance criteria due to low bias.

A summary of the investigation is presented in the table below.

| Overall Study purpose                  | Investigate the cause of Bortezomib instability in human plasma                         |
|----------------------------------------|-----------------------------------------------------------------------------------------|
| Impact of anticoagulant                | K2EDTA and NaHeparin                                                                    |
| Impactoftemperature                    | -70°℃,-20°C,1-8°℃and room temperature                                                   |
| ImpactofpH inhuman plasma              | Pooled Humanplasma treated with FA and pooled human plasma (NaHep)treatedwithFA         |
| Impactofenzymeactivity in human plasma | pooled Human plasma treated with heat and pooled human plasma (NaHep) treated with heat |
| Impact of individual human plasma      | Untreated individual human plasma (K2EDTA)                                              |
| QC evaluated                           | OnesetofHQCandLQCateachconditiontested                                                  |

## To test whether the instability was caused by storage conditions

The result shows that the QC's and curves that were prepared on the day of run 17 extraction met the acceptance criteria. All the QC's qualified in run 12 and run 16 failed to meet acceptance criteria except for MQC 16. QC 13 is further biased low comparing to QC16. These results demonstrate that bortezomib is unstable in human plasma K2EDTA. However, the failure of QCs was not due to storage conditions (-20 °C or -70 °C) of the samples.

<div style=\"page-break-after: always\"></div>

## To test Bortezomib stability in untreated and treated pooled human plasma K2EDTA or Na Heparin

Human plasma K2EDTA and human plasma Na-Heparin were treated with Formic Acid (2% FA in human plasma) to alter matrix pH value or heated in 50 ºC for two hours to inhibit possible enzyme activity. HQC and LQC were prepared in these matrixes to test Bortezomib stability. After having been qualified in each matrix, the fresh prepared HQC and LQC were aliquoted to be stored at -70 ºC, -20 ºC, on ice and at room temperature. These samples were tested on a later day with a second set of HQC/LQC freshly spiked and processed in the same quantification runs.

The results demonstrated in untreated human plasma Na-Heparin, bortezomib degraded the same way as in human plasma K2EDTA in previous runs. Heat treatment did not stabilize bortezomib. However, when the matrix was treated with final FA content of 2%, the stability was greatly improved compared to the untreated: in human plasma Na-Heparin containing 2% FA, both QC aliquot stored at -20 ºC and -70 ºC met the acceptance criteria, but not the ones stored at 5 ºC or room temperature.

In human plasma K2EDTA, the HQC and LQC met the acceptance criteria after been stored at -20 ºC or -70 ºC, which is inconsistent with earlier observation. Heat treatment did not further improve the stability comparing to untreated. In contrast to FA treated matrix, QC's met the acceptance criteria in all storage condition besides RT, which is ~28% low bias.

## To understand the instability in untreated individual human plasma K2EDTA

There were more than two lots of K2EDTA matrixes used during MD. In at least two lots, bortezomib did not exhibit stability at -20 ºC or -70 ºC. In troubleshooting experiments, 20 individual lots of human plasma K2EDTA were used to prepare HQC and LQC together with one of the pooled matrix lot used in MD and the lot used in matrix treatment test mentioned above. The qualified QC was then stored at -20 ºC and -70 ºC to be tested 48 hours later with HQC and LQC prepared again with the same lot on the day of extraction.

Different levels of stability were displayed in the 20 individual lots after been stored. In total, 6 lots out of 20 failed after being stored at -70 ºC for 48 hours revealing degradation of 19-56% in HQC and 1448% in LQC. After being stored at -20 ºC, HQC and LQC prepared in 9 individual lots met the acceptance criteria, while the other 11 lots either failed at HQC or both concentrations.

In conclusion, the investigation into bortezomib instability in human plasma K2EDTA indicates that bortezomib can be unstable in certain untreated human plasma K2EDTA. The observed instability is dependent on unknown interactions in human plasma K2EDTA. In some individual matrix lots, bortezomib was stable after 48 hours of storage at -20 ºC or -70 ºC. Pretreatment with formic acid is needed to stabilize bortezomib in K2EDTA (stored at 5 ºC, -20 ºC or -70 ºC) or NaHeparin (stored at 20 ºC or -70 ºC) human plasma.

The report is to summarize the observations leading to the final assessment that the study samples could not be analyzed in a regulated study (KPT-330-023).

## Absorption

Selinexor  is  orally  bioavailable.  The  absorption  is  moderately  rapid  with  a  median  time  to  the  peak plasma concentration (tmax) of 2 to 4 hours. The consistent tmax across the range of doses evaluated (3 to 85 mg/m 2 ) suggests dose-independent absorption. Although selinexor is a low soluble compound, it  exhibited high permeability in Caco-2 cells. The absolute bioavailability has not been conducted in humans. Oral bioavailability of selinexor in mice, rats, and monkeys is high, and allometric scaling is consistent with high oral bioavailability in humans.

<div style=\"page-break-after: always\"></div>

## Distribution

The distribution of selinexor is driven by plasma protein binding, which is approximately 95% and is not concentration dependent within the clinically relevant range. The blood to plasma ratio was less than 1, suggesting minimal association with red blood cells. The apparent central volume of distribution (Vc/F) was 113 L and the apparent peripheral volume of distribution (Vp/F) was 20 L (corresponding to an apparent volume of distribution at steady state [Vss/F] of 133 L or approximately 2 L/kg, assuming a 65 kg mass). The Vss/F exceeded the total body water (approximately 40 L), consistent with distribution of selinexor into tissues.

## Elimination

## Metabolism

Since  the  initial  MAA  submission  of  selinexor,  no  new  information  has  been  obtained  regarding  the metabolism of selinexor. The results summarized below were previously presented in the initial MAA submission.

Selinexor, as unchanged parent, is the major circulating moiety in human plasma. The most common circulating metabolite (&lt;5% of peak of parent levels) is the trans-isomer of selinexor, designated KPT375. This isomer, which likely derives from cis-trans isomerization of selinexor, has approximately 10% of the XPO1 inhibiting activity of selinexor and no other known biological properties. In plasma, other metabolites individually accounted for less than 1% of parent at peak selinexor plasma concentrations.

In  human  faeces,  the  predominant  metabolite  observed  was  KPT-452  (N-dealkylation;  inactive metabolite), which is catalyzed by cytochrome P450 (CYP)3A4. In human urine, the primary metabolite observed was KPT-5000 (cysteine adduct; inactive metabolite), which is catalyzed by glutathione stransferase (GST).

Selinexor  was  metabolically  stable  in  human  liver  microsomes  (HLM)  and  hepatocytes.  In  reaction phenotyping for CYPs and uridine 5'-diphospho-glucuronosyltransferases (UGTs), limited metabolism of selinexor was observed and was catalyzed only by CYP3A4 and multiple UGTs. Similar to observations in humans, in nonclinical species, including radio-profiling in rats and cold metabolism in monkeys, low levels  of  circulating  metabolites  were  observed  and  unchanged  selinexor  was  the  primary  (&gt;90%) circulating  moiety.  The  metabolites  observed  in  excreta  of  nonclinical  species  were  similar  to  those observed in humans.

Thus, parent selinexor is the main moiety in plasma and the limited metabolism of selinexor is catalyzed by multiple enzymes, including CYP3A4, UGTs, and GSTs. Importantly, the metabolites include KPT-375 (which  has  minimal  biological  activity),  and  at  lower  levels,  inactive  products  of  N-dealkylation, glucuronidation,  and  glutathione  (GSH)  conjugation.  Thus,  the  contribution  of  metabolites  to  the pharmacological activity of selinexor is negligible.

## Excretion

Based on quantitation of selinexor in human urine in Study 003, urinary excretion is a minor elimination pathway for selinexor. In the rat mass balance and quantitative whole-body autoradiography study, total recovery was 93% suggesting minimal long-term retention, selinexor was found to be excreted primarily by the hepatobiliary route into faeces with minimal excretion in urine (&lt;1% unchanged parent). The terminal phase half-life (t½) of selinexor is approximately 6 hours and apparent clearance (CL/F) is 18.4 L/h.

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

In dose escalation studies in patients with advanced hematologic and solid tumour malignancies (Study 001 and 002, respectively), selinexor exhibited linear PK, demonstrating dose-proportional increase in exposure area under the concentration versus time curve [AUC] and maximum observed concentration [Cmax]). Selinexor was dosed 2 or 3 times weekly as a single agent and no substantial accumulation was evident following repeat dosing. At the 100 mg dose, the mean Cmax was 693 ng/mL and the mean AUC0∞ was 6998 ng·h/mL (Study 001).

## Food effects

The  presence  of  food  (high-  or  low-fat  meals)  delayed  selinexor  absorption  (tmax  from  1.7  to approximately 4 hours), however, there was minimal impact on exposures (geometric mean ratio [GMR] ranged between 114.7% and 125.5%) and this was not clinically relevant (Study 003). Meals with highor low-fat content did not have a substantial effect on selinexor PK parameters. Therefore, selinexor should be taken with fluids and can be administered with or without food. The above results on food effect were previously presented in the initial MAA.

## Bioequivalence

Selinexor  exposure  following  oral  administration  of  all  tested  formulations  was  considered  to  be functionally bioequivalent.

Tablet formulation 2.2 (also known as TF2.2) and several other formulations were tested in Study 003: hard-gelatin capsules, first-generation tablets (also known as tablet formulation 1 or TF1) and TF2.2, and  a  suspension  formulation  (prepared  from  TF1).  All  3  formulations  tested  in  Study  003  were considered to be functionally bioequivalent based on AUC from the time of dosing to time t (AUC0-t) and AUC from the time of dosing extrapolated to infinity (AUC0∞). The second -generation tablet TF2 was developed in preparation for registration and commercial batches of formulation. There is clinical tablet formulation (TF2.2) and the commercial/clinical formulation (TF2.3). The only difference in the TF2.3 relative to TF2.2 is the removal of the trace yellow-colour pigment tartrazine from the outer top-coat, as a Scale-up and Post Approval Change (SUPAC) Level 1 change (FDA Guidance for Industry 1995). TF2.3 was found to exhibit similar in vitro dissolution performance with TF2.2 in f2 testing.

## Pharmacokinetic in the target population

The population PK model was first developed and submitted with the initial MAA. The model was updated based on data from 793 patients across 7 clinical studies (second population PK model, Report MS-001) which was provided during the initial MAA procedure.

Population PK model in patients with DLBCL and other cancer types

Dataset

<div style=\"page-break-after: always\"></div>

Table 1 Sumimary of StudiesIncluded in the Analysis

| Protocol/Population (N)                                                                                                            | Description                                                                                                                                                                                                      | Treatment                                                                                                                                                                                                                                                                                                                                         | PK samples                                                                                                                                                                                                                                                                                            |
|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| KCP-330-001Phase 1 Pts with advanced hematological malignancies (N = 285. 81 pts with MM)                                          | A Phase I Study of the Safety. Pharmacokinetics and Pharmacodynamics of Escalating Doses of the SelectiveInhibitor ofNuclear Export/SINEIM Compound KPT-330 in Patients with Advanced Hematological Malignancies | Selinexor Dose:ranging from3 mg/m² to80 mg/m² or a fixed dose up to 80 mg Regimens:3-wkand 4-wk cycles, with QW or twice Weekly, or QoDx3 (Wks 1 and 3) and twice weekly (wks 2 and 4)                                                                                                                                                            | Schedule 1 to 5: Days 1, 2, 3, 15/17 of cycle 1. Day 15/17 of cycles 2 and 3. Schedule 7: Days 1 of cycles 1, 2 and 3. Schedule 8: Days 1 and 8 of cycle 1. Day 1 of cycles 2 and 3. Schedule 9: Days 1, 2 and3ofcycle 1.Day1 of cycles 2 and3.                                                       |
| KCP-330-002 Phase 1 Pts with advanced or metastatic solid tumor malignancies (N =189)                                              | Safety Study ofKPT-330 in Patients with Advanced or Metastatic Solid Tumors                                                                                                                                      | Selinexor Dose: ranging from 3 to 85 mg/m² Regimens:QW,twice weekly or QoDx3 (Wks 1 and 3) and twice weekly (Wks 2 and 4)21-or 28- day cycles                                                                                                                                                                                                     | Schedule 1 to6: Mostly in days 1, 2, 3. 7 and 15 of cycle 1. Day 15-17 of cycle 2 and 3. Schedule 7:Day 1 of cycles 1 to 3. Schedule 8:Days 1 and 8 or cycle 1. Day 8 of                                                                                                                              |
| KCP-330-003Phase 1b Pts with metastatic. locally advanced, unresectable, or locally fecurrent soft tissue or bone sarcoma (N = 54) | Phase I Trial to Assess the Effects of Food and Formulation on PK ofKPT-330 in Patients with Sarcoma                                                                                                             | Selinexor Dose Regimen: 30 or 50 mg/m² or 60 mg twice weekly (4-wk cycles) Formulations: capsules, tablets (both first and second generation), and a liquid suspension (3 mg/mL). Arms 1 and 2:Evaluated formulation (capsule and tablet) and food effect. Arms 4,5 and6: Compared 2\"d generation tablet and suspension to 1\"* generation tablet. | Arms 1 and 2:Weeks 1-4 of Cycle 1 at pre- dose and 0.25,0.5,1, 1.5,2,3,4,5,6,8,10 18 (only for hospitalized patients) and 24 hr post-dose. Arms 4,5and 6:Day 1 of Weeks 1-3 of Cycle 1atpre-doseand 0.167,0.25,0.5,1,1.5, 2,3,4,5,6.8,10,18 (only for hospitalized patients), 24 and 48 hr post-dose. |
| KCP-330-008SOPRA Phase 2 Pts with Relapsed o1 Refractory Acute                                                                     | A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years                                       | Selinexor Dose Regimen: 60 mg fixed dose or 55 mg/m² twice weekly, 4- wk cycle                                                                                                                                                                                                                                                                    | Cycle 1: Day 1 of weeks 1 to 4. Cycles 2 to 5:Day 1 and Day 15. Cycle >=6: Day 1.                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Myeloid Leukemia (N=213)                                                                                                        | Old with Relapsed or Reffractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation                                                                                                                         | Control arm: One of the following: · BSC including blood product transfusions, antimicrobials,&GF ·BSC + low dose AraC - BSC + hypomethylating agent                                                        |                                                                                                                                                              |
|---------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| KCP-330-009SADAL Phase 2b Pts with RR DLBCL (N=220)                                                                             | Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)                                                                                                                                                             | Low dose: Selinexor 60 mg. twice-weekly, 4-week cycle. High dose: Selinexor 100 mg. twice-weekly. 4-week cycle.                                                                                             | Cycle 1: Day 1of weeks 1 to 4. Cycle 2: Day 1.                                                                                                               |
| KCP-330-010SIRRT Phase 2 Pts with initial or RR RT (N = 26)                                                                     | Selinexor in Initial of Relapsed/Refractory Richter's Transformation (SIRRT)                                                                                                                                                                               | Selinexor 60 mg twice weekly. 4-wk cycle                                                                                                                                                                    | Cycle 1: Day 1of weeks 1 to 3. Cycles 2 to 5: Day 1 and Day 15. Cycle > 6: Day 1.                                                                            |
| KCP-330-012ST0RM Phase 2b Part 1: Pts with penta refractory MM (N = 79) Part 2: Pts with quad- of penta reffactory MM (N = 123) | A Phase 2b, Open-Label, Single Arm Study of Selinexor (KPT- 330) Plus Low--Dose Dexamethasone (Sd) in Patients with Multiple Myeloma Exposed to Bortezomib, Carfilzomib Lenalidomide and Pomalidomide and Refractory to an IMiD and a Proteasome Inhibitor | Part 1: Selinexor 80 mg + dexamethasone 20 mg twice weekly (Days 1 and 3 for Wks 1 to 4),4-wk cycles. Part 2: Selinexor 80 mg + dexamethasone e20mg twice weekly (Days 1 and 3 for Wks 1 to 3). 4-wk cycles | PK was evaluated in Part 1 only. Cycle 1: Day （predose,1,2.4,hr postdose). Day 8 and 15 (predose, 1 hr post dose) Cycle 2: Day (predose, 1,2.4,hr postdose). |

<div style=\"page-break-after: always\"></div>

Table 3 Summary of the Number of PK Sanples and Exclusions

| # of PK samples or Reason of exclusion                  | KCP- 330- 001                     | KCP- 330- 002                     | KCP- 330- 003                     | KCP- 330- 008                     | KCP- 330- 009                     | KCP- 330- 010                     | KCP- 330- 012                     | Total                             |
|---------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| All PK samples                                          | 1978                              | 1036                              | 1367                              | 2724                              | 2547                              | 237                               | 799                               | 10688                             |
| Excluded in the final model (MI4)                       | Excluded in the final model (MI4) | Excluded in the final model (MI4) | Excluded in the final model (MI4) | Excluded in the final model (MI4) | Excluded in the final model (MI4) | Excluded in the final model (MI4) | Excluded in the final model (MI4) | Excluded in the final model (MI4) |
| Pre-dose samples                                        | 128                               | 58                                | 29                                | 171                               | 0                                 | 27                                | 78                                | 491                               |
| Incomplete PK sampling time                             | 19                                | 14                                | 49                                | 201                               | 0                                 | 16                                | 69                                | 368                               |
| TAD>200hr                                               | 4                                 | 6                                 | 6                                 | 60                                | 71                                | 10                                | 38                                | 195                               |
| Incomplete dosing time                                  | 0                                 | 26                                | 0                                 | 54                                | 0                                 | 4                                 | 13                                | 97                                |
| Above LLOQ samples collected between TAD 100 and 200 hr | 0                                 | 0                                 | 0                                 | 12                                | 39                                | 0                                 | 0                                 | 51                                |
| BLQ samples collected between TAD 1 to24 hr             | 4                                 | 1                                 | 7                                 | 21                                | 15                                | 0                                 | 3                                 | 51                                |
| Duplicated samples                                      | 0                                 | 8                                 | 0                                 | 9                                 | 0                                 | 0                                 | 13                                | 30                                |
| CWRES|>5                                                | 0                                 | 0                                 | 1                                 | 2                                 | 3                                 | 0                                 | 0                                 | 6                                 |
| N (%), M4 Method                                        | 1823 (92.2%)                      | 923 (89.1%)                       | 1275 (93.3%)                      | 2194 (80.5%)                      | 2419 (95%)                        | 180 (75.9%)                       | 585 (73.2%)                       | 9399 (87.9%)                      |
| BLQ excludedin M1 method                                | 214                               | 105                               | 138                               | 693                               | 760                               | 37                                | 133                               | 2080                              |
| N(%o), Ml Method                                        | 1609 (81.3%)                      | 818 (79%)                         | 1137 (83.2%)                      | 1501 (55.1%)                      | 1659 (65.1%)                      | 143 (60.3%)                       | 452 (56.6%)                       | 7319 (68.5%)                      |

Source: script\\ 201901010-pk-summary-exploratory-v6.r

Abbreviations: TAD= time after last dose; BLQ= below the limit of quantification; LLOQ = lower limit of quantification ; CWRES= conditional weighted residuals.

<div style=\"page-break-after: always\"></div>

## Covariates distribution

Table 4 Summary of Continuous Covariates

| Study         | KCP-330-001          | KCP-330-002          | KCP-330-003          | KCP-330-008          | KCP-330-009          | KCP-330-010          | KCP-330-012          | Total                |
|---------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| N patient     | 131                  | 59                   | 37                   | 200                  | 261                  | 26                   | 79                   | 793                  |
| Dose (mg)     | 55 (4 to 175)        | 25 (6 to 125)        | 60 (45 to 65)        | 60 (20 to 120)       | 60 (60 to 120)       | 60 (60 to 60)        | 80 (80 to 80)        | 60 (4 to 175)        |
| Age (y)       | 66 (24 to 89)        | 62 (31 to 76)        | 55 (18 to 80)        | 73 (60 to 94)        | 66 (18 to 91)        | 68 (41 to 79)        | 63 (34 to 78)        | 68 (18 to 94)        |
| Weight (kg)   | 73 (38.6 to 144.7)   | 74.8 (36.5 to 129.4) | 74 (45 to 132.1)     | 76 (43.4 to 134)     | 75 (45 to 157.9)     | 74.4 (47.3 to 115)   | 73.2 (39.3 to 168.5) | 74.9 (36.5 to 168.5) |
| BMI (kg/m2)   | 25.4 (15.4 to 47.8)  | 25.5 (10.6 to 51.4)  | 27.2 (18.3 to 49.1)  | 26.2 (16.6 to 46.9)  | 26.1 (17 to 48.2)    | 25.1 (18.8 to 34.4)  | 26.4 (17.5 to 49.1)  | 25.9 (10.6 to 51.4)  |
| BSA (m2)      | 1.8 (1.1 to 2.6)     | 1.9 (1.4 to 2.5)     | 1.8 (1.4 to 2.5)     | 1.9 (1.4 to 2.5)     | 1.9 (1.4 to 2.7)     | 1.9 (1.4 to 2.4)     | 1.9 (1.3 to 2.8)     | 1.9 (1.1 to 2.8)     |
| ALB (g/L)     | 37 (21 to 65)        | 38 (19 to 47)        | 41 (28 to 50)        | 37.7 (22 to 49)      | 40 (21.5 to 53)      | 36.5 (24 to 44)      | 35 (19 to 46)        | 38 (19 to 65)        |
| ALP (IU/L)    | 80.2 (26.1 to 779.6) | 116 (48 to 505)      | 79.2 (50.1 to 246.5) | 78.2 (43.1 to 732.5) | 94 (31 to 561)       | 93.2 (45.1 to 590.2) | 63.1 (30.1 to 539.1) | 85 (26.1 to 779.6)   |
| ALT (IU/L)    | 24 (1 to 192.4)      | 24 (6 to 132)        | 16 (5 to 86.2)       | 20 (6 to 135.3)      | 20 (4 to 267)        | 20.7 (7 to 137.3)    | 18 (6 to 67.1)       | 20 (l to 267)        |
| AST (IU/L)    | 24 (4 to 169.3)      | 29 (11 to 120)       | 18 (9 to 65.1)       | 21 (3 to 122.2)      | 24 (9 to 164)        | 25.4 (11 to 151.3)   | 22 (8 to 100.2)      | 23 (3 to 169.3)      |
| BILI (mg/dL)  | 0.5 (0.1 to 6)       | 0.41 (0.1 to 3.74)   | 0.4 (0.18 to 0.88)   | 0.5 (0.12 to 3.2)    | 0.409 (0.088 to 5.1) | 0.605 (0.3 to 2.8)   | 0.4 (0.2 to 1.6)     | 0.474 (0.088 to 6)   |
| CRCL (mL/min) | 77 (23.8 to 217.3)   | 94.8 (44.8 to 159.3) | 99.5 (42.3 to 295.3) | 72.9 (27.8 to 185.7) | 78.2 (21.6 to 263.7) | 71.4 (39.2 to 133.9) | 68.9 (20 to 240.4)   | 77.7 (20 to 295.3)   |

Source: scriptl 201901010-pk-summary-exploratory-v6.r

Note: Continuous values are reported as median (range).

Abbreviations: WT= body weight, BMI= body mass index, BSA= body suface area, ALB= serum albumin, ALP= alkaline phosphatase, ALT= serum alanine aminotransferase, AST= serum aspartate aminotransferase, BILI= total bilirubin, CRCL= creatinine clearance.

Table 5 Sunmary of theNuinber of Patients for Categorical Covariates

| Study                                             | KCP-330- 001   | KCP-330- 002   | KCP-330- 003   | KCP-330- 008   | KCP-330-009    | KCP-330- 010   | KCP-330- 012   | Total            |
|---------------------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|------------------|
| N patient                                         | 131            | 59             | 37             | 200            | 261            | 26             | 79             | 793              |
| Sex (M/F)                                         | 76/55          | 35/24          | 17/20          | 122/78         | 163/98         | 17/9           | 37/42          | 467/326          |
| Race (U/W/B/A/O)                                  | 2/114/10/4/1   | 0/54/4/1/0     | 1/29/2/5/0     | 4/174/7/2/13   | 15/204/8/14/20 | 0/26/0/0/0     | 0/62/14/0/3    | 22/663/45/26/37  |
| Disease ( haematological -Non- DLBCL/Solid/DLBCL) | 131/0/0        | 0/59/0         | 0/37/0         | 200/0/0        | 0/0/261        | 26/0/0         | 79/0/0         | 436/96/261       |
| EC0G (Missing/0/1/2/3)                            | 0/33/92/6/0    | 0/14/45/0/0    | 0/18/19/0/0    | 5/54/111/30/0  | 1/99/128/32/1  | 1/7/13/5/0     | 6/15/49/9/0    | 13/240/457/82/1  |
| FORM (Capsule/Tablet)                             | 129/2          | 59/0           | 0/37           | 0/200          | 0/261          | 0/26           | 0/79           | 188/605          |
| RI(Missing/Nonmal/Mild/Moderate/Severe)           | 1/38/62/26/4   | 0/34/18/7/0    | 0/22/12/3/0    | 0/62/80/54/3   | 1/97/95/66/2   | 0/6/13/7/0     | 0/24/29/22/4   | 2/283/309/185/13 |
| HI (Missing/Nonmal/Mild/Moderate/Severe)          | 0/106/23/1/1   | 0/41/15/2/1    | 0/34/3/0/0     | 0/176/23/1/0   | 5/215/37/3/1   | 0/19/4/3/0     | 0/65/14/0/0    | 5/656/119/10/3   |
| CYP3A4 inhibitor (None/weak/moderate/strong)      | 94/0/32/5      | 56/0/2/1       | 35/0/2/0       | 107/0/76/17    | 154/47/52/8    | 21/0/5/0       | 75/0/2/2       | 542/47/171/33    |
| CYP3A4 inducer (None/ weak/moderate/strong)*      | 131/0/0/0      | 59/0/0/0       | 37/0/0/0       | 199/0/0/1      | 116/142/1/2    | 26/0/0/0       | 78/0/0/1       | 646/142/1/4      |
| CYP2D6 inhibitor (Noue/weak/strong)*              | 129/0/2        | 57/0/2         | 36/0/1         | 199/0/1        | 21838/5        | 26/0/0         | 76/0/3         | 741/38/14        |
| CYP2C8 inhibitor (None/ weak/ strong)*            | 130/0/1        | 59/0/0         | 37/0/0         | 194/0/6        | 257/3/1        | 26/0/0         | 79/0/0         | 782/3/8          |
| Dexamethasone (No/ Yes)*                          | 75/56          | 38/21          | 9/28           | 108/92         | 153/108        | 16/10          | 0/79           | 399/394          |
| (SLON Id)                                         | 131/0          | 59/0           | 37/0           | 98/102         | 115/146        | 14/12          | 38/41          | 492/301          |
| H2 blockers (No/ Yes)                             | 131/0          | 59/0           | 37/0           | 175/25         | 247/14         | 22/4           | 62/17          | 733/60           |

Source: scriptl 201901010-pk-summary-exploratory-v6.r

Note: * Concomitant medications were coumted for the strongest level of each patient.

Race abbreviation: U=mknowm; W=white; B=Black; A=Asian; O=others.

Renal impairment (RI): Normal =CrCL &gt;= 90 mL/min; Mild= CrCL 60 - &lt; 90 mL/min; Moderate=CrCL 30 - &lt; 60 mL/min; Severe=CrCL 15 - &lt; 30 mL/min:

<div style=\"page-break-after: always\"></div>

## Final population PK model

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 9 Final Model Paraimeter Estimates for Selinexor PK

| Parameters                 | Symbol   | Estimate   | RSE (%)   | Bootstrap Median [2.5 to 97.5%6ile]   |
|----------------------------|----------|------------|-----------|---------------------------------------|
| CL/F (L/hr)                | 0        | 18.6       | 1.76      | 18.5 [17.9, 19.2]                     |
| Vc/F (L)                   |          | 113        | 1.86      | 113 [109, 116]                        |
| Q/F (L/hr)                 | 0        | 3.73       | 14        | 3.73 [2.92,4.64]                      |
| Vp/F (L)                   | 04       | 20.3       | 8.78      | 20.8 [17.3, 25.1]                     |
| Ka (1/hr)                  |          | 2.27       | 7.2       | 2.05 [1.65, 2.69]                     |
| D1 (hr)                    | 6        | 1.1        | 3.65      | 1.12 [1.02,1.22]                      |
| WT-CL/F                    | 0g       | 0.577      | 9.58      | 0.575 [0.454, 0.705]                  |
| SEXF-CL/F                  | 10       | -0.0882    | 29.3      | -0.0844 [-0.136,-0.0323]              |
| WT-Vc/F                    |          | 0.957      | 5.37      | 0.95 [0.842,1.05]                     |
| Randon effects             |          |            |           |                                       |
| CL/F                       | 01.1     | 0.0383     | 11.6      | 0.0368[0.0264,0.05]                   |
| VcF x CL/F                 |          | 0.0135     | 30        | 0.0115 [0.00149, 0.0219]              |
| VcF                        |          | 0.0354     | 18.2      | 0.0292 [0.0151, 0.0447]               |
| Ka                         | 0'3.3    | 1.94       | 9.59      | 1.73 [1.02,2.53]                      |
| Kax D1                     | 03,4     | -0.376     | 15.5      | -0.412[-0.542,-0.278]                 |
| D1                         | +t-0     | 0.387      | 12.6      | 0.347 [0.26,0.444]                    |
| Inter-Occasion variability |          |            |           |                                       |
| Ka                         | 023.3    | 3.7        | 6.68      | 3.5 [2.69,4.57]                       |
| Residual error             |          |            |           |                                       |
| Proportional               | 0        | 0.441      | 1.19      | 0.443 [0.427, 0.455]                  |
| Additive (ng/mL)           |          | 0.744      | 1.8       | 0.734 [0.145, 1.15]                   |

Figure 6 GOF Plots for the Final Model

<!-- image -->

Notes: Dots are individual data points, and dashed red lines are smoothed LOESS lines. In the two plots in the left columm row, solid lines are lines of identity, while in the two plots in the right column, solid horizontal lines show

Source: script/20191010-fimal-model-review-model12M4imp.r the zero value.

Abbreviations: CWRES=conditional weighted residuals.

<div style=\"page-break-after: always\"></div>

Figure 8 Prediction-Corrected VPC of the Final Model Over Hours 0-12 (left) and 0-50 (right)

<!-- image -->

Source: scnipt/20191010-final-model-review-model12M4imp.r

Notes: Blue dots are observed data points; red solid line is the observed median; red dashed lines are observed p5 and p95. The pink area is the 95% prediction interval (Pl) of the simuated median, and puple areas are the 95% PI of the simulated p5 and p95.

Impact of covariates on PK exposure

<div style=\"page-break-after: always\"></div>

Figure 9 Impact of Covariates on Steady State Cmax

<!-- image -->

Source: script/20191010 final pk model simulations model12M4imp.r

Notes: Black bar represents 5th to 95th percentile of the exposure caleulated using Empiical Bayes Estimates of the population at week 4 for a dose regimen of 60 mg BIW (dose given on Day l and Day 3 of a week). The impact of a covariate on the exposure was caleulated using the parameter(s) incorporating the isolated effect of that covariate, with other umaffected parameters fixed to the typieal values (estimated for a male patient with baseline body weight

<div style=\"page-break-after: always\"></div>

Figure 10 Impact of Covariates on Steady State AUC

<!-- image -->

rdumtnttepom suoyemus tapom qdteuy otothtotiduos :aomos Notes: Black bar represents 5th to 95th percentile of the exposure calculated using Empinical Bayes Estimates of the eyo poedmy aql (aam e go g 4e pue 1 Ae uo tang asop) mig 3m 0ggo uahai asop e 1og t yaam pe toyendod covariate on the exposure was caleulated using the parameter(s) incoiporating the isolated effect of that covaniate, with other umaffected parameters fixed to the typical values (estimated for a male patient with baseline body weight of 70 kg). Baseline body weight were evaluated at 10th to 90th percentile of the population. SEXF is covariate effect of female zender.

Other covariates evaluated, including dose, formulation, patient type, ECOG status, baseline labs and concomitant medications (CYP3A4 inhibitors/inducers, CYP2D6 inhibitors, CYP2C8 inhibitors, dexamethasone, PPIs and H2 blockers), had no impact on the selinexor PK. The exposure of selinexor is dose proportional in the dose range from 4 to 175 mg. Patients with DLBCL had similar exposure level to patients with Non-DLBCL haematological malignancies or solid tumour.

## Population PK model in patients with multiple myeloma

## Dataset

Forty  (40)  selinexor  PK  samples  were  collected  from  8  patients  with  relapsed  or  refractory  multiple myeloma in study BOSTON. The PK results of study BOSTON were combined with the dataset used for the previous analysis [1] to form an updated analysis dataset. The consolidated dataset included 9439 selinexor PK observations from 801 patients with acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), MM, other hematologic cancers or other solid cancers.

<div style=\"page-break-after: always\"></div>

Table l Summaryof ContinuousBaselineCovariatesbyStudy

<!-- image -->

| Study         | KCP-330-001          | KCP-330-002          | KCP-330-003          | SOPRA (KCP-330- 008)   | SADAL (KCP-330- (600   | SIRRT (KCP-330- 010)   | STORM (KCP-330- 012)   | BOSTON (KCP-330- 023)   | Total                |
|---------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|------------------------|-------------------------|----------------------|
| N patient     | 131                  | 59                   | 37                   | 200                    | 261                    | 26                     | 79                     | 8                       | 801                  |
| Dose (mg)     | 55 (4 to 175)        | 25 (6 to 125)        | 60 (45 to 65)        | 60 (20 to 120)         | 60 (60 to 120)         | 60 (60 to 60)          | 80 (80 to 80)          | 100 (100 to 100)        | 60 (4 to 175)        |
| Age (y)       | 66 (24to 89)         | 62 (31 to 76)        | 55 (18 to 80)        | 73 (60 to 94)          | 66 (18 to 91)          | 68 (41 to 79)          | 63 (34 to 78)          | 51 (40 to 81)           | 68 (18 to 94)        |
| Weight(kg)    | 73 (38.6 to 144.7)   | 74.8 (36.5 to 129.4) | 74 (45 to 132.1)     | 76 (43.4 to 134)       | 75 (45 to 157.9)       | 74.4 (47.3 to 115)     | 73.2 (39.3 to 168.5)   | 79 (70.3 to 92.9)       | 75 (36.5 to 168.5)   |
| BMI (kg/m)    | 25.4 (15.4 to 47.8)  | 25.5 (10.6 to 51.4)  | 27.2 (18.3 to 49.1)  | 26.2 (16.6 to 46.9)    | 26.1 (17 to 48.2)      | 25.1 (18.8 to 34.4)    | 26.4 (17.5 to 49.1)    | 26 (20.9 to 32.5)       | 25.9 (10.6 to 51.4)  |
| BSA (m)       | 1.85 (1.05 to 2.61)  | 1.89 (1.41 to 2.50)  | 1.80 (1.41 to 2.45)  | 1.88 (1.35 to 2.51)    | 1.86 (1.38 to 2.68)    | 1.92 (1.45 to 2.36)    | 1.86 (1.29 to 2.82)    | 16'1 (1.79 to 2.08)     | 1.86 (1.05 to 2.82)  |
| ALB (gL)      | 37 (21to 65)         | 38 (19 to 47)        | 41 (28 to 50)        | 37.7 (22 to 49)        | 40 (21.5 to 53)        | 36.5 (24 to 44)        | 35 (19 to 46)          | 38 (31 to 42)           | 38 (s9 0161)         |
| ALP(IU/L)     | 80.2 (26.1 to 779.6) | 116 (48 to 505)      | 79.2 (50.1 to 246.5) | 78.2 (43.1 to 732.5)   | 94 (31 to 561)         | 93.2 (45.1 to 590.2)   | 63.1 (30.1 to 539.1)   | 71.5 (51 to 78)         | 84.2 (26.1 to 779.6) |
| ALT (IU/L)    | 24 (1 to 192.4)      | 24 (6 to 132)        | 16 (5 to 86.2)       | 20 (6 to 135.3)        | 20 (4 to 267)          | 20.7 (7 to 137.3)      | 18 (6 to 67.1)         | 17.5 (12 to 58)         | 20 (1 to 267)        |
| AST (IU/L)    | 24 (4 to 169.3)      | 29 (11 to 120)       | 18 (9 to 65.1)       | 21 (3 to 122.2)        | 24 (9 to 164)          | 25.4 (11 to 151.3)     | 22 (8 to 100.2)        | 22.5 (12 to 43)         | 23 (3 to 169.3)      |
| BILI(mg/dL)   | 0.5 (0.1 to 6)       | 0.41 (0.1 to 3.74)   | 0.4 (0.18 to 0.88)   | 0.5 (0.12 to 3.2)      | 0.409 (0.088 to 5.1)   | 0.605 (0.3 to 2.8)     | 0.4 (0.2 to 1.6)       | 0.35 (0.2 to 0.6)       | 0.47 (0.088 to 6)    |
| CRCL (mL/min) | 77 (23.8 to 217.3)   | 94.8 (44.8 to 159.3) | 99.5 (42.3 to 295.3) | 72.9 (27.8 to 185.7)   | 78.2 (21.6 to 263.7)   | 71.4 (39.2 to 133.9)   | 68.9 (20 to 240.4)     | 106.1 (32.8 to 119.1)   | 78 (20 to 295.3)     |

Source:scriptl20200317-pk-summary-exploratory-v3.r

Abbreviations: WT= body weight, BMI= body mass index, BSA= body suface area, ALB= serum albumin, ALP= alkaline phosphatase, ALT= serum alanine aminotransferase, AST= serum aspartate aminotransferase, BILI= total bilirubin, CRCL= creatinine clearance.

## Covariates distribution

Table l

Summaryof ContinuousBaselineCovariatesbyStudy

<!-- image -->

| Study        | KCP-330-001          | KCP-330-002          | KCP-330-003          | SOPRA (KCP-330- 008)   | SADAL (KCP-330- (600   | SIRRT (KCP-330- 010)   | STORMI (KCP-330- 012)   | BOSTON (KCP-330- 023)   | Total                |
|--------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|-------------------------|-------------------------|----------------------|
| N patient    | 131                  | 59                   | 37                   | 200                    | 261                    | 26                     | 79                      | 8                       | 801                  |
| Dose (mg)    | 55 (4 to 175)        | 25 (6 to 125)        | 60 (45 to 65)        | 60 (20 to 120)         | 60 (60 to 120)         | 60 (60 to 60)          | 80 (80 to 80)           | 100 (100 to100)         | 60 (4 to 175)        |
| Age (ym)     | 66 (24 to 89)        | 62 (31 to 76)        | 55 (18 to 80)        | 73 (60 to 94)          | 66 (18 to 91)          | 68 (41 to 79)          | 63 (34 to 78)           | 51 (40 to 81)           | 68 (18 to 94)        |
| Weight (kg)  | 73 (38.6 to 144.7)   | 74.8 (36.5 to 129.4) | 74 (45 to 132.1)     | 76 (43.4 to 134)       | 75 (45 to 157.9)       | 74.4 (47.3 to 115)     | 73.2 (39.3 to 168.5)    | 79 (70.3 to 92.9)       | 75 (36.5 to 168.5)   |
| BMII (kg/m)  | 25.4 (15.4 to 47.8)  | 25.5 (10.6 to 51.4)  | 27.2 (18.3 to 49.1)  | 26.2 (16.6 to 46.9)    | 26.1 (17 to 48.2)      | 25.1 (18.8 to 34.4)    | 26.4 (17.5 to 49.1)     | 26 (20.9 to 32.5)       | 25.9 (10.6 to 51.4)  |
| BSA (m)      | 1.85 (1.05 to 2.61)  | 1.89 (1.41 to 2.50)  | 1.80 (1.41 to 2.45)  | 1.88 (1.35 to 2.51)    | 1.86 (1.38 to 2.68)    | 1.92 (1.45 to 2.36)    | 1.86 (1.29 to 2.82)     | 16'1 (1.79 to 2.08)     | 1.86 (1.05 to 2.82)  |
| ALB (g/L)    | 37 (21 to 65)        | 38 (19 to 47)        | 41 (28 to 50)        | 37.7 (22 to 49)        | 40 (21.5 to 53)        | 36.5 (24 to 44)        | 35 (19 to 46)           | 38 (31 to 42)           | 38 (19 to 65)        |
| ALP(IU/L)    | 80.2 (26.1 to 779.6) | 116 (48 to 505)      | 79.2 (50.1 to 246.5) | 78.2 (43.1 to 732.5)   | 94 (31 to 561)         | 93.2 (45.1 to 590.2)   | 63.1 (30.1 to 539.1)    | 71.5 (51 to 78)         | 84.2 (26.1 to 779.6) |
| ALT (IU/L)   | 24 (1 to 192.4)      | 24 (6 to 132)        | 16 (5 to 86.2)       | 20 (6 to 135.3)        | 20 (4 to 267)          | 20.7 (7 to 137.3)      | 18 (6 to 67.1)          | 17.5 (12 to 58)         | 20 (1 to 267)        |
| AST (IU/L)   | 24 (4 to 169.3)      | 29 (11 to 120)       | 18 (9 to 65.1)       | 21 (3 to 122.2)        | 24 (9 to 164)          | 25.4 (1l to 151.3)     | 22 (8 to 100.2)         | 22.5 (12 to 43)         | 23 (3 to 169.3)      |
| BLLI (mg/dL) | 0.5 (0.1 to 6)       | 0.41 (0.1 to 3.74)   | 0.4 (0.18 to 0.88)   | 0.5 (0.12 to 3.2)      | 0.409 (0.088 to 5.1)   | 0.605 (0.3 to 2.8)     | 0.4 (0.2 to 1.6)        | 0.35 (0.2 to 0.6)       | 0.47 (0.088 to 6)    |
| CRCL(mL/min) | 77 (23.8 to 217.3)   | 94.8 (44.8 to 159.3) | 99.5 (42.3 to 295.3) | 72.9 (27.8 to 185.7)   | 78.2 (21.6 to 263.7)   | 71.4 (39.2 to 133.9)   | 68.9 (20 to 240.4)      | 106.1 (32.8 to 119.1)   | 78 (20 to 295.3)     |

Note: Continuous values are reported as median (range).

Source: scriptl 20200317-pk-summary-exploratory-v3.r

Abbreviations: WT= body weight, BMI= body mass index, BSA= body suface area, ALB= serum albumin, ALP= alkaline phosphatase, ALT= serum alanine aminotransferase, AST= serum aspartate aminotransferase, BILI= total bilirubin, CRCL= creatinine clearance.

<div style=\"page-break-after: always\"></div>

Table 2 SummaiyoftheNumberofPatientsforCategoricalBaselineCovariatesbyStudy

<!-- image -->

| Study                                                                 | KCP-330- 001   | KCP-330- 002   | KCP-330- 003   | SOPRA (KCP-330- 008)   | SADAL (KCP-330- 009)   | SIRRT (KCP- 330-010)   | STORM (KCP-330- 012)   | BOSTON (KCP- 330-023)   | Total             |
|-----------------------------------------------------------------------|----------------|----------------|----------------|------------------------|------------------------|------------------------|------------------------|-------------------------|-------------------|
| N patient                                                             | 131            | 59             | 37             | 200                    | 261                    | 26                     | 79                     | 8                       | 801               |
| Sex (M/F)                                                             | 76/55          | 35/24          | 17/20          | 122/78                 | 163/98                 | 17/9                   | 37/42                  | 711                     | 474/327           |
| Race (U/W/B/A/O)                                                      | 2/114/10/4/1   | 0/54/4/1/0     | 1/29/2/5/0     | 4/174/7/2/13           | 15/204/8/14/20         | 0/26/0/0/0             | 0/62/14/0/3            | 0/5/2/1/0               | 22/668/47/27/37   |
| Tumor type (AML/DLBCL/MM/Other Hematologic Cancer/Other Solid Cancer) | 54/20/26/31/0  | 0/0/0/0/59     | 0/0/0/0/37     | 200/0/0/0/0            | 0/261/0/0/0            | 0/0/0/26/0             | 0/0/79/0/0             | 0/0/8/0/0               | 254/281/113/57/96 |
| ECOG (Missing/0/1/2/3)                                                | 0/33/92/6/0    | 0/14/45/0/0    | 0/0/61/81/0    | 5/54/111/30/0          | 1/99/128/32/1          | 1/7/13/5/0             | 6/15/49/9/0            | 0/4/4/0/0               | 13/244/461/82/1   |
| Formulation(Capsule/Tablet)                                           | 129/2          | 59/0           | 0/37           | 0/200                  | 0/261                  | 0/26                   | 0/79                   | 0/8                     | 188/613           |
| Renal impairment (RI) (Missing/Nonmal/Mild/Moderate/Severe)           | 1/38/62/26/4   | 0/34/18/7/0    | 0/22/12/3/0    | 1/62/80/54/3           | 1/97/95/66/2           | 0/6/13/7/0             | 0/24/29/22/4           | 0/5/1/2/0               | 3/288/310/187/13  |
| Hepatic impainment (HI) (Missing/Nonmal/Mild/Moderate/Severe)         | 0/106/23/1/1   | 0/41/15/2/1    | 0/34/3/0/0     | 0/176/23/1/0           | 5/215/37/3/1           | 0/19/4/3/0             | 0/65/14/0/0            | 0/8/0/0/0               | 5/664/119/10/3    |
| CYP3A4 inhibitor (Noue/weak/moderate/strong)                          | 94/0/32/5      | 56/0/2/1       | 35/0/2/0       | 105/0/77/18            | 154/47/52/8            | 21/0/5/0               | 75/0/2/2               | 5/1/2/0                 | 545/48/174/34     |
| CYP3A4 inducer (None/ weak/moderate/strong)*                          | 131/0/0/0      | 59/0/0/0       | 37/0/0/0       | 199/0/0/1              | 116/142/1/2            | 26/0/0/0               | 78/0/0/1               | 0/8/0/0                 | 646/150/1/4       |
| CYP2D6inhibitor(None/weak/strong)*                                    | 129/0/2        | 57/0/2         | 36/0/1         | 199/0/1                | 218/38/5               | 26/0/0                 | 76/0/3                 | 8/0/0                   | 749/38/14         |
| CYP2C8 inhibitor(None/weak/ strong)                                   | 130/0/1        | 59/0/0         | 37/0/0         | 194/0/6                | 257/3/1                | 26/0/0                 | 79/0/0                 | 8/0/0                   | 790/3/8           |
| Dexamethasone (No/Yes)                                                | 75/56          | 38/21          | 9/28           | 108/92                 | 153/108                | 16/10                  | 0/79                   | 0/8                     | 399/402           |
| Proton pump inhibitor (PPI, No/Yes)                                   | 131/0          | 59/0           | 37/0           | 98/102                 | 115/146                | 14/12                  | 38/41                  | 5/3                     | 497/304           |
| H2 blockers (No/Yes)                                                  | 131/0          | 59/0           | 37/0           | 175/25                 | 247/14                 | 22/4                   | 62/17                  | 7/1                     | 740/61            |

Source:scriptl20200317-pk-summary-exploratory-v3.r

Note:*Concomitantmedicationswere counted for theshrongest level ofeachpatient.

Raceabbreviation:U=unknown;W=white;B=Black;A=Asian;O=others.

Hepatic impaiment (HI) : Normal = AST and BILI &lt;= ULN; Mild = BILI between 1 and 1.5 times the ULN, regardless of AST; Mild = BILI &lt;=ULN and AST &gt;ULN; Moderate=BIL between 1.5and3.0 times the ULN;Severe=BIL&gt;3 times the ULN.

Renalimpaiment (RI): Normal =CrCL &gt;=90 mL/min; Mild=CrCL 60 - &lt;90 mL/min; Moderate=CiCL 30 -&lt;60 mL/min;Severe=CiCL 15 - &lt;30 mL/min;

Cancer types: AML= acute myeloid leukemia; DLBCL= diffuse large B-cell lymphoma; MM = multiple myeloma.

Final population PK model

<div style=\"page-break-after: always\"></div>

Table 3 Final Model Parameter Estimates for Selinexor PK

|                            |                            | Previous model [1]         | Previous model [1]         | Updated Final Model        | Updated Final Model        |
|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Parameters                 | Synbol                     | Estimate                   | RSE (%)                    | Estimate                   | RSE (%)                    |
| CL/F (L/hr)                |                            | 18.6                       | 1.76                       | 18.5                       | 1.76                       |
| Vc/F (L)                   | 0                          | 113                        | 1.86                       | 113                        | 1.81                       |
| Q/F (L/hr)                 | 0                          | 3.73                       | 14                         | 3.69                       | 14.3                       |
| Vp/F (L)                   |                            | 20.3                       | 8.78                       | 20.3                       | 9.04                       |
| Ka (1/hr)                  | 05                         | 2.27                       | 7.2                        | 2.30                       | 15.2                       |
| D1 (h)                     | 6                          | 1.1                        | 3.65                       | 1.13                       | 4.47                       |
| WT-CL/F                    | 60                         | 0.577                      | 9.58                       | 0.578                      | 9.65                       |
| SEXF-CL/F                  | 010                        | -0.0882                    | 29.3                       | -0.0847                    | 29.9                       |
| WT-Vc/F                    | 011                        | 0.957                      | 5.37                       | 0.932                      | 5.72                       |
| Random effects             | Random effects             | Random effects             | Random effects             | Random effects             | Random effects             |
| CL/F                       | 01.1                       | 0.0383                     | 11.6                       | 0.0361                     | 11.1                       |
| Vc/F x CL/F                | 0²1.2                      | 0.0135                     | 30                         | 0.0113                     | 28.6                       |
| Vc/F                       | 00*2.2                     | 0.0354                     | 18.2                       | 0.0323                     | 16.7                       |
| Ka                         | 00*3.3                     | 1.94                       | 9.59                       | 2.00                       | 12.8                       |
| Ka xD1                     | 00*3.4                     | -0.376                     | 15.5                       | -0.376                     | 15.1                       |
| D1                         |                            | 0.387                      | 12.6                       | 0.360                      | 12.6                       |
| Inter-Occasion vaniability | Inter-Occasion vaniability | Inter-Occasion vaniability | Inter-Occasion vaniability | Inter-Occasion vaniability | Inter-Occasion vaniability |
| Ka                         | 0'5.5                      | 3.7                        | 6.68                       | 3.69                       | 6.87                       |
| Residual error             | Residual error             | Residual error             | Residual error             | Residual error             | Residual error             |
| Proportional               | 40                         | 0.441                      | 1.19                       | 0.442                      | 1.2                        |
| Additive (ng/mL)           |                            | 0.744                      | 1.8                        | 0.743                      | 1.79                       |

Source: script/ 20200330-final-model-review-model2.r

Abbreviations: F= bioavailability: CL/F=apparent clearance; Ve/F=apparent cenhal volume of dishibution; Q/F=apparent inter-compartmental clearance; V,/F=apparent peripheral volume of dishibution; Ka=absorption rate constant; Dl=zero-order dug release duration; RSE=relative standard error, WT = body weight; SEXF=female sex.

<div style=\"page-break-after: always\"></div>

Figure 3 GOF Plots of the Final Model (All studies)

<!-- image -->

Source: script/ 20200330-final-model-review-model2.r

Notes: Dots are individual data points, and dashed red lines are smoothed LO WESS lines. In the two plots in the left cohumn, solid lines are lines of identity, while in the two plots in the night column, solid horizontal lines show the zero value. PK observations with concenhation below the LLOQ are not included in the GOF plots.

Abbreviations: IWRES=individual weighted residuals.

<div style=\"page-break-after: always\"></div>

Figure 4 GOF Plots for the Final MIodel (Study BOSTON)

<!-- image -->

Source: script/ 20200330-final-model-review-model2.r

Notes: Dots are individual data points, and dashed red lines are smoothed LOWESS lines. In the two plots in the left column, solid lines are lines of identity, while in the two plots in the right columm, solid horizontal lines show the zero value. PK observations with concenhation below the LLOQ are not included in the GOF plots.

Abbreviations: IWRES=individual weighted residuals.

## Model simulations

Steady state selinexor PK exposure were simulated using the Bayesian post-hoc PK parameters of each individual, where the impact of covariates and their correlation were accounted for. The simulation was done for the regimen of 100 mg QW.

Boxplots of PK exposure are illustrated in Figure 6 and Figure 7 by study and tumour type, respectively. Although the number of patients was limited, PK exposure of study BOSTON appear to be similar to other studies including study KCP-330-012 (also in patients with MM) and study KCP-330-009 (patients with DLBCL). Selinexor was co-administrated with bortezomib and dexamethasone in study BOSTON, while it was co-administrated with dexamethasone alone in study KCP-330-012. The addition of bortezomib appears to have no impact on the selinexor PK. Comparing the PK exposure in patients with different patient types, Cmax and AUC in patients with MM were similar to the values in patients with AML, DLBCL and other hematologic and solid tumour types (Figure 7).

<div style=\"page-break-after: always\"></div>

Figure 6 Boxplots of Simulated Steady State Cmar or AUC with 100 mg Selinexor QW by Study

<!-- image -->

Source: script/20200330-final-pk-model-simulations-model2.r

Notes: circles -- simulated individual PK exposure for 100 mg QW regimen at steady state. Boxplots show the median (solid bold line), the interquartile range (boxes), 1.5 times the interquartile range (whiskers). Points are jittered in the x-axis direction for clarity. Dashed horizonal line indicates median exposure of the overall population. Two patients with extreme AUC values are outside of the plotting range but are included in the interquartile analysis. Red box indicates the new shudy (study B0ST0N). 001 = KCP-330-001; 002 = KCP-330-002; 003 = KCP-330003; 008=KCP-330-008; 009 =KCP-330-009;010=KCP-330-010;012 =KCP-330-012;023 =KCP-330-023.

Figure 7 Boxplots of Simulated Steady State Cmar or AUC with 100 mg Selinexor QW by Tumor Types

<!-- image -->

Source: script/20200330-final-pk-model-simulations-model2.r

Notes: circles - simulated individual PK exposure for 100 mg QW regimen at steady state. Boxplots show the median (solid bold line), the interquartile range (boxes), 1.5 times the interquartile range (whiskers). Points are jiftered im the x-axis direction for clarity. Dashed horizonal line indieates median exposuwe of the overall population. Two patients with exhreme AUC values are outside of the plotting range but are included in the interquartile analysis.

## Special populations

Hepatic impairment

<div style=\"page-break-after: always\"></div>

To verify previous findings and to satisfy PMR 3657-3, the effect of hepatic impairment on selinexor PK was formally evaluated in a separate clinical trial.

Based on the second set of population PK analyses from pooled Phase 1 and 2 studies, the PK of selinexor was not substantially altered in patients with various degrees of hepatic impairment (based on National Cancer Institute organ dysfunction working group [NCI-ODWG] criteria) present either at baseline (N = 119 for mild, N = 10 for moderate, N = 3 for severe). The effect of liver function on clearance of selinexor was evaluated across patients with various liver function test values in these population PK analyses. No significant relationships were identified between PK parameters and baseline total bilirubin, AST, ALT, ALB, or hepatic impairment.

Taken together, the results demonstrated that selinexor clearance was not altered substantially as a function of the severity of liver impairment. Therefore, no dose adjustment is necessary in patients with mild, moderate, or severe hepatic impairment.

## Renal impairment

Based on the concentrations of selinexor measured in urine (Study 003), renal clearance is a minor route of elimination for selinexor. Population PK analyses from patients with normal (N = 283), mild (N = 309), moderate (N = 185), or severe (N = 13), renal dysfunction were evaluated (mean [min, max] baseline CrCL = 77.7 [20, 295.3] mL/min) from Phase 1 and 2 studies were conducted. Baseline CrCL had no impact on the PK of selinexor. Therefore, mild, moderate, or severe renal impairment is not expected to alter selinexor PK, and no selinexor dose adjustments are required in patients with renal dysfunction.

## Pharmacokinetic interaction studies

The effect of a strong CYP3A inhibitor on the PK of selinexor will be formally evaluated in Study KCP330-017 (Study 017/STOMP) to verify the findings from population PK analyses and to satisfy postmarketing requirement (PMR) 3657-4.

Selinexor once weekly (QW) is not expected to alter exposures of other drugs and exposures to selinexor are  unlikely  to  be  affected  by  concomitant  administrations  of  modulators  of  major  CYP  enzymes, including CYP3A4, based on in vitro drug-drug interaction (DDI) evaluations and population PK analysis that included more than 700 patients with PK data.

A thorough investigation for drug interaction potential was done by conducting a series of in vitro studies which  included  CYP  phenotyping,  UGT  phenotyping,  metabolic  stability,  substrate  and  inhibition assessment  of  metabolic  transporters,  and  inhibition  of  major  human  CYP  enzymes.  The  very  low turnover  in  HLM  and  recombinant  enzymes  suggested  selinexor  is  metabolically  stable.  The  limited metabolism was catalyzed by CYP3A4 (and not the other CYP enzymes), UGTs and GSTs.

Selinexor is not a substrate for major metabolic hepatic, renal, and intestinal transporters breast cancer resistance  protein  (BCRP),  permeability  glycoprotein  (P-gp),  organic  anion  transporting  polypeptide OATP1B1, OATP1B3, organic anion transporter OAT1, OAT3, organic cation transporter OCT1, OCT2, multidrug and toxin extrusion MATE1 and MATE2-K (Section 2.1.4). Selinexor did not inhibit metabolic solute carrier (SLC) transporters except for marginal inhibition of OATP1B1 and 1B3, which may not be clinically relevant. The potential for DDIs due to inhibition of major human CYPs (CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5) is very low (all concentrations resulting in 50% of the maximum inhibition (IC50s) values for CYP inhibition &gt;10 μM), including CYP3A4/5 IC50 of 24 μM a nd no demonstrable CYP induction is observed.

Although  selinexor  is  metabolized  by  conjugation  with  GSH,  co-administration  with  acetaminophen (paracetamol) at therapeutic dose was found not to affect the PK of selinexor. In a subset of patients

<div style=\"page-break-after: always\"></div>

evaluated in Study 002 co-administration of acetaminophen at doses up to 1000 mg appeared to have no effect on the exposure of selinexor.

In  the  second  population  PK  model,  no  significant  relationships  were  identified  between  model parameters and concomitant administration of CYP3A4/2D6/2C8 modulators, dexamethasone, proton pump inhibitors, and H2 blockers.

Based on the metabolism and in vitro drug interaction profiles of selinexor and bortezomib, no drugdrug interaction between selinexor and bortezomib is expected. Exposure parameters (Cmax and AUC) of  selinexor  in  patients  in  BOSTON  who  received  combination  dosing  of  selinexor,  bortezomib  and dexamethasone were shown to be similar to patients in selinexor monotherapy studies (MS-003) and confirm the lack of effect of bortezomib on the PK of selinexor.

Based on findings from in vitro studies and given that there have been no clinically significant DDIs reported in &gt;3200 patients treated with selinexor alone or in combination as of this Type II variation, the overall risk for PK based DDIs with selinexor is considered to be low. Moreover, no DDIs have been reported in post-marketing studies to date.

## 2.3.3. Pharmacodynamics

## Primary and secondary pharmacology

## Exposure-QT analyses

No proarrhythmic effects of selinexor have been documented to date, and none of the new analyses as described below have raised concerns along these lines.

The concentration-QT modelling analyses included data for PK time-matched QTc from 85 patients from the two Phase 1 studies Study 001 and Study 003. No significant (p&gt;0.05) relationship by dose levels was observed between QT interval corrected by Fridericia's formula (ΔQTcF) and selinexor concentrations. Linear mixed-effect modelling demonstrated a small positive slope such that a selinexor concentration of 1200 ng/mL (approximately 2-fold of the anticipated therapeutic concentration [Cmax] from the 100 mg dose) correlates with a potential mean ΔQTcF increase of 7.2 msec, with a 90% CI of &lt;20 msec increase above baseline. Therefore, selinexor is not expected to cause clinically relevant QTc prolongation at the therapeutic dose concentrations of selinexor with ΔQTcF expected to remain within 20 msec of baseline. Additionally, none of the patients had a ΔQTcF of &gt;60 msec in the PK population.

A categorical outlier analysis and an analysis of proarrhythmic AEs of the ECG intervals in Study 001 and Study 003 was also conducted. In addition, all patients with posttreatment QTcF ≥500 msec or QTcF &gt;60 msec change from baseline were on concomitant medications known to prolong QT and many had electrolyte abnormalities. The majority of proarrhythmic AEs were at Grade 2 or less and were considered by investigators as not related to the study treatment. The results from all the analyses discussed above demonstrated  that  selinexor  does  not  cause  QT  prolongation  at  exposures  or  doses  well  above therapeutic doses.

## 2.3.4. PK/PD modelling

Selinexor exposure-efficacy relationships in RRMM patients and exposure-safety relationships in patients with advanced hematologic malignancies were evaluated in the initial MAA.

Exposure-response efficacy analyses were conducted to evaluate the effect of exposure (AUC) and dose intensity on the measures of efficacy, including overall response rate (ORR), clinical benefit rate (CBR), best overall response (BOR), progression-free survival (PFS), and overall survival (OS), in patients with heavily pre-treated MM who received selinexor plus dexamethasone (Sd regimen) assuming that efficacy

<div style=\"page-break-after: always\"></div>

responses were driven by selinexor. No discernible exposure-efficacy relationships were observed for patients who received 80 mg selinexor plus low-dose dexamethasone.

Exposure-safety logistic regression analyses were conducted for the five endpoints (thrombocytopenia, hyponatremia, and fatigue Grade ≥3 TEAEs as well as AEs leading to discontinuation or death). Both AUC  and  Cmax  were  used  as  exposure  metrics  in  the  analyses.  Statistically  significant  trends  for increases in ≥ Grade 3 events of hyponatremia, fatigue, and AEs leading to discontinuation were found through logistic regression modelling.

Exposure-response analyses were not conducted using data from the BOSTON study given the limited PK data obtained (8 patients and 40 samples) and given the availability of prior analyses and data (STORM study) to inform the expected efficacy and safety of selinexor and bortezomib combination therapy.  Exposure-response  relationships  presented  in  the  initial  MAA  are  useful  to  inform  the contribution of selinexor and dexamethasone when used in combination with bortezomib in BOSTON on applicable safety endpoints for patients with multiple myeloma.

## 2.3.5. Discussion on clinical pharmacology

The investigation into bortezomib instability in human plasma K2EDTA indicates that bortezomib can be unstable in certain untreated human plasma K2EDTA. The observed instability is dependent on unknown interactions in human plasma K2EDTA. In some individual matrix lots, bortezomib was stable after 48 hours of storage at -20 ºC or -70 ºC. Pretreatment with formic acid is needed to stabilize bortezomib in K2EDTA (stored at 5 ºC, -20 ºC or -70 ºC) or NaHeparin (stored at -20 ºC or -70 ºC) human plasma.

The clinical pharmacology properties of selinexor have been evaluated to fulfil the Specific Obligation of the Conditional Marketing Authorization on the use of selinexor in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. An  additional  indication  has  been  requested  to  support  the  use  of  selinexor  in  combination  with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least 1 prior therapy, based on the global Phase 3 BOSTON (KCP-330-023) study. The proposed dosing regimen for the new indication is selinexor 100 mg QW PO, bortezomib 1.3 mg/m2 QW, and dexamethasone 20 mg BIW PO.

## DLBCL and other cancer types

In order to support the positive opinion for the initial MAA, the Applicant applied a two-compartment model with sequential zero- and first-order absorption kinetics to data from 793 patients across 7 clinical studies. The final population PK parameters were precisely estimated, based on the relative standard error (&lt;30%) and statistically significant, based on the 95% confidence interval (CI). However, the large inter-individual  variability  associated  to  ka  (1.94)  leads  to  an  over-estimation  of  the  inter-individual random effects, which translates into an over-prediction of the Cmax (Figures 6 and 8). The Applicant evaluated additional factors on ka, but none of them were statistically significant or led to clinically relevant differences in exposure. Final population PK model incorporates sex on CL/F, and body weight on CL/F and Vc/F and the final parameter estimates are in agreement with standard values reported in the literature. The impact of covariates on selinexor exposure of patients with DLBCL and other cancer types suggested no clinically relevant changes in terms of selinexor AUC.

## Multiple myeloma

<div style=\"page-break-after: always\"></div>

In order to support the indication of selinexor in patients with multiple myeloma (MM), the PK properties of selinexor were characterized based on the previously developed population PK model in patients with DLBCL and other cancer types. The Applicant has conducted the evaluation of experimental evidence gathered from study BOSTON to inform that neither the disease condition nor the combination with bortezomib are affecting the PK properties of selinexor. The lack of significant differences in the adequacy of the popPK predictions among the different study types demonstrated the validity of the experimental evidence considered to develop the population PK model. No significant differences were observed on CL/F and V/F between patients with MM from the STORM and BOSTON studies. At the same time, the pc-VPC is able to characterize the experimental evidence with good agreement, although the prediction interval covers the 5-95 th  percentiles (which should be done only when sparse data (KCP-330-023 study) is available).

## 2.3.6. Conclusions on clinical pharmacology

The characterization of the clinical pharmacology properties of Selinexor, regarding the indication of selinexor in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least 1 prior therapy, is endorsed. The level of evidence provided is considered sufficient.

## 2.4. Clinical efficacy

The data presented by the MAH is for supporting this Grouped Type II /Type IB variation:

- The Type II variation is to extend the indication for Nexpovio to be used ' in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy '. In addition, the results from the pivotal study in support of this application were intended to fulfil the Specific Obligation (SOB) in the context of the Conditional Marketing Authorisation (CMA) of Nexpovio (selinexor) which was granted on 26 March 2021.
- The Type IB variation relates to the introduction of a new pack size (8 tablets per pack) for added convenience to patients for dose modification in the new intended treatment setting.

<div style=\"page-break-after: always\"></div>

Table 1. Company-Sponsored Pivotal and Supportive Studies for Type II Variation

<!-- image -->

|                    | Pivotal Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Supportive Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                    | KCP-330-023/B0ST0N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | KCP-330-017/STOMP SVdArm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Protocol version   | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Number of patients | 402                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Indication         | MM that has been previously treated with 1 to 3 anti-MM regimens                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Relapsed/refractory MM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Study status       | Ongoing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Ongoinga                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Prior therapies    | Patients who had at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens. Induction therapy followed by stem cell transplant and conisolidation/maintenance therapy was considered as I anti-MM regimen.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Patients whose MM was relapsing after ≥l line of therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dose               | SVd arm: Selinexor: 100 mg PO on Days 1, 8, 15, 22 and 29 of each 35-day cycle Bortezomib: 1.3 mg/m² SC on Days 1, 8, 15, and 22 of each 35-day cycle Dexamethasone: 20 mg PO on Days 1, 2, 8, 9 15,16,22,23,29,and 30 of each 35-day cycle Vd arm: First 8 cycles: Bortezomib: 1.3 mg/m² SC on Days 1, 4, 8, and 11 ofeach 21-day cycle. Dexamethasone: 20 mg PO dose on Days 1, 2 4,5. 8, 9, 11, and 12 of each 21-day cycle. Cycles ≥9 Bortezomib 1.3 mg/m² SC on Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone: 20 mg PO dose on Days 1, 2. 8,9,15,16,22,23,29,and 30 of each 35-day cycle. SVdX arm: PatientswhocrossedoverfromVd treatment to SVdX following the Cycle 1 of SVd treatment as described above. | Dose escalation: Selinexor QWschedule: 1)Bortezomib QWschedule (35-day cycle), 7 patients Selinexor: 80/100 mg PO QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle Bortezomib: 1.3 mg/m² SC QW on Days 1, 8, 15, and 22 of each 35-day cycle Dexamethasone: 40 mg PO QW Days 1, 8, 15, 22, and 29 of each 35-day cycle 2) Bortezomib BIW schedule (21-day cycle), 6 patients Selinexor: 80 mg PO QW on Days 1, 8, and 15 of each 21-day cycle Bortezomib: 1.3 mg/m² SC BIW on Days 1, 4, 8, and 11 of each 21-day cyele Dexamethasone: 40 mg PO QW Days 1, 8, and 15 of each 21-day cycle Selinexor BIWschedule (35-day cycle), 9 patients: Selinexor: 60/80 mg PO BIW on Days 1,3,8, 10, 15,17,22,and 24 of each 35-day cycle Bortezomib: 1.3 mg/m² SC QW on Days 1, 8. 15, and 22 of each 35-day cycle Dexamethasone: 20 mg PO BIW on Days 1, 3. 8, 10,15,17,22,24,29,and 31 ofeach 35-day cycle |
|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Expansion,20 patients: As of Protocol, v.3.0, the RP2D for SVd in the expansion phase was determined to be selinexor 100 mg + dexamethasone 40 mg + bortezomib 1.3 mg/m² SC, all QW. If a patient did not have at least a PR after 2 cycles at the RP2D (and had no AEs >Grade 2 [CTCAE 4.03] at the time of dose escalation), the Sd dose was escalated to selinexor 60 mg + dexamethasone 20 mg. BIW (total weekly selinexor dose = 120 mg).                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

Source:  KCP-330-017  Protocol  versions  3.0-5.0,  KCP-330-017  CSR,  KCP-330-023  Protocol  version  4.0,  KCP-330-023  CSR.  AE: adverse event; BIW: twice weekly; CTCAE: Common Terminology Criteria for Adverse Events; MM: multiple myeloma; PO: orally; PR: partial response; QW: once weekly; RP2D: recommended Phase 2 dose; SC: subcutaneously; Sd: selinexor plus dexamethasone; SVd:  selinexor  plus  bortezomib  plus  low-dose  dexamethasone;  SVdX:  selinexor  plus  bortezomib  plus  low-dose  dexamethasone treatment after crossover;

Vd: bortezomib plus low-dose dexamethasone.a Enrollment has been completed for SVd arm in KCP-330-017 (STOMP)

<div style=\"page-break-after: always\"></div>

## 2.4.1. Dose response study

## Phase 1b/2 Study KCP-330-017 (STOMP)

The  STOMP  study  was  a  Phase  1b/2,  multi-arm  open  label,  multicenter,  clinical  study  with Dose Escalation (Phase 1) and Expansion (Phase 2) to independently assess the maximum tolerated dose ( MTD )/recommended Phase 2 dose ( RP2D ),  safety,  and  efficacy  of  7  treatment  arms  (selinexor  in combination with backbone treatments) in patients with either newly diagnosed MM or previously treated MM.

Each arm started with a Dose Escalation Phase followed by a RP2D Expansion Phase.

Approximately 241 to 321 patients were considered needed for this study. This includes 96-186 patients in the Dose Escalation Phase and 145 patients in the Expansion Phase.

Phase 1 - Dose Escalation Phase (in SVd Arm):

Arm 2 (SVd) had 2 cohorts to evaluate once-weekly (QW) vs. twice-weekly (BIW) selinexor dosing. The dose of selinexor was escalated from 80 mg to 100 mg in once-weekly cohorts and from 60 mg to 80 mg in twice-weekly cohorts, given with bortezomib once or BIW along with 'low dose' (40 mg weekly) dexamethasone.

Using the MTD results for both Cohorts, the SRC determine which MTD schedule will become the RP2D in the Expansion Phase.

## Phase 2 - Expansion Phase

During the Expansion Phase, it was planned that a total of approximately 146-243 patients across the 7 Arms will receive the RP2D determined by the SRC for each Arm separately. Dose modifications to manage tolerability were allowed during the Expansion Phase.

Patients  continued  to  receive  treatment  until  disease  progression  (however  patients  may  stay  on treatment if they have clinical benefit per the Investigator), death, toxicity (i.e., adverse events (AEs) that cannot be managed with medical care), or withdrawal from the study. The study will end when all patients  have  completed  the  one-year  Follow-up  Period  (i.e.,  when  the  last  patient  has  died,  been followed for 12 months after last dose of study drug (selinexor, bortezomib, or dexamethasone), been lost to follow-up, or has withdrawn consent, whichever occurs first).

The RP2D established in the SVd arm [Arm 2 SVd (selinexor +bortezomib + dexamethasone)] of STOMP was to be used in the BOSTON study .

Based  on  the  results,  the  selected  dose/regimen  for  further  exploration  in  the  BOSTON  study  was selinexor 100 mg QW and bortezomib 1.3 mg/m2 QW plus dexamethasone 40 mg QW .

## 2.4.2. Main study: KCP-330-023/BOSTON study

KCP-330-023 is a confirmatory phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study that compares the efficacy and health-related quality of life (HR-QoL)  and  assesses  the  safety  of  selinexor  plus  bortezomib  (Velcade  or  generic equivalent) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-MM regimens.

<div style=\"page-break-after: always\"></div>

## Methods

The study overview is presented in the Figure below:

Figure 1. BOSTON: Bortezomib, Selinexor, and Dexamethasone in Patients with Multiple Myeloma- Study Overview

<!-- image -->

- 1stIAafter~30%PFSeventsforpossiblesamplesizere-estimation
- 2ndIAafter~75%PFSeventsforfutilityorsuperiority
- PFSprimary analysis（~33monthsafterfirstpatientisrandomized)

Abbreviations: IA = interim analysis; IRC = Independent Review Committee; ITT = intent-to-treat; PD = progressive disease; PFS = progression-free survival; SdX = selinexor plus low-dose dexamethasone treatment after crossover; SVd = selinexor plus bortezomib plus low-dose dexamethasone; SVdX = SVd treatment after crossover; Vd = bortezomib plus low-dose dexamethasone.

## Data cut-off:

- Primary analysis : Data cut-off date of 18 February 2020 (main efficacy data).
- Updated analysis : 15 February 2021.

Patients in the Vd Arm who have progressive disease (PD) that is confirmed by the Independent Review Committee (IRC) were allowed to cross over to a regimen that includes selinexor:

- 1) SVd treatment (SVdX) for patients who are able to tolerate continued bortezomib, or
- 2) SdX for patients who have significant tolerability issues with bortezomib.

Patients who crossed over are referred to as SVdX patients or SdX patients, respectively.

Patients who do not elect to cross over to SVdX or SdX from the Vd Arm will discontinue treatment, proceed to the End of Treatment (EoT) Visit, and be followed for survival.

The following process was used to prevent premature crossover:

- Investigators assessed PD according to the IMWG criteria, including repeat testing if PD was based on serum and/or urine M-protein, quantitative immunoglobulins for IgA/IgD, or serum free light chain (FLC). PD could also be based on new or enlarging plasmacytoma(s) or bone lesion(s) or on other symptoms and signs of clinical progression that met the IMWG criteria.
- All cases of PD were confirmed by the IRC prior to crossover.

<div style=\"page-break-after: always\"></div>

- Crossover was not permitted based purely on Investigator assessed progression that did not meet any IMWG criteria for PD and could not be verified by IRC (e.g., deteriorating performance status).
- Crossover was not permitted if dosing of bortezomib was terminated before PD was confirmed by the  IRC,  unless  termination  of  bortezomib  was  due  to  significant  toxicities  such  as  PN,  and  all treatment measures addressing these toxicities were exhausted and documented prior to bortezomib termination. Early termination of bortezomib was discussed and approved by the Sponsor's Medical Monitor in order to allow crossover to SdX after progression was confirmed by the IRC.
- Investigator assessed presumptive PD events that were not confirmed by the IRC had their PFS censored at the time of treatment discontinuation.

Multiple myeloma evaluations for both arms were done every 3 weeks from baseline on Cycle 1 Day 1 (C1D1) through the first day of Week 37 (i.e.  12  MM evaluations occurred after C1D1) to identify patients who progressed quickly, then every 5 weeks for the remainder of the study, regardless of cycle length.

Dose modifications for selinexor to manage tolerability were allowed.

## Independent Review Committee

An IRC was formed to review MM disease assessment data for this study, to independently assess disease response and time of PD.

PD based on site generated MM disease assessment data were to be confirmed by the IRC prior to discontinuing treatment from either arm (unless medically contraindicated).

PD as a result of plasmacytoma(s) or bone lesion(s) was to be reviewed by the IRC and results to be compared with baseline assessments.

IRC confirmation of PD was required for all patients and, for those patients in the Vd Arm, confirmation was required prior to initiation of SVdX treatment in the crossover. The IRC reviewed data (generated by the local and central laboratory) that was to be used for the final analysis of the primary endpoints.

The IRC's assessments of PFS and ORR were planned to be used as the basis for the evaluation of the primary endpoints.

## Study participants

This study enrolled patients aged ≥18 years with RRMM who had received 1 to 3 prior anti-MM regimens and who met all of the inclusion criteria and none of the exclusion criteria.

Inclusion/exclusion criteria were assessed during Screening. Patients who met all of the inclusion criteria were enrolled in this study.

The main inclusion criteria were:

1. Histologically confirmed MM with measurable disease per IMWG guidelines as defined by at least one of the following:
- a) Serum  M-protein ≥ 0.5  g/dL  (&gt;5  g/L)  by  serum  protein  electrophoresis  (SPEP)  or  for  IgA myeloma by quantitative serum IgA levels; or
- b) Urinary M-protein excretion at least 200 mg/24 hours; or
- c) Serum free light chain (FLC) ≥ 100 mg/L, provided that the serum FLC ratio is abnormal (normal FLC ratio: 0.26 to 1.65).
2. Have at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens.

<div style=\"page-break-after: always\"></div>

Induction  therapy  followed  by  stem  cell  transplant  and  consolidation/maintenance  therapy  were considered as 1 anti-MM regimen.

3. Documented evidence of progressive MM (based on the Investigator's determination according to the IMWG response criteria) on or after their most recent regimen.
4. Prior treatment with bortezomib or other PI was allowed, provided all of the following  criteria were met:
- a) Best response achieved with prior bortezomib at any time was ≥ PR and with the last PI therapy (alone or in combination) was ≥ PR, AND
- b) Participant did not discontinue bortezomib due to Grade ≥ 3-related toxicity, AND
- c) Must have had at least a 6-month PI-treatment-free interval prior to C1D1 of study treatment.

Eligible patients were also required to have Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of ≤ 2 and adequate hepatic, renal and hematopoietic function.

## Main exclusion criteria:

1. Prior exposure to a SINE compound, including selinexor.
2. Prior  malignancy that required treatment or has shown evidence of recurrence (except for nonmelanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for &gt;5 years previously and without evidence of recurrence will be allowed.
3. Has any concurrent medical condition or disease (eg, uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with study procedures.
4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to C1D1. Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.
5. Active plasma cell leukemia, documented systemic light chain amyloidosis; MM involving the central nervous system.
6. Polyneuropathy,  organomegaly,  endocrinopathy,  monoclonal  gammopathy,  and  skin  changes (POEMS) syndrome.
7. Spinal cord compression.
8. Greater  than  Grade  2  periphera l  neuropathy  or  Grade  ≥2  peripheral  neuropathy  with  pain  at baseline, regardless of whether or not the patient is currently receiving medication.
9. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.
10. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy (including investigational therapies) ≤2 weeks prior to C1D1. Localized radiation to a single site at least 1 week before C1D1 is permitted. Glucocorticoids within 2 weeks of C1D1 are permitted. Patients on longterm glucocorticoids during Screening do not require a washout period but must be able to tolerate the specified dexamethasone dose in this study.
11. Prior  autologous  stem  cell  transplantation  &lt;1  month  or  allogeneic  stem  cell  transplantation  &lt;4 months prior to C1D1.
12. Active graft versus host disease (after allogeneic stem cell transplantation) at C1D1.

<div style=\"page-break-after: always\"></div>

13. Active, unstable cardiovascular function:
- a) Symptomatic ischemia, or
- b) Uncontrolled  clinically  significant  conduction  abnormalities  (eg,  patients  with  ventricular tachycardia on anti-arrhythmics are excluded; patients with first-degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or
- c) Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction &lt;40%, or
- d) Myocardial infarction within 3 months prior to C1D1.
14. Known active human immunodeficiency virus (HIV) infection or HIV sero-positivity. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.

## Treatments

## SVd arm :

- Selinexor: 100 mg PO on Days 1, 8, 15, 22, and 29 of each 35-day cycle
- Bortezomib: 1.3 mg/m2 SC on Days 1, 8, 15, and 22 of each 35-day cycle
- Dexamethasone: 20 mg PO on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle

## Vd arm :

## First 8 cycles:

- Bortezomib: 1.3 mg/m2 SC on Days 1, 4, 8, and 11 of each 21-day cycle.
- Dexamethasone: 20 mg PO dose on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.

## Cycles ≥9 :

- Bortezomib 1.3 mg/m2 SC on Days 1, 8, 15, and 22 of each 35-day cycle.
- Dexamethasone: 20 mg PO dose on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.

## SVdX arm:

Patients who crossed over from Vd treatment to SVdX following the Cycle 1 of SVd treatment as described above.

Dose modifications for selinexor, dexamethasone, and bortezomib were allowed to manage tolerability.

Study treatment (SVd, Vd, or crossover) continued until PD was confirmed by the IRC , Investigator or patient decision to discontinue study treatment, pregnancy, unacceptable adverse events (AEs) or toxicity that could not be managed by supportive care, withdrawal of consent, death, or Sponsor decision to terminate the study.

PD  confirmation  by  IRC  was  needed  prior  to  discontinuation,  unless  medically  contraindicated.  An exception was allowed for patients in the Vd arm who terminated bortezomib treatment prior to IRCconfirmed PD if the termination was due to significant toxicities, such as PN, and all treatment measures addressing  these  toxicities  were  exhausted  and  documented  prior  to  bortezomib  termination.  Early

<div style=\"page-break-after: always\"></div>

termination of bortezomib was discussed and approved by the Sponsor's Medical Monitor in order to allow crossover to SdX after progression was confirmed by the IRC.

After IRC-confirmed PD:

- Patients in the SVd arm completed the End of Treatment Visit and were followed for survival.
- Patients in the Vd arm either crossed over or discontinued study treatment, completed the End of Treatment Visit, and were followed for survival

Crossover from the Vd arm to a treatment that included Sd ± bortezomib (i.e., SVdX or SdX) was allowed at the point of IRC-confirmed objective PD per the IMWG criteria for patients in the Vd arm.

Patients in the Vd arm who were able to tolerate continued bortezomib treatment were allowed to cross over to SVdX treatment.

Patients  in  the  Vd  arm  who  had  significant  tolerability  issues  with  bortezomib  (i.e.,  were  unable  to tolerate any continued bortezomib treatment (e.g., due to Grade &gt;2 PN or Grade ≥2 PN with pain) were allowed to cross over to SdX treatment.

## Selinexor Dose Escalation

A selinexor dose escalation may be considered up cycle 3 (C3) for patients being treated with a selinexorcontaining regimen (ie, SVd Arm, SVdX treatment, or SdX treatment) who meet the following 3 criteria :

- 1) do not achieve at least a PR within the first 2 cycles,
- 2) are tolerating SVd well at dose level 0, and
- 3) do not have any AEs related to study treatment Grade &gt;2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.03) at the time of dose escalation. For Cycles ≥3, selinexor may be increased to a fixed oral 60 mg dose twice weekly during Weeks 1 through 5.

For patients who dose escalate, selinexor will be given as a fixed oral 60 mg dose on Days 1, 3, 8, 10, 15, 17, 22, 24, 29, and 31 of each 35-day cycle.

Dexamethasone (20 mg) will be given on the same days as selinexor.

Figure 2. SVd Arm Dose Schedule; 5-Week (35-Day) Cycle

<!-- image -->

Abbreviations: AE = adverse event; BIW = twice weekly; Bort = bortezomib; BSA = body surface area; CTCAE = Common Terminology Criteria for Adverse Events; D = Day; Dex = dexamethasone; eCRF = electronic case report form; MM = multiple myeloma; NCI = National Cancer Institute; PR = partial response: QW = once weekly; SC = subcutaneous; Sel = selinexor; SVd = selinexor plus bortezomib plus low-dose dexamethasone. 1 Selinexor will be given as a fixed oral 100 mg dose QW. In no case may the selinexor dose exceed 70 mg/m2 per dose for any patient. If the patient's weight fluctuates substantially from baseline (i.e., &gt; 20%) during SVd treatment, BSA should be recalculated. 2 Bortezomib will be given at a dose of 1.3 mg/m2 SC QW during Weeks 1 through 4, followed by a 13-day rest period. 3 Dexamethasone will be given as an oral 20 mg dose BIW (i.e., a total of 40 mg weekly). For patients who develop partial intolerance to glucocorticoids during the study (as determined by the Investigator), a dose reduction to a minimum dose of 10 to 12 mg dexamethasone BIW (i.e., a total of 20 to 24 mg weekly) is permitted after a clear documentation of intolerance. Any dose reductions should be documented in the patient's research record and the eCRF. 4 Selinexor will be given as a fixed oral 60 mg dose BIW during Weeks 1 through 5 of Cycles ≥ 3. If the patient's weight fluc tuates substantially from baseline (i.e., &gt; 20%) during SVd treatment, BSA should be recalculated.

<div style=\"page-break-after: always\"></div>

## Duration of Treatment and Follow-up

Study treatment (SVd, Vd, SVdX, or SdX) may continue until PD is confirmed by the IRC, Investigator or patient decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that cannot be managed by supportive care, withdrawal of consent, death, or Sponsor decision to terminate the study.

After discontinuation of SVd, Vd, SVdX, or SdX patients will be followed for survival every 3 months until the end of study (ie, when the last patient treated in the study has been followed for up to 5 years after their last dose of SVd/Vd/SVdX/SdX treatment).

## Objectives

Disease response has been assessed according to the International Myeloma Working Group (IMWG) response criteria based on Kumar (Kumar 2016).

## Primary Objective

- To compare progression-free survival (PFS) based on the e Independent Review Committee's (IRC) disease outcome assessments in patients randomized to the SVd Arm versus the Vd Arm.

## Secondary Objectives

- To compare the overall response rate (ORR) ( ≥ partial response [PR]) based on the IRC's response outcome assessments, in patients randomized to the SVd Arm versus the Vd Arm
- To compare the incidence of any Grade ≥ 2 peripheral neuropathy events in patients randomized to the SVd Arm versus patients randomized to the Vd Arm
- To  compare  the  number  of  patients  with  response ≥ very  good  partial  response  (VGPR), ≥ complete response (CR), ≥ stringent  complete  response  (sCR),  or  minimal  residual  disease (MRD) negative (for patients who achieve CR or sCR) in patients randomized to the SVd Arm versus the Vd Arm
- To compare overall survival (OS) in all patients randomized to the SVd Arm versus the Vd Arm
- To compare the duration of response (DOR) in patients randomized to the SVd Arm versus the Vd Arm
- To determine ORR1 (ORR during SVdX treatment only)
- To determine PFS1 (PFS during SVdX treatment only)
- To compare time-to-next-treatment (TTNT) in patients randomized to the SVd Arm versus the Vd Arm who receive post-SVd/Vd treatment
- To compare time-to-response (TTR) in patients randomized to the SVd Arm versus the Vd Arm
- To compare PFS2 (PFS on first post-SVd/Vd/SVdX treatment) in patients randomized to the SVd Arm versus the Vd Arm who receive post-SVd/Vd/SVdX treatment
- To assess the safety and tolerability of treatment with SVd versus Vd in patients with RRMM.
- To compare patient-reported peripheral neuropathy as measured by the European Organization for Research and Treatment of Cancer (EORTC) Chemotherapy-induced Peripheral Neuropathy (QLQ-CIPN20) instrument in patients randomized to the SVd Arm versus the Vd Arm

## Exploratory Objectives

<div style=\"page-break-after: always\"></div>

- To evaluate PFS and ORR in patient subsets based on the IMWG Revised International Staging System (R-ISS) criteria and International Staging System (ISS) criteria (Palumbo et al., 2015), in patients randomized to the SVd Arm versus the Vd Arm
- To compare time to discontinuation of SVd and Vd treatment in patients randomized to the SVd Arm versus the Vd Arm

To compare health-related quality of life (HR-QoL) outcomes as measured by the EORTC core quality of life (QLQ-C30) instrument and the EuroQoL Group Health (EQ-5D-5L) instrument in patients randomized to the SVd Arm versus the Vd Arm

- To correlate incidence and severity of peripheral neuropathy by AE reports with QLQCIPN20 outcomes
- To assess disease response to SdX treatment

## Outcomes/endpoints

Primary efficacy endpoint for the BOSTON study:

- PFS , defined as the time from the date of randomization until the first date of IRC confirmed PD, per IMWG response criteria, or death due to any cause, whichever occurred first.

## Key secondary efficacy endpoints were:

- ORR ,  defined  as  any  response ≥ partial  response  (PR)  (i.e.,  PR,  very  good  partial  response [VGPR], complete response [CR], or stringent complete response [sCR]) based on the IRC's response outcome assessments, according to the IMWG response criteria.
- Response rates at any time prior to PD or death due to any cause, pooled and separately for the following responses: ≥ VGPR, ≥ CR, ≥ sCR, or minimal residual disease-negative (for patients who achieved a CR or sCR).

## Non-Key secondary Efficacy Endpoints

- OS , defined as time to death, measured from the date of randomization until death due to any cause
- DOR , defined as the duration from first IRCconfirmed response ≥ PR until the first date of IRC -confirmed PD or death due to any cause, whichever occurs first
- ORR1 (ORR for SVdX patients only)
- PFS1 (PFS for SVdX patients only), defined as the duration from date of first dose of SVdX treatment after crossover from the Vd Arm until the first date of PD, or death due to any cause
- TTNT ,  defined as duration from date of randomization to start of next anti-MM treatment or death, whichever occurs first
- TTR ,  defined  as  duration  from  date  of  randomization  until  the  date  of  first  IRC-confirmed response ( ≥ PR) per IMWG response criteria
- PFS2 (PFS for patients who receive post-SVd/Vd/SVdX treatment), defined as the duration from the  date  of  first  dose  of  post-SVd/Vd/SVdX  treatment  until  the  first  date  of  PD  on  postSVd/Vd/SVdX treatment, or death due to any cause.

## Secondary HR-QoL Endpoint

- Patient-reported peripheral neuropathy, as measured by the EORTC QLQ-CIPN20 instrument

<div style=\"page-break-after: always\"></div>

## Exploratory Endpoints

- Time to discontinuation of SVd and Vd treatment
- HR-QoL, as measured by the EORTC QLQ-C30 and the EQ-5D-5L instruments
- Disease response to SdX treatment according to the IMWG response criteria

## Sample size

The sample size was designed to have 80% power to  detect a median time to PFS for  patients treated with SVd of 13.5 months versus patients treated with Vd of 9.4 months , using a 1-sided alpha of 0.025 ,  15  months accrual and 18 months follow up, and a 1:1 allocation of treatment to SVd:Vd, and allowing for an interim analysis (IA) of PFS (second IA) for futility or superiority, with the treatment difference assessed by a log-rank test.

Based on these statistical  assumptions, a  total  of  267  PFS  events  were  required  for  the  final analysis . To achieve these events, a total of approximately 364 patients (~ 182 patients/arm ) were required for enrolment.

The justification of a median time to PFS of 9.4 months in the Vd Arm was based on previous clinical studies (ENDEAVOR and CASTOR), both of which had similar eligibility criteria to the BOSTON study where PFS was 9.4 months (Dimopoulos et al., 2016) and 7.2 months , respectively (Palumbo et al., 2016). Median time to PFS in the SVd Arm was based on preliminary results from Karyopharm's STOMP study  (Study  KCP-330-017).  An  exponential  dropout  rate  of  0.65%  per  month  (equivalently approximately 10% dropout after 18 months) is assumed.

## Randomisation

Patients were randomized in a 1:1 ratio to 1 of the 2 treatment arms ( SVd or Vd ). Randomization was stratified for prior PI therapy (yes or no), number of prior anti-MM regimens (1 versus &gt;1 and disease severity at study entry (based on the revised International Staging System [ R-ISS ]; Stage III versus Stage I or II ).

Patients were randomized to 1 of 2 treatment arms ( SVd or Vd ) in a 1:1 allocation , as follows:

- SVd arm : selinexor (QW) + SC bortezomib (QW) + dexamethasone.
- Vd arm : SC bortezomib (Cycles 18 BIW, Cycles ≥9 QW) + dexamethasone.

Randomization will be stratified based on:

- ─ 4 Regions
- o Region 1 (USA, Canada)
- o Region 2 (Austria, Belgium, France, Germany, Italy, Spain, UK, Israel, Australia)
- o Region 3 (Czech Republic, Greece, Hungary, Poland)
- o Region 4 (India, Russia, Ukraine, Bulgaria, Romania, Serbia)
- ─ Prior PI therapies (Yes or No)
- ─ Number of prior anti-MM regimens (1 versus &gt; 1)
- ─ Revised International Staging System ( R-ISS ) stage at study entry based on screening results (R-ISS  Stage  III  versus  R-ISS  Stage  I  or  II)  (Palumbo  2016).  If  data  for  chromosomal abnormalities and serum lactate dehydrogenase required for R-ISS staging were not available, patients  were  assigned  to  the  R-ISS  category  corresponding  to  their  International  Staging System (ISS) stage.

<div style=\"page-break-after: always\"></div>

It is planned to randomize patients within individual countries in a 1:1 allocation to SVd:Vd.

## Blinding (masking)

Not applicable, as this was a 2-arm, open-label study.

## Statistical methods

## Changes to the Planned Analyses

There were 3 versions of the SAP (Version 1.0 dated 15 August 2018, Version 2.0 dated 30 September 2019, and Version 3.0 dated 24 February 2020).

Summary of Major Changes to Statistical Analysis Plan:

| Version                         | Summary of Major Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Version 3.0 (24 February 2020)  | Provided the results of the first IA. • Changed timing of the final PFS analysis to when the second IA was originally planned (i.e., after 201 PFS events occurred). • Removed the CHW method since sample size did not change after the first IA. • Removed the type I error adjustment for the second IA since the second IA will be treated as final analysis. • Added more details to the definition of TEAE. • Modified the Adverse Event of Clinical Interest (AECI) categories.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Version 2.0 (30 September 2019) | Clarified the start date of the SVdX (SdX) treatment to be the earliest non-zero dose date of at least 1 dose of selinexor or bortezomib (for the SVdX treatment only) or dexamethasone for the SVdX (SdX) treatment after crossover • Clarified that for patients who cross over from the Vd arm to the SVdX or SdX treatment, the following derivations will be based on the initiation of the SVdX and SdX treatment: ─ The handling of missing or partial dates for adverse events or concomitant medications ─ Definition of concomitant medications ─ The end date of the Vd treatment ─ TEAE definition after crossover to the SVdX/SdX treatment • Clarified the PP population definition • Clarified that the best response and duration of the most recent prior anti-MM regimen will be summarized • Modified the calculation of the duration of the most recent prior anti-MM regimen in days • Removed region as the stratum used for analyses and clarified that the stratification factors include prior PI therapies, the number of prior anti-MM regimens, and R-ISS stage at study entry • Clarified the censoring criteria for patients who do not have an event in the corresponding sections • Modified 'Adverse Event of Special Interest (AESI)' to 'AECI' • Modified the AECI categories |

Source: SAP Version 3.0 Section 1.8. MM=multiple myeloma; PI=proteasome inhibitor; SdX=selinexor plus low-dose dexamethasone treatment after  crossover;  SVdX=selinexor  plus  bortezomib  plus  low-dose  dexamethasone  treatment  after  crossover;  Vd=bortezomib  plus  low-dose dexamethasone

## Study plan

For each patient that signs the informed consent, the study consists of:

Screening/baseline visit occurs within 28 days prior to receiving the 1st dose of study treatment

Treatment period : there is no maximum treatment duration.

<div style=\"page-break-after: always\"></div>

Follow-up period: up to 5 years after their last dose of SVd/Vd/SVdX/SdX treatment, patients will be contacted approximately every 3 months for durability of response and survival follow-up. Completion of follow-up for the last patient will occur when the last patient in the study has been followed for up to 5 years after their last dose of SVd/Vd/SVdX/SdX treatment, has withdrawn consent, has been withdrawn from the study by the Investigator, has died, or has been lost to follow-up, whichever occurs first.

## Study hypothesis: Superiority

## Interim analyses

Two interim analyses for primary PFS endpoint are planned.

## Interim Analysis for Sample Size Re-estimation

The first interim analysis (IA) was conducted with data cut of 21 Jan 2019 after 113 events were accrued. The purpose of the first IA was for sample size re-adjustment. The DSMB met on 21 Feb 2019 and based on the safety and efficacy data, the DSMB recommendation was continuation of the study with no change to safety monitoring and no sample size adjustment. Thus, there is no need for type I error adjustment for final analysis according to CHW method (Cui et al., 1999).

## Interim Analysis for Futility or Superiority

A second interim analysis was originally planned after approximately 75% of the planned number of PFS events (i.e., approximately 201 PFS events) have occurred, and would allow for a conclusion of efficacy, and stopping for futility (non-binding).

Due to concerns that the trial was not going to reach the planned 267 events, and that it would take an extended period of time to accrue additional PFS events with minimal gain in power, the MAH proposed to use the second IA as the final efficacy analyses no matter the outcome is positive or not. With DSMB agreement, the second IA was used as the final PFS analysis and used all one-sided alpha of 0.025.

The null hypothesis of PFS endpoint will not be re-tested at any subsequent timepoint.

Patient response will be assessed centrally by an IRC according to IMWG response criteria (Kumar, 2016) for MM. Unless otherwise specified, MM response assessment refers to assessment determined by IRC.

For patients in the Vd arm, crossing over to SVdX or SdX will be considered as initiating a new MM treatment.

## Primary endpoint

PFS: The  primary  analysis  of  PFS  will  be  performed  by  treatment  (SVd  versus  Vd)  on  the ITT population . The analysis will be repeated for the PP population as a supportive analysis.

## PFS outcome and censoring definition

<div style=\"page-break-after: always\"></div>

| Situation                                                                                                                                                                                                          | Date of event or censoring                                                                                                        | Outcome   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-----------|
| No adequate post-baseline disease status assessment unless death occurs prior to first post-baseline assessment                                                                                                    | Randomization                                                                                                                     | Censored  |
| Death before IRC-determined PD                                                                                                                                                                                     | Date of death                                                                                                                     | PFS event |
| IRC-determined PD                                                                                                                                                                                                  | Date of PD                                                                                                                        | PFS event |
| No IRC-determined PD or death on or before a. database cut, b. withdrawal of informed consent, lost to follow-up. C. d. documented treatment discontinuation e.  start of new MM treatment, whichever occurs first | Date of last adequate disease assessment on or prior to the earliest occuirence of the events (a. - e.) listed in the left column | Censored  |

A stratified log-rank test will be used to compare the PFS between treatment arms (SVd versus Vd) for the primary efficacy assessment. The strata will include prior PI therapies, number of prior anti-MM regimens, and R-ISS stage at study entry.

Hazard ratios and its 95% CI will be estimated by a stratified Cox proportional hazards model, with Efron's method of tie handling, with treatment as the factor. The strata will include prior PI therapies, number of prior anti-MM regimens, and R-ISS stage at study entry. A non-stratified log-rank test and a Cox proportional hazards model will be used as sensitivity analyses.

Additional sensitivity analyses will be performed on the ITT population for the PFS primary endpoint as outlined below:

- Events are defined as IRC-confirmed progression or death, whichever occurs first.
- Patients are censored at the date of last disease assessment if no progression is confirmed by the IRC, or treatment is discontinued for any reason, or new anticancer treatment is started, or death or progression occurs after 2 or more missed visits
- Similar to the primary PFS endpoint analysis but where treatment discontinuation for any reason is counted as an event
- Similar to the primary PFS endpoint analysis but where the initiation of non-study antineoplastic therapy is counted as an event
- Similar to the primary PFS endpoint analysis but where clinical progression is counted as an event in addition to IRC-confirmed PD. Clinical progression is defined as the event when a patient discontinues the treatment with reason of PD but is not classified as PD by IRC.
- Similar to the primary PFS endpoint analysis but where the timing of IRC-confirmed PD at an unscheduled visit is changed to the next scheduled visit

<div style=\"page-break-after: always\"></div>

- Comparison of PFS endpoint by treatment based on investigator's assessment

## Analyses of Key Secondary Endpoints

The following 3 endpoints are defined as key secondary endpoints: ORR, the incidence of any &gt; Grade 2 peripheral neuropathy events and response rate for responses &gt;VGPR will be tested at the time of the second PFS IA.

Statistical significance of key secondary endpoints will not be claimed until the primary endpoint of PFS have reached significance. The key secondary endpoints will be tested using the hierarchical testing procedure to maintain the overall type I error at a 1-sided 0.025 level of significance.

The testing sequence will be:

- ORR, defined as any response &gt; PR (i.e. PR, VGPR, CR or sCR) based on the IRC's response outcome assessments, according to the IMWG response criteria.
- Incidence of any &gt;Grade 2 peripheral neuropathy events
- Response rates for &gt; VGPR based on the IRC's assessment

Regarding secondary endpoints, specifically for OS analysis, since patients in the Vd arm are allowed to crossover to SVdX and SdX treatment after PD, adjustment for the effect of crossover on OS may be performed based on Rank Preserving Structural Failure Time (RPSFT) model proposed by Robins and Tsiatis (1991).

## Multiple comparisons/multiplicity

The overall type I error for the primary endpoint and each key secondary endpoint is strictly controlled at 2.5% (one-sided).

Statistical significance of key secondary endpoints will not be claimed until the primary endpoint of PFS have reached significance. The key secondary endpoints will be tested using the hierarchical testing procedure to maintain the overall type I error.

## Graphical illustration of the propagation of endpoint-specific alpha

<!-- image -->

<div style=\"page-break-after: always\"></div>

The updated analysis based on the data cut-off date of 15 Feb 2021 was conducted per CHMP request. The updated analysis is non-inferential and the p-values from the updated analysis were nominal.

## Results

## Participant flow

A total of 457 patients were screened for inclusion in the study; 402 patients were randomized, and 399 patients received at least one dose of study treatment.

Of the 402 randomized patients, 195 were randomized onto the SVd arm (all dosed) and 207 patients were randomized to the Vd arm, of which 204 were dosed. Three patients randomized to the Vd arm were not dosed due to withdrawal of consent, death, and AE.

Figure 3. CONSORT Diagram of Patient Disposition in Study KCP-330-023. Primary Analysis

<!-- image -->

Source: Table 14.1.1.1, Table 14.1.1.2. Data cut-off date: 18 Feb 2020.

AE=adverse event; IRC=independent review committee; PD=progressive disease; SdX=selinexor plus low-dose dexamethasone treatment after crossover; SVd=selinexor plus bortezomib plus low-dose dexamethasone; SVdX=selinexor plus bortezomib plus low-dose dexamethasone treatment after crossover; Vd=bortezomib plus low dose dexamethasone.

<div style=\"page-break-after: always\"></div>

At the time of the udpdated cut-off (DBL: 15 Feb 2021) the distribution in terms of treatment discontinuations and patients on treatment was as included in the table below.

Table 2. Patients Disposition- Updated analysis

<!-- image -->

| Disposition Category                              | SVd Arm (N=195 n (%)   | Vd Arm (N=204) (%) uI   | Total (N=399) (%) uI   |
|---------------------------------------------------|------------------------|-------------------------|------------------------|
| Total Numberof PatientsScreened                   |                        |                         | 457                    |
| Total Number of RandomizedPatients                | 195                    | 207                     | 402                    |
| End of Treatment                                  |                        |                         |                        |
| On-treatment                                      | 21 (10.8)              | 16 (7.8)                | 37 (9.3)               |
| Discontinued Treatment and Reasons                | 174 (89.2)             | 188 (92.2)              | 362 (90.7)             |
| Disease Progression                               | 76 (39.0)              | 118 (57.8)              | 194 (48.6)             |
| Withdrawal by Patient                             | 37 (19.0)              | 21 (10.3)               | 58 (14.5)              |
| Adverse Eventb                                    | 33 (16.9)              | 26 (12.7)               | 59 (14.8)              |
| Death                                             | 14 (7.2)               | 14 (6.9)                | 28 (7.0)               |
| Lost to Follow-up                                 | 3 (1.5)                | 2 (1.0)                 | 5 (1.3)                |
| Non-compliance with Study Drug/Protocol Deviation | 1 (0.5)                | 2 (1.0)                 | 3 (0.8)                |
| Physician Decision                                | 10 (5.1)               | 5 (2.5)                 | 15 (3.8)               |
| End of Study                                      |                        |                         |                        |
| On-study                                          | 73 (37.4)              | 78 (38.2)               | 151 (37.8)             |
| Discontinued from Study and Reasons               | 122 (62.6)             | 126 (61.8)              | 248 (62.2)             |
| Withdrawal by Patient                             | 39 (20.0)              | 39 (19.1)               | 78 (19.5)              |
| Death                                             | 68 (34.9)              | 79 (38.7)               | 147 (36.8)             |
| Lost to Follow-up                                 | 12 (6.2)               | 7 (3.4)                 | 19 (4.8)               |
| Physician Decision                                | 1 (0.5)                | 0                       | 1 (0.3)                |
| Other                                             | 2 (1.0)                | 1 (0.5)                 | 3 (0.8)                |

Source: Table 14.1.1.1\\_updated. Data cut-off date: 15 Feb 2021.

SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone.

a Three patients were randomized but did not receive any dose of study drug due to withdrawal of consent, death or AE. b Includes toxicity to study drug.

Table 3. Patients on Treatment or in Follow-up

PatientsonTreatmentorinFollow-up -PrimaryAnalysis

-UpdatedAnalysis

| Disposition Category                                                               | SVdArm (N=195) n (%)   | Vd Arm (N=204) n (%)   | Total (N=399) n (%)   | SVdArm (N=195) n (%)   | Vd Arm (N=204) n (%)   | Total (N=399) n (%)   |
|------------------------------------------------------------------------------------|------------------------|------------------------|-----------------------|------------------------|------------------------|-----------------------|
| Patients On Treatment                                                              | 37 (19.0)              | 36 (17.0)              | 73 (18.3)             | 21 (10.8)              | 16 (7.8)               | 37 (9.3)              |
| PatientsinSurvival Follow-up                                                       | 65 (33.3)              | 51 (25.0)              | 116 (29.1)            | 52 (26.7)              | 58 (28.4)              | 110 (27.6)            |
| PatientsWhoDiscontinuedFrom the Study Without Completing 5-year Survival Follow-up |                        |                        |                       | 13 (6.7)               | 16 (7.8)               | 29 (7.3)              |

Source:Table14.1.1.1.Datacut-offdate:18Feb2020. SVd=selinexorplusbortezomibpluslow-dosedexamethasone; Vd=bortezomibpluslow-dosedexamethasone.aPatientsin follow-upconsistsofpatientswhoarewillingtocontinueinto SurvivalFollow-up,stillalive,notlosttofollow-upandhavenot discontinuedfromthestudy.

Source:Table14.1.1.1\\_updated.Datacut-offdate:15Feb2021. SVd=selinexorplusbortezomibpluslow-dosedexamethasone; Vd=bortezomibpluslow-dosedexamethasone.a Patientsin follow-upconsistsofpatientswhoarewillingtocontinueinto SurvivalFollow-up,stillalive,notlosttofollow-upandhavenot discontinuedfromthestudy.

<div style=\"page-break-after: always\"></div>

As of the data cut-off date of 18 Feb 2020 (primary analysis) , the median follow-up was 17.3 months in the SVd arm and 17.5 months in the Vd arm. In the updated analysis (15 Feb 2021) , the median follow-up was 28.71 months in the SVd arm and 28.65 months in the Vd arm.

The  most  common  reasons  for  overall  treatment  discontinuation  were  PD  (174  patients  [43.6%]), withdrawal by patient (55 patients [13.8%]), and AEs (56 patients [14.0%]). More patients discontinued due to PD in the Vd arm compared to the SVd arm (52.5% versus 34.4%).

Discontinuations due to deaths on or within 30 days of last dose of treatment were similar in the 2 arms. However, there were more discontinuations due to AEs in the SVd arm versus the Vd arm (16.9% versus 11.3%).

## Recruitment

- First patient treated: 07 June 2017
- Last patient completed: 21 October 2016
- Date of Data Cut-Off (Primary analysis): 18 February 2020
- Date of Data Cut-Off (Updated analysis): 15 February 2021

## Study Locations

This multicenter study was conducted at 165 clinical investigative sites in 21 countries. Of the 165 investigative sites, 123 sites enrolled 402 patients in the study.

## Conduct of the study

Summary of Major Changes Made in Protocol Amendments

| Amendment                                 | Summary of Major Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 3, Version 4.0 (17 August 2018) | • Changed ORR from a primary endpoint to a key secondary endpoint to address concerns expressed by the Agencies regarding including ORR as a primary endpoint (i.e., an analysis of ORR could jeopardize the integrity of the study for the ultimate assessment of PFS) • Revised the definition of 'IRC-confirmed PD' and renamed the term as 'IRC PD confirmation.' • Added a description of 8 tumor lysis syndrome cases reported across all of selinexor development as of May 2018/ • Removed the split of the alpha level between PFS (0.02) and ORR (0.005) and added the assumed exponential dropout rate of 0.65% • Revised the total number of PFS events required for the final analysis from 284 to 267, for the IA for sample size re-estimation from 85 to 81, and for the IA for futility or superiority from 213 to 201 • Removed the secondary OS1 objective/endpoint • Removed the secondary objective/endpoint comparing ORR, PFS, and DOR for patients with 1 versus >1 prior anti-MM regimen and added it as a subgroup exploratory analysis • Revised the basis for the determination of the Revised International Staging System stage used in stratification of randomization from 'at original MM diagnosis' to 'at study entry, based on screening results.' • Added an exception to the requirement that patients were to either remain on the study treatment until PD was confirmed by the IRC or until the patient discontinued the study treatment, completed the End of Treatment Visit, and was followed for survival. The exception only applied to patients in the Vd arm who had to terminate bortezomib prior to IRC-confirmed PD due to significant toxicities • Revised inclusion criterion #12 for contraception requirements and guidance for pregnancy and breastfeeding |

<div style=\"page-break-after: always\"></div>

|                                          | • Clarified the wording for how selinexor should be administered and removed the need to take selinexor with food • Revised the guidance for the doses of the study treatment that had to be missed due to protocol- or study-related reasons to: 1) Provided 72 hours between 2 consecutive doses of bortezomib and 2) Removed the requirement for 36 hours between doses • Updated the supportive care instructions for consistency with the current clinical practice • Deleted the restriction for alcohol use on the study treatment dosing days • Added text in a new subsection to indicate that a portion of the bone marrow aspirate was to be collected to isolate plasma, non-tumor CD138-, and tumor CD138+ cell fractions for subsequent pharmacodynamic studies • Removed the North American restriction for pharmacokinetic sampling • Added the specific grading system (i.e., the American Optometric Association) for                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                          | cataract/lens opacity • Added a new subsection with text clarifying the definition of events that did not meet the definition of a serious AE • Changed the reporting mechanism for reporting overdose, abuse, misuse, medication errors, and occupational exposure from fax to email • Revised the timing for reporting of overdose, abuse, misuse, medication errors, and occupational exposure for events that were not AEs or serious AEs from 'as soon as possible' to 'within 24 hours of awareness.' • Moved OS from a key secondary efficacy endpoint to a non-key secondary efficacy endpoint • Moved response rates for responses ≥ very good partial response from #2 to #3 (to replace OS) • Removed the following from the analysis of the secondary endpoint of ORR1: 'It is expected that approximately 70 patients will cross over from the Vd arm to SVdX. This sample size results in a power of 92% assuming an ORR1 of 25% and 1-sided type I error of 0.025.' • Added details for the cytogenetic alteration analyses • A definition of clinical progression was added for the primary analysis of PFS • Added the following sensitivity analysis: Comparison of PFS endpoint by treatment based on Investigator's assessment • Aligned the points, analyses, and concomitant medications with the Statistical Analysis Plan • Aligned the safety sections with the new safety language template provided by the                                                                                                                                                                                                                                                                                                                               |
| Amendment 2, Version 3.0 (06 April 2017) | • Added details for the Interactive Response Technology system that was to used to perform treatment randomization • Added details for continuation of the study treatment for patients if the study was terminated early to comply with International Council for Harmonization Good Clinical Practice E6 • Clarified that double-barrier contraception methods were considered effective but not highly effective to align with the recommendations of the Clinical Trial Facilitation Group. Also clarified that sexual partners who were surgically sterilized were not exempt from the contraception requirements unless they were 'permanently' surgically sterilized • Added the requirement for pregnancy testing (serum human chorionic gonadotropin or urine) for females of childbearing potential before dosing on Day 1 of Cycles ≥2 to align with the recommendations of the Clinical Trial Facilitation Group • For the PFS primary efficacy endpoint, changed the analysis to the stratified log-rank test and stratified Cox model (previously in Version 1.0 of the protocol). Also, specified that the stratified log-rank test was to be used for the secondary analyses of OS, DOR, and OS1, and that the exploratory analysis of the treatment discontinuation rate was to be performed using the stratified log-rank test • For the ORR efficacy analysis, specified that patients missing MM disease assessments after C1D1 were to be imputed as non-responders • Changed the timing of the secondary analyses from 'after significance is reached for PFS' to 'at the time of ORR analysis' and specified that 'statistical significance of the secondary endpoints will not be claimed until the ORR and PFS have reached significance.' |

<div style=\"page-break-after: always\"></div>

|                                             | • Changed the Hochberg procedure for testing the secondary endpoints to a hierarchical testing procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 1, Version 2.0 (22 February 2017) | • Added crossover to treatment with selinexor and dexamethasone (SdX) as an option for patients in the Vd arm after PD was confirmed by the IRC if they had significant tolerability issues with bortezomib (e.g., higher than Grade 2 PN or Grade 2 or higher PN with pain) • Changed the third key secondary efficacy objective/endpoint from DOR to OS • Revised the OS1 and time-to-next-treatment secondary objectives to add SdX and added a new exploratory objective (i.e., to assess disease response to SdX treatment) and endpoint (i.e., IMWG response criteria for patients treated with SdX) for SdX to assess response for patients who crossed over to SdX. Also clarified that for OS1, patients on the Vd arm who crossed over were censored at the date of crossover • Revised the definition of the time to response to 'the duration of the time from randomization to the first documented response ( ≥ PR) per IMWG response criteria' • Updated the IMWG response criteria for myeloma to align with the most recent IMWG criteria (Kumar 2016). The definition for minimal residual disease was changed from 'minor' to 'minimal' response to align with the IMWG Consensus Criteria • The process for crossover was modified to prevent premature crossover • Revised exclusion #12 to clarify that patients treated with an investigational anticancer therapy within 2 weeks before C1D1 were specifically excluded from the study • Clarified that symptom-directed physical examinations were only to be performed if clinically indicated • Clarified that clinical plasmacytoma assessments are to be performed if clinically indicated at MM Disease Assessment Visits and at Durability of Response and Survival Follow-up Visits. Also corrected the window for detection of plasmacytomas at baseline by physical examination/palpation from 'within 45 days' to 'within 28 days' before C1D1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                             | • Removed the requirement for dose escalation for patients in the SVd arm who did not achieve at least a PR within the first 2 cycles, are tolerating SVd well, and did not have any AEs related to the study treatment that were higher than Grade 2 at the time of the dose escalation • Added a requirement for baseline bone marrow aspirate at Screening for all patients. Also, clarified that a portion of the bone marrow aspirate collected at Screening was to be provided to the central laboratory for karyotyping and fluorescence in situ hybridization analysis to confirm diagnosis and classify cytogenetic MM subtypes for Revised International Staging System staging • Removed turbidometry as an acceptable method for measuring quantitative Ig levels. Also clarified that nephelometry could be used in place of serum protein electrophoresis for routine M-protein measurement for patients with IgD myeloma in addition to patients with IgA myeloma • Added pharmacokinetic assessments for bortezomib and selinexor in a subset of patients randomized to each arm (i.e., the Vd arm and the SVd arm) • Clarified that body surface area was to be recalculated if the patient's weight fluctuates substantially from baseline (i.e., >20%) during treatment (including Vd, SVd, SVdX, and SdX) • Revised the definition of the per-protocol population from all intent-to-treat patients who had received 'any amount' to 'at least 1 dose 'of the study treatment • Added a justification for the sample size calculation assumptions • Specified that an independent third party (the Data Safety Monitoring Board) was to conduct and review the sample size re-estimation and that an interim analysis charter was to be created to outline the operational procedures associated with both PFS IAs • Clarified the timing and details for the second IA • Added a sensitivity analysis using the Breslow-Day test to evaluate the homogeneity of the odds ratios across the strata associated with the ORR endpoint and the 2 secondary efficacy endpoint analyses which were analyzed using the Cochran-Mantel- Haenszel test • Added a sensitivity analyses for the primary efficacy endpoint and key secondary efficacy endpoints • Clarified that all changes in MM disease assessments were based on baseline MM disease assessments from C1D1 of the study treatment • Added a method for testing the proportional hazard assumption associated with the analyses of the primary and key secondary time-to-event endpoints |

<div style=\"page-break-after: always\"></div>

## Baseline data

Patients were enrolled at 165 sites in 21 countries, grouped into 4 regions

Table 4. Enrolment by Region and Country (Intent-to-Treat Population)

| Region/ Country n (%)           | SVd Arm (N=195)   | Vd Arm (N=207)   | Total (N=402)   |
|---------------------------------|-------------------|------------------|-----------------|
| Region l                        | 18 (9.2)          | 18 (8.7)         | 36 (9.0)        |
| Canada                          | 5 (2.6)           | 11 (5.3)         | 16 (4.0)        |
| United States ofAmerica         | 13 (6.7)          | 7 (3.4)          | 20 (5.0)        |
| Region 2                        | 61 (31.3)         | 66 (31.9)        | 127 (31.6)      |
| Australia                       | 12 (6.2)          | 9 (4.3)          | 21 (5.2)        |
| Austria                         | 4 (2.1)           | 5 (2.4)          | 9 (2.2)         |
| Belgium                         | 0                 | 3 (1.4)          | 3 (0.7)         |
| France                          | 6 (3.1)           | 10 (4.8)         | 16 (4.0)        |
| Germany                         | 3 (1.5)           | 5 (2.4)          | 8 (2.0)         |
| Israel                          | 3 (1.5)           | 2 (1.0)          | 5 (1.2)         |
| Italy                           | 6 (3.1)           | 12 (5.8)         | 18 (4.5)        |
| Spain                           | 8 (4.1)           | 3 (1.4)          | 11 (2.7)        |
| United Kingdom of Great Britain | 19 (9.7)          | 17 (8.2)         | 36 (9.0)        |
| Region 3                        | 47 (24.1)         | 53 (25.6)        | 100 (24.9)      |
| CzechRepublic                   | 15 (7.7)          | 18 (8.7)         | 33 (8.2)        |
| Greece                          | 14 (7.2)          | 15 (7.2)         | 29 (7.2)        |
| Hungary                         | 3 (1.5)           | 0                | 3 (0.7)         |
| Poland                          | 15 (7.7)          | 20 (9.7)         | 35 (8.7)        |
| Region 4                        | 69 (35.4)         | 70 (33.8)        | 139 (34.6)      |
| Bulgaria                        | 6 (3.1)           | 6 (2.9)          | 12 (3.0)        |
| India                           | 23 (11.8)         | 20 (9.7)         | 43 (10.7)       |
| Romania                         | 0                 | 6 (2.9)          | 6 (1.5)         |
| RussianFederation               | 12 (6.2)          | 7 (3.4)          | 19 (4.7)        |
| Serbia                          | 4 (2.1)           | 10 (4.8)         | 14 (3.5)        |
| Ukraine                         | 24 (12.3)         | 21 (10.1)        | 45 (11.2)       |

Source: Table 14.1.2.1. SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone.

The median ages of the patients in BOSTON were 66 and 67 years in the SVd and Vd arms, respectively. The majority of the patients were 65 years of age or older (SVd, 55.9%; Vd, 63.8%) and ~20% were ≥ 75 years of age. More males were enrolled in the study than females (males: SVd, 59.0%; Vd, 55.6%) and the race was predominantly White (SVd, 82.6%; Vd, 79.7%).

- Provided additional details, including subgroups, for the exploratory analyses
- Revised the correction for QT corrected interval from Bazett's to Fridericia's
- Text for safety definitions, recording, and reporting revised

<div style=\"page-break-after: always\"></div>

Table 5. Patient Demographics (Intent-to-Treat Population)

<!-- image -->

|                          | SVd Arm (N=195)   | Vd Arm (N=207)   | Total (N=402)   |
|--------------------------|-------------------|------------------|-----------------|
| Age (Years)              |                   |                  |                 |
| N                        | 195               | 207              | 402             |
| Median                   | 66.0              | 67.0             | 67.0            |
| Min, Max                 | 40, 87            | 38, 90           | 38, 90          |
| Age Category n (%6)a     |                   |                  |                 |
| 18-50                    | 15 (7.7)          | 11 (5.3)         | 26 (6.5)        |
| 51 - 64                  | 71 (36.4)         | 64 (30.9)        | 135 (33.6)      |
| 65 - 74                  | 75 (38.5)         | 85 (41.1)        | 160 (39.8)      |
| 275                      | 34 (17.4)         | 47 (22.7)        | 81 (20.1)       |
| Sex n (%)                |                   |                  |                 |
| Male                     | 115 (59.0)        | 115 (55.6)       | 230 (57.2)      |
| Female                   | 80 (41.0)         | 92 (44.4)        | 172 (42.8)      |
| Race n (%)               |                   |                  |                 |
| Asian                    | 25 (12.8)         | 25 (12.1)        | 50 (12.4)       |
| Black or Afican Americam | 4 (2.1)           | 7 (3.4)          | 11 (2.7)        |
| White                    | 161 (82.6)        | 165 (79.7)       | 326 (81.1)      |
| Other                    | 0                 | 1 (0.5)          | 1 (0.2)         |
| Missing                  | 5 (2.6)           | 9 (4.3)          | 14 (3.5)        |
| Ethnicity n (%)          |                   |                  |                 |
| Hispanic or Latino       | 6 (3.1)           | 5 (2.4)          | 11 (2.7)        |
| Not Hispanic or Latino   | 171 (87.7)        | 188 (90.8)       | 359 (89.3)      |
| Not Reported             | 14 (7.2)          | 11 (5.3)         | 25 (6.2)        |
| Unknowm                  | 4 (2.1)           | 2 (1.0)          | 6 (1.5)         |
| Missing                  | 0                 | 1 (0.5)          | 1 (0.2)         |

Source: Table 14.1.2.1. Max=maximum; min=minimum; SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone. a Age is the age at date of randomization.

Baseline disease characteristics were well balanced across the 2 arms:

- ECOG PS: score of 0-1; SVd, 89.8%; Vd, 92.3%
- Median time from diagnosis: SVd, 3.8 years; Vd, 3.6 years
- R-ISS stage: score I or II: SVd, 88.7%; Vd, 85.5%
- Renal function: CrCl of 30&lt;60 or ≥60 mL/min: SVd, 27.2% and 71.3%; Vd, 29.0%and 66.2%
- High-risk chromosomal abnormalities (including: del[17p]/p53, t[14;16], t[4;14],1q21): SVd, 49.7%; Vd, 45.9%

<div style=\"page-break-after: always\"></div>

Table 6. Baseline Disease Characteristics (Intent-to-Treat Population)

|                                                                                           | SVd Arm (N=195)                                                                           | Vd Arm (N=207)                                                                            | Total (N=402)                                                                             |
|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Baseline ECOG Performance Status n (%)                                                    | Baseline ECOG Performance Status n (%)                                                    | Baseline ECOG Performance Status n (%)                                                    | Baseline ECOG Performance Status n (%)                                                    |
| 0                                                                                         | 69 (35.4)                                                                                 | 77 (37.2)                                                                                 | 146 (36.3)                                                                                |
| 1                                                                                         | 106 (54.4)                                                                                | 114 (55.1)                                                                                | 220 (54.7)                                                                                |
| 2                                                                                         | 20 (10.3)                                                                                 | 16 (7.7)                                                                                  | 36 (9.0)                                                                                  |
| Time from Initial Diagnosis (Years)*                                                      | Time from Initial Diagnosis (Years)*                                                      | Time from Initial Diagnosis (Years)*                                                      | Time from Initial Diagnosis (Years)*                                                      |
| N                                                                                         | 195                                                                                       | 207                                                                                       | 402                                                                                       |
| Median                                                                                    | 3.81                                                                                      | 3.59                                                                                      | 3.70                                                                                      |
| Min, Max                                                                                  | 0.4, 23.0                                                                                 | 0.4, 22.0                                                                                 | 0.4, 23.0                                                                                 |
| Creatinine Clearance at Baseline (mL/min),n (%6)                                          | Creatinine Clearance at Baseline (mL/min),n (%6)                                          | Creatinine Clearance at Baseline (mL/min),n (%6)                                          | Creatinine Clearance at Baseline (mL/min),n (%6)                                          |
| ≤30                                                                                       | 3 (1.5)                                                                                   | 10 (4.8)                                                                                  | 13 (3.2)                                                                                  |
| 30 - ≤60                                                                                  | 53 (27.2)                                                                                 | 60 (29.0)                                                                                 | 113 (28.1)                                                                                |
| ≥60                                                                                       | 139 (71.3)                                                                                | 137 (66.2)                                                                                | 276 (68.7)                                                                                |
| R-ISS Stage at Screening, n (%)                                                           | R-ISS Stage at Screening, n (%)                                                           | R-ISS Stage at Screening, n (%)                                                           | R-ISS Stage at Screening, n (%)                                                           |
| I                                                                                         | 56 (28.7)                                                                                 | 52 (25.1)                                                                                 | 108 (26.9)                                                                                |
| Ⅱ                                                                                         | 117 (60.0)                                                                                | 125 (60.4)                                                                                | 242 (60.2)                                                                                |
| Ⅲ                                                                                         | 12 (6.2)                                                                                  | 16 (7.7)                                                                                  | 28 (7.0)                                                                                  |
|                                                                                           | SVd Arm (N=195)                                                                           | Vd Arm (N=207)                                                                            | Total (N=402)                                                                             |
| Not available                                                                             | 10 (5.1)                                                                                  | 14 (6.8)                                                                                  | 24 (6.0)                                                                                  |
| % Plasma Cells at Initial Diagnosis                                                       | % Plasma Cells at Initial Diagnosis                                                       | % Plasma Cells at Initial Diagnosis                                                       | % Plasma Cells at Initial Diagnosis                                                       |
| N                                                                                         | 169                                                                                       | 170                                                                                       | 339                                                                                       |
| Median                                                                                    | 33.7                                                                                      | 40.0                                                                                      | 35.6                                                                                      |
| Min, Max                                                                                  | 0.0, 99.0                                                                                 | 0.0, 95.0                                                                                 | 0.0, 99.0                                                                                 |
| % Plasma Cells at Initial Diagnosis, n (%)                                                | % Plasma Cells at Initial Diagnosis, n (%)                                                | % Plasma Cells at Initial Diagnosis, n (%)                                                | % Plasma Cells at Initial Diagnosis, n (%)                                                |
| 50                                                                                        | 116 (59.5)                                                                                | 100 (48.3)                                                                                | 216 (53.7)                                                                                |
| ≥50                                                                                       | 53 (27.2)                                                                                 | 70 (33.8)                                                                                 | 123 (30.6)                                                                                |
| Patients with High-Risk Chromosomal Abnormalities (Baseline or Initial Diagnosis), n (%)b | Patients with High-Risk Chromosomal Abnormalities (Baseline or Initial Diagnosis), n (%)b | Patients with High-Risk Chromosomal Abnormalities (Baseline or Initial Diagnosis), n (%)b | Patients with High-Risk Chromosomal Abnormalities (Baseline or Initial Diagnosis), n (%)b |
| del (17p)/p53                                                                             | 21 (10.8)                                                                                 | 16 (7.7)                                                                                  | 37 (9.2)                                                                                  |
| t (14;16)                                                                                 | 7 (3.6)                                                                                   | 11 (5.3)                                                                                  | 18 (4.5)                                                                                  |
| t (4;14)                                                                                  | 22 (11.3)                                                                                 | 28 (13.5)                                                                                 | 50 (12.4)                                                                                 |
| 1q21                                                                                      | 80 (41.0)                                                                                 | 71 (34.3)                                                                                 | 151 (37.6)                                                                                |
| Any of del(17p)/p53, t(14;16), t(4;14), 1q21                                              | 97 (49.7)                                                                                 | 95 (45.9)                                                                                 | 192 (47.8)                                                                                |
| Patients with Other Gene Mutations (Baseline or Initial Diagnosis):b                      | Patients with Other Gene Mutations (Baseline or Initial Diagnosis):b                      | Patients with Other Gene Mutations (Baseline or Initial Diagnosis):b                      | Patients with Other Gene Mutations (Baseline or Initial Diagnosis):b                      |
| del(13)                                                                                   | 16 (8.2)                                                                                  | 17 (8.2)                                                                                  | 33 (8.2)                                                                                  |
| t(6;14)                                                                                   | 0                                                                                         | 0                                                                                         | 0                                                                                         |
| t(11;14)                                                                                  | 17 (8.7)                                                                                  | 12 (5.8)                                                                                  | 29 (7.2)                                                                                  |
| t(14;20)                                                                                  | 2 (1.0)                                                                                   | 1 (0.5)                                                                                   | 3 (0.7)                                                                                   |

Source: Table 14.1.3.1, Table 14.1.4.1.1, Table 14.1.4.1.2, Table 14.1.4.1.4.

ECOG=Eastern Cooperative Oncology Group; max=maximum; min=minimum; R-ISS=The Revised International Staging System; SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone. a Time from initial diagnosis to date of randomization (prior to dosing at Cycle 1 Day 1). b These are not mutually exclusive genetic abnormalities (patients may have &gt;1 abnormality). Of note, 56 (28.7%) patients in the SVd arm and 70 (33.8%) in the Vd arm had moderate to severe renal dysfunction with a creatinine clearance of &lt;60 mL/min at baseline.

As expected, patients in the BOSTON study had multiple ongoing comorbidities at baseline, (median of 4 for both arms; Module 2.7.3, Section 3.1.4). Of note the most frequent comorbidity was cataract as seen in 60% and 62.3% of patients in the SVd and Vd arm respectively. Additional frequent comorbidities

<div style=\"page-break-after: always\"></div>

included hypertension (SVd, 45.6%; Vd, 49.3%), PN (SVd, 12.3%; Vd, 15.5%), hypothyroidism (SVd, 11.3%; Vd, 5.3%), and type 2 diabetes mellitus (SVd, 10.3%; Vd, 7.7%).

Approximately 50% of the patients had received 1 prior anti-MM therapy (SVd, 50.8%; Vd, 47.8%) with one-third having 2 prior regimens, and the remainder having 3 prior regimens for MM.

Table 7. Prior Anti-myeloma Therapies (Intent-to-Treat Population)

|                                                             | SVd Arm (N=195)   | Vd Arm (N=207)   | Total (N=402)   |
|-------------------------------------------------------------|-------------------|------------------|-----------------|
| Patients Who Received any Prior Anti-MM Drugs, n (%)        | 195 (100.0)       | 207 (100.0)      | 402 (100.0)     |
| Number of Unique Prior Anti-MM Drugs                        |                   |                  |                 |
| Median                                                      | 5.0               | 5.0              | 5.0             |
| Min, Max                                                    | 1, 9              | 1, 9             | 1, 9            |
| Number of Prior Anti-MM Regimens, n (%)                     |                   |                  |                 |
| 1                                                           | 99 (50.8)         | 99 (47.8)        | 198 (49.3)      |
| 2                                                           | 65 (33.3)         | 64 (30.9)        | 129 (32.1)      |
| 3                                                           | 31 (15.9)         | 44 (21.3)        | 75 (18.7)       |
| Number of Prior Anti-MM Regimens                            |                   |                  |                 |
| Mean (STD)                                                  | 1.7 (0.74)        | 1.7 (0.79)       | 1.7 (0.77)      |
| Min, Max                                                    | 1, 3              | 1, 3             | 1,3             |
| Prior PI Therapies, n (%)                                   |                   |                  |                 |
| Yes                                                         | 148 (75.9)        | 159 (76.8)       | 307 (76.4)      |
| No                                                          | 47 (24.1)         | 48 (23.2)        | 95 (23.6)       |
| Prior Anti-myeloma Drugs, n (%)                             |                   |                  |                 |
| Bortezomib                                                  | 134 (68.7)        | 145 (70.0)       | 279 (69.4)      |
| Carfilzomib                                                 | 20 (10.3)         | 21 (10.1)        | 41 (10.2)       |
| Ixazomib                                                    | 6 (3.1)           | 3 (1.4)          | 9 (2.2)         |
| Daratumumab                                                 | 11 (5.6)          | 6 (2.9)          | 17 (4.2)        |
| Lenalidomide                                                | 77 (39.5)         | 77 (37.2)        | 154 (38.3)      |
| Pomalidomide                                                | 11 (5.6)          | 7 (3.4)          | 18 (4.5)        |
| Prior Stem Cell Transplant n (%)                            | 76 (39.0)         | 63 (30.4)        | 139 (34.6)      |
| Patients Who Received any Prior Anti-MM Radiotherapy, n (%) | 30 (15.4)         | 41 (19.8)        | 71 (17.7)       |

Source:  Table  14.1.5.1.1,  Table  14.1.5.1.2.  Max=  maximum;  min=minimum;  MM=multiple  myeloma;  PI= proteasome inhibitor; STD=standard deviation. a Duration from most recent prior anti-MM therapy is calculated as date of randomization - stop date of most recent anti-MM therapy +1

Approximately 75% of patients (SVd, 75.9%; Vd, 76.8 %), had previously received a PI with the majority receiving bortezomib (SVd, 68.7%; Vd, 70.0%). Prior lenalidomide treatment was also common (SVd, 39.5%; Vd, 37.2%). Prior high dose chemotherapy with stem cell rescue had been administered

<div style=\"page-break-after: always\"></div>

to 39.0% and 30.4% of patients in the SVd and Vd arms, respectively. Of note, more patients in the SVd arm had received prior pomalidomide and/or daratumumab than in the Vd arm (pomalidomide, 5.6% vs 3.4% and daratumumab, 5.6% vs 2.9%, respectively).

Approximately one-third of patients had prior stem cell transplantation. Similar proportions of patients in both arms had received prior anti-MM radiotherapy (15.4% in the SVd arm, 19.8% in Vd arm) and prior anti-MM surgery (5.6% in the SVd arm, 6.8% in Vd arm).

Details on previous lines of anti-MM treatment received are presented in table 20and details on prior antineoplastic therapy refractoriness by treatment arm are presented in table 21.

Table 8: All Previous Common Lines ( ≥ 2%) of Anti-MM Treatment Received

|                                                 | SVd Arm (N=195)   | Vd Arm (N=207)   | Total (N=402)   |
|-------------------------------------------------|-------------------|------------------|-----------------|
| Bortezomib, cyclophosphamide, dexamethasone     | 33(16.9)          | 33(15.9)         | 66(16.4)        |
| Lenalidomide, dexamethasone                     | 27(13.8)          | 32(15.5)         | 59(14.7)        |
| Cyclophosphamide, thalidomide, dexamethasone    | 19(9.7)           | 22(10.6)         | 41(10.2)        |
| Bortezomib, melphalan, prednisone/prednisolone  | 14(7.2)           | 16(7.7)          | 30(7.5)         |
| Bortezomib, dexamethasone                       | 7(3.6)            | 16(7.7)          | 23(5.7)         |
| Bortezomib, thalidomide, dexamethasone          | 7(3.6)            | 16(7.7)          | 23(5.7)         |
| Thalidomide, dexamethasone                      | 8(4.1)            | 8(3.9)           | 16(4.0)         |
| Melphalan, thalidomide, prednisone/prednisolone | 4(2.1)            | 10(4.8)          | 14(3.5)         |
| Carfilzomib, melphalan, prednisone/prednisolone | 5(2.6)            | 8(3.9)           | 13(3.2)         |
| Bortezomib, lenalidomide, dexamethasone         | 5(2.6)            | 5(2.4)           | 10(2.5)         |
| Doxorubicin, vincristine, dexamethasone         | 3(1.5)            | 7(3.4)           | 10(2.5)         |
| Lenalidomide                                    | 7(3.6)            | 3(1.4)           | 10(2.5)         |
| Melphalan, prednisone/prednisolone              | 1(0.5)            | 9(4.3)           | 10(2.5)         |
| Pomalidomide, dexamethasone                     | 5(2.6)            | 3(1.4)           | 8(2.0)          |

## Table 9 : Prior Antineoplastic Therapy Refractoriness by Treatment Arm (All Patients in the Intent-to-Treat Population)

|                                          | SVd Arm (N = 195)                        | Vd Arm (N = 207)                         | Total (N = 402)                          |
|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| Number of Prior Lines of Anti-MM Therapy | Number of Prior Lines of Anti-MM Therapy | Number of Prior Lines of Anti-MM Therapy | Number of Prior Lines of Anti-MM Therapy |
| n                                        | 195                                      | 207                                      | 402                                      |
| Median                                   | 1                                        | 2                                        | 2                                        |
| Mean (STD)                               | 1.7 (0.74)                               | 1.7 (0.79)                               | 1.7 (0.77)                               |

<div style=\"page-break-after: always\"></div>

|                                                    | SVd Arm (N = 195)                               | Vd Arm (N = 207)                                | Total (N = 402)                                 |
|----------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Min, Max                                           | 1, 3                                            | 1, 3                                            | 1, 3                                            |
| Number of Prior Lines of Anti-MM Therapy, n (%)    | Number of Prior Lines of Anti-MM Therapy, n (%) | Number of Prior Lines of Anti-MM Therapy, n (%) | Number of Prior Lines of Anti-MM Therapy, n (%) |
| 1                                                  | 99 (50.8)                                       | 99 (47.8)                                       | 198 (49.3)                                      |
| 2                                                  | 65 (33.3)                                       | 64 (30.9)                                       | 129 (32.1)                                      |
| 3                                                  | 31 (15.9)                                       | 44 (21.3)                                       | 75 (18.7)                                       |
| Previously Exposed , n(%)                          | Previously Exposed , n(%)                       | Previously Exposed , n(%)                       | Previously Exposed , n(%)                       |
| Bortezomib                                         | 134 (68.7)                                      | 145 (70.0)                                      | 279 (69.4)                                      |
| Carfilzomib                                        | 20 (10.3)                                       | 21 (10.1)                                       | 41 (10.2)                                       |
| Ixazomib                                           | 6 (3.1)                                         | 3 (1.4)                                         | 9 (2.2)                                         |
| Thalidomide                                        | 78 (40.0)                                       | 87 (42.0)                                       | 165 (41.0)                                      |
| Lenalidomide                                       | 77 (39.5)                                       | 77 (37.2)                                       | 154 (38.3)                                      |
| Pomalidomide                                       | 11 (5.6)                                        | 7 (3.4)                                         | 18 (4.5)                                        |
| Daratumumab                                        | 11 (5.6)                                        | 6 (2.9)                                         | 17 (4.2)                                        |
| PI (Bortezomib or Carfilzomib or Ixazomib)         | 148 (75.9)                                      | 159 (76.8)                                      | 307 (76.4)                                      |
| IMiD (Thalidomide or Lenalidomide or Pomalidomide) | 138 (70.8)                                      | 147 (71.0)                                      | 285 (70.9)                                      |
| Refractory , n(%)                                  | Refractory , n(%)                               | Refractory , n(%)                               | Refractory , n(%)                               |
| Bortezomib                                         | 18 (9.2)                                        | 29 (14.0)                                       | 47 (11.7)                                       |
| Carfilzomib                                        | 5 (2.6)                                         | 5 (2.4)                                         | 10 (2.5)                                        |
| Ixazomib                                           | 2 (1.0)                                         | 1 (0.5)                                         | 3 (0.7)                                         |
| Thalidomide                                        | 24 (12.3)                                       | 34 (16.4)                                       | 58 (14.4)                                       |
| Lenalidomide                                       | 53 (27.2)                                       | 53 (25.6)                                       | 106 (26.4)                                      |
| Pomalidomide                                       | 10 (5.1)                                        | 6 (2.9)                                         | 16 (4.0)                                        |
| Daratumumab                                        | 10 (5.1)                                        | 6 (2.9)                                         | 16 (4.0)                                        |
| PI (Bortezomib or Carfilzomib or Ixazomib)         | 24 (12.3)                                       | 34 (16.4)                                       | 58 (14.4)                                       |
| IMiD (Thalidomide or Lenalidomide or Pomalidomide) | 74 (37.9)                                       | 86 (41.5)                                       | 160 (39.8)                                      |

Source: CSR KCP-330-023; Updated Analysis; Table 14.4.1.1

Overall, a 34% of patients received an SCT prior to entering the BOSTON study (39% in the SvD arms and 30.4% in the Vd arm). Of note, 33% of patients were &gt;70 years old at enrolment (at diagnosis 24%

<div style=\"page-break-after: always\"></div>

of patients were &gt;70 years old) and would generally not be considered for ASCT per the European Society for Medical Oncology (ESMO) guidelines.

## Numbers analysed

For the BOSTON study, the intent-to-treat (ITT) population (N=402) consisted of 195 and 207 patients randomized to the SVd and Vd arms, respectively.

Three patients never received study drug in the Vd arm and were excluded from the per-protocol (PP) population.

In addition, 2 patients from the Vd arm and 1 patient from the SVd arm were excluded from the PP population due to &lt;70% compliance of study drug (2 patients) and protocol deviation (1 patient).

Table 22. Analysis Populations

| Populations                     | Total (tot=ND) (%) u   |
|---------------------------------|------------------------|
| Total Randomized Patients       | 402 (100.0)            |
| Efficacy Populations            |                        |
| ITT Population                  | 402 (100.0)            |
| SVdAm                           | 195 (48.5)             |
| Vd Am                           | 207 (51.5)             |
| Per-Protocol Population         | 396 (98.5)             |
| SVd Am                          | 194 (48.3)             |
| Vd Am                           | 202 (50.2)             |
| Safety Populations              |                        |
| Total Safety Population         | 399 (99.3)             |
| SVd Am                          | 195 (48.5)             |
| Vd Am                           | 204 (50.7)             |
| Additional Analysis Populations |                        |
| SVdX Am*                        | 63 (15.7)              |
| SdX Armb                        | 11 (2.7)               |

Source:  Table  14.1.1.3.  SdX=selinexor  plus  low-dose  dexamethasone  treatment  after  crossover;  SVd=selinexor  plus bortezomib plus lowdose dexamethasone; SVdX=selinexor plus bortezomib plus low-dose dexamethasone treatment after crossover;  Vd=bortezomib  plus  low-dose  dexamethasone.  Note:  Denominator  is  total  number  of  patients  who  were randomized. a Patients in the safety population who crossed over from the Vd arm to the SVdX treatment and have received at least 1 dose of selinexor. b Patients in the safety population who crossed over from the Vd arm to the SdX treatment and have received at least 1 dose of selinexor.

A total of 74 patients who were originally randomized to the Vd arm experienced PD and crossed over to SVd (n=63) or Sd (n=11) treatment.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Patient response was assessed centrally by an IRC according to the IMWG response criteria for MM (Kumar 2016). The response data presented in the following sections refer to these assessments by the IRC, unless otherwise specified.

All efficacy analyses were conducted using the ITT population , unless otherwise specified and all tests (log-rank tests, Cochran-Mantel-Haenszel tests) were one-sided, unless otherwise stated.

## Primary Efficacy Endpoint: Progression-Free Survival

As per the primary analysis the KCP-330-023 (BOSTON) study achieved its primary endpoint with a statistically significant improvement in median PFS in the SVd arm (13.93 months) compared with the Vd arm (9.46 months; p=0.0075; HR, 0.70; 95% CI: 0.5279-0.9335). This represents an increase in median PFS of more than 4.4 months (a 47% improvement) and a 30% reduction in the risk of PD or death. The PFS on the Vd control arm was similar to that reported in recent studies.

Table 23. Progression-Free Survival Based on IRC Assessment by Treatment Arm (ITT Population)

PrimaryAnalysisDcodate:18Feb2020.

UpdatedAnalysisDcodate:15Feb2021

|                                                  | SVd Arm (N=195)   | VdArm (N=207)   | SVd Aim (N=195)   | Vd Arm (N=207)   |
|--------------------------------------------------|-------------------|-----------------|-------------------|------------------|
| Patients with Events, n (%)                      | 80 (41.0)         | 124 (59.9)      | 92 (47.2)         | 137 (66.2)       |
| PD                                               | 69 (35.4)         | 111 (53.6)      | 79 (40.5)         | 122 (58.9)       |
| Death                                            | 11 (5.6)          | 13 (6.3)        | 13 (6.7)          | 15 (7.2)         |
| Patients Censored, n (%)                         | 115 (59.0)        | 83 (40.1)       | 103 (52.8)        | 70 (33.8)        |
| NoAdequatePost-BaselineResponseAssessment        | 3 (1.5)           | 6 (2.9)         | 3 (1.5)           | 6 (2.9)          |
| Documented Treatment Discontinuation and Reasons | 73 (37.4)         | 41 (19.8)       | 77 (39.5)         | 48 (23.2)        |
| PDperInvestigatorAssessment                      | 0                 | 1 (0.5)         | 0                 | 1 (0.5)          |
| Withdrawal byPatient                             | 35 (17.9)         | 16 (7.7)        | 35 (17.9)         | 19 (9.2)         |
| Adverse Event                                    | 31 (15.9)         | 20 (9.7)        | 31 (15.9)         | 23 (11.1)        |
| Physician Decision                               | 7 (3.6)           | 4 (1.9)         | 10 (5.1)          | 4 (1.9)          |
| Lost to Follow-up                                | 2 (1.0)           | 2 (1.0)         | 1 (0.5) 3 (1.5)   | 1 (0.5) 2 (1.0)  |
| Database Cut                                     | 37 (19.0)         | 34 (16.4)       | 20 (10.3)         | 14 (6.8)         |
| MedianFollow-upTime (Months)                     | 13.17             | 16.53           | 13.47             | 24.48            |
| IN%S6                                            | (10.64, 15.34)    | (14.39, 17.71)  | (10.64, 24.87)    | (21.16, 29.17)   |
| Progression-FreeSurvival(Months)                 |                   |                 |                   |                  |
| Median                                           | 13.93             | 9.46            | 13.24             | 9.46             |
| 1 %S6                                            | (11.73, NE)       | (8.11, 10.78)   | (11.73, 23.43)    | (8.11, 10.78)    |
| StratifiedLog-rankTest?                          |                   |                 |                   |                  |
| One Sided P-value                                | 0.0075            | 0.0075          | 0.0064            | 0.0064           |
| Hazard Ratio ab                                  | 0.7020            | 0.7020          | 0.7096            | 0.7096           |
| 95% CI                                           | (0.5279,0.9335)   | (0.5279,0.9335) | (0.5417,0.9296)   | (0.5417,0.9296)  |
| SupremumTestforProportionalsHazards Assumption   | 0.6520            | 0.6520          | 0.7020            | 0.7020           |

Source: Table 14.2.1.1.1.1 and Table 14.2.1.1.1.1\\_updated

aStratifiedforpriorproteasome inhibitor therapies,numberof prioranti-MMregimens andR-ISSStageatstudy entry.

CI=confidence interval;IRC=independentreview committee; MM=multiple myeloma;NE=not evaluable;PD=progressive disease;R-ISS=Revised International Staging System; SVd=selinexor plus bortezomib plus lowdose dexamethasone; Vd=bortezomib plus low-dose dexamethasone.Note:Progression-free survival is calculated from date of randomization until thefirstdateof IRC-confirmedPDperInternational Myeloma Working Groupresponse criteria,or death due to any cause,whichever occursfirst.

bBasedonstratifiedCoxProportionalHazardmodelwithEfron'sMethodofhandling ties.

Data are similar to the previously reported.

<div style=\"page-break-after: always\"></div>

Figure 4. Kaplan-Meier Curve of Progression-free Survival by Treatment Based per IRC Assessment - Study KCP-330-023/BOSTON - ITT Population Primary Analysis (A)

<!-- image -->

Source: Module 5.3.5.1, KCP-330-023 CSR, Figure 14.2.1.1.1.1 Data cut-off date: 18 Feb 2020.

IRC=independent review committee; SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone.

Note: Progression-free survival is calculated from date of randomization until the first date of IRC-confirmed progressive disease per International Myeloma Working Group response criteria, or death due to any cause, whichever occurred first.

## Updated  Analysis (B)

## With Number of Subjects at Risk

<!-- image -->

HR=hazard ratio; PFS=progression-free survival; IRC=independent review committee; SVd=selinexor plus bortezomib plus

low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone. Note: Progression-free survival is calculated from date of randomization until the first date of IRC-confirmed progressive disease per International Myeloma Working Group response criteria, or death due to any cause, whichever occurred first.

Data cut-off date updated: 15 February 2021

## Additional Sensitivity Analyses and Supportive Analyses for primary endpoint-PFS

Modifications of the primary PFS endpoint analysis were used for sensitivity analyses.

A sensitivity analysis in which patients with PD or death after 2 or more missed visits were censored was performed, confirming the results from the primary analysis. The median PFS was 15.21 months (95%

<div style=\"page-break-after: always\"></div>

CI: 11.76, NE) in the SVd arm and 9.46 months (95% CI: 8.11, 10.78) in the Vd arm (stratified logrank test: p=0.0042)

Similar improvement in PFS was noted when patients were not censored at treatment discontinuation: the median PFS was 13.24 months (95% CI: 10.28, NE) in the SVd arm and 9.46 months (95% CI: 8.11, 10.78) in the Vd arm (stratified log-rank test: 0.0086).

When initiation of non-study antineoplastic therapy was also counted as an event, results similar to the results of the primary analysis were obtained: the median PFS was 13.24 months (95% CI: 10.28, NE) in  the  SVd  arm  and  9.43  months  (95%  CI:  7.62,  10.71)  in  the  Vd  arm  (stratified  log  rank  test: p=0.0097).

Similar results were obtained when clinical progression (i.e., PD not confirmed by IRC) was also counted as an event: the median PFS was 13.93 months (95% CI: 11.73, NE) in the SVd arm and 9.46 months (95% CI: 8.11, 10.78) in the Vd arm (stratified logrank test: p=0.0075). When the date of IRC-confirmed PD at an unscheduled visit was changed to the next scheduled visit: the median PFS was 13.40 months (95% CI: 11.76, NE) in the SVd arm and 9.46 months (95% CI: 8.21, 10.78) in the Vd arm (stratified log-rank test: p=0.0069). If the confirmation of PD was based on the Investigator's assessment instead of the IRC's assessment, the median PFS was 13.93 months (95% CI: 11.73, NE) in the SVd arm and 9.46 months (95% CI: 8.44, 11.89) in the Vd arm (stratified log-rank test: p=0.0171).

The improvement in PFS in the SVd arm was maintained during all the different sensitivity analyses. However, when treatment discontinuation for any reason was counted as a PFS event, there were no major differences between treatment arms: the median PFS was 6.70 months (95% CI: 5.75, 7.66) in the SVd arm and 6.97 months (95% CI: 5.78, 8.34) in the Vd arm (stratified log-rank test: p=0.3325).

Importantly, the ORRs for patients who discontinued without reaching a PFS event were similar to the ORR in the entire SVd arm, and higher in the SVd arm (N=78, ORR=76.9%) as compared with the Vd arm (N=49, ORR=63.3%); these differences were similar to the overall ORRs in the SVd and Vd for the entire study.

Figure 5. PFS Sensitivity Analyses

|                                                                       | Median PFS and 95% CI (Months)   | Median PFS and 95% CI (Months)   | Stratified Log- rank   |
|-----------------------------------------------------------------------|----------------------------------|----------------------------------|------------------------|
| PFS analysis                                                          | SVd                              | PA                               | p-value                |
| Primary analysis, median (months)                                     | 13.93 (11.73, NE)                | 9.46 (8.11, 10.78)               | 0.0075                 |
| Sensitivity analyses                                                  |                                  |                                  |                        |
| Patients with PD or death after 2 or more missed visits were censored | 15.21 (11.76, NE)                | 9.46 (8.11, 10.78)               | 0.0042                 |
| Initiation of non-study antineoplastic therapy counted as an event    | 13.24 (10.28, NE)                | 9.43 (7.62, 10.71)               | 0.0097                 |

Source: Table 14.2.1.1.1.1, Table 14.2.1.1.1.3, Table 14.2.1.1.1.5. CI=confidence interval; NE=not evaluable; PD=progressive  disease;  PFS=progression-free  survival;  SVd=Selinexor  plus  bortezomib  plus  low-dose  dexamethasone; Vd=bortezomib plus low-dose dexamethasone.

<div style=\"page-break-after: always\"></div>

## Subgroup analysis

Subgroup analyses indicated that the treatment effect on PFS was consistent regardless of age, gender, number of prior lines of anti-MM therapy, stem cell transplant, presence of a high-risk chromosomal abnormality, level of renal function, frail versus fit, and baseline ECOG PS.

Importantly, marked differences were noted in patients without prior PI treatment (n=95), where there was a significant ~74% reduction (HR=0.2585; 95% CI, 0.1116-0.5988) in progression or death with SVd (median PFS not yet reached) versus Vd (median PFS: 9.69 months).

In patients with impaired renal functio n (creatinine clearance: 30 to 60 mL/min), the median PFS was 16.62 months (95% CI: 7.95, NE) in the SVd arm (n=53) versus 7.26 months (95% CI: 5.09, 14.13) in the Vd arm (n=60) (stratified log-rank test: p=0.0083). The hazard ratio was 0.4903 (95% CI: 0.2705, 0.8889).

The  subgroup  of  patients  with  creatinine  clearance  of  &lt;30  mL/min  was  too  small  for  a  meaningful analysis (n=13 in total).

Overall, the results of the subgroup analyses suggest that the prolongations of PFS demonstrated with SVd regimen compared with Vd in the overall study population was similar in all subgroups studied.

<div style=\"page-break-after: always\"></div>

Figure 6. Forest Plot of Hazard Ratio (SVd vs Vd) for Progression-free Survival Based on IRC Assessment by Subgroup (Intent-to-Treat Population)

Source: Figure 14.2.3.1.1.1. ECOG=Eastern Cooperative Oncology Group, MM=multiple myeloma; PI=proteasome inhibitor; R-ISS=Revised  International  Staging  System  Stage;  SVd=selinexor  plus  bortezomib  plus  low-dose  dexamethasone; Vd=bortezomib plus  low-dose dexamethasone.   Region  1: Canada,  USA;  Region  2:  Australia,  Austria,  Belgium,  France, Germany, Israel, Italy, Spain, UK; Region 3: Czech Republic, Greece, Hungary, Poland; Region 4: Bulgaria, India, Romania, Russian Federation, Serbia, Ukraine. Note: Please refer to Table 14.2.3.1.1.1 for exact number of hazard ratio and the 95% confidence interval. Note: Analysis based on Cox Proportional Hazard model with Efron method of handling ties.

<!-- image -->

## PFS Regarding prior SCT

Median PFS (mPFS; months) based on IRC assessment in the SVd arm was similar in patients with (13.14; 95% CI: 9.59, NE) and without a prior SCT (13.24; 95% CI: 10.18, 23.43) ( Table 10 ).

<div style=\"page-break-after: always\"></div>

Table 10: PFS Based on IRC Assessment by Treatment Arm and Prior SCT (All Patients in the Intent-to-Treat Population)

|                            | Prior SCT        | Prior SCT       | No Prior SCT      | No Prior SCT     |
|----------------------------|------------------|-----------------|-------------------|------------------|
|                            | SVd Arm (N = 76) | Vd Arm (N = 63) | SVd Arm (N = 119) | Vd Arm (N = 144) |
| Patients with Events, n(%) | 33 (43.4)        | 39 (61.9)       | 59 (49.6)         | 98 (68.1)        |
| PD                         | 30 (39.5)        | 39 (61.9)       | 49 (41.2)         | 83 (57.6)        |
| Death                      | 3 (3.9)          | 0               | 10 (8.4)          | 15 (10.4)        |
| PFS (Months)               |                  |                 |                   |                  |
| 50th Percentile            | 13.14            | 9.43            | 13.24             | 9.56             |
| 95% CI                     | (9.59, NE)       | (5.91, 10.87)   | (10.18, 23.43)    | (8.11, 13.60)    |
| Log-rank Test              |                  |                 |                   |                  |
| 1-Sided p-value            | 0.0074           |                 | 0.0293            |                  |
| Hazard Ratio (HR)          | 0.5645           |                 | 0.7325            |                  |
| 95% CI                     | (0.3546, 0.8986) |                 | (0.5301, 1.0121)  |                  |

Source: Table 14.4.1.3.1.

## Secondary Efficacy Endpoints

## Overall Response Rate

The primary analysis showed a higher ORR in the SVd arm than in the Vd arm based on IRC-determined ORR (i.e., the proportion of patients who achieved a partial response or better before IRC confirmed PD, initiated a new MM treatment or crossover).

The ORR was 76.4% (95% CI: 69.8, 82.2) (149 of 195 patients) in the SVd arm and 62.3% (95% CI: 55.3, 68.9) (129 of 207 patients) in the Vd arm. The stratified Cochran-Mantel-Haenszel test confirmed the statistical significance of the ORR improvement in the SVd arm over the Vd arm (odds ratio: 1.9626; 95% CI; 1.2641, 3.0471; p=0.0012).

The ≥ VGPR rates were 44.6% and 32.4% (p=0.0082), and the rates of CR/sCR were 7.2%/9.7% and 4.3%/6.3% in the SVd and Vd arms, respectively (one-sided p=0.0373 for rates of CR or sCR between the SVd and Vd arms). Importantly, 9 of 33 patients with sCR or CR from the SVd arm and 8 of 22 patients with sCR or CR from the Vd arm were assessed as MRD negative.

<div style=\"page-break-after: always\"></div>

## Table 25. Overall Response Rate Based on IRC Assessment by Treatment Arm (Intent-ToTreat Population)

-UpdatedAnalysisDcodate15Feb2021

|                                        | SVd Arm (N=195)                        | Vd Arm (N=207)                         |                                         | SVd Arm (N=195)         | Vd Arm (N=207)          |
|----------------------------------------|----------------------------------------|----------------------------------------|-----------------------------------------|-------------------------|-------------------------|
| Overall Response Rate, n(%)*           | 149 (76.4)                             | 129 (02.3)                             | Overall Response Rate, n (%)a           | 150 (76.9)              | 131 (63.3)              |
| Exact 95% CI                           | (69.8, 82.2)                           | (55.3, 68.9)                           | Exact 95% CI                            | (70.4, 82.0)            |                         |
| Cochran-Mantel-HaenszelTest(SVdvs.Vd)b | Cochran-Mantel-HaenszelTest(SVdvs.Vd)b | Cochran-Mantel-HaenszelTest(SVdvs.Vd)b |                                         |                         | (56.3, 69.9)            |
| Odds Ratio (95% CI)                    | 1.96 (1.26, 3.05)                      | 1.96 (1.26, 3.05)                      | Cochran-Mantel-Haenszel Test(SVd vs.Vd) |                         |                         |
| One Sided P-value                      | 0.0012                                 | 0.0012                                 | Odds Ratio (95% CI)                     | 1.9441 (1.2468, 3.0314) | 1.9441 (1.2468, 3.0314) |
| Breslow-Day Test for Homogeneity       |                                        |                                        | One Sided P-value                       | 0.0016                  | 0.0016                  |
| P-value                                | 0.2430                                 | 0.2430                                 | Breslow-DayTestforHomogeneity           |                         |                         |
| Best Overall Response, n(%)            |                                        |                                        | P-value                                 | 0.4154                  |                         |
| StringentCompleteResponse              | 19 (9.7)                               | 13 (6.3)                               | Best Overall Response, n(%)             |                         |                         |
| Exact 95% CI                           | (6.0, 14.8)                            | (3.4, 10.5)                            |                                         |                         |                         |
| Complete Response                      | 14 (7.2)                               | 9 (4.3)                                | Stringent Complete Response             | 19 (9.7)                | 13 (6.3)                |
| Exact 95% CI                           | (4.0, 11.8)                            | (2.0, 8.1)                             | Exact 95% CI                            | (6.0, 14.8)             | (3.4, 10.5)             |
| ≥VeryGoodPartialResponse               | 87 (44.6)                              | 67 (32.4)                              | Complete Response                       | 14 (7.2)                | 9 (4.3)                 |
| Exact 95% CI                           | (37.5, 51.9)                           | (26.0, 39.2)                           | Exact 95% CI                            | (4.0, 11.8)             | (2.0, 8.1)              |
| Very Good Partial Response             | 54 (27.7)                              | 45 (21.7)                              | Very Good Partial Response              | 54 (27.7)               | 45 (21.7)               |
| Exact 95% CI                           | (21.5,34.5)                            | (16.3,28.0)                            | Exact 95% CI                            | (21.5, 34.5)            | (16.3, 28.0)            |
| Partial Response                       | 62 (31.8)                              | 62 (30.0)                              | Partial Response                        | 63 (32.3)               | 64 (30.9)               |
| Exact 95% CI                           | (25.3, 38.8)                           | (23.8, 36.7)                           |                                         |                         |                         |
| Minimal Response                       | 16 (8.2)                               | 20 (9.7)                               | Exact 95% CI                            | (25.8, 39.4)            | (24.7, 37.7)            |
| Exact 95%CI                            | (4.8, 13.0)                            | (6.0, 14.5)                            | Minimal Response                        | 15 (7.7)                | 18 (8.7)                |
| StableDisease                          | 25 (12.8)                              | 40 (19.3)                              | Exact 95% CI                            | (4.4, 12.4)             | (5.2,13.4)              |
| Exact 95%CI                            | (8.5, 18.3)                            | (14.2, 25.4)                           | StableDisease                           | 25 (12.8)               | 40 (19.3)               |
| PD                                     | 1 (0.5)                                | 10 (4.8)                               | Exact 95% CI                            | (8.5, 18.3)             | (14.2, 25.4)            |
| Exact 95% CI                           | (0.0, 2.8)                             | (2.3, 8.7)                             | PD                                      | 1 (0.5)                 | 10 (4.8)                |
| Not Evaluable                          | 4 (2.1)                                | 8 (3.9)                                |                                         |                         |                         |
| Exact 95% CI                           | (0.6, 5.2)                             | (1.7,7.5)                              | Exact 95% CI                            | (0.0, 2.8)              | (2.3, 8.7)              |
| MRDnegative                            | 9 (4.0)                                | 8 (3.9)                                | Not Evaluable                           | 4 (2.1)                 | 8 (3.9)                 |
| Exact95%CI                             | (2.1,8.0)                              | (1.7, 7.5)                             | Exact 95% CI                            | (0.6, 5.2)              | (1.7, 7.5)              |

Source:Table14.2.2.1.1.1,Table 14.2.2.2.1.1，Table 14.2.2.2.1.2andupadted.CI=confidence interval;IRC=Independent Review Committee;MM=multiple myeloma;MRD=minimal residual disease;PI= proteasome inhibitors;R-ISS=RevisedInternationalStagingSystem;SVd=selinexorplusbortezomibpluslow-dose dexamethasone;Vd=bortezomibpluslow-dose dexamethasone.aOverallresponserateistheproportionof patients who achieve a partialresponse or better,before IRC-confirmedPD or initiating a new MMtreatment or crossover.bAnalysis using Cochran-Mantel-Haenszel test stratified byprior PI therapies, number of prior anti-MMregimens,andR-ISSstageatscreening.cMRDwasassessedforpatientswhoachievedCRorSCR.

## Additional Sensitivity Analyses and Supportive Analyses for ORR

A sensitivity analysis that considered the patients who did not complete at least 2 scheduled postC1D1 MM evaluations as non-responders led to similar results as the above analysis.

ORRs based on Investigator assessments instead of IRC assessments were also similar: the stratified Cochran-Mantel-Haenszel test showed that the ORR based on Investigator assessments was markedly higher in the SVd arm (76.9%) than in the Vd arm (63.8%) in the Vd arm (odds ratio: 1.8799; 95% CI; 1.2075, 2.9265; p=0.0023).

Of note, only 1 patient (0.5%) in the SVd arm had PD as their best response, as compared with 10 patients (4.8%) in the Vd arm.

## Subgroup Analyses

Subgroup analyses demonstrate that ORR differences between the SVd arm compared to the Vd arm in the overall study population was similar in all subgroups studied.

<div style=\"page-break-after: always\"></div>

## Table 26. Forest Plot of Odds Ratio (SVd vs Vd) for Overall Response Rate Based on IRC Assessment By Subgroup (Intent To-Treat Population)

<!-- image -->

ECOG=Eastern  Cooperative  Oncology  Group,  MM=multiple  myeloma;  PI=proteasome  inhibitor;  R-ISS=The  Revised International Staging System Stage; SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone. Note: Refer to Table 14.2.3.1.1.2 for exact number of odds ratio and the 95% confidence interval.

Rate of Very Good Partial Responses or Better Responses

<div style=\"page-break-after: always\"></div>

In the primary analysis , VGPR, CR, or sCR was observed in 87 (44.6%) of 195 patients from the SVd arm and 67 (32.4%) of 207 patients from the Vd arm (odds ratio: 1.6594; 95% CI: 1.0993, 2.5049; p=0.0082; Cochran-Mantel-Haenszel test [SVd arm versus Vd arm]).

Overall, the results of the subgroup a nalyses suggest that the increased ≥VGPR rates demonstrated with SVd compared with Vd in the overall study population were similar in all subgroups studied.

There were no changes in the ≥VGPR rate in the updated analysis compared to the primary analysis. A VGPR, CR, or sCR was observed in 87 (44.6%) of 195 patients from the SVd arm and 67 (32.4%) of 207 patients from the Vd arm (odds ratio: 1.6594; 95% CI: 1.0993, 2.5049; p=0.0082; Cochran-MantelHaenszel test [SVd arm versus Vd arm]).

## Overall Survival

Median OS was not reached for SVd at the time of the primary analysis, with 24.1% to 30.0% of death events having occurred in the SVd and Vd arms, respectively. At a median follow-up of 17.5 months , the median OS for patients in the Vd arm was 24.97 months (95% CI: 23.49, NE). At a median followup of 17.3 months , the median OS for patients in the SVd arm was not reached.

Seventy-four (36%) patients from the Vd arm crossed over after confirmed PD to receive a regimen that included selinexor (SVdX or SdX).

Table 27. Overall Survival by Treatment Arm (Intent-To-Treat Population)

-Primary Analysis-Updated Analysis (DCOD18Feb2020) (DCOD 15Feb2021)

| Patients with Events, n (%)                   | SVdArm (N=195)   | Vd Arm (N=207)   | SVd Arm (N=195)   | Vd Arm (N=207)   |
|-----------------------------------------------|------------------|------------------|-------------------|------------------|
| Death                                         | 47 (24.1)        | 62 (30.0)        | 68 (34.9)         | 80 (38.6)        |
| Patients Censored, n (%)                      | 148 (75.9)       | 145 (70.0)       | 127 (65.1)        | 127 (61.4)       |
| StudyDiscontinuationdueto                     | 39 (20.0)        | 38 (18.4)        | 42 (21.5)         | 42 (20.3)        |
| Patient Withdrawal                            | 37 (19.0)        | 37 (17.9)        | 39 (20.0)         | 41 (19.8)        |
| Other                                         | 2 (1.0)          | 1 (0.5)          | 3 (1.5)           | 1 (0.5)          |
| Lost to Follow-up                             | 7 (3.6)          | 6 (2.9)          | 12 (6.2)          | 7 (3.4)          |
| Database Cut                                  | 102 (52.3)       | 101 (48.8)       | 73 (37.4)         | 78 (37.7)        |
| MedianFollow-upTime (Months)                  | 17.28            | 17.51            | 28.71             | 28.65            |
| I %56                                         | (16.56, 18.27)   | (17.08, 18.23)   | (27.24, 29.90)    | (27.63, 29.67)   |
| Overall Survival (Months)                     |                  |                  |                   |                  |
| Median                                        | NE               | 24.97            | 36.67             | 32.76            |
| ID %S6                                        | (NE, NE)         | (23.49, NE)      | (30.19, NE)       | (27.83, NE)      |
| Stratifiedlog-ranktest                        |                  |                  |                   |                  |
| OneSided P-value                              | 0.1852           | 0.1852           | 0.2152            | 0.2152           |
| Hazard Ratio ab                               | 0.84             | 0.84             | 0.8764            | 0.8764           |
| ID %56                                        | (0.57, 1.23)     | (0.57, 1.23)     | (0.6313,1.2168)   | (0.6313,1.2168)  |
| SupremumTestforProportionalsHazardsAssumption | 0.8330           | 0.8330           | 0.8350            | 0.8350           |

Source: Table 14.2.2.3.1.1, Table 14.2.2.3.1.2 and \\_updated..CI=confidence interval; MM=multiple myeloma; NE=not evaluable; PI=proteasome  inhibitors;  R-ISS=Revised  International  Staging  System;  SVd=selinexor  plus  bortezomib  plus  low-dose  dexamethasone; Vd=bortezomib plus low-dose dexamethasone. Note: Overall survival is calculated from date of randomization to date of death. Patients without events were censored at the date of study discontinuation or date of last participating visit, whichever occurred first. a  Stratified for prior PI therapies, number of prior anti-MM regimens and R-ISS Stage at screening. b  Based on stratified Cox Proportional Hazard model with Efron's Method of handling ties.

Figure 7. Kaplan-Meier Curve of Overall Survival by Treatment Arm (Intent-to-Treat Population)

<div style=\"page-break-after: always\"></div>

## - Primary Analysis

<!-- image -->

Source: Figure 14.2.2.3.1.1.

## - Updated Analysis

<!-- image -->

Source: Figure 14.2.2.3.1.1\\_updated. Data cut-off date: 15 Feb 2021. CI=confidence interval; mOS=median overall survival; SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone. Note: Overall survival was calculated from date of randomization to date of death. Patients without events were censored at the date of study discontinuation or date of last participating visit, whichever occurred first.

<div style=\"page-break-after: always\"></div>

Figure 8. Forest Plot of Overall Survival Hazard Ratios (Intent-to-Treat Population)

<!-- image -->

Source: Figure 14.2.3.1.1.4. Data cut-off date: 18 Feb 2020. MM=multiple myeloma; PI=proteasome inhibitor; R-ISS: The Revised International Staging System Stage;SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus  low-dose  dexamethasone.Note:  Please  refer  to  Table  14.2.3.1.1.4  for  exact  number  of  hazard  ratio  and  the  95% confidence interval.

With a longer follow-up, at the time of the updated analysis (15 Feb 2021), the median OS was 36.67 (95% CI: 30.19, NE) months in the SVd arm and 32.76 (95 CI: 27.83, NE) months in the Vd arm, what is translated to a median improvement of approximately 4 months in patients treated with selinexor.

Futher updated OS data , with a data cut-off of 22 March 2022, were provided. As of 22 March 2022, there were a total of 74 (37.9%) and 83 (40.1%) deaths in the SVd and Vd arms, respectively. Based on these data, OS was overall consistent with the previous data cut and there was no detrimental effect of SVd in terms of OS. Bearing in mind that cross-over was allowed in the BOSTON study,a 2stage estimation method accounting for cross-over effect on OS was conducted with the 22 March 2022 data cut, reporting a switch-adjusted HR for OS of 0.88 (95%C CI: 0.64, 1.22).

<div style=\"page-break-after: always\"></div>

Overall Survival By Treatment Arm - Intent-To-Treat Population (22 March 2022)

|                                                    | SVd Arm (N = 195)            | Vd Am (N = 207)              |
|----------------------------------------------------|------------------------------|------------------------------|
| Patients with Events, n(%)                         |                              |                              |
| Death                                              | 74 ( 37.9)                   | 83 ( 40.1)                   |
| Patients Censored, n(%)                            | 121 (62.1)                   | 124 ( 59.9)                  |
| Study Discontinuation due to                       | 107 ( 54.9)                  | 115 ( 55.6)                  |
| Patient Withdrawal                                 | 39 ( 20.0)                   | 43 ( 20.8)                   |
| Other                                              | 68 (34.9)                    | 72 ( 34.8)                   |
| Lost to Follow-up                                  | 13( 6.7)                     | 8(3.9)                       |
| Database Cut                                       | 1(0.5)                       | 1( 0.5)                      |
| Median Follow-up Time (Months)                     | 33.61                        | 33.84                        |
| 95% CI                                             |                              | (32.26, 35.19)(32.92, 35.71) |
| Overall Survival (Months)                          |                              |                              |
| 25th Percentile                                    | 16.59                        | 14.72                        |
| 95% CI                                             | (13.93, 22.87)(11.10, 17.45) |                              |
| 50th Percentile                                    | 36.67                        | NE                           |
| 95% CI                                             | (31.74, NE)                  | (26.91, NE)                  |
| 75th Percentile                                    | NE                           | NE                           |
| 95% CI                                             | (NE, NE)                     | (NE, NE)                     |
| Stratified log-rank test [1]                       |                              |                              |
| One Sided P-value                                  | 0.3167                       |                              |
| Hazard Ratio [1] [2]                               | 0.9257                       |                              |
| 10 %56                                             | (0.6738,                     |                              |
|                                                    | 1.2719)                      |                              |
| Supremum Test for Proportionals Hazards Assumption | 0.6120                       |                              |

(Database Cutoff Date: 2022-03-22)

CI=Confidence Interval.

Note: Overall survival is calculated from date of randomization to date of death. Patients without events were censored at the date of study discontinuation or date of last participating visit, whichever occurred first.

[1] Stratified for prior PI therapies, number of prior anti-MM regimens and R-ISS Stage at screening.

[2] Based on stratified Cox Proportional Hazard model with Efron's Method of handling ties.

<div style=\"page-break-after: always\"></div>

Figure 9: Kaplan-Meier Curve of Overall Survival by Treatment Arm for the Intent-toTreat Population (15 February 2021 and 22 March 2022)

<!-- image -->

## Overall Survival Sensitivity Analysis

Of the 207 Vd-treated patients in the ITT population, 111 (53.6%) patients had PD.

Of these patients who had PD, 74 (66.7%) patients crossed over to SVdX or SdX.

The median duration from PD to cross over was 43 days with 97.3% switching within 4 months. A switchadjusted HR based on the two-stage estimation method (Latimer 2017, Latimer 2018) comparing overall survival  on  SVd  versus  Vd  at  any  point  in  the  study  was  0.77  (95%  CI:  0.52,  1.14).  On  average, treatment with SVd over the trial produced an estimated approximately 23% lower risk of death. The 27-month survival rate based on Kaplan-Meier estimates was 45% and 63% for the Vd arm and SVd arm, respectively.

The two-stage estimation method proceeded by using the PD time point as a secondary baseline for all Vd-treated patients and comparing post-progression survival in the Vd arm switchers and non-switchers based on a Weibull accelerated failure time model, adjusting for prognostic characteristics measured at baseline and the time of PD. The accelerated failure time model adjusted for age at enrollment (centered at the mean), number of ongoing medical history terms, number of adverse events of special interest, R-ISS stage, time of progression, physician experience with SVd (measured with number of SVd patient in a site), ECOG score, prior exposure, sensory component of EORTC QLQ-CIPN20, and number of prior anti-MM regimens. The acceleration factor from this model was used to adjust the observed survival times in Vdswitching patients to obtain counterfactual survival times.

A Cox proportional hazards regression model (stratified by R-ISS stage, prior PI therapy, and number of prior anti-MM regimens) was then fitted to the observed SVd arm survival times and the counterfactual Vd arm survival times to estimate a treatment switch-adjusted HR. The standard error of the log HR estimates  was  obtained  from  2,000  bootstrap  samples;  hence,  CI  and  p-value  were  based  on  a  tdistribution using normal distribution theory method with the bootstrapped standard error. The possible artificial reduction of survival times when the goal of treatment is to extend survival times precluded re-

<div style=\"page-break-after: always\"></div>

censoring in the sensitivity analysis using a two-stage estimation method. Likewise, beside the relatively small number of deaths and sample size, the artificial censoring of death when deaths are, in fact, known to have occurred favored a two-stage estimation method over inverse probability of censoring weight (IPCW; Robins 2000, Herman 2001) in the present context.

A switch-adjusted HR based on IPCW with weights trimmed at the 99th percentile was 0.86 (95% CI: 0.53, 1.40). The variables included in the model for IPCW were selected to cover domains of disease stage, functions, and tolerability.

## OS in patients with prior SCT

Median OS (mOS; months) in the SVd arm was not significantly different in patients with a prior SCT (36.67; 95% CI: 31.74, NE) than those without a prior SCT (31.41; 95% CI: 26.68, NE) (table 28).

Table 28: Overall Survival by Treatment Arm and Prior SCT (All Patients in the Intentto-Treat Population)

|                            | Prior SCT        | Prior SCT       | No Prior SCT      | No Prior SCT     |
|----------------------------|------------------|-----------------|-------------------|------------------|
|                            | SVd Arm (N = 76) | Vd Arm (N = 63) | SVd Arm (N = 119) | Vd Arm (N = 144) |
| Patients with Events, n(%) |                  |                 |                   |                  |
| Death                      | 25 (32.9)        | 22 (34.9)       | 43 (36.1)         | 58 (40.3)        |
| Overall Survival (Months)  |                  |                 |                   |                  |
| 50th Percentile            | 36.67            | NE              | 31.41             | 32.76            |
| 95% CI                     | (31.74, NE)      | (24.84, NE)     | (26.68, NE)       | (26.58, NE)      |
| Log-rank Test              |                  |                 |                   |                  |
| 1-Sided p-value            | 0.2777           |                 | 0.3842            |                  |
| Hazard Ratio (HR)          | 0.8421           |                 | 0.9427            |                  |
| 95% CI                     | (0.4745, 1.4942) |                 | (0.6354, 1.3987)  |                  |

Source: Table 14.4.1.3.2

## Duration of Response

The median DOR in patients with confirmed PR or better (i.e., the duration of the time interval between the first IRC-confirmed PR or better response and the first IRC-confirmed PD or death due to any cause, whichever occurred first), was 20.3 months (95% CI: 12.55, NE) in the SVd arm and 12.9 months (95% CI: 9.26, 15.77) in the Vd arm (p=0.1364, stratified log-rank test)

<div style=\"page-break-after: always\"></div>

Figure 10. Kaplan-Meier Curves of Duration of Response by Treatment Arm (Intent-to- Treat Population)

## - Primary Analysis

<!-- image -->

Source: Figure 14.2.2.4.1.1, Table 14.2.2.4.2.1. Data cut-off date: 18 Feb 2020.

## - Updated Analysis

<!-- image -->

With Number of Subjects at Risk

Source: Figure 14.2.2.4.1.1\\_updated. Data cut-off date: 15 Feb 2021.

SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone. Note: Duration of response (DOR) is defined for patients with a confirmed PR or better as the duration from the date of first IRCconfirmed PR or better to the date of first IRC-confirmed PD, or death due to any cause, whichever occurred first.

With a longer follow-up (updated analysis), the SVd arm continued to have a longer DOR compared to Vd arm. The median DOR in patients with confirmed PR or better, was 17.3 months (95% CI: 12.55, 26.25) in the SVd arm and 12.9 months (95% CI: 9.26, 15.77) in the Vd arm (p=0.1103, stratified log-rank test).

## Time to Next Treatment

A total of 69 (35.4%) patients in the SVd arm and 116 (56.0%) patients in the Vd arm received a new anti-MM treatment.

<div style=\"page-break-after: always\"></div>

The median TTNT (time between randomization and start of next anti-MM treatment or death) was 16.13 months in the SVd arm, which was markedly longer than the 10.84 months in the Vd arm (p=0.0012, stratified log-rank test.

Table 29. Time to Next Treatment by Treatment Arm (Intent-To-Treat Population)

|                                                                   | SVdArm (N=195)                                                    | Vd Arm (N=207)                                                    |
|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
| Patients with Events, n (%)                                       | 88 (45.1)                                                         | 135 (65.2)                                                        |
| New MM Treatment                                                  | 69 (35.4)                                                         | 116 (56.0)                                                        |
| Death                                                             | 19 (9.7)                                                          | 19 (9.2)                                                          |
| Patients Censored, n (%)                                          | 107 (54.9)                                                        | 72 (34.8)                                                         |
| StudyDiscontinuationdueto                                         | 32 (16.4)                                                         | 21 (10.1)                                                         |
| Patient Withdrawal                                                | 31 (15.9)                                                         | 20 (9.7)                                                          |
| Other                                                             | 1 (0.5)                                                           | 1 (0.5)                                                           |
| Lost to Follow-up                                                 | 7 (3.6)                                                           | 5 (2.4)                                                           |
| Database Cut                                                      | 68 (34.9)                                                         | 46 (22.2)                                                         |
| Time to Next Treatment (Months)                                   |                                                                   |                                                                   |
| Median                                                            | 16.13                                                             | 10.84                                                             |
| I%56                                                              | (13.93, NE)                                                       | (9.82, 13.40)                                                     |
| Stratified log-rank test?                                         |                                                                   |                                                                   |
| One Sided P-value                                                 | 0.0012                                                            | 0.0012                                                            |
| Hazard Ratio adb                                                  | 0.6587                                                            | 0.6587                                                            |
| ID%56                                                             | (0.5017, 0.8648)                                                  | (0.5017, 0.8648)                                                  |
| SupremumTestforProportionalsHazardsAssumption                     | 0.0640                                                            | 0.0640                                                            |
| Treatment-free Interval for Patients with New MM Treatment (Days) | Treatment-free Interval for Patients with New MM Treatment (Days) | Treatment-free Interval for Patients with New MM Treatment (Days) |
| N                                                                 | 69                                                                | 116                                                               |
| Median                                                            | 28.0                                                              | 14.0                                                              |
| Min, Max                                                          | 1,447                                                             | 1, 419                                                            |

Source: Table 14.2.2.7.1.1.CI=confidence interval; MM=multiple myeloma; NE=not evaluable; R-ISS=Revised International Staging System; SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone. Note: Time to next treatment was calculated from the date of randomization to the start of next anti-MM treatment or death, whichever occurred first. Patients without an event were censored at the date of discontinuation from the study or last participating visit or database cut-off date, whichever occurred first. a Stratified for prior PI therapies, number of prior of anti-MM regimens and R-ISS Stage at screening. ,b Based on stratified Cox Proportional Hazard model with Efron's Method of handling ties

<div style=\"page-break-after: always\"></div>

Table  30.  Kaplan-Meier  Curve  of  Time  to  Next  Treatment  by  Treatment;  Study  KCP-330023/BOSTON, ITT Population-Primary Analysis

<!-- image -->

Source: KCP-330-023 CSR, Figure 14.2.2.7.1.1. HR=hazard ratio; MM=multiple myeloma; SVd=selinexor plus bortezomib plus low-dose dexamethasone; TTNT= time to next treatment; Vd=bortezomib plus low-dose dexamethasone.

Note: Time to Next Treatment (TTNT) was calculated from the date of randomization to the start of next anti-MM treatment or death, whichever occurred first. Patients without an event is censored at the date of discontinuation from the study or last participating visit or database cutoff date, whichever occurred first.

## Time to Response

The median TTR was shorter in the SVd arm than in the Vd arm (1.41 versus 1.61 months, respectively; p&lt;0.0001, stratified log-rank test).

Table 31. Time to Response by Treatment Arm (Intent-To-Treat Population)

|                                                    | SVd Arm (N=195)   | Vd Arm (N=207)   |
|----------------------------------------------------|-------------------|------------------|
| Patients with an IRC-confirmed PR or Better, n(%6) | 149 (76.4)        | 129 (62.3)       |
| Time to Partial Response or Better (Months)        |                   |                  |
| Median                                             | 1.1               | 1.4              |
| Min, Max                                           | 1,5               | 0, 13            |
| Patients Censored, n(%6)                           | 46 (23.6)         | 78 (37.7)        |
| Tine to Response (Months)                          |                   |                  |
| Median                                             | 1.41              | 1.61             |
| 10 %56                                             | (1.35, 1.51)      | (1.51, 2.14)     |
| Stratified log-rank test                           |                   |                  |
| One Sided P-value                                  | <0.0001           | <0.0001          |
| Hazard Ratio ab                                    | 1.6712            | 1.6712           |
| 95% CI                                             | (1.3064, 2.1379)  | (1.3064, 2.1379) |
| Supremum Test for Proportionals Hazards Assumption | 0.3280            | 0.3280           |

Source: Table 14.2.2.8.1.1. CI=confidence interval;  IRC=independent  review  committee;  MM=multiple  myeloma; PD=progressive  disease;  PI=proteasome  inhibitors;  PR=partial  response;  R-ISS=Revised  International  Staging  System;

<div style=\"page-break-after: always\"></div>

SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone. Note: Time to Response (TTR) is calculated from the date of randomization to the date of first IRC-confirmed PR or better before IRCconfirmed PD or initiating a new MM treatment or crossover. Patients without an event are censored at the last disease assessment.

a Stratified for prior PI therapies, number of prior of anti-MM regimens and R-ISS Stage at screening. b Based on stratified Cox Proportional Hazard model with Efron's Method of handling ties.

## Quality of Life-Primary Analysis

For the primary analysis, patient-reported PN was assessed using the EORTC-QLQ-CIPN20 tool. Baseline CIPN20 severity was similar between the SVd and Vd arms in the ITT population on the sensory, motor, and autonomic symptom scales. Over the course of the study, a lower rate of change from baseline score was observed in the SVd arm compared with the Vd arm for the sensory scale (p=0.0038, indicating a lower sensory symptom burden) while scores were similar in both arms for the motor and autonomic scales.

For  sensory  PN,  patients in  the  Vd  arm  consistently  showed higher  symptom  scores  compared  with patients in the SVd arm. These differences were most pronounced during the first 169 days of the study when patients in the Vd arm were receiving BIW bortezomib compared with QW in the SVd arm. Similarly, based on the analysis of covariance model (adjusted for prior PI therapies, number of prior anti-MM regimens, R-ISS stage at screening, and baseline value of the subscale score), the adjusted mean change from baseline in EORTC QLQ CIPN20 scores at the target day (Day 106) was significantly lower in the SVd arm than in the Vd arm for sensory symptom scores (estimated mean treatment difference: 3.56; 95% CI: 6.99, 0.12; p=0.0423).

Health-related QoL domains of the EORTC-QLQ-C30 were included  as  exploratory  analyses.  At baseline, the measures were similar across the SVd and Vd arms. Over time, scores of the cognitive domain were lower for the SVd arm than the Vd arm (indicating worse functioning) whereas scores in the  SVd  arm  were  higher  for  the  social  domain  (indicating  improved  functioning)  while  no  major differences were observed for other functional domains.

For  the  symptom  domains  of  the  EORTC-QLQ-C30,  over  time,  scores  in  the  SVd  arm  were  higher (indicating worse symptoms) compared with the Vd arm for nausea/vomiting and decreased appetite. While fatigue scores in the SVd and Vd arms were similar for the first 3 months of treatment, scores trended  higher  (indicating  worse  symptoms)  in  the  SVd  arm  over  subsequent  cycles  of  treatment. Constipation scores for the SVd arm were also higher (indicating worse symptoms) compared with the Vd arm during the majority of the study. However, pain scores in the SVd arm were lower (indicating improved symptoms) compared with the Vd arm over the course of the study.

The initial reductions in pain scores observed during the first 60 days of the study (in both arms) are likely due to control of MM; this effect persisted in the SVd arm during the course of the study. No major differences were observed for other symptom domains.

## Response in Patients with Cytogenetic Abnormalities

Nearly half of the patients had high-risk cytogenetic abnormalities; 97 patients (49.7%) in the SVd arm and 95 patients (45.9%) in the Vd arm.

The median PFS in patients with any high-risk cytogenetic abnormality was 12.91 months on SVd versus 8.15  months  on  Vd  (one-sided  p-value=0.0192).  Similarly,  the  ORRs  were  77.3%  and  55.8%, respectively. The median OS was not reached for the SVd arm and was 23.5 months for the Vd arm.

Among patients with del[17p], the median PFS was 12.22 months (95% CI: 5.62, NE) in the SVd arm (n=21) compared to 5.91 months (95% CI: 2.04, 11.89) in the Vd arm (n=16), for a HR of 0.3762 (onesided p-value=0.0080).

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

Subgroup and sensitivity analysis have been described above.

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 32. Summary of Efficacy for trial KCP-330-023 (BOSTON Study)

| Title: A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM)   | Title: A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Title: A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                       | KCP-330-023/ BOSTON EudraCT: 2016-003957-14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | KCP-330-023/ BOSTON EudraCT: 2016-003957-14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Design                                                                                                                                                                                                                 | The BOSTON study is a Phase 3, 2-arm, global, randomized, active comparator- controlled, open-label, multicenter study which compared the efficacy, safety and Health Related-Quality of Life of SVd versus Vd in adult patients with RRMM who had received 1 to 3 prior anti-MM regimens. Patients were randomized in a 1:1 allocation, as follows: • SVd arm: selinexor (QW) + SC bortezomib (QW) + dexamethasone. • Vd arm: SC bortezomib (Cycles 1- 8 BIW, Cycles ≥9 QW) dexamethasone. Randomization was stratified based on: • Prior PI therapies (Yes or No). • Number of prior anti-MM regimens (1 versus >1). • Revised International Staging System (R-ISS) stage at study entry based on screening results (R-ISS Stage III versus R-ISS Stage I or II) (Palumbo 2016). Following confirmation of PD by the IRC, patients who received Vd were allowed to cross over to receive either SVd (i.e., the SVdX treatment arm) or | The BOSTON study is a Phase 3, 2-arm, global, randomized, active comparator- controlled, open-label, multicenter study which compared the efficacy, safety and Health Related-Quality of Life of SVd versus Vd in adult patients with RRMM who had received 1 to 3 prior anti-MM regimens. Patients were randomized in a 1:1 allocation, as follows: • SVd arm: selinexor (QW) + SC bortezomib (QW) + dexamethasone. • Vd arm: SC bortezomib (Cycles 1- 8 BIW, Cycles ≥9 QW) dexamethasone. Randomization was stratified based on: • Prior PI therapies (Yes or No). • Number of prior anti-MM regimens (1 versus >1). • Revised International Staging System (R-ISS) stage at study entry based on screening results (R-ISS Stage III versus R-ISS Stage I or II) (Palumbo 2016). Following confirmation of PD by the IRC, patients who received Vd were allowed to cross over to receive either SVd (i.e., the SVdX treatment arm) or |
| Design                                                                                                                                                                                                                 | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Study treatment (SVd, Vd, or crossover) was continued until PD was confirmed by the IRC, Investigator or patient decision to discontinue study treatment, pregnancy, unacceptable adverse events (AEs) or toxicity that could not be managed by supportive care, withdrawal of consent, death, or Sponsor decision to terminate the study. not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                           | Duration of Extension phase: Initiation of the study: First patient enrolled: First patient dosed: Last patient enrolled: Last patient Last patient                                                                                                                                 | dosed: last visit:                                                                                                                                                                                                                                                                  | not applicable December 2016 05-June-2017 07-June-2017 31-Jan-2019 05-Feb-2019 Patients still on treatment as of June 2021                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis                | Hypothesis testing will be used for the primary efficacy endpoint and for selected secondary efficacy endpoints in order to evaluate the superiority of SVd compared with Vd. No formal hypothesis testing will be used for other study data, such as demographics and safety data. | Hypothesis testing will be used for the primary efficacy endpoint and for selected secondary efficacy endpoints in order to evaluate the superiority of SVd compared with Vd. No formal hypothesis testing will be used for other study data, such as demographics and safety data. | Hypothesis testing will be used for the primary efficacy endpoint and for selected secondary efficacy endpoints in order to evaluate the superiority of SVd compared with Vd. No formal hypothesis testing will be used for other study data, such as demographics and safety data.                                                                                                                                                                                                  |
| Treatments groups         | SVd arm: selinexor + bortezomib (QW) dexamethasone                                                                                                                                                                                                                                  | SVd arm: selinexor + bortezomib (QW) dexamethasone                                                                                                                                                                                                                                  | + Selinexor will be given as a fixed oral 100 mg dose on Days 1, 8, 15, 22, and 29 of each 35- day cycle.  Bortezomib will be given at a dose of 1.3 mg/m 2 SC on Days 1, 8, 15, and 22 of each 35-day cycle.  Dexamethasone will be given as an oral 20 mg dose on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle. Cycles 1 through 8 (3-week [21-day] cycle)                                                                                                   |
|                           | Vd arm: bortezomib (Cycles 1-8 BIW, Cycles ≥9 [QW]) + dexamethasone                                                                                                                                                                                                                 | Vd arm: bortezomib (Cycles 1-8 BIW, Cycles ≥9 [QW]) + dexamethasone                                                                                                                                                                                                                 |  Bortezomib will be given at a dose of 1.3 mg/m 2 SC on Days 1, 4, 8, and 11 of each 21-day cycle.  Dexamethasone will be given as an oral 20-mg dose on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle. Cycles ≥ 9 ( 5-week [35-day] cycle)  Bortezomib will be given at a dose of 1.3 mg/m 2 SC on Days 1, 8, 15, and 22 of each 35-day cycle.  Dexamethasone will be given as an oral 20 mg dose on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle. |
|                           | SVdX arm selinexor + bortezomib (QW) +                                                                                                                                                                                                                                              | SVdX arm selinexor + bortezomib (QW) +                                                                                                                                                                                                                                              | Crossover patients return to Cycle 1 for SVd treatment                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                           | dexamethasone SdX Selinexor (QW) + dexamethasone                                                                                                                                                                                                                                    | dexamethasone SdX Selinexor (QW) + dexamethasone                                                                                                                                                                                                                                    | Selinexor will be given as a fixed oral 100 mg dose on Days 1, 8, 15, 22, and 29 of each 35- day cycle.  Dexamethasone will be given as an oral 20 mg dose on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.                                                                                                                                                                                                                                                     |
| Endpoints and definitions | Primary endpoint                                                                                                                                                                                                                                                                    | Progression Free Survival (PFS)                                                                                                                                                                                                                                                     | Defined as time from date of randomization until the first date of PD, per IMWG response criteria, or death due to any cause, whichever occurs first. For the purposes of PFS determination, PD will be determined by the IRC.                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                                                                    | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Overall Response Rate (ORR)                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Defined as any response ≥ PR based on the IRC's response outcome assessments, according to the IMWG response criteria. All changes in MM disease assessments will be based on baseline MM disease assessments prior randomization.                                                                                                                                                                                                                                                      | Defined as any response ≥ PR based on the IRC's response outcome assessments, according to the IMWG response criteria. All changes in MM disease assessments will be based on baseline MM disease assessments prior randomization.                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                    | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Response rates for responses ≥ VGPR                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Response rates at any time prior to PD or death due to any cause, for responses ≥ VGPR,                                                                                                                                                                                                                                                                                                                                                                                                 | Response rates at any time prior to PD or death due to any cause, for responses ≥ VGPR,                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                    | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Overall Survival (OS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | OS, defined as time to death or lost to follow-up, measured from the date of randomization until death due to any cause or                                                                                                                                                                                                                                                                                                                                                              | OS, defined as time to death or lost to follow-up, measured from the date of randomization until death due to any cause or                                                                                                                                                                                                                                                                                                                                                              |
|                                                                    | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Duration of Response (DOR)                                                                                                                                                                                                                                                                                                                                                                                                                                                              | until lost to follow-up, for all patients DOR, defined as the duration of time from first occurrence of response ≥ PR until the first date of PD or death, whichever occurs first                                                                                                                                                                                                                                                                                                       | until lost to follow-up, for all patients DOR, defined as the duration of time from first occurrence of response ≥ PR until the first date of PD or death, whichever occurs first                                                                                                                                                                                                                                                                                                       |
| Database lock (cut- off)                                           | 18-Feb-2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 18-Feb-2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 18-Feb-2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 18-Feb-2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Results and Analysis                                               | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Analysis description                                               | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis population and time point description                     | The ITT population consisted of all patients who are randomized to study treatment, regardless of whether or not they receive study treatment. The ITT population included patients who have discontinued study treatment due to toxicity or PD and patients who have died from any cause. This population has been used for primary analyses of efficacy. Patients were analyzed in the treatment arm to which they were randomized and strata assignment at the time of randomization | The ITT population consisted of all patients who are randomized to study treatment, regardless of whether or not they receive study treatment. The ITT population included patients who have discontinued study treatment due to toxicity or PD and patients who have died from any cause. This population has been used for primary analyses of efficacy. Patients were analyzed in the treatment arm to which they were randomized and strata assignment at the time of randomization | The ITT population consisted of all patients who are randomized to study treatment, regardless of whether or not they receive study treatment. The ITT population included patients who have discontinued study treatment due to toxicity or PD and patients who have died from any cause. This population has been used for primary analyses of efficacy. Patients were analyzed in the treatment arm to which they were randomized and strata assignment at the time of randomization | The ITT population consisted of all patients who are randomized to study treatment, regardless of whether or not they receive study treatment. The ITT population included patients who have discontinued study treatment due to toxicity or PD and patients who have died from any cause. This population has been used for primary analyses of efficacy. Patients were analyzed in the treatment arm to which they were randomized and strata assignment at the time of randomization |
| Effect estimate per comparison statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | SVd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Vd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison statistics and estimate variability | Number of patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Number of patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | n=195                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | n=207                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison statistics and estimate variability | Progression Free Survival (PFS) Hazard Ratio (95% CI) One-sided p-value                                                                                                                                                                                                                                                                                                                                                                                                                 | Progression Free Survival (PFS) Hazard Ratio (95% CI) One-sided p-value                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.70 (0.53, 0.93) 0.0075                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.70 (0.53, 0.93) 0.0075                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimate per comparison statistics and estimate variability | Median PFS in months (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Median PFS in months (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 13.9 (11.7, Not Reached)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 9.5 (8.1, 10.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison statistics and estimate variability | Overall Response rate (ORR),                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Overall Response rate (ORR),                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 149 (76.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 129 (62.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison statistics and estimate variability | 95% CI One-sided p-value sCR CR                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 95% CI One-sided p-value sCR CR                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (69.8, 82.2) 0.0012 19 (10) 14 (7) 54 (28) 62 (32) 87 (44.6)                                                                                                                                                                                                                                                                                                                                                                                                                            | (55.3, 68.9) 0.0012 13 (6) 9 (4) 45 (22) 62 (30)                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison statistics and estimate variability | VGPR PR ≥ VGPR Response Rate, 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                    | VGPR PR ≥ VGPR Response Rate, 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (37.5,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 67 (32.4) (26.0,                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison statistics and estimate variability | n(%) One-sided p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | n(%) One-sided p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 51.9) 0.0082                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 39.2) 0.0082                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| DoR Median months 95% CI      | 20.3 (12.55, NE)                       | 12.9 (9.26, 15.77)         |
|-------------------------------|----------------------------------------|----------------------------|
| OS n (%) Median months 95% CI | Not Reached (Not Reached, Not Reached) | 24.97 (23.49, Not Reached) |
| Notes                         | Notes                                  | Notes                      |

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable.

## Clinical studies in special populations

Table 33: Number of Subjects by Age Group in Controlled and Non-Controlled Trials

|                                          | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85 + (Older subjects number /total number)   |
|------------------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------------|
| Controlled Trials (KCP-330-023 only)     | 160/402                                           | 78/402                                            | 3/402                                            |
| Non Controlled Trials (KCP-330-017 only) | 19/42                                             | 1/42                                              | 0/42                                             |

## Supportive studies

The supportive STOMP study Arm 2 has been described in section 4.4.1.

## 2.4.3. Discussion on clinical efficacy

The MAH is submitting a Grouped Type II /Type IB variation for selinexor (Nexpovio).

The Type IB variation relates to the introduction of a new pack size (8 tablets per pack) for added convenience to patients for dose modification in the new intended treatment setting.

The Type II variation is aimed at extending the indication for Nexpovio to be used:

'in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy' .

In addition, results from the pivotal study in support of this application are intended to fulfil the Specific Obligation (SOB) in the context of the Conditional Marketing Authorisation (CMA) of Nexpovio (selinexor) which was granted on 26 March 2021.

This application is based on the efficacy results from the pivotal ongoing phase 3 KCP-330-023 (BOSTON) study and supported by the Phase 1b/2 KCP-330-017 (STOMP) study .

<div style=\"page-break-after: always\"></div>

## Dose finding - Dose response study

KCP-330-017  (STOMP) study  is  a  multicenter,  multi-arm,  open-label,  clinical  study  with  a  DoseEscalation (Phase 1) and an Expansion (Phase 2) to independently assess the MTD/RP2D, safety, and efficacy  in  patients  with  either  newly  diagnosed  MM  or  previously treated  MM.  The  study  includes 7 treatment arms.

Arm 2 of SVd (selinexor in combination with bortezomib and low-dose dexamethasone) was one of the combinations evaluated in STOMP study in patients with relapsed or refractory MM who had received at least one prior line of therapy. The primary endpoint of the phase 1 part was to establish MTD and define the RP2D dose. The primary endpoints of the Phase 2 include overall response rate (ORR), DOR, and clinical benefit rate (CBR).

Of the 42 patients treated on the SVd arm 40 patients were evaluable for efficacy. The ORR was 75% in patients with PI-nonrefractory MM (n = 20), while patients with PI-refractory MM (n= 20) had an ORR of 40%. As reported by the MAH, the PI-refractory population is a more pre-treated population (median of  6.5  previous  lines,  85%  of  patients  with  more  than  3  lines,  with  100%  of  patients  exposed  to lenalidomide  and  75%  of  refractory  to  lenalidomide  and/or  pomalidomide),  and  with  different characteristics from those proposed in the BOSTON study. Therefore, the 'BOSTON-like' population is the  non-PI  refractory  population  and  results  in  this  subset  of  patients  guided  next  steps  of  the development.

The RP2D of SVd in the STOMP study was established to be selinexor 100 mg QW and bortezomib 1.3 mg/m2 QW plus dexamethasone 40 mg QW. Selinexor 100 mg QW showed a response rate similar to selinexor 80 mg BW with a lower cumulative dose and expected lower toxicity. The rationale for selecting this dose appears adequate also given the efficacy results reported in the 'BOSTON-like' population (see above).

Of note, as concomitant therapy all patients must receive 5-HT3 antagonists (ondansetron or equivalent) during selinexor treatment. Additionally, it has been reported by the MAH that supportive measures for optimal medical care should be provided as appetite stimulants (megestrol acetate), centrally acting agents and NK1R antagonist, given the fact that the main side effects have been primarily related to anorexia  with  poor  caloric  and  fluid  intake,  fatigue,  and  nausea.  This  point  raises  concerns  about tolerability of the drug.

## Main clinical study

## Design and conduct

The KCP-330-023 (BOSTON) study is a confirmatory phase 3, open-label, 2-arm, randomized, active comparator-controlled, multicenter study that compares the efficacy and health-related quality of life (HR-QoL) and assesses the safety of selinexor plus bortezomib plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-MM regimens.

As noted above the dose/regimen of SVd was selected on the basis of results from the phase 2 study STOMP, i.e. the observed activity of the combination and safety and tolerability considerations. This regimen allows patients in the experimental arm to receive approximately 40% less bortezomib and approximately 25% less dexamethasone than patients in the Vd arm since Vd is given at different dose in the experimental and control arms of the BOSTON study. The design is considered acceptable, but it is  indeed  not  a  classical  add-on  study  with  the  same  backbone  in  both  treatments'  arms,  therefore preventing blinding which is a drawback of the current design.

The Vd regimen is still an acceptable option for patients with RRMM, although other options (such as lenalidomide  +  dexamethasone  or  carfilzomib  +  lenalidomide  +  dexamethasone  or  elotuzumab  +

<div style=\"page-break-after: always\"></div>

lenalidomide + dexamethasone) were approved for patients who have received at least one prior line of therapy, as well as pomalidomide + dexamethasone for those who have received at least two prior therapies, when the BOSTON study was planned. Indeed, although the control arm in the BOSTON study is an accepted standard of care, the room for improvement of response of a patient previously exposed to  bortezomib,  alone  or  in  combination  in  a  previous  first  line,  appears  limited  with  the  proposed combination and in fact Vd is usually considered as an option in later lines of treatment. In this context, the control arm in the BOSTON study can be considered, at present, as a suboptimal treatment option in the intended treatment setting. This having said it is acknowledged that the treatment landscape for MM patients is evolving quickly and demonstration of superiority vs. the proposed control arm should in principle suffice for regulatory approval.

A total of 402 patients were randomized in a 1:1 ratio to either SVd (n=195) or Vd (n=207). Three hundred ninety-nine subjects (SVd: 195, Vd: 204) received study treatment. At the time of the clinical cut-off date of 18 Feb 2020, 19% SVd subjects and 17.6% of Vd subjects were still on study treatment.

Randomization was stratified by prior PI therapy (yes or no), number of prior anti-MM regimens (1 versus &gt;1), and disease severity at study entry (based on the revised International Staging System [R-ISS]; Stage III versus Stage I or II). The 1:1 randomisation ratio is agreed, and the proposed stratification factors  are  considered  acceptable  as  they  represent  basal  characteristics  with  well-known  potential impact on clinical responses. Furthermore, taking into account that both SVd and Vd are expected to rely on conserved sensitivity to bortezomib, stratification based on prior exposure to PI is agreed. Region 2 guarantees representation of the target population in the EU.

Following  confirmation  of  progressive  disease  (PD)  by  the  Independent  Review  Committee  (IRC), patients who received Vd were allowed to cross over to receive either SVd (i.e. the SVdX treatment arm) or selinexor and low-dose dexamethasone (i.e. the SdX treatment arm) for those patients who were intolerant to bortezomib. The possibility offered to patients in the Vd arm to crossover to SVd appears reasonable also considering that there are some (preliminary) clinical data suggesting that selinexor is able to restore sensitivity to bortezomib. This was in fact agreed at the time when SA was sought. The generation of potential valuable information on the activity of SVd in patients resistant to bortezomib has however to be weighed against the potential impact of the crossover on the assessment of longterm time-dependent endpoints, especially OS which is a secondary endpoint in the BOSTON study. As discussed also during the SA, precise estimates of long-term OS in the targeted early stage of MM (1-3 prior lines) are not required for approval but rather the absence of a detrimental effect. This is so in view of  the  long-expected  survival  after  progression.  In  this  regard  the  MAH  has  conducted  several  OS sentivity analyses to account for the crossover. Further, the number of patients who crossed over is limited, and therefore not expected to have a major impact on the results of the study. The proposed rules for prevention of premature cross over are overall supported.

The MAH states that if PD is suspected but the IRC does not confirm PD, patients will either remain on study treatment until PD is confirmed by the IRC or discontinue study treatment, complete the End of Treatment (EoT) Visit, and be followed for survival. Upon request the MAH provided information that for the primary analysis, 3 patients (SVd n=2; Vd n=1) had only one progression as the last MM assessment and that at the time of the DCO date for the updated analysis, 5 patients (SVd n=3; Vd n= 2) had only 1 progression as the last MM assessment. The MAH confirmed that these eight patients were not counted as PFS events but censored.

The target population of the study is considered well represented. Overall, the proposed inclusion and exclusion  criteria  are  supported.  In  the  study  patients  were  included  based  on  investigator-based evidence of PD and had confirmed PD, i.e. they were required to have confirmed PD on or after their most recent regimen based on the Investigator's assessment (Inclusion Criterion #3).

<div style=\"page-break-after: always\"></div>

Regarding patient demographics, the median ages of the patients in BOSTON were 66 and 67 years in the SVd and Vd arms, respectively. The majority of the patients were 65 years of age or older (SVd, 55.9%; Vd, 63.8%) and ~20% were ≥75 years of age. More males were enrolled in the study t han females (males: SVd, 59.0%; Vd, 55.6%) and the race was predominantly white (SVd, 82.6%; Vd, 79.7%).

Patients with plasma cell leukemia, associated AL amyloidosis, CNS involvement or POEMS syndrome were excluded from trial participation to reduce heterogeneity. This has been reflected in the SmPC.

Approximately 50% of the patients had received 1 prior anti-MM therapy (SVd: 50.8%; Vd: 47.8%) with one-third having 2 prior regimens, and the remainder having 3 prior regimens for MM.

A slightly higher previous exposure to bortezomib-dexamethasone is reported in the Vd arm, although overall, bortezomib previous exposure was similar in both treatment arms. Bortezomib-refractoriness was numerically slightly higher in the Vd treatment arm, as well as Thalidomide refractoriness and IMiD refractoriness in general. Median previous treatment lines were 2 in the Vd arm, whereas in the SVd arm median previous lines of treatment was 1.The reported differences are generally small, and it is not considered that they can have a significant impact on the results.

Regarding refractoriness, bortezomib refractory patients were excluded. The following was required for patients  previously  treated  with  bortezomib  (inclusion  criteria):'Best  response  achieved  with  prior bortezomib at any time was ≥PR and with the last PI therapy (alone or in combination) was ≥PR AND participant did not discontinue bortezomib due to Grade ≥3 -related toxicity AND must have had at least a 6-month PI-treatment-free interval prior to C1D1 of study treatment.' All patients in the BOSTON study who had achieved a response to lines of prior therapy that included bortezomib had been treated with that therapy for at least 60 days and/or achieved a response to a bortezomib-containing therapy that lasted for &gt;60 days, with except one patient. This patient was previously exposed to bortezomib and achieved less that PR. However, bortezomib exposure was too short to consider refractoriness. Additionally, this patient was treated in the Vd arm achieving a VGPR, what is understood as bortezomib sensitivity.

Several patients in the BOSTON study received stem cell transplantation (SCT). It is assumed that only autologous stem cell transplant (ASCT) has been considered, as patients are in earlier lines of therapy. However, the uncertainty surrounding the allogeneic SCT and the impact it may have on subsequent treatments should be taken into account. In the 8 patients in whom the type of transplant is unknown, it cannot be assumed, in the absence of indirect data that would suggest so, that it was an autologous transplant. The MAH has provided additional information on these 8 patients with \"unspecified type of transplant', in terms of previous therapies and subsequent clinical outcomes. As per the reported data, an autologous STC transplant is the most likely procedure conducted in these patients. One out of these 8 patients achieved a PR after receiving selinexor in combination.

According to the current ESMO guideline, in MM for fit newly diagnosed MM (NDMM) patients, aged 70 years, without comorbidities, induction followed by high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) and lenalidomide maintenance is the recommended treatment. In this context, it is surprising that only 39% of the included patients have received an ASCT before entering the study, given that this treatment option is considered as a standard of care in newly diagnosed MM (NDMM) patients in many countries. The MAH reported that 33% of patients were &gt;70 years old at enrolment (at diagnosis 24% of patients were &gt;70 years old) and would generally not be considered for ASCT per the ESMO guidelines. The proportion of patients who received a previous transplant was higher in the study arm (SVd) than in the control arm (Vd). No relevant differences in efficacy among the two groups, with and without prior SCT, were however reported.

<div style=\"page-break-after: always\"></div>

In the SVd arm of the supportive study STOMP 7 out of 12 patients with PI-refractory MM responded (ORR 58%). These patients with PI-refractory MM are similar to the ones treated in the Vd Arm of the BOSTON study who will be given the opportunity to cross over to SVd. Since preliminary clinical data suggest that selinexor is able to restore sensitivity to bortezomib, this is acceptable and could provide additional valuable information on the activity of SVd in patients resistant to bortezomib.

As reported by the MAH, 63 patients from the Vd arm crossed-over to SVdX (regarding ITT population 111/207 Vd treated patients were reported as PD and 74 crossed-over: 11 crossed to SdX and 63 to SVdX). The ORR in these 63 patients under SVdX was 19% (3 patients (4.8%) achieved VGPR and 9 patients (14.3%) achieved a PR). Nine (14.3%) patients achieved a MR, 30 patients (47.6%) SD, 5 patients (7.9%) showed PD, and 7 patients (11.1%) were not evaluable. Median PFS in these 63 patients was 3.91 months (95% CI: 3.48 to 6.93). As of the database cut-off date (14 February 2021) the median (95% CI) duration of response in the SVdX population was 5.78 months (4.34, NE). Of the 11 patients in  the  SdX  population,  1 (9.1%) patient achieved a very good partial response, 8 (72.7%) patients achieved stable disease, 1 (9.1%) patient had progressive disease (PD), and 1 patient's response was non-evaluable. Based on the IRC assessment, at the time of the data cut-off date, from these SdX treated patients 6 patients had events, 5 (45.5%) had PD and 1 (9.1%) patient died. The median (95% CI) PFS was 2.33 months (2.30, non-evaluable)

The main hypothesis of the BOSTON study is of superiority of SVd compared with Vd for the primary efficacy endpoint progression free survival ( PFS ), based on IRC assessment. Disease response has been assessed according to the International Myeloma Working Group (IMWG) response criteria for MM (Kumar 2016). The BOSTON study was originally designed with PFS and ORR as co-primary endpoints. At the time when scientific advice was sought, the MAH was however discouraged to include ORR as coprimary endpoint in the context of such an early stage of relapse (1-3 prior therapies, no refractoriness to bortezomib), when relatively high response rates are still expected, questioning the relative value of that endpoint. Further, the MAH was discouraged to use ORR results for a potential conditional approval, since ORR is not currently recognized as a reliable surrogate for PFS (or OS) in RRMM, and the actual value of endpoints based on response rates to define clinical benefit in the absence of long-term data is still debated. PFS was recommended as the primary endpoint, consistent with all recent approvals in MM. In this regard, the design was modified (Protocol Version 4.0 dated 17 August 2018) and PFS became the single primary endpoint. ORR was moved to a secondary endpoint.

Secondary objectives included to compare the 2 arms in terms of overall response rate (ORR) (≥partial response [PR]), as well as n umber of patients achieving ≥ very go od partial response (VGPR), ≥ complete response (CR) or minimal residual disease (MRD) negative (for patients who achieve CR or stringent CR [sCR]. An additional secondary objective was to compare the incidence of any Grade ≥2 peripheral neuropathy events between the two arms (see safety section). Other secondary endpoints include overall survival (OS), duration of response (DOR) and time to next treatment (TTNT).

A  number  of  (major)  amendments  were  made  to  the protocol including  changes  in  the  primary endpoint(s), number of events required for the analyses (final and interim; see below), definition of response, etc. These revisions together with the late finalization of the SAP including a major change affecting the primary efficacy analysis in the context of open-label study called into question the integrity of  the  study.  To  address these concerns the MAH presented a detailed description on how the data integrity was maintained from the beginning of the trial until the data cut-off when the pre-planned second IA for efficacy was changed into the final analysis, at a very late stage. Apparently, the main reason to have performed this major change was due to predictions that the 267 PFS events planned would  not  be  achieved  in  a  reasonable  period  of  time.  In  addition,  the  MAH  presented  relevant information  on  a  calendar  time  basis  from  the  beginning  of  the  trial,  including  amendments  in  the protocol, SAP and interactions with the DSMB. The justification of the MAH was acknowleged and it appeared that they remained blinded to the results.

<div style=\"page-break-after: always\"></div>

A GCP inspection was conducted as proposed by the CHMP, bearing in mind what was stated in the Integrated Inspection Report (IIR) of the routine GCP inspection requested by the CHMP at the time of initial MAA (GCP/2019/001); see section 4.1.4. The IIR from this new inspection was submitted on 17 th March 2022. According to it, although certain measures had been implemented after the first inspection, which was performed at the time of the initial CMA application, critical findings in relation to the clinical conduct and management of the trial by the Sponsor were identified. Based on these several critical findings, the inspectors could not confirm that trial data were reliable and had adequate quality to be used in support of the applied extension of the indication for Nexpovio. Importantly, the inspectors identified ' a risk of potentially biased decisions been taken by potentially unblinded key personnel from the Cy and a risk of introducing bias on IRC members' assessment '. This is of special relevance since the primary endpoint in the BOSTON trial was PFS by the IRC. At the time of the primary analysis a statistically significant improvement in PFS was observed (see below). In addition, a sensitivity analysis, where  the  confirmation  of  PD  was  based  on  the  investigator's  assessment  instead  of  the  IRC's assessment, was conducted and showed consistent results, i.e. median PFS was 13.93 months (95% CI: 11.73, NE) in the SVd arm and 9.46 months (95% CI: 8.44, 11.89) in the Vd arm; HR 0.73 (95% CI: 0.55, 0.98). This is reassuring. However, the BOSTON study is an open label study and concerns affecting the assessment of the primary endpoint of PFS by IRC could be expected to have resulted in loss of control of type I error questioning the robustness of the results. In this context, OS data (which was a secondary endpoint in the trial) could be considered of special relevance. Reported OS results in the BOSTON study are included below, showing that  a detrimental effect of SVd in terms of OS does not seem likely, though still these data corresponded to 148 survival events (37%, n=402) (DCO 15 Feb 2021).  In  the  context  of  the  reported  GCP  findings  a  further  update  of  OS  data  was  provided corresponding  to  157  survival  events  (DCO  22  March  2022).    Results  seem  overall  consistent  and supportive of benefit of selinexor in the claimed indication.

Further, based on the criticality of the GCP findings identified, the MAH was requested to address them (by conducting a reanalysis of data used by the IRC to determine progression of the disease) and justify how the provided data can be considered reliable to support a B/R assessment. The IRC data review consisted of two parts (Part 1 and Part 2). Part 1 was comprised of the assessment from each IRC member while Part 2 was an adjudication meeting between the IRC members, to achieve consensus, in which the Sponsor was also present (according to the MAH for administrative and training purposes only). To address the identified concerns, the MAH has provided (instead of a full reanalysis) a sensitivity analysis of PFS results using only data from Part 1 of the 'IRC data review' without any information from Part 2 (adjudication meeting). According to this sensitivity analysis (of PFS assessment review), only for 10 patients (3 in the SVd arm and 7 in the Vd arm) the PFS assessment was affected (~2.5% of all randomised  patients  in  the  study).  Among  those  10  patients  in  whom  changes  in  the  adjudication affected PFS, a total of 5 (2 in the SVd arm and 3 in the Vd arm) had their PFS event/censoring status affected, which is balanced between the two treatment arms. Median PFS (95% CI) according to this analysis is of 13.93 (11.73, NE) vs. 9.46 (8.11, 10.87) months for the SVd and Vd arms, respectively. These results are in line with data reported in the primary efficacy analysis in the BOSTON study (see below). The reported HR (95% CI) for this sensitivity analysis, i.e. 0.7058 (0.5303, 0.9395), is also consistent with that of the primary analysis. Taking all these into account and considering that PFS results according to the investigator are also consistent, the reported PFS data can be considered reliable to support B/R assessment.

## Statistical aspects

There were 3 versions of the SAP (Version 1.0 dated 15 August 2018, Version 2.0 dated 30 September 2019, and Version 3.0 dated 24 February 2020).

<div style=\"page-break-after: always\"></div>

Two interim analyses were planned with different objectives. The first (unblinded) interim analysis (IA) was conducted to assess the conditional power at the time when approximately 30% PFS events had been achieved to consider if a sample size re-estimation was necessary using the CHW method (Cui et al., 1999). This analysis was conducted with data cut of 21 Jan 2019 after 113 events were accrued. On 21 Feb 2019 the DSMB met and recommended continuing the study with no sample size adjustment and no change to the safety monitoring.

A second IA was planned after approximately 75% of PFS events had occurred that would have allowed for a conclusion of efficacy or to stop for futility. The MAH planned to use the Lan DeMets alpha spending function with the O'Brien-Fleming boundary. However, the MAH later decided to change the original design and to consider this second IA as the final efficacy analysis 'no matter the outcome is positive or not'. The MAH did not discuss their proposal with any regulatory Agency but instead notes that the DSMB agreed. Because of this decision the testing of the primary efficacy endpoint was done using all onesided alpha of 0.025 instead of the corresponding level of alpha using the spending function originally proposed.

The decision to change the second IA into the final analysis using the full level of alpha was triggered at a very late stage. In fact, this change was included in an updated statistical analysis plan (Version 4.0) dated 24 Feb 2020 (see above), 6 days after the data cut-off for the primary efficacy endpoint (18 Feb 2020). To justify the change the MAH argues that there were concerns that the trial was not going to reach the planned 267 events, and that an extended period of time would have been needed to accrue additional PFS events with minimal gain in power. The provided justification was not entirely followed since a total of 204 PFS events were achieved at the time of submission (76.40% of planned events) and in the updated primary analysis one year later, a total of 229 of PFS events had been achieved (85.76% of planned events).

As stated above, considering the open-label design of the trial it was not possible to exclude that these changes were partially driven by data and therefore no formal adjustment for inference would be feasible translating into lack of type I error control. For that reason, and in order to assess the robustness of the results, the MAH was requested to submit the analyses for the primary efficacy endpoint considering the corresponding  alpha  value  using  the  Lan  DeMets  alpha  spending  function  with  the  O'Brien-Fleming boundary as initially proposed (pre-planned IA2). Using the alpha spending function as initially planned, the boundary p-value would have been 0.0103 instead of the 0.025 used for the primary efficacy analysis and still the results are statistically significant.

## Efficacy data and additional analyses

All  efficacy  analyses  were  conducted  using  the ITT  population ;  all  tests  (log-rank  tests,  CochranMantel-Haenszel tests) were one-sided.

Updated  data  as  of  15  Feb  2021  cut-off  date  (i.e.  from  an  additional  year  of  follow-up)  were  also submitted by the MAH and included updated results for the primary endpoint, key secondary endpoints, and safety data: cumulative PFS, DOR, OS, ORR, AEs, SAEs, AECIs, and deaths.

## Primary endpoint

The BOSTON study met its primary endpoint . A statistically significant improvement in median PFS in the SVd arm (13.93 months) compared with the Vd arm (9.46 months; p=0.0075; HR, 0.70; 95% CI: 0.5279-0.9335) was reported at a median overall follow-up of 13.17 and 16.53 months for the SVd and Vd  arms,  respectively.  The  results  were  generally  consistent  across  multiple  sensitivity  analyses (including according to EMA censoring rules) and across pre-specified subgroups by relevant patient and disease characteristics, including regardless of prior therapeutic regimens. Results from the updated analysis were also consistent. However, it is noted that the median follow-up for Vd in the updated analysis is 24.48 (21.16- 29.17) months, which is 11 months longer (almost double) than that reported

<div style=\"page-break-after: always\"></div>

for the SVd arm of 13.47 (10.64-24.87) months, with a wider range. Of note, patients were not always followed after treatment discontinuation, but only when they 'were willing to continue survival followup, still alive, not lost to follow-up and have not discontinued from the study'. As reported by the MAH, the SVd arm had a higher proportion of patients censored in PFS analysis compared to the Vd arm, explaining why the estimated median follow-up time using the reverse KM method is shorter for SVd.

## Secondary endpoints

Among the key secondary endpoints, a statistically significant improvement in ORR from 62.3% (95%CI: 55.3, 68.9) in the Vd arm to 76.4% (95%CI: 69.8, 82.2) in the SVd arm (p=0.0012) was reported. The rate of ≥VGPR improved from 32.4% in the Vd a rm to 44.6% in the SVd arm. In terms of ORR, the results observed in the updated analysis were consistent with the previously reported in the primary analysis. It has been reported that 9 of 33 patients (27%) with sCR or CR from the SVd arm and 8 of 22 patients (36%) with sCR or CR from the Vd arm were assessed as MRD negative. These data suggest that  no  deeper  responses  are  achieved  in  patients  treated  with  selinexor,  with  MRD  negativity percentages lower in the SVd arm.

The median DOR according to the primary analysis were 20.3 (95% CI: 12.55, NE) months in the SVd arm and 12.9 (95% CI: 9.26, 15.77) months in the Vd arm. In the updated analysis, median DOR has been reported as 17.3 months (95% CI: 12.55, 26.25) in the SVd arm and 12.9 months (95% CI: 9.26, 15.77) in the Vd arm. The MAH was requested to submit a further update of the DoR results and it was confirmed that the median DOR remained the same as of 01 December 2021.

A clinically significant increase in the TTNT was achieved with the proposed SVd regimen. The median TTNT in the SVd arm was 16.1 months (95% CI: 13.9, NE) compared to 10.8 months (95% CI: 9.8, 13.4) in the Vd arm.

Median OS was not reached for SVd at a median follow-up of 17.3 months (primary analysis). The median OS for patients in the Vd arm was 24.97 months (95% CI: 23.49, NE). In the updated efficacy analysis at a median follow-up of 28.71 months, the median OS was 36.67 months (95% CI: 30.19, NE) for SVd compared to 32.76 months (95% CI: 27.83, NE) in the Vd arm; HR=0.88 (95% CI: 0.63, 1.22). At that time, data were immature but a detrimental effect of SVd in terms of OS did not seem likely also bearing in mind that cross-over was allowed in the BOSTON study. As already stated, further OS data were provided during the procedure with a median follow-up of 33.6 months in the SVd arm and 33.84 months in the Vd arm, which remained overall consistent with the previous data submitted (HR 0.93; 95% CI: 0.67, 1.27).

## Additional expert consultation

N/A

## Assessment of paediatric data on clinical efficacy

N/A

## 2.4.4. Conclusions on the clinical efficacy

Treatment with the (once weekly) combination of selinexor with bortezomib and dexamethasone tested in the BOSTON study (SVd) leads to a significant improvement in median PFS compared to the standard (BIW) Vd regimen in the targeted patient population, i.e. adult patients with MM who have received at least  one  prior  therapy.  This  benefit  in  terms  of  PFS  is  supported  by  several  secondary  endpoints. Importantly, no evidence of detrimental effect on survival has been observed also considering that cross over, to either SVd or Sd, was allowed in the trial.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

The primary study supporting this Type II Variation is the Phase 3 confirmatory Study KCP-330-023 (BOSTON) , in which adult patients with MM who had received 1 to 3 prior MM regimens were randomized 1:1  to  receive  QW  SVd  versus  BIW  Vd.  Of  note,  in  the  SVd  arm,  selinexor  and  bortezomib  are administered  QW,  whereas  in  the  Vd  arm,  bortezomib  is  administered  BIW  (consistent  with  the bortezomib  label)  with  both  regimens  given  with  low-dose  dexamethasone. At  the  time  of  primary analysis (18 Feb 2020), BOSTON was ongoing and had completed enrolment with 402 patients (195 randomized to SVd and 207 to Vd) of whom 203 remained on study (102 and 101 in the SVd and Vd arms,  respectively). Updated  analysis  for  BOSTON  study  data  included  in  this  Type  II  Variation submission has a data cut-off date of 15 Feb 2021.

In addition to this primary study, supporting safety data are provided from the preceding Phase 1b/2 study ( KCP-330-017) STOMP . The enrolment in the SVd arm (Arm 2) of STOMP was completed as of 01 Sep 2019, with 42 patients dosed, of whom 2 remained on study.

<div style=\"page-break-after: always\"></div>

Table 1: Company-Sponsored Pivotal and Supportive Studies for Type II Variation

Source: Module 5.3.5.2, Study KCP-330-017 CSR, Protocol version 5.0 and Module 5.3.5.1, Study KCP-330-023 CSR, Protocol version 4.0.

|                    | Pivotal Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Supportive Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                    | KCP-330-023 (B0STON)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | KCP-330-017(ST0MP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Number of patients | 258                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Population         | Relapsed or refractory multiple myeloma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Relapsed/refractory multiple myeloma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Study status       | Ongoing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Ongoingb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Prior therapies    | Patients who had at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens. Induction therapy followed by stem cell transplant and consolidation/maintenance therapy was considered as 1 anti-MMregimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Arm 2 (SVd) in RRMM: Patients whose MM was relapsing after ≥1 line of therapy, and whose MM was not refactory to bortezomib in their most recent line of therapy (i.e., relapsed but not refractory to prior bortezomib therapy) Note:19 of the 42patientsfrom theSVd arm of STOMP would have been eligible for BOSTON. The remaining patients were more heavily pretreated and/or had disease refiractory to proteasome inhibitors                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Dose               | Selinexor: 100 mg PO on Days 1, 8, 15, 22, and 29 ofeach 35-day cycle Bortezomib: 1.3 mg/m² SC on Days 1, 8, 15 and 22 of each 35-day cycle Dexamethasone:20mgPO onDays 1.2.8.9 15,16,22,23,29,and30 ofeach35-day cyle :e PA First 8 cycles: Bortezomib: 1.3 mg/m² SC on Days 1, 4, 8, and 11 ofeach 21-day cycle. Dexamethasone: 20 mg PO dose on Days 1, 2 4,5,8,9,11,and12 ofeach21-day cycle. Cycles ≥9 Bortezomib 1.3 mg/m²SC on Days 1, 8, 15 and 22 of each 35-day cycle. Dexamethasone: 20 mg PO dose on Days 1, 2 8,9,15,16,22,23,29,and30 of each 35-day cycle. SVdX arm: Patients who crossed overfromVd treatment to SVdXfollowing theCycle 1 of SVd treatment as descnibed above. | Dose escalation: Bortezomib QW schedule:(35 days cycle), 7patients: Selinexor.80/100 mg PO QW on Days 1,8,15, 22, and 29 of each 35-day cycle Bortezomib: 1.3 mg/m²SC QW on Days 1, 8 15,and 22 of each35-day cycle Dexamethasone: 40 mgPO QW Days 1,8,15 22, and 29 of each 35-day cycle Bortezomib BIW schedule: (2l days cycle), 6 patients: Selinexor. 80 mg PO QW on Days 1, 8,and 15 ofeach 21-day cycle Bortezomib: 1.3 mg/m² SC QW on Days 1, 4, 8, and 11 of each 21-day cycle Dexamethasone:40mgPO QWDays1,8,and 15 of each 21-day cycle Selinexor BIW schedule: (35-day cycle), 9 patients: Selinexor.60/80 mg PO BIW on Days 1,3,8. 10,15,17,22,and24ofeach35-day cycle Bortezomib: 1.3 mg/m²SC QW onDays 1, 8 15, and 22 of each 35-day cycle Dexamethasone: 20 mg PO BIW on Days 1, 3 8,10,15,17,22,24,29,and31ofeach35-day cycle DoseExpansion,20patients: |

AE: adverse event; BIW: twice weekly; CTCAE: Common Terminology Criteria for Adverse Events; MM: multiple myeloma; PO: orally; PR: partial response; QW: once weekly; RP2D: recommended Phase 2 dose; RRMM: relapsed or refractory multiple myeloma; SC: subcutaneously; SVd: selinexor with bortezomib and dexamethasone;

including the primary safety population and the SVdX patients.

SVdX: patients who crossed over from VdtoSVd treatment;Vd: bortezomib and dexamethasone.

b Enrollment has been completed for SVd am in KCP-330-017 (STOMP).

<div style=\"page-break-after: always\"></div>

The SCS includes an integrated summary of the safety from these 2 company-sponsored clinical studies evaluating selinexor in patients with MM.

Table 2: Pivotal and Supportive Studies Contributing to Analysis Populations

| Study       | Allsyd (N=300)                                                            | BOSTONSVd (N=195)          | BOSTONVd (N=204)         |
|-------------|---------------------------------------------------------------------------|----------------------------|--------------------------|
| KCP-330-023 | Allpatientsdosed in SVd arm(195 [BOSTON]+42[STOMP] + 63[SVdX population]) | Allpatients dosed inSVdarm | Allpatientsdosed inVdarm |
| KCP-330-017 | Allpatientsdosed inSVd arm                                                |                            |                          |

## Patient exposure

Table 3: Disposition of all Patients by Treatment Group, Safety Population - Updated Analysis

<!-- image -->

| Disposition Category                                                          | All SVd (N=301) (%6) Ⅱ   | BOSIONSVd Arm (N=195) n (%)   | BOSTON VdArm (N=204) n (%)   |
|-------------------------------------------------------------------------------|--------------------------|-------------------------------|------------------------------|
| Enrolled patients in treatment group                                          | 301 (100.0)              | 195 (100.0)                   | 204 (100.0)                  |
| End-of-treatment disposition                                                  |                          |                               |                              |
| On-treatment                                                                  | 24 (8.0)                 | 21 (10.8)                     | 16 (7.8)                     |
| Discontinued treatment and reasons                                            | 277 (92.0)               | 174 (89.2)                    | 188 (92.2)                   |
| Disease progression                                                           | 128 (42.5)               | 76 (39.0)                     | 118 (57.8)                   |
| Withdrawal by patient                                                         | 54 (17.9)                | 37 (19.0)                     | 21 (10.3)                    |
| Adverse event/toxicity to study dug                                           | 52 (17.3)                | 33 (16.9)                     | 26 (12.7)                    |
| Death                                                                         | 24 (8.0)                 | 14 (7.2)                      | 14 (6.9)                     |
| Lost to follow-up                                                             | 3 (1.0)                  | 3 (1.5)                       | 2 (1.0)                      |
| Non-compliance with study drug/protocol deviation                             | 4 (1.3)                  | 1 (0.5)                       | 2 (1.0)                      |
| Physician decision                                                            | 11 (3.7)                 | 10 (5.1)                      | 5 (2.5)                      |
| Other                                                                         | 1 (0.3)                  | 0                             | 0                            |
| Patients in suuvival follow-upb                                               | 72 (23.9)                | 52 (26.7)                     | 58 (28.4)                    |
| Patients who have completed suvival follow-up                                 | 18 (6.0)                 | 0                             | 0                            |
| Patients who die duing suvival follow-up                                      | 97 (32.2)                | 54 (27.7)                     | 55 (27.0)                    |
| Patients who discontinued from the study without completing suvival follow-up | 16 (5.3)                 | 13 (6.7)                      | 16 (7.8)                     |
| End-of-study disposition                                                      |                          |                               |                              |
| On-study                                                                      | 96 (31.9)                | 73 (37.4)                     | 78 (38.2)                    |
| Completed                                                                     | 18 (6.0)                 | 0                             | 0                            |
| Discontinued from study and reasons                                           | 187 (62.1)               | 122 (62.6)                    | 126 (61.8)                   |
| Disease progression                                                           | 1 (0.3)                  | 0                             | 0                            |
| Withdrawal by patient                                                         | 49 (16.3)                | 39 (20.0)                     | 39 (19.1)                    |
| Adverse event/toxicity to study dnug                                          | 0                        | 0                             | 0                            |
| Death                                                                         | 121 (40.2)               | 68 (34.9)                     | 79 (38.7)                    |
| Lost to follow-up                                                             | 12 (4.0)                 | 12 (6.2)                      | 7 (3.4)                      |
| Non-compliance with study dnug                                                | 0                        | 0                             | 0                            |
| Physician decision                                                            | 2 (0.7)                  | 1 (0.5)                       | 0                            |
| Other                                                                         | 2 (0.7)                  | 2 (1.0)                       | 1 (0.5)                      |

<div style=\"page-break-after: always\"></div>

Data cut-off date: 15 Feb 2021 (B0STON); 01 Sep 2019 (ST0MP)

SVd: selinexor with bortezomib and dexamethasone; Vd: bortezomib and dexamethasone.

All SVd population includes 195 patients from the BOSTON SVd arm + 64 patients from the BOSTON crossover am (SVdX), including 1 additional patient who crossed over from the Vd aim since the pnimary amalysis 42 patients from the supportive study, STOMP.

Patients in follow-up ConsIsts of patients who are willing to contimue into suuvival follow-up, still alive, not lost to follow-up and have not discontimued from the study.

Table 4 below provides a summary of the exposure to study treatment by treatment group for all patients in the safety population based on updated analysis. One additional patient, who crossed over from Vd arm to the SVdX arm in BOSTON study since primary analysis (N=300), was included in the All SVd population for the updated analysis (N=301).

In the All SVd population , the median duration of exposure to SVd was 27.0 weeks (range: 1 to 206), with a maj ority (56.1%) of patients receiving study treatment for ≥24 weeks, and 29.2% of patients receiving treatment for ≥48 weeks.

In the BOSTON SVd arm , the median duration of exposure to study treatment was longer (30.0 weeks; range: 1 to 171), the proportion of patients treated for ≥48 weeks was higher (35.9% of patients), patients received a higher median number of doses (26.0), and a higher median total dose (2300.0 mg) of selinexor, than in the All SVd population. The longest duration of study treatment exposure was 171 weeks.

In the BOSTON Vd arm , the median duration of exposure to Vd was 32.0 weeks (range: 1 to 173), with a majority (60.3%) of patients receiving study treatment for ≥24 weeks, and 32.4% of patients receiving treatment for ≥48 wee ks. The longest duration of study treatment exposure was 173 weeks.

Table 4: Exposure by treatment group - All Patients in the Safety Population

| Parameter                                                 | All SVd (N= 301)   | BOSTON SVd Arm (N=195)   | BOSTON Vd Arm (N= 204)   |
|-----------------------------------------------------------|--------------------|--------------------------|--------------------------|
| Duration of Selinexor Exposure (Weeks)                    |                    |                          |                          |
|                                                           | 301                | 195                      | 0                        |
| Median                                                    | 26.0               | 29.0                     |                          |
| Mean (STD)                                                | 40.9 (40.92)       | 47.2 (44.00)             |                          |
| Min, Max                                                  | 1,205              | 1,170                    |                          |
| Duration of Selinexor Exposure (Weeks), n (%)             |                    |                          |                          |
| 2                                                         | 6( 2.0)            | 2( 1.0)                  | 0                        |
| 2-<4                                                      | 10( 3.3)           | 4 ( 2.1)                 | 0                        |
| 4-<12                                                     | 46 ( 15.3)         | 25 ( 12.8)               | 0                        |
| 12 -<24                                                   | 71 (23.6)          | 44 ( 22.6)               | 0                        |
| 24 -<48                                                   | 83 (27.6)          | 53 (27.2)                | 0                        |
| >=48                                                      | 85 ( 28.2)         | 67 (34.4)                | 0                        |
| Total Selinexor Dose Received (mg)                        |                    |                          |                          |
|                                                           |                    | 195                      |                          |
| Median                                                    | 2000.0             | 2300.0                   |                          |
| Mean (STD)                                                | 3087.9 (2989.10)   | 3559.4 (3328.84)         |                          |
| Min, Max                                                  | 100,16800          | 100,16800                |                          |
| Parameter                                                 | All SVd (N= 301)   | BOSTONSVdArm (N= 195)    | BOSTON Vd Arm (N= 204)   |
| Average Selinexor Dose Received per Week (mg/week) [1]    |                    |                          |                          |
| 11                                                        | 301                | 195                      | 0                        |
| Median                                                    | 81.89              | 80.00                    |                          |
| Mean (STD)                                                | 80.41 (19.147)     | 78.89 (18.822)           |                          |
| Min, Max                                                  | 28.6 , 150.0       | 29.7, 136.7              |                          |
| Number of SelinexorDosesReceived                          |                    |                          |                          |
|                                                           | 301                | 195                      |                          |
| Median                                                    | 24.0               | 26.0                     |                          |
| Mean (STD)                                                | 37.7 (38.14)       | 42.9 (41.55)             |                          |
| Min, Max                                                  | 1,168              | 1,168                    |                          |
| Patients with Dose Reduction to Selinexor, n (%)          | 177 (58.8)         | 128 ( 65.6)              | 0                        |
| Patients with Dose Delay/Interruption to Selinexor, n (%) | 250 ( 83.1)        | 169 ( 86.7)              | 0                        |
| Patientswith Dose ModificationtoSelinexor,n (%)           | 259 (86.0)         | 174 ( 89.2)              | 0                        |
| Patients with Missed Dose toSelinexor, n (%)              | 69 (22.9)          | 31 (15.9)                | 0                        |
| Patients withDoseEscalation toSelinexor,n (%)             | 71 ( 23.6)         | 48 ( 24.6)               | 0                        |

<div style=\"page-break-after: always\"></div>

| Parameter                                                                                                 | AlI SVd                  | BOSTON SVd Arm             | BOSTONVdArm              |
|-----------------------------------------------------------------------------------------------------------|--------------------------|----------------------------|--------------------------|
| Duration of Bortezomib Exposure (Weeks)                                                                   | (N = 301)                | (N=195)                    | (N=204)                  |
|                                                                                                           |                          | 195                        | 204                      |
| n Median                                                                                                  | 301 25.0                 | 29.0                       | 31.0                     |
| Mean (STD)                                                                                                | 39.3 (39.87)             | 45.4 (42.73)               | 43.4 (39.18)             |
| Min, Max                                                                                                  | 1,204                    | 1,170                      | 1,173                    |
| Duration of Bortezomib Exposure (Weeks), n (%)                                                            |                          |                            |                          |
| <2                                                                                                        | 7( 2.3)                  | 2 ( 1.0)                   | 2( 1.0)                  |
| 2-<4                                                                                                      | 8 (2.7)                  | 4 ( 2.1)                   | 8( 3.9)                  |
| 4-<12                                                                                                     | 48 ( 15.9)               | 25 ( 12.8)                 | 30 ( 14.7)               |
| 12 -<24                                                                                                   | 75 ( 24.9)               | 47 (24.1)                  | 44 ( 21.6)               |
| 24 - <48                                                                                                  | 84 (27.9)                | 55 (28.2)                  | 55 (27.0)                |
| >=48                                                                                                      | 79 ( 26.2)               | 62 (31.8)                  | 65 ( 31.9)               |
| Total Bortezomib Dose Received (mg)                                                                       |                          |                            |                          |
| 11                                                                                                        | 301                      | 195                        | 204                      |
| Median                                                                                                    | 40.8                     | 46.1                       | 72.6                     |
| Mean (STD)                                                                                                | 63.2 (63.81)             | 72.0 (68.47)               | 90.3 (69.08)             |
| Min, Max                                                                                                  | 2,335                    | 3,335                      | 2,327                    |
| Average Bortezomib Dose Received per Week(mg/week) [1]                                                    |                          |                            |                          |
| n                                                                                                         | 301                      | 195                        | 204                      |
| Median                                                                                                    | 1.71                     | 1.70                       | 2.46                     |
| Mean (STD)                                                                                                | 1.72 (0.467)             | 1.70 (0.478)               | 2.49 (0.782)             |
| Min, Max                                                                                                  | 0.6,5.2                  | 0.6,5.2                    | 0.9 , 5.7                |
| Total Bortezomib Dose(mg/m^2) Received                                                                    |                          |                            |                          |
|                                                                                                           | 301                      | 195                        | 204                      |
| Median                                                                                                    | 22.25                    | 25.36                      | 40.28                    |
| Mean (STD)                                                                                                | 33.64 (32.703)           | 38.45 (35.319)             | 49.38 (37.674)           |
| Min, Max                                                                                                  | 1.3 , 176.1              | 1.3 , 176.1                | 1.3, 197.5               |
| Average Bortezomib Dose Received per Week (mg/m^2 per week) [1]                                           |                          |                            |                          |
|                                                                                                           | 301                      | 195                        | 204                      |
| Median                                                                                                    | 0.95                     | 0.93                       | 1.32                     |
| Mean (STD)                                                                                                | 0.93 (0.219)             | 0.92 (0.225)               | 1.37 (0.402)             |
| Min, Max                                                                                                  | 0.3,2.6                  | 0.3,2.6                    | 0.5,2.6                  |
|                                                                                                           |                          |                            | BOSTON Vd Arm            |
|                                                                                                           | All SVd                  | BOSTON SVd Arm             | (N= 204)                 |
| Parameter Number of BortezomibDoses Received                                                              | (N= 301)                 | (N =195)                   |                          |
|                                                                                                           | 301                      | 195                        | 204                      |
| Median                                                                                                    | 19.0                     | 21.0                       | 31.5                     |
|                                                                                                           |                          | 32.4 (30.14)               | 39.7 (30.33)             |
| Mean (STD)                                                                                                | 28.1 (27.37)             |                            |                          |
| Min, Max                                                                                                  | 1,135                    | 1,135                      | 1, 151                   |
| Patients withDose Reduction toBortezomib,n (%) Patients with Dose Delay/Interruption to Bortezomib, n (%) | 111 (36.9) 241 ( 80.1)   | 85 (43.6) 160 ( 82.1)      | 93 (45.6) 151 ( 74.0)    |
| Patients with Dose Modification to Bortezomib, n (%)                                                      | 248 ( 82.4)              | 164 ( 84.1)                | 164 ( 80.4)              |
| Patients with Missed Dose to Bortezomib, n (%)                                                            | 68 (22.6)                | 34 (17.4)                  | 38 (18.6)                |
| Patients withDose Escalation to Bortezomib, n (%)                                                         | 10( 3.3)                 | 10( 5.1)                   | 7( 3.4)                  |
|                                                                                                           | All SVd                  | BOSTONSVdArm               | BOSTON Vd Arm            |
| Parameter                                                                                                 | (N= 301)                 | (N = 195)                  | (N = 204)                |
| Duration of Dexamethasone Exposure (Weeks)                                                                | 299                      | 195                        | 204                      |
| Median                                                                                                    | 26.0                     | 30.0                       | 31.0                     |
| Mean (STD)                                                                                                | 41.0 (40.99)             | 47.5 (43.84)               | 43.2 (38.62)             |
| Min, Max                                                                                                  | 1,206                    | 1, 171                     | 1, 173                   |
| Duration of Dexamethasone Exposure (Weeks), n (%)                                                         |                          |                            |                          |
| <2                                                                                                        | 4( 1.3)                  | 1( 0.5)                    | 2( 1.0)                  |
| 2-<4                                                                                                      | 11( 3.7)                 | 5 ( 2.6)                   | 8( 3.9)                  |
| 4-<12                                                                                                     | 48 ( 15.9)               | 26 ( 13.3)                 | 30 ( 14.7)               |
| 12 -<24                                                                                                   | 71 (23.6)                | 42 (21.5)                  | 42 ( 20.6)               |
| 24 -<48                                                                                                   | 78 (25.9)                | 51 (26.2)                  | 58 (28.4)                |
| >=48                                                                                                      | 87 (28.9)                | 70 (35.9)                  | 64 (31.4)                |
| Total Dexamethasone Dose Received (mg)                                                                    |                          |                            |                          |
|                                                                                                           | 299                      | 195                        | 204                      |
| Median                                                                                                    |                          | 1080.0                     |                          |
| Mean (STD) Min, Max                                                                                       | 920.0                    |                            | 1220.0                   |
|                                                                                                           | 1314.0 (1283.87) 20,7200 | 1520.4 (1375.80) 40 , 6720 | 1616.7 (1341.30) 20,7200 |

<div style=\"page-break-after: always\"></div>

| Parameter                                                  | All SVd (N= 301)   | BOSTONSVd Arm (N = 195)   | BOSTONVdArm (N = 204)   |
|------------------------------------------------------------|--------------------|---------------------------|-------------------------|
| Average Dexamethasone Dose Received per Week (mg/week) [1] |                    |                           |                         |
| n                                                          | 299                | 195                       | 204                     |
| Median                                                     | 36.23              | 36.19                     | 43.64                   |
| Mean (STD)                                                 | 33.40 (7.219)      | 33.59 (6.958)             | 43.37 (13.099)          |
| Min, Max                                                   | 9.6 , 42.1         | 11.9 ,41.7                | 8.4, 80.0               |
| Numberof DexamethasoneDosesReceived                        |                    |                           |                         |
|                                                            | 299                | 195                       | 204                     |
| Median                                                     | 44.0               | 55.0                      | 70.0                    |
| Mean (STD)                                                 | 69.5 (70.55)       | 84.3 (78.13)              | 87.4 (71.26)            |
| Min, Max                                                   | 1,336              | 2,336                     | 1,360                   |
| Patients with DoseReduction toDexamethasone,n(%)           | 72 (23.9)          | 55 (28.2)                 | 74 (36.3)               |
| PatientswithDoseDelay/Interruption toDexamethasone,n (%)   | 235 ( 78.1)        | 156 ( 80.0)               | 148 ( 72.5)             |
| Patients with Dose Modification toDexamethasone,n (%)      | 239 ( 79.4)        | 158 ( 81.0)               | 155 ( 76.0)             |
| Patients with Missed Dose to Dexamethasone, n (%)          | 75 ( 24.9)         | 39 (20.0)                 | 44 (21.6)               |
| Patients with Dose Escalation to Dexamethasone, n (%)      | 8 (2.7)            | 7( 3.6)                   | 10 ( 4.9)               |

(DatabaseCutoff Date:2021-02-15;SourceData:ADBASE,ADEXSUM)

Executed:2021-03-09 11:08

Note:Study treatment is selinexorwithbortezomiband dexamethasone forSVd treatment.Study treatment is bortezomibwith dexamethasone forVd treatment.

Note:Dose modification includes dose reduction, dose delay and dose interruption.

[1] Average dose receivedperweek is defined as total dose received divided by duration of exposure.

F:\\Biostatistics\\KPT-330ISS\\_BOSTON\\Data\\_Cuts\\2021-02-15\\Dev\\MAA\\_Update\\T-14-1-8-1-Exposure-by-Treatment-Group-Safety-updated.sas

## Adverse events

Table 5: Summary of Adverse Events By Treatment Group - All Patients in the Safety Population - Updated analysis

| Patients with at Least One                                              | All SVd (N =301) n (%)   | BOSTON SVd BOSTON Vd Am (N = 195) n (%)   | Arm (N = 204) n (%)   |
|-------------------------------------------------------------------------|--------------------------|-------------------------------------------|-----------------------|
| Treatment-Emergent Adverse Event                                        | 299 ( 99.3)              | 194 ( 99.5)                               | 198 ( 97.1)           |
| Grade 3/4 TEAE [1]                                                      | 226 ( 75.1)              | 153 ( 78.5)                               | 115 (56.4)            |
| Grade 4 TEAE [1]                                                        | 64 ( 21.3)               | 37 (19.0)                                 | 22 ( 10.8)            |
| Serious TEAE                                                            | 148 ( 49.2)              | 106 ( 54.4)                               | 79 ( 38.7)            |
| TEAE Leading to Dose Modification in Any Study                          | 255 ( 84.7)              | 173 ( 88.7)                               | 156 ( 76.5)           |
| Treatment [2] [3] TEAE Leading to Dose Reduction in Any Study Treatment | 194 ( 64.5)              | 141 ( 72.3)                               | 106 ( 52.0)           |
| TEAE Leading to Dose Interruption in Any Study Treatment                | 245 ( 81.4)              | 167 ( 85.6)                               | 139 ( 68.1)           |
| TEAE Leading to Study Treatment Discontinuation                         | 67 ( 22.3)               | 41 ( 21.0)                                | 34 ( 16.7)            |
| TEAE Leading to Death                                                   | 25(8.3)                  | 14(7.2)                                   | 13 (6.4)              |
| Treatment-Emergent Treatment-Related Adverse Event [4]                  | 284 ( 94.4)              | 187 ( 95.9)                               | 167 ( 81.9)           |
| Grade 3/4 TRAE [1]                                                      | 205 ( 68.1)              | 137 ( 70.3)                               | 84 (41.2)             |
| Grade 4 TRAE [1]                                                        | 54 ( 17.9)               | 28 ( 14.4)                                | 17(8.3)               |
| Serious TRAE                                                            | 84 ( 27.9)               | 58 (29.7)                                 | 24 ( 11.8)            |
| TRAE Leading to Dose Modification in Any Study                          | 229 ( 76.1)              | 158 ( 81.0)                               | 131 ( 64.2)           |
| Treatment [2] [3] TRAE Leading to Dose Reduction in Any Study Treatment | 190 ( 63.1)              | 139 ( 71.3)                               | 102 ( 50.0)           |
| TRAE Leading to Dose Interruption in Any Study Treatment                | 208 ( 69.1)              | 145 ( 74.4)                               | 97 ( 47.5)            |
| TRAE Leading to Study Treatment Discontinuation                         | 53 (17.6)                | 32 (16.4)                                 | 27 ( 13.2)            |
| TRAE Leading to Death                                                   | 7(2.3)                   | 4( 2.1)                                   | 1( 0.5)               |

<div style=\"page-break-after: always\"></div>

(DatabaseCutoffDate:2021-02-15;SourceData:ADAE,ADDENOM)

[1]Basedonmaximumseveritygradeofeachpatient.

[2]The number of patients with dose modification(s) is not necessarily equal to the sum of the number of patients who had a modified dose or a drug interruption since the same patient couldfall intomore thanone of thesecategories.

[3]Study treatmentis selinexorwithbortezomib anddexamethasoneforSVdArm,and bortezomibwithdexamethasone forVdArm.

[4]AnAE is considered treatment-relatedifitisselinexor-relatedand/orbortezomib-related and/ordexamethasone-related.

## Common adverse events

Table 6: Treatment-Emergent Adverse Events occurring in ≥10% of Patients in the All SVd Population, Safety Population - Updated analysis

| MedDRAPreferredTerm               | Wy PAS (N =195) n (%)   | Vd Arm (N = 204) n (%)   | Total (N=399) n(%)   |
|-----------------------------------|-------------------------|--------------------------|----------------------|
| Thrombocytopenia                  | 121 (62.1)              | 56 (27.5)                | 177 (44.4)           |
| Neuropathy peripheral             | 65 (33.3)               | 99 (48.5)                | 164 (41.1)           |
| Anaemia                           | 73 (37.4)               | 48 (23.5)                | 121 (30.3)           |
| Fatigue                           | 82 (42.1)               | 37 (18.1)                | 119 (29.8)           |
| Nausea                            | 98 (50.3)               | 21 (10.3)                | 119 (29.8)           |
| Diarrhoea                         | 65 (33.3)               | 52 (25.5)                | 117 (29.3)           |
| Decreased appetite                | 69 (35.4)               | 11 (5.4)                 | 80 (20.1)            |
| Asthenia                          | 49 (25.1)               | 27 (13.2)                | 76 (19.0)            |
| Weight decreased                  | 51 (26.2)               | 25 (12.3)                | 76 (19.0)            |
| Upper respiratory tract infection | 40 (20.5)               | 30 (14.7)                | 70 (17.5)            |
| Constipation                      | 33 (16.9)               | 36 (17.6)                | 69 (17.3)            |
| Cough                             | 36 (18.5)               | 31 (15.2)                | 67 (16.8)            |
| Insomnia                          | 31 (15.9)               | 32 (15.7)                | 63 (15.8)            |
| Cataract                          | 46 (23.6)               | 15 (7.4)                 | 61 (15.3)            |
| Back pain                         | 31 (15.9)               | 29 (14.2)                | 60 (15.0)            |
| Pneumonia                         | 29 (14.9)               | 29 (14.2)                | 58 (14.5)            |
| Pyrexia                           | 31 (15.9)               | 26 (12.7)                | 57 (14.3)            |
| Oedema peripheral                 | 23 (11.8)               | 29 (14.2)                | 52 (13.0)            |
| Vomiting                          | 40 (20.5)               | 10 (4.9)                 | 50 (12.5)            |
| Bronchitis                        | 25 (12.8)               | 21 (10.3)                | 46 (11.5)            |
| Dyspnoea                          | 18 (9.2)                | 28 (13.7)                | 46 (11.5)            |
| Neutropenia                       | 30 (15.4)               | 13 (6.4)                 | 43 (10.8)            |
| Dizziness                         | 24 (12.3)               | 9 (4.4)                  | 33 (8.3)             |
| Headache                          | 20 (10.3)               | 13 (6.4)                 | 33 (8.3)             |
| Nasopharyngitis                   | 23 (11.8)               | 10 (4.9)                 | 33 (8.3)             |

In the updated analysis, the most frequently reported TEAEs in the All SVd population and BOSTON SVd arm, all of which occurred at a higher frequency compared with the BOSTON Vd arm, were thrombocytopenia (58.5% and 62.1%, respectively), compared with 27.5% in BOSTON Vd arm; nausea (49.8% and 50.3%), compared with 10.3% in BOSTON Vd arm; fatigue (40.9% and 42.1%), compared with 18.1% in BOSTON Vd arm; anaemia (39.9% and 37.4%), compared with 23.5% in BOSTON Vd arm; decreased appetite (37.2% and 35.4%), compared with 5.4% in BOSTON Vd arm; and diarrhoea (34.6% and 33.3%) compared with 25.5% in BOSTON Vd arm.

Peripheral neuropathy was the most frequently reported TEAE (48.5%) in the BOSTON Vd arm compared with the All SVd population (28.2%) and BOSTON SVd arm (33.3%).

The incidence of Grade ≥3 TEAEs as of the updated analysis data cut was higher in the All SVd population (83.4%) and the BOSTON SVd arm (85.6%) compared with the BOSTON Vd arm (62.7%).

Executed:2021-03-0911:09

<div style=\"page-break-after: always\"></div>

The most frequent (≥10.0%) Grade 3/4 TEAEs in the All SVd population compared with the BOSTON Vd arm were thrombocytopenia (39.9% and 17.6%, respectively), anaemia (20.3% and 9.8%, respectively), fatigue (11.3% and 1.0%, respectively), neutropenia (12.6% and 3.4%, respectively), and cataract (10.0% and 2.0%, respectively). Grade 3/4 TEAEs of PN were reported at a higher frequency in the BOSTON Vd arm compared with the All SVd population (8.8% and 3.7%, respectively).

TreatmentEmergent Grade 3/4 Adverse Events Occurring in ≥5% of Patients in Either Group (Safety Population)

| MedDRA Preferred Term                                                 | All SVd (N = 301) n (%)   | sVd Arm (N=195) n (%)   | Vd Arm (N=204) n (%)   |
|-----------------------------------------------------------------------|---------------------------|-------------------------|------------------------|
| Patients with At Least One Treatment-Emergent Grade 3/4 Adverse Event | 226 (75.1)                | 153 (78.5)              | 115 (56.4)             |
| Thrombocytopenia                                                      | 120 (39.9)                | 79 (40.5)               | 36 (17.6)              |
| Pneumoniaa                                                            | 31 (10.3)                 | 24 (12.3)               | 21 (10.3)              |
| Anaemia                                                               | 61 (20.3)                 | 32 (16.4)               | 20 (9.8)               |
| Fatigue                                                               | 34 (11.3)                 | 26 (13.3)               | 2 (1.0)                |
| Peripheral neuropathy                                                 | 11 (3.7)                  | 9 (4.6)                 | 18 (8.8)               |
| Asthenia                                                              | 18 (6.0)                  | 16 (8.2)                | 9 (4.4)                |
| Neutropenia                                                           | 38 (12.6)                 | 18 (9.2)                | 7 (3.4)                |
| Cataract                                                              | 30 (10.0)                 | 22 (11.3)               | 4 (2.0)                |
| Nausea                                                                | 20 (6.6)                  | 15 (7.7)                | 0                      |
| Diarrhoea                                                             | 17 (5.6)                  | 13 (6.7)                | 1 (0.5)                |
| Hypophosphatasemia                                                    | 15 (5.0)                  | 11 (5.6)                | 3 (1.5)                |
| Hyponatremia                                                          | 16 (5.3)                  | 9 (4.6)                 | 1 (0.5)                |

Source:Table 14.3.1.2.1.4, Table 14.3.2.1.1.7

a Adverse events of pneumonia grouped by CMQ.

<div style=\"page-break-after: always\"></div>

## Treatment-related adverse events

Table 7: Treatmentrelated adverse events occurring in ≥5% of Patients in the All SVd Population, Safety Population - Updated analysis

| MedDRAPreferredTerm                | WV PAS (N=195) n (%)   | Vd Arm (N =204) n (%)   | Total (N=399) n (%)   |
|------------------------------------|------------------------|-------------------------|-----------------------|
| Thrombocytopenia                   | 112 (57.4)             | 48 (23.5)               | 160 (40.1)            |
| Neuropathy peripheral              | 63 (32.3)              | 96 (47.1)               | 159 (39.8)            |
| Nausea                             | 93 (47.7)              | 12 (5.9)                | 105 (26.3)            |
| Fatigue                            | 69 (35.4)              | 19 (9.3)                | 88 (22.1)             |
| Decreased appetite                 | 63 (32.3)              | 8 (3.9)                 | 71 (17.8)             |
| Diarrhoea                          | 38 (19.5)              | 31 (15.2)               | 69 (17.3)             |
| Anaemia                            | 44 (22.6)              | 18 (8.8)                | 62 (15.5)             |
| Insomnia                           | 29 (14.9)              | 27 (13.2)               | 56 (14.0)             |
| Asthenia                           | 38 (19.5)              | 11 (5.4)                | 49 (12.3)             |
| Weight decreased                   | 38 (19.5)              | 8 (3.9)                 | 46 (11.5)             |
| Constipation                       | 18 (9.2)               | 25 (12.3)               | 43 (10.8)             |
| Cataract                           | 35 (17.9)              | 6 (2.9)                 | 41 (10.3)             |
| Vomiting                           | 34 (17.4)              | 5 (2.5)                 | 39 (9.8)              |
| Neutropenia                        | 27 (13.8)              | 7 (3.4)                 | 34 (8.5)              |
| Oedema peripheral                  | 15 (7.7)               | 17 (8.3)                | 32 (8.0)              |
| Dyspnoea                           | 11 (5.6)               | 13 (6.4)                | 24 (6.0)              |
| Pneumonia                          | 10 (5.1)               | 10 (4.9)                | 20 (5.0)              |
| Vision blurred                     | 10 (5.1)               | 8 (3.9)                 | 18 (4.5)              |
| Paraesthesia                       | 4 (2.1)                | 12 (5.9)                | 16 (4.0)              |
| Hyponatraemia                      | 13 (6.7)               | 2 (1.0)                 | 15 (3.8)              |
| Pyrexia                            | 12 (6.2)               | 3 (1.5)                 | 15 (3.8)              |
| Dizziness                          | 11 (5.6)               | 3 (1.5)                 | 14 (3.5)              |
| Visual impairment                  | 12 (6.2)               | 2 (1.0)                 | 14 (3.5)              |
| Dysgeusia                          | 12 (6.2)               | 1 (0.5)                 | 13 (3.3)              |
| Alanine aminotransferase increased | 10 (5.1)               | 1 (0.5)                 | 11 (2.8)              |
| Confusional state                  | 11 (5.6)               | 0                       | 11 (2.8)              |

The overall incidence of TRAEs as of the updated analysis data cut was higher in the All SVd population and BOSTON SVd arm compared with the BOSTON Vd arm (94.4% and 95.9%, respectively vs 81.9%) and the imbalance was primarily due to the known AEs of selinexor.

The most common TRAEs (reported in ≥20% patients in the All SVd population), which were reported more frequently in the All SVd population and BOSTON SVd arm than the BOSTON Vd arm, were thrombocytopenia (53.5% and 57.4%, respectively, vs 23.5%), nausea (47.2% and 47.7%, respectively, vs 5.9%) fatigue (34.2% and 35.4%, respectively vs 9.3%), decreased appetite (34.2% and 32.3%, respectively, vs. 3.9%), diarrhoea (23.3% and 19.5%, respectively vs. 15.2%), anaemia (22.3% and 22.6%, respectively, vs. 8.8%), and weight decreased (21.6% and 19.5%, respectively, vs. 3.9%).

Treatment-related PN was more frequently reported in the BOSTON Vd arm (47.1%) than the All SVd population (26.9%) and BOSTON SVd arm (32.3%).

<div style=\"page-break-after: always\"></div>

## Incidence of any Grade ≥ 2 peripheral neuropathy events (secondary endpoint)

As of the updated analysis data cut-off date (15 Feb 2021), Grade ≥ 2 PN events were reported in a total of 42 (21.5%) patients in the SVd arm and 73 (35.8%) patients in the Vd arm.

## Incidence of Grade ≥ 2 Peripheral Neuropathy Events by Treatment Arm (Safety Population) - Updated Analysis

|                                                                      | SVd Arm (N=195)         | Vd Arm (N=204)          |
|----------------------------------------------------------------------|-------------------------|-------------------------|
| Patients with At Least 1 Grade≥2 Peripheral Neuropathy Events, n (%) | 42 (21.5)               | 73 (35.8)               |
| Grade 2                                                              | 33 (16.9)               | 55 (27.0)               |
| Grade 3                                                              | 8 (4.1)                 | 18 (8.8)                |
| Grade 4                                                              | 1 (0.5)                 | 0                       |
| Grade 5                                                              | 0                       | 0                       |
| Cochran-Mantel-Haenszel Test (SVd vs Vd)                             |                         |                         |
| Odds Ratio (95% CI)                                                  | 0.4878 (0.3124, 0.7617) | 0.4878 (0.3124, 0.7617) |
| One-sided P-value                                                    | 0.0008                  | 0.0008                  |
| Breslow-Day Test forHomogeneity                                      |                         |                         |
| P-value                                                              | 0.6722                  | 0.6722                  |

Source: Table 14.3.3.1.1\\_updated.

Data cutoffdate:15Feb2021

For patients who cross over, peripheral neuropathy events that occurred after the crossover are not included. Severity grade presented is the maximum grade of each patient.

## Serious adverse event/deaths/other significant events

## Deaths

In the All SVd population , 31 (10.3%) patients died within 30 days of last dose of study treatment. Of the 31 patients, 24 (7.9%) had the primary cause of death attributed to AEs and 7 (2.3%) patients died due to PD.

In the BOSTON study , as of the updated analysis data cut, a total of 148 (36.8%) patients died on the study (before withdrawal of consent): 68 (16.9%) patients in the SVd arm and 80 (19.9%) patients randomized in the Vd arm. Of the 80 deaths that occurred in the Vd arm, one of the deaths occurred in a patient prior to initiation of therapy and is therefore not included in the Safety Population. A total of 34 (8.5%) patients in the safety population died on treatment or within 30 days of last dose of study drug, with a similar frequency in the 2 treatment arms (8.2% and 8.8% in SVd and Vd arms, respectively). Among the 148 patients who died on study, the most common cause of death was PD in both the SVd arm (33/68 [48.5%]) and Vd arm (35/80 [43.8%]). Patients with TEAEs leading to death were comparable between the 2 arms with 14 (7.2%) patients in the SVd arm and 13 (6.4%) patients in the Vd arm.

Four of the 13 deaths due to TEAEs on the SVd arm occurred in India during the period between 2 Aug 2018 and 31 Oct 2018; no deaths on the Vd arm occurred in India. Thus, one-third of the TEAEs leading to death on SVd occurred in India within a span of 3 months. To address the confluence of factors that led to the observed imbalance in the death rate relative to other countries, the Sponsor took the following steps to attempt to improve outcomes in patients in India:

- Retrained Investigators in India on the importance of supportive care and the specific supportive care recommendations included in the study protocol.

<div style=\"page-break-after: always\"></div>

- Implemented additional safety monitoring BIW, which established a parallel assessment schedule between the SVd and Vd arms.
- Increased communication between Sponsor and study Investigators in India.

After the implementation of the additional measures, no new cases of sepsis or deaths were reported from India.

Table 8: Overview of Deaths and Primary Cause of Death (Safety Population) - Updated Analysis

|                                                                                                                                         | SVd Arm (N=195) n (%)   | Vd Arm (N=204) n (%)   | Total (N=399) n (%)   |
|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------|-----------------------|
| TotalDeathsonStudy                                                                                                                      | 68                      | 79a                    | 147                   |
| Deaths OccurringWithin 30Days of Last Dose of Study Drugb                                                                               | 16 (8.2)                | 18 (8.8)               | 34 (8.5)              |
| Primary Cause of Death                                                                                                                  |                         |                        |                       |
| PD                                                                                                                                      | 3 (1.5)                 | 4 (2.0)                | 7 (1.8)               |
| AEs                                                                                                                                     | 13 (6.7)s               | 14 (6.9)c              | 27 (6.8)              |
| DeathsOccurringAftertheCrossoverandWithin 30 Days of Last Dose of Crossover Treatmentd                                                  | NA                      | 14 (6.9)               | 14 (3.5)              |
| Deaths Occurring After the Crossover and Within 30 Days of Last Dose of Bortezomib inVd and Within 7 Days of Study Drug in the SVdX/SdX | NA                      | 4 (5.2)                | 4 (5.2)               |
| Primary Cause of Death                                                                                                                  |                         |                        |                       |
| PD                                                                                                                                      | NA                      | 0                      | 0                     |
| AEs                                                                                                                                     | NA                      | 4 (5.2)e               | 4 (5.2)e              |
| Deaths OccurringAfter 30Days of Last Dose of Study Druge                                                                                | 52 (26.7)               | 47 (23.0)f             | 99 (24.8)             |

Data cut-off date: 15 Feb 2021

AE=adverse event; MedDRA=Medical Dictionary for Regulatory Activities; PD=progressive disease; PT=preferred term; SdX=selinexor plus low-dose dexamethasone treatment after crossover; SVd=selinexor with bortezomib and dexamethasone; SVdX=SVd treatment after crossover; TEAE=treatment-emergent adverse event; Vd=bortezomib with dexamethasone.

a  One additional patient died on the Vd arm, but death occurred before Vd treatment had begun.

b For patients who crossed over, only deaths that occurred within 30 days of the last dose of Vd treatment and before the first dose of selinexor are included.

c  One patient died due to TEAE in the context of PD and is counted in the TEAE group. Of these 14 patients with deaths due to AEs, in one patient (Patient ID: xxxxxxx), the event of pneumonia was not considered as treatment-emergent as it occurred after the patient started new anti-cancer treatment and is not reflected in Table 49 (TEAEs leading to death).

d  For patients who crossed over, only deaths that occurred after the first dose of selinexor and within 30 days of the last dose of SVdX or SdX treatment are included. e Four of the 9 patients with TEAEs leading to death in the crossover arm died within 30 days of the last dose of Vd and within 7 days of SVdX study treatment. Denominator for the group is 74 (all crossover patients).

f  The number 47 includes 24 patients who died in the crossover arms, 30 days after the last dose of crossover treatment.

g  In addition to the 13 deaths due to TEAEs within 30 days of last dose of study drug, one patient (Patient ID: xxxxxxx) had a TEAE leading to death (PT: Pneumonia); the onset date was within 30 days of the last dose of the study drug; but, its outcome of death was reported as occurred 30 days after the last dose of study drug

<div style=\"page-break-after: always\"></div>

Table 9: Treatment-Emergent Adverse Events Leading to Death by treatment group Primary cause of death (Safety Population) - Updated Analysis

| MedDRA Preferred Term                          | All SVd (N=301°) n (%)   | BOSTON SVd Arm (N=195) n (%)   | BOSTON Vd Arm (N=204) n (%)   |
|------------------------------------------------|--------------------------|--------------------------------|-------------------------------|
| Patients with at least 1 TEAE leading to death | 25 (8.3)                 | 14 (7.2)                       | 13 (6.4)                      |
| Pneumoniab                                     | 4 (1.3)                  | 3 (1.5)                        | 4 (2.0)                       |
| Sepsis/Septic shock                            | 5 (1.7)                  | 3 (1.5)                        | 0                             |
| Myocardial infarction                          | 3 (1.0)                  | 1 (0.5)                        | 0                             |
| Acute kidney injury                            | 1 (0.3)                  | 0                              | 0                             |
| Cerebral haemorrhage                           | 2 (0.7)                  | 1 (0.5)                        | 0                             |
| Shock haemorrhagic                             | 1 (0.3)                  | 1 (0.5)                        | 0                             |
| Bronchitis                                     | 1 (0.3)                  | 1 (0.5)                        | 0                             |
| Cardiac failure acute                          | 2 (0.7)                  | 1 (0.5)                        | 0                             |
| Cerebrovascular accident                       | 1 (0.3)                  | 0                              | 0                             |
| Death                                          | 1 (0.3)                  | 1 (0.5)                        | 0                             |
| Influenza                                      | 1 (0.3)                  | 0                              | 0                             |
| Injury                                         | 1 (0.3)                  | 1 (0.5)                        | 0                             |
| Pulmonary oedema                               | 1 (0.3)                  | 1 (0.5)                        | 1 (0.5)                       |
| Sudden death                                   | 1 (0.3)                  | 0                              | 0                             |
| Anaemiad                                       | 0                        | 0                              | 1 (0.5)                       |
| Cardiomyopathy                                 | 0                        | 0                              | 1 (0.5)                       |
| Circulatory collapse                           | 0                        | 0                              | 1 (0.5)                       |
| Left ventrieular failure                       | 0                        | 0                              | 1 (0.5)                       |
| Myelodysplastic syndrome                       | 0                        | 0                              | 1 (0.5)                       |
| Myocardial ischaemia                           | 0                        | 0                              | 1 (0.5)                       |
| Respiratory failure                            | 0                        | 0                              | 1 (0.5)                       |
| Subdural haemorrhage                           | 0                        | 0                              | 1 (0.5)                       |

Source: Table 14.3.1.8.1.2\\_updated and Listing 16.2.7.1.4\\_updated.

Data cut-off date: 15 Feb 2021 (BOSTON); 01 Sep 2019 (STOMP)

MedDRA: Medical Dictionary for Regulatory Activities; SVd: selinexor with bortezomib and dexamethasone;

Note: This table uses MedDRA version 22.0. Preferred Terms were recoded to aggregate medically similar Preferred Terms.

TEAE: treatment-emergent adverse event; Vd: bortezomib and dexamethasone.

All SVd population includes 195 patients from the BOSTON SVd arm + 64 patients from the BOSTON crossover arm (SVdX), including I additional patient who crossed over from Vd arm since the primary analysis + 42 patients from the supportive sludy, STOMP.

one patient (BOSTON SVd) also had multiple organ dysfunction syndrome fatal; another patient (BOSTON SVd) also had pneumonia fatal and acute kidney injury fatal (both cases occurred in India).

one patient (BOSTON SVd) also had fatal cardio-respiratory alrest.

<div style=\"page-break-after: always\"></div>

Table 10: Results of Activities to Improve Outcomes in India - Primary Analysis

|                            | India SVd Patients with AE Onset<1 Feb 2019 (N=23)   | India SVd Patients with AE Onset<1 Feb 2019 (N=23)   | India SVd Patients Still on Treatment as of 1 Feb 2019 (N=12)   | India SVd Patients Still on Treatment as of 1 Feb 2019 (N=12)   | India Vd Patients with AE Onsct<1Fcb 2019 (N=20)   | India Vd Patients with AE Onsct<1Fcb 2019 (N=20)   | India Vd Patients Still on Treatment as of 1 Feb 2019 (N=11)   | India Vd Patients Still on Treatment as of 1 Feb 2019 (N=11)   |
|----------------------------|------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                            | n                                                    | %                                                    | N                                                               | %                                                               | n                                                  | %                                                  | n                                                              | %                                                              |
| TEAE                       | 23                                                   | 100                                                  | 12                                                              | 100                                                             | 20                                                 | 100                                                | 9                                                              | 81.8                                                           |
| SAE                        | 13                                                   | 56.5                                                 | 3                                                               | 25.0                                                            | 7                                                  | 35.0                                               | 0                                                              | 0                                                              |
| ≥Grade 3 AE                | 17                                                   | 73.9                                                 | 6                                                               | 50.0                                                            | 14                                                 | 70.0                                               | 4                                                              | 36.4                                                           |
| Maximum Severity (Grade 3) | 12                                                   | 52.2                                                 | 5                                                               | 41.7                                                            | 12                                                 | 60.0                                               | 3                                                              | 27.3                                                           |
| Maximum Severity (Grade 4) | 1                                                    | 4.3                                                  | 1                                                               | 8.3                                                             | 2                                                  | 10.0                                               | 1                                                              | 9.1                                                            |
| Maximum Severity (Grade 5) | 4                                                    | 17.4                                                 | 0                                                               | 0                                                               | 0                                                  | 0                                                  | 0                                                              | 0                                                              |

Source:Table 14.3.1.1.13.5.2,Table 14.3.1.1.13.5.3.

Datacut-off date:18Feb2020

AE=adverse event;SAE=serious adverse event;SVd=selinexorwithbortezomib and dexamethasone;

TEAE=treatment-emergent adverse event;Vd=bortezomibwith dexamethasone.

In the crossover population , 13 (20.3%) patients in the SVdX arm and 1 (7.7%) patient in the SdX arm died after crossing over from the Vd arm and within 30 days of the last dose of study drug (SVdX or SdX). In total, 9 (14.1%) patients in the SVdX arm and 1 (7.7%) patient in the SdX arm experienced TEAEs leading to death after crossover.

Table 11: Overview of Deaths and Primary Cause of Death (Crossover Population) - Updated Analysis

|                                                                                                                                        | SVdX Arm (N =64) n (%)   | SdX Arm (N=13) n (%)   |
|----------------------------------------------------------------------------------------------------------------------------------------|--------------------------|------------------------|
| Deaths OccurringWithin 30 Days of Last Dose of Study Drug                                                                              | 13 (20.3)                | 1 (7.7)                |
| PrimaryCauseofDeath                                                                                                                    |                          |                        |
| PD                                                                                                                                     | 4 (6.3)                  | 0                      |
| AdverseEvents                                                                                                                          | 9 (14.1)a                | 1 (7.7)a               |
| TEAEsLeadingtoDeathAfter theCrossover andWithin30 Days of Last Dose of Bortezomib inVd and Within 7 Days of Study Drug in the SVdX/SdX | 4 (6.3)b                 | 0 (0)                  |
| Deaths Occurring After 30 Days of Last Dose of Study Drug                                                                              | 22 (34.4)                | 2 (15.4)               |

Datacut-offdate:15Feb2021

PD=progressive disease; PT=preferred term; SdX=selinexor plus low-dose dexamethasone treatment after crossover; SVdX=SVd treatment after crossover;TEAE=treatment-emergent adverse event.

Note:Onlydeathevents that occurred afterthecrossovertotheSVdXorSdXtreatment areincluded.

a The Investigator reported that 1 patient died due to PD and TEAE in each arm (SVdX and SdX). To be conservative,theSponsor counted these asTEAEs.

b Four of the 8 patients with TEAEs leading to death in the SVdX arm died within 30 days of the last dose of Vd and within 7 days of SVdX study treatment.

Table 32. Summary of Efficacy for trial KCP-330-023 (BOSTON Study)

<div style=\"page-break-after: always\"></div>

## Serious adverse events

Table 12: Treatment-Emergent Serious Adverse Events o ccurring in ≥2% of Patients in the All SVd Population, Safety Population - Updated Analysis

| MedDRA System Organ Class MedDRA Preferred Term   | All SVd (N=3012) n (%)   | BOSTON SVd Arm (N=195) n (%)   | BOSTON Vd Arm (N=204) n (%)   |
|---------------------------------------------------|--------------------------|--------------------------------|-------------------------------|
| Patients with at least 1 treatment-emergent SAE   | 148 (49.2)               | 106 (54.4)                     | 79 (38.7)                     |
| Blood and lymphatic system disorders              | 15 (5.0)                 | 9 (4.6)                        | 5 (2.5)                       |
| Anaemia                                           | 9 (3.0)                  | 6 (3.1)                        | 3 (1.5)                       |
| Thrombocytopenia                                  | 6 (2.0)                  | 3 (1.5)                        | 1 (0.5)                       |
| Eye disorders                                     | 12 (4.0)                 | 9 (4.6)                        | 0                             |
| Cataract                                          | 11 (3.7)                 | 9 (4.6)                        | 0                             |
| Gastrointestinal disorders                        | 26 (8.6)                 | 18 (9.2)                       | 4 (2.0)                       |
| Diarrhoea                                         | 9 (3.0)                  | 7 (3.6)                        | 0                             |
| Vomiting                                          | 9 (3.0)                  | 7 (3.6)                        | 0                             |
| Nausea                                            | 7 (2.3)                  | 4 (2.1)                        | 0                             |
| Infections and infestations                       | 75 (24.9)                | 54 (27.7)                      | 40 (19.6)                     |
| Pneumoniac                                        | 38 (12.6)                | 29 (14.9)                      | 27 (13.2)                     |
| Sepsisc                                           | 10 (3.3)                 | 8 (4.1)                        | 2 (1.0)                       |
| Urinary tract infection                           | 6 (2.0)                  | 4 (2.1)                        | 0                             |
| Renal and urinary disorders                       | 8 (2.7)                  | 5 (2.6)                        | 2 (1.0)                       |
| Acute kidney injury                               | 7 (2.3)                  | 4 (2.1)                        | 2 (1.0)                       |

Table 14.3.2.1.1.8\\_updated.

Data cut-off date: 15 Feb 2021 (BOSTON); 01 Sep 2019 (STOMP)

Note: This table uses MedDRA version 22.0. System Organ Classes were recoded to aggregate medically similar SOCs. Preferred Terms were recoded to aggregate medically similar PTs.

MedDRA: Medical Dictionary for Regulatory Activities; PT: preferred term; SAE: serious adverse event;

SOC: system organ class; SVd: selinexor with bortezomib and dexamethasone; Vd: bortezomib and dexamethasone.

a All SVd population includes 195 patients from the BOSTON SVd arm + 64 patients from the BOSTON crossover arm (SVdX), including 1 additional patient who crossed over from the Vd arm since the primary analysis + 42 patients from the supportive study, STOMP.

c includes all PTs from sepsis Customized MedDRA Query (Table 14.3.2.1.1.8).

b includes all PTs from pneumonia Customized MedDRA Query (see Section 3.1.5.3.1).

<div style=\"page-break-after: always\"></div>

## Other significant adverse events

Table 13: Adverse Event of Clinical Interest Categories

| Group Category                   | AECI Category                       |
|----------------------------------|-------------------------------------|
| Cytopenias                       | Thrombocytopenia                    |
| Cytopenias                       | Neutropenia                         |
| Gastrointestinalevents           | Nausea/vomiting                     |
| Gastrointestinalevents           | Decreased appetite/decreased weight |
| Infectionandinfestationevents    | Pneumonia                           |
| Infectionandinfestationevents    | Sepsis                              |
| Infectionandinfestationevents    | Opportunistic infection             |
| Eyedisorder'sevents              | Blurred vision                      |
| Eyedisorder'sevents              | Cataract                            |
| Metabolismandnutritiondisorder's | Hyponatremia                        |
| Nervoussystemdisorder's          | Neurological toxicity               |
| Hepatic events                   | Hepatobiliary disorders             |
| Cardiac events                   | Cardiac toxicity                    |

## Cytopenias

## Thrombocytopenia

As of the updated analysis, the incidence of SMQ of thrombocytopenia was comparable in the All SVd population and BOSTON SVd arm (58.5% and 62.1%, respectively) and was higher than the BOSTON Vd arm (27.5%). The incidence of Grade 3/4 TEAEs and Grade 4 TEAEs of thrombocytopenia was higher in All SVd population and BOSTON SVd arm (Grade 3/4: 39.9% and 40.5%; Grade 4: 15.6% and 11.3%, respectively) compared with BOSTON Vd arm (Grade 3/4: 17.6%; Grade 4: 6.9%). Since the primary analysis, 4, 2, and 1 additional patient reported Grade 3/4 TEAEs; and 1, 1, and 0 additional patients reported Grade 4 TEAEs in All SVd population, BOSTON SVd arm, and BOSTON Vd arm, respectively. The Grade 4 TEAE reported in the BOSTON SVd arm was not associated with any Grade ≥3 bleeding events. The incidence of SAEs and discontinuations due to thrombocytopenia was low across all arms (SAEs: 2.0%, 1.5%, and 0.5% and discontinuations: 2.7%, 2.1%, and 0.5%, in All SVd population, BOSTON SVd arm, and BOSTON Vd arm, respectively) with no change in the incidence in any of the groups since primary analysis. The majority of the TEAEs were managed by dose modifications (36.9%, 40.0%, and 9.8%, in All SVd population, BOSTON SVd arm, and BOSTON Vd arm, respectively). In the ALL SVd population, BOSTON SVd arm, and the BOSTON Vd arm, the incidence of Grade ≥3 bleeding events among the patients with Grade ≥3 thrombocytopenia was same as the primary analysis (5.0%, 5.1% and 5.6%, respectively).

<div style=\"page-break-after: always\"></div>

Table 14: Summary of Thrombocytopenia (Safety Population) - Updated Analysis

| Patientswithatleast 1                                        | AllSVd (N=3012) n (%)   | BOSION SVd Arm (N=195) n (%)   | BOSTON Vd Arm (N=204) n (%)   |
|--------------------------------------------------------------|-------------------------|--------------------------------|-------------------------------|
| Treatment-emergentTEAE                                       | 176 (58.5)              | 121 (62.1)                     | 56 (27.5)                     |
| Grade 3/4 TEAEb                                              | 120 (39.9)              | 79 (40.5)                      | 36 (17.6)                     |
| Grade 4 TEAEb                                                | 47 (15.6)               | 22 (11.3)                      | 14 (6.9)                      |
| Treatment-emergent SAE                                       | 6 (2.0)                 | 3 (1.5)                        | 1 (0.5)                       |
| TEAE leading to dose modification in any study treatmentc. d | 111 (36.9)              | 78 (40.0)                      | 20 (9.8)                      |
| TEAE leading to dose reduction in any study treatment        | 86 (28.6)               | 65 (33.3)                      | 9 (4.4)                       |
| TEAE leading to dose interruption in any study treatment     | 98 (32.6)               | 69 (35.4)                      | 16 (7.8)                      |
| TEAE leading to study treatment discontinuation              | 8 (2.7)                 | 4 (2.1)                        | 1 (0.5)                       |
| TEAEleading to death                                         | 0                       | 0                              | 0                             |

Source:Table14.3.2.1.1.1\\_Updated

Data cut-off date:15 Feb 2021 (BOSTON);01 Sep 2019 (STOMP)

SVd: selinexor with bortezomib and dexamethasone; TEAE: treatment-emergent adverse event;

TRAE: treatment-related adverse event; Vd: bortezomib and dexamethasone.

- a All SVd population includes 195 patients from the BOSTON SVd arm + 64 patients from the BOSTON crossover arm(SVdX),including1 additionalpatient whocrossed overfrom theVd armsince theprimary analysis + 42 patients from the supportive study, STOMP.
- c The number of patients with dose modification(s) was not necessarily equal to the sum of the number of patients who had a modified dose or a drug interruption since the same patient could fall into more than one of these categories.

b Based on maximum severity grade of each patient.

d Study treatment was selinexor with bortezomib and dexamethasone for SVd arm, and bortezomib with dexamethasoneforVd arm.

<div style=\"page-break-after: always\"></div>

## Neutropenia

Table 15: Summary of Neutropenia, Safety Population - Updated Analysis

| Patientswithatleast1                                       | All SVd (N=301\") n (%)   | BOSTON SVd Arm (N=195) n (%)   | BOSTON Vd Arm (N=204) n (%)   |
|------------------------------------------------------------|--------------------------|--------------------------------|-------------------------------|
| Treatment-emergent adverseevent                            | 61 (20.3)                | 31 (15.9)                      | 14 (6.9)                      |
| Grade 3/4 TEAEb                                            | 41 (13.6)                | 19 (9.7)                       | 8 (3.9)                       |
| Grade 4 TEAEb                                              | 8 (2.7)                  | 5 (2.6)                        | 3 (1.5)                       |
| Treatment-emergent SAE                                     | 4 (1.3)                  | 2 (1.0)                        | 1 (0.5)                       |
| TEAE leading to dosemodification in any study treatmente.d | 29 (9.6)                 | 18 (9.2)                       | 3 (1.5)                       |
| TEAE leading to dose reduction in any study treatment      | 14 (4.7)                 | 9 (4.6)                        | 0                             |
| TEAE leading to dose interruption in any study treatment   | 28 (9.3)                 | 18 (9.2)                       | 3 (1.5)                       |
| TEAEleadingtostudytreatment discontinuation                | 1 (0.3)                  | 0                              | 0                             |
| TEAEleading todeath                                        | 0                        | 0                              | 0                             |

Source: Table 14.3.2.1.1.2\\_updated.

Data cut-off date:15Feb2021(BOSTON);01Sep2019(STOMP)

SAE:adverseevent;SVd:selinexorwithbortezomibanddexamethasone,TEAE:treatment-emergent adverseevent;

TRAE: treatment-related adverse event Vd: bortezomib and dexamethasone.

b Based on maximum severity grade of each patient.

aAll SVd population includes 195patients from the BOSTON SVd arm+ 64 patients from theBOSTON crossover arm(SVdX),including 1 additional patient who crossed over from theVd arm since the primary analysis + 42 patients from the supportive study, STOMP.

c The number of patients with dose modification(s) was not necessarily equal to the sum of the number of patients whohad a modified dose ora druginterruptionsince the same patient could fall intomore than one of these categories.

d Study treatment was selinexor with bortezomib and dexamethasone for SVd am, and bortezomib with dexamethasoneforVd arm.

## Gastrointestinal events

## Nausea/vomiting

The incidence of nausea and vomiting based on updated analysis was same as the primary analysis in All SVD population and BOSTON SVd arm; 1 additional patient reported TEAE of nausea and vomiting each in Vd arm since the primary analysis. No new ≥Grade 3 TEAEs, dose modifications due to AEs, SAEs, or discontinuations due to nausea or vomiting were reported in either arms since the primary analysis and the incidence of these events was same as the primary analysis.

<div style=\"page-break-after: always\"></div>

Table 16: Summary of Nausea, Safety Population -Updated Analysis

| Patients with at Least One                                               | All SVd (N=301) n (%)   | BOSTONSVd Am (N= 195) n (%)   | BOSTON Vd Arm (N=204) n (%)   |
|--------------------------------------------------------------------------|-------------------------|-------------------------------|-------------------------------|
| Treatment-Emergent AdverseEvent                                          | 150 ( 49.8)             | 98 (50.3)                     | 21 ( 10.3)                    |
| Grade 3/4 TEAE [1]                                                       | 20 ( 6.6)               | 15 ( 7.7)                     | 0                             |
| Grade 4 TEAE [1]                                                         | 0                       | 0                             | 0                             |
| Serious TEAE                                                             | 7( 2.3)                 | 4( 2.1)                       | 0                             |
| TEAE Leading to Dose Modification in Any Study                           | 35 ( 11.6)              | 21 (10.8)                     | 0                             |
| Treatment [2] [3] TEAE Leading tpo Dose Reduction in Any Study Treatment | 22( 7.3)                | 14( 7.2)                      | 0                             |
| TEAE Leading to Dose Interruption in Any Study Treatment                 | 22( 7.3)                | 14( 7.2)                      | 0                             |
| TEAE LeadingtoStudyTreatmentDiscontinuation                              | 9( 3.0)                 | 6( 3.1)                       | 0                             |
| TEAE Leading to Death                                                    | 0                       | 0                             | 0                             |
| Treatment-Emergent Treatment-Related Adverse Event [4]                   | 142 (47.2)              | 93 (47.7)                     | 12 ( 5.9)                     |
| Grade 3/4 TRAE [1]                                                       | 20( 6.6)                | 15 ( 7.7)                     | 0                             |
| Grade 4 TRAE [1]                                                         | 0                       | 0                             | 0                             |
| Serious TRAE                                                             | 7( 2.3)                 | 4( 2.1)                       | 0                             |
| TRAE Leading to Dose Modification in Any Study                           | 34 ( 11.3)              | 20 ( 10.3)                    | 0                             |
| Treatment [2] [3] TRAE Leading to Dose Reduction in Any Study Treatment  | 22 ( 7.3)               | 14 ( 7.2)                     | 0                             |
| TRAE Leading to Dose Interruption in Any Study Treatment                 | 21( 7.0)                | 13 ( 6.7)                     | 0                             |
| TRAE Leading to Study Treatment Discontinuation                          | 9( 3.0)                 | 6( 3.1)                       | 0                             |
| TRAE Leading to Death                                                    | 0                       | 0                             | 0                             |

(Database Cutoff Date: 2021-02-15; Source Data: ADAE, ADDENOM)

Executed: 2021-03-09 12:24

[2] The number of patients with dose modification(s) is not necessarily equal to the sum of the number of patients who had a modified dose or a drug intemuption since the same patient could fall into more than one of these categories.

[4] An AE is considered treatment-related if it is selinexor-related and/or bortezomib-related and/or dexamethasone-related.

[3]Study treatment isselinexorwith bortezomiband dexamethasone forSVdArmand bortezomibwith dexamethasoneforVd Am.

Table 17: Summary of Vomiting, Safety Population - Updated analysis

| Patientswith at Least One                                               | AllSVd (N=301) n (%)   | BOSTON SVd Arm (N= 195) n (%)   | BOSTON Vd Am (N=204) n (%)   |
|-------------------------------------------------------------------------|------------------------|---------------------------------|------------------------------|
| Treatment-Emergent Adverse Evpnt                                        | 69 ( 22.9)             | 40 (20.5)                       | 10 ( 4.9)                    |
| Grade 3/4 TEAE [1]                                                      | 11( 3.7)               | 8( 4.1)                         | 0                            |
| Grade 4 TEAE [1]                                                        | 0                      | 0                               | 0                            |
| Serious TEAE                                                            | 9( 3.0)                | 7( 3.6)                         | 0                            |
| TEAE Leading to Dose Modification in Any Study                          | 14 ( 4.7)              | 9( 4.6)                         | 1( 0.5)                      |
| Treatment [2] [3] TEAE Leading to Dose Reduction in Any Study Treatment | 9( 3.0)                | 6( 3.1)                         | 1( 0.5)                      |
| TEAE Leading to Dose Intemuption in Any Study Treatment                 | 9( 3.0)                | 6( 3.1)                         | 0                            |
| TEAE Leading to Study Treatment Discontinuation                         | 4( 1.3)                | 4( 2.1)                         | 0                            |
| TEAE Leading to Death                                                   | 0                      | 0                               | 0                            |
| Treatment-Emergent Treatment-Related Adverse Event [4]                  | 57 (18.9)              | 34 (17.4)                       | 5( 2.5)                      |
| Grade 3/4 TRAE [1]                                                      | 11( 3.7)               | 8( 4.1)                         | 0                            |
| Grade 4 TRAE [1]                                                        | 0                      | 0                               | 0                            |
| Serious TRAE                                                            | 9( 3.0)                | 7( 3.6)                         | 0                            |

<div style=\"page-break-after: always\"></div>

| PatientswithatLeastOne                                    | All SVd (N = 301) n (%)   | BOSTONSVd Arm (N=195) n (%)   | BOSTONVd Arm (N=204) n (%)   |
|-----------------------------------------------------------|---------------------------|-------------------------------|------------------------------|
| TRAELeadingtoDoseModificationinAnyStudy Treatment [2] [3] | 12 ( 4.0)                 | 8 ( 4.1)                      | 1( 0.5)                      |
| TRAE Leading toDoseReduction in Any Study Treatment       | 9(3.0)                    | 6 ( 3.1)                      | 1( 0.5)                      |
| TRAE Leading toDoseInterruption in Any Study Treatment    | 6( 2.0)                   | 4( 2.1)                       | 0                            |
| TRAELeading toStudyTreatmentDiscontinuation               | 4( 1.3)                   | 4 ( 2.1)                      | 0                            |
| TRAE Leading to Death                                     | 0                         | 0                             | 0                            |

(DatabaseCutoffDate:2021-02-15;SourceData:ADAE,ADDENOM)

[1]Based onmaximum severity grade of each patient.

[2]The number ofpatientswith dose modification(s)is not necessarily equal to the sum of the number of patientswho had a modified dose or a drug intemuption since the same patient could fall into more than one of these categories.

[3]Study treatmentis selinexorwithbortezomib anddexamethasone forSVdAm,andbortezomibwith dexamethasone forVd Am.

[4]An AEis considered treatment-relatedifit is selinexor-related and/orbortezomib-relatedand/ordexamethasone-related.

## Decreased appetite/weight decreased

For the TEAE of decreased appetite, there was no change in the incidence of TEAEs, Grade 3 TEAEs, SAEs, TEAEs leading to dose modifications, and TEAEs leading to discontinuation compared with the primary analysis in all 3 groups. No Grade 4 TEAEs or deaths were reported in any of the 3 groups.

For the TEAE of decreased weight, the incidence of all TEAEs, SAEs, TEAEs leading to dose modifications, or discontinuations of treatment was similar to the primary analysis in all 3 groups. One additional patient reported a Grade 3 TEAE of weight decreased in the All SVd population and BOSTON SVd arm since the primary analysis. No Grade 4 TEAEs or deaths were reported in any of the 3 groups.

Decreased appetite

Table 18: Summary of Decreased Appetite, Safety Population - Updated analysis

| PatientswithatLeast One                                                 | All SVd (N=301) n (%)   | BOSTON SVd Arm (N= 195) n (%)   | BOSTON Vd Arm (N= 204) n (%)   |
|-------------------------------------------------------------------------|-------------------------|---------------------------------|--------------------------------|
| Treatment-Emergent AdverseEvent                                         | 112 (37.2)              | 69 (35.4)                       | 11( 5.4)                       |
| Grade 3/4 TEAE [1]                                                      | 10( 3.3)                | 7( 3.6)                         | 0                              |
| Grade 4 TEAE [1]                                                        | 0                       | 0                               | 0                              |
| Serious TEAE                                                            | 2( 0.7)                 | 1( 0.5)                         | 0                              |
| TEAE Leading to Dose Modification in Any Study                          | 36 ( 12.0)              | 27 (13.8)                       | 2( 1.0)                        |
| Treatment [2] [3] TEAE Leading to Dose Reduction in Any Study Treatment | 19 ( 6.3)               | 17( 8.7)                        | 0                              |
| TEAE Leading to DoseIntenruption in Any Study Treatment                 | 26 ( 8.6)               | 18 ( 9.2)                       | 2( 1.0)                        |
| TEAE Leading to Study Treatment Discontinuation                         | 6( 2.0)                 | 4( 2.1)                         | 1( 0.5)                        |
| TEAE LeadingtoDeath                                                     | 0                       | 0                               | 0                              |
| Treatment-Emergent Treatment-Related Adverse Event [4]                  | 103 ( 34.2)             | 63 (32.3)                       | 8( 3.9)                        |
| Grade 3/4 TRAE [1]                                                      | 10 ( 3.3)               | 7( 3.6)                         | 0                              |
| Grade 4 TRAE [1]                                                        | 0                       | 0                               | 0                              |

<div style=\"page-break-after: always\"></div>

| Patients with at Least One                             | All SVd (N = 301) n (%)   | BOSTON SVd Arm (N = 195) n (%)   | BOSTON Vd Arm (N = 204) n (%)   |
|--------------------------------------------------------|---------------------------|----------------------------------|---------------------------------|
| Serious TRAE                                           | 2 ( 0.7)                  | 1( 0.5)                          |                                 |
| TRAE Leading to Dose Modification in Any Study         | 34 ( 11.3)                | 26 (13.3)                        | 1( 0.5)                         |
| Treatment [2] [3]                                      |                           |                                  |                                 |
| TRAE Leading to Dose Reduction in Any Study Treatment  | 16 (5.3)                  | 15 ( 7.7)                        | 0                               |
| TRAE Leading toDoseInterruption in Any Study Treatment | 25 ( 8.3)                 | 17 ( 8.7)                        | 1( 0.5)                         |
| TRAE Leading to Study Treatment Discontinuation        | 6 ( 2.0)                  | 4( 2.1)                          | 1( 0.5)                         |
| TRAE Leading to Death                                  | 0                         | 0                                | 0                               |

(DatabaseCutoffDate:2021-02-15;SourceData:ADAE,ADDENOM)

[1]Based onmaximum severity grade of each patient.

[3]Study treatment isselinexorwith bortezomiband dexamethasonefor SVdAm,and bortezomibwithdexamethasone for Vd Arm

[2] The number ofpatientswith dose modification(s)isnotnecessarily equalto the sum of the number ofpatients who had a modified dose ora drug interruption since the same patient could fallinto more than one of these categories.

[4] An AEis considered treatment-relatedif it is selinexor-related and/or bortezomib-related and/or dexamethasone-related.

## Decreased weight

Table 19: Summary of Decreased Weight, Safety Population - Updated analysis

| Patients with at Least One                                              | AllSVd (N=301) n (%)   | BOSTONSVd Arm (N= 195) n (%)   | BOSTON Vd Arm (N=204) n (%)   |
|-------------------------------------------------------------------------|------------------------|--------------------------------|-------------------------------|
| Treatment-EmergentAdverseEvent                                          | 85 (28.2)              | 51 (26.2)                      | 25 (12.3)                     |
| Grade 3/4 TEAE [1]                                                      | 6( 2.0)                | 5( 2.6)                        | 2( 1.0)                       |
| Grade 4 TEAE [1]                                                        | 0                      | 0                              | 0                             |
| Serious TEAE                                                            | 0                      | 0                              | 0                             |
| TEAE Leading to Dose Modification in Any Study                          | 27( 9.0)               | 19 ( 9.7)                      | 5( 2.5)                       |
| Treatment [2] [3] TEAE Leading to Dose Reduction in Any Study Treatment | 20 ( 6.6)              | 14( 7.2)                       | 4( 2.0)                       |
| TEAE Leading to Dose Interruption in Any Study Treatment                | 18 ( 6.0)              | 12( 6.2)                       | 2( 1.0)                       |
| TEAE Leading to Study Treatment Discontinuation                         | 3( 1.0)                | 2( 1.0)                        | 1( 0.5)                       |
| TEAE Leading to Death                                                   | 0                      | 0                              | 0                             |
| Treatment-Emergent Treatment-Related Adverse Event [4]                  | 65 (21.6)              | 38 (19.5)                      | 8( 3.9)                       |
| Grade 3/4 TRAE [1]                                                      | 3( 1.0)                | 3( 1.5)                        | 0                             |
| Grade 4 TRAE [1]                                                        | 0                      | 0                              | 0                             |
| Serious TRAE                                                            | D                      | 0                              | 0                             |
| TRAE Leading to Dose Modification in Any Study                          | 23( 7.6)               | 18 (9.2)                       | 3( 1.5)                       |
| Treatment [2] [3] TRAE Leading to Dose Reduction in Any Study Treatment | 18 ( 6.0)              | 14( 7.2)                       | 2( 1.0)                       |
| TRAE Leading to Dose Intermuption in Any Study Treatment                | 15 ( 5.0)              | 11( 5.6)                       | 1( 0.5)                       |
| TRAE Leading to Study Treatment Discontinuation                         | 2 ( 0.7)               | 2 ( 1.0)                       | 0                             |
| TRAE Leading to Death                                                   | 0                      | 0                              | 0                             |

(DatabaseCutoff Date:2021-02-15;SourceData:ADAE,ADDENOM)

[1]Based on maximum severity grade of each patient.

[3] Study treatment is selinexor with bortezomib and dexamethasone for SVd Arm, and bortezomib with dexamethasone for Vd Arm

[2]The number ofpatients with dose modification(s)is not necessarily equal to the sum of the number ofpatients who had amodified dose ora drug interuptionsince the same patient could fall into more than one of these categories.

[4] An AE is considered treatment-relatedifit isselinexor-related and/or bortezomib-related and/or dexamethasone-related.

## Infection ad infestation events

Pneumonia

<div style=\"page-break-after: always\"></div>

Table 20: Summary of Pneumonia, Safety Population - Updated Analysis

| Patients With At Least l                                     | All SVd (N=301) n (%)   | BOSION SVd Arm (N=195) n (%)   | BOSTON Vd Arm (N=204) n (%)   |
|--------------------------------------------------------------|-------------------------|--------------------------------|-------------------------------|
| Treatment-emergent adverse event                             | 49 (16.3)               | 37 (19.0)                      | 35 (17.2)                     |
| Grade 3/4 TEAEb                                              | 31 (10.3)               | 24 (12.3)                      | 21 (10.3)                     |
| Grade 4 TEAEbb                                               | 4 (1.3)                 | 2 (1.0)                        | 0                             |
| Treatment-emergent SAE                                       | 38 (12.6)               | 29 (14.9)                      | 27 (13.2)                     |
| TEAE leading to dose modification in any study treatmentc. d | 37 (12.3)               | 28 (14.4)                      | 27 (13.2)                     |
| TEAE leading to dose reduction in any shudy treatment        | 8 (2.7)                 | 8 (4.1)                        | 2 (1.0)                       |
| TEAE leading to dose intemuption in any study treahment      | 37 (12.3)               | 28 (14.4)                      | 27 (13.2)                     |
| TEAE leading to study treatment discontimation               | 3 (1.0)                 | 1 (0.5)                        | 0                             |
| TEAE leading to death                                        | 5 (1.7)                 | 4 (2.1)                        | 4 (2.0)                       |

Source: Table 14.3.2.1.1.7 updated

Data cut-off date: 15 Feb 2021 (B0ST0N); 01 Sep 2019 (ST0MP)

SAE: serious adverse event; SVd: selinexor plus bortezomib plus low-dose dexamethasone; TEAE: treatment emergent adverse event; TRAE: treatment-related adverse event; Vd: bortezomib plus low-dose dexamethasone.

- b Based on maximmum severity grade of each patient.
- All SVd population includes 195 patients from the BOSTON SVd am + 64 patients from the BOSTON crossover am (SVdX), including 1 additional patient who crossed over from Vd arm since the primary amalysis + 42 patients from the supportive study, STOMP.
- The mumber of patients with dose modification(s) was not necessarily equal to the sum of the number of patients who had a modified dose or a dnug intemuption since the same patient could fall into more tham one of these categonies.
- d Study treatment was selinexor with bortezomib and dexamethasone for SVd am, and bortezomib with dexamethasone for Vd arm.

## Sepsis

In the updated analysis the incidence of CMQ of sepsis in all 3 groups was similar to the primary analysis and no new patients reported events of sepsis, including Grade 3/4 events, SAEs, events leading to dose modifications or dose discontinuations, and deaths due to sepsis since the primary analysis.

<div style=\"page-break-after: always\"></div>

Table 21: Summary of Sepsis, Safety Population - Updated analysis

| Patients with at Least One                                              | All SVd (N=301) n (%)   | BOSTONSVdBOSTONVd Arm (N= 195) n (%)   | Arm (N=204) n (%)   |
|-------------------------------------------------------------------------|-------------------------|----------------------------------------|---------------------|
| Treatment-EmergentAdverseEvent                                          | 11( 3.7)                | 8( 4.1)                                | 2( 1.0)             |
| Grade 3/4 TEAE []                                                       | 5( 1.7)                 | 5( 2.6)                                | 2( 1.0)             |
| Grade 4 TEAE [1]                                                        | 4( 1.3)                 | 4( 2.1)                                | 0                   |
| Serious TEAE                                                            | 10( 3.3)                | 8( 4.1)                                | 2( 1.0)             |
| TEAE Leading to Dose Modification in Any Study                          | 5( 1.7)                 | 4( 2.1)                                | 1( 0.5)             |
| Treatment [2] [3] TEAE Leading to Dose Reduction in Any Study Treatment | 0                       | 0                                      | 1( 0.5)             |
| TEAE Leading toDose Interruption in Any Study Treatment                 | 5( 1.7)                 | 4( 2.1)                                | 1( 0.5)             |
| TEAE Leading toStudyTreatment Discontinuation                           | 1( 0.3)                 | 1( 0.5)                                | 0                   |
| TEAE Leading to Death                                                   | 5( 1.7)                 | 3( 1.5)                                | 0                   |
| Treatment-Emergent Treatment-Related Adverse Event [4]                  | 8( 2.7)                 | 5( 2.6)                                | 1( 0.5)             |
| Grade 3/4 TRAE [1]                                                      | 3( 1.0)                 | 3( 1.5)                                | 1( 0.5)             |
| Grade 4 TRAE [1]                                                        | 2( 0.7)                 | 2( 1.0)                                | 0                   |
| Serious TRAE                                                            | 7( 2.3)                 | 5( 2.6)                                | 1( 0.5)             |
| TRAE Leading to Dose Modification in Any Study Treatment [2] [3]        | 3 ( 1.0)                | 2( 1.0)                                | 1( 0.5)             |
| TRAE Leading to Dose Reduction in Any Study Treatment                   | 0                       | 0                                      | 1( 0.5)             |
| TRAE Leading to Dose Intemuption in Any Study Treatment                 | 3( 1.0)                 | 2( 1.0)                                | 1( 0.5)             |
| TRAE Leading to Study Treatment Discontinuation                         | 1 ( 0.3)                | 1 ( 0.5)                               | 0                   |
| TRAE Leading to Death                                                   | 4( 1.3)                 | 2( 1.0)                                | 0                   |

(DatabaseCutoffDate:2021-02-15;SourceData:ADAE,ADDENOM)

[1] Based on maximum severity grade of each patient.

[3] Study treatment is selinexor with bortezomib and dexamethasone for SVd Arm, and bortezomib with dexamethasone for Vd Am.

[2]The numberofpatients withdose modification(s)isnotnecessarily equaltothe sumof thenumberofpatients who had amodified doseora drug inteuptionsince the same patient could fall into more than one ofthese categories.

[4] An AE is considered treatment-relatedifit is selinexor-related and/orbortezomib-related and/or dexamethasone-related.

F:BiostatisticsKPT-330ISS\\_BOSTONData\\_Cuts/2021-02-15Dev\\MAA\\_Update\\T-14-3-2-1-1-8-AE-Summary-by-Treatment-Group-Safety-Sepsis-CMQ-updated.saS

## Opportunistic infection

Table 22: Summary of Opportunistic Infection, Safety Population - Updated analysis

| Patients with at Least One                               | All SVd (N=301) n (%)   | All SVd (N=301) n (%)   | BOSTON Vd Am (N= 204) n (%)   |
|----------------------------------------------------------|-------------------------|-------------------------|-------------------------------|
| Treatment-EmergentAdverseEvent                           | 24( 8.0)                | 16( 8.2)                | 9( 4.4)                       |
| Grade 3/4 TEAE [1]                                       | 6(2.0)                  | 5( 2.6)                 | 3( 1.5)                       |
| Grade 4 TEAE [1]                                         | 1( 0.3)                 | 1( 0.5)                 | 0                             |
| Serious TEAE                                             | 4( 1.3)                 | 3( 1.5)                 | 2( 1.0)                       |
| TEAE Leading to Dose Modification in Any Study           | 12 ( 4.0)               | 9( 4.6)                 | 6( 2.9)                       |
| Treatment [2] [3]                                        |                         |                         |                               |
| TEAE Leading to Dose Reduction in Any Study Treatment    | 1( 0.3)                 | 1( 0.5)                 | 0                             |
| TEAE Leading to Dose Intenruption in Any Study Treatment | 12( 4.0)                | 9( 4.6)                 | 6( 2.9)                       |
| TEAE Leading to Study Treatment Discontinuation          | 0                       | 0                       | 1( 0.5)                       |
| TEAE Leading toDeath                                     | 0                       | 0                       | 0                             |
| Treatment-Emergent Treatment-Related Adverse Event [4]   | 12 ( 4.0)               | 8( 4.1)                 | 5( 2.5)                       |
| Grade 3/4 TRAE [1]                                       | 3( 1.0)                 | 2( 1.0)                 | 2( 1.0)                       |
| Grade 4 TRAE [1]                                         | 1( 0.3)                 | 1( 0.5)                 | 0                             |

<div style=\"page-break-after: always\"></div>

| Patientswith at LeastOne                          | AllSVd (N =301) n (%)   | BOSTONSVd Arm (N= 195) n (%)   | BOSTONVd Arm (N=204) n (%)   |
|---------------------------------------------------|-------------------------|--------------------------------|------------------------------|
| SeriousTRAE                                       | 2 ( 0.7)                | 1( 0.5)                        | 1( 0.5)                      |
| TRAE Leading to Dose Modification in Any Study    | 5 ( 1.7)                | 4 ( 2.1)                       | 3 ( 1.5)                     |
| Treatment [2] [3]                                 |                         |                                |                              |
| TRAELeadingtoDoseReductioninAnyStudy              | 0                       | 0                              | 0                            |
| Treatment                                         |                         |                                |                              |
| TRAELeadingtoDoseInterruptioninAnyStudy Treatment | 5( 1.7)                 | 4( 2.1)                        | 3( 1.5)                      |
| TRAE Leading to Study Treatment Discontinuation   | 0                       | 0                              | 1( 0.5)                      |
| TRAELeadingtoDeath                                | 0                       | 0                              | 0                            |

## Eye disorders events

## Blurred vision

The incidence of blurred vision (CMQ) was comparable in the All SVd population and BOSTON SVd arm and higher than the BOSTON Vd arm (13.0%, 13.8%, 7.4%, respectively).

Table 23: Summary of Blurred Vision, Safety Population - Updated Analysis

| Patients With At Least One                                  | AllSId (N=301) n (%)   | BOSTON SVd Arm (N=195) n (%)   | BOSTON VdArm (N=204) n (%)   |
|-------------------------------------------------------------|------------------------|--------------------------------|------------------------------|
| Treatment-emergent adverse event                            | 39 (13.0)              | 27 (13.8)                      | 15 (7.4)                     |
| Grade 3/4 TEAEb                                             | 3 (1.0)                | 2 (1.0)                        | 0                            |
| Grade 4 TEAEb                                               | 0                      | 0                              | 0                            |
| Treatment-emergent SAE                                      | 0                      | 0                              | 0                            |
| TEAE leading to dose modification in any study treatmente.d | 6 (2.0)                | 3 (1.5)                        | 2 (1.0)                      |
| TEAE leading to dose reduction in any study treatment       | 4 (1.3)                | 2 (1.0)                        | 1 (0.5)                      |
| TEAE leading to dose intemuption in any study treatment     | 4 (1.3)                | 2 (1.0)                        | 1 (0.5)                      |
| TEAE leading to study treatment discontinuation             | 0                      | 0                              | 0                            |
| TEAE leading to death                                       | 0                      | 0                              | 0                            |

Source: Table 14.3.2.1.1.10\\_updated

Data cut-off date: 15 Feb 2021 (B0STON); 01 Sep 2019 (SI0MP)

SAE: adverse event; SVd selinexor with bortezomib and dexamethasone, TEAE: treatment-emergent adverse event; TRAE: treatment-related adverse event Vd: bortezomib and dexamethasone.

- b Based on maximum severity grade of each patient.
- All SVd population includes 195 patients from the BOSTON SVd am + 64 patients fiom the BOSTON crossover am (SVdX), including 1 additional patient who crossed over from Vd am since the primary amalysis + 42 patients from the supportive study, STOMP.
- The number of patients with dose modification(s) was not necessarily equal to the sum of the mumber of patients who had a modified dose or a dug intemuption since the same patient could fall into more than one of these categonies.
- d Study treatment was selinexor with bortezomib and dexamethasone for SVd am, and bortezomib with dexamethasone for Vd anm.

## Cataract

In the BOSTON study, 386 of 399 patients in the Safety Population had a screening OE. At baseline, 120 (61.5%) patients on the SVd arm and 130 (63.7%) patients on the Vd arm had cataract on OE.

Based on OE, occurrence of new cataracts was seen in 19 (25.3%) in the BOSTON SVd arm and 10 (12.2%) patients on the BOSTON Vd arm with 1 additional patient in BOSTON SVd arm and 3

<div style=\"page-break-after: always\"></div>

additional patients in BOSTON Vd arm developing new-onset cataracts per OE since the primary analysis.

Worsening of cataracts (identified based on reported TEAEs of cataract) was noted in 27/117 (23.1%) patients with no ongoing cataract at baseline in the SVd arm versus 10/127 (7.9%) patients in the Vd arm.

Table 24: Summary of Cataract, Safety Population - Updated Analysis

| Patients With At Least 1                                     | All SVd (N=3012) n (%)   | BOSTON SVd Arm (N=195) n (%)   | BOSTON Vd Arm (N=204) n (%)   |
|--------------------------------------------------------------|--------------------------|--------------------------------|-------------------------------|
| Treatment-emergent adverseevent                              | 67 (22.3)                | 46 (23.6)b                     | 15 (7.4)b                     |
| Grade 3/4 TEAEc                                              | 30 (10.0)                | 22 (11.3)                      | 4 (2.0)                       |
| Grade 4 TEAEc                                                | 4 (1.3)                  | 2 (1.0)                        | 3 (1.5)                       |
| Treatment-emergent SAE                                       | 11 (3.7)                 | 9 (4.6)                        | 0                             |
| TEAE leading to dose modification in any study treatmentd. e | 13 (4.3)                 | 11 (5.6)                       | 1 (0.5)                       |
| TEAE leading to dose reduction in any study treatment        | 5 (1.7)                  | 5 (2.6)                        | 1 (0.5)                       |
| TEAE leading to dose interruption in any study treatment     | 10 (3.3)                 | 8 (4.1)                        | 0                             |
| TEAE leading to study treatment discontinuation              | 0                        | 0                              | 0                             |
| TEAE leading to death                                        | 0                        | 0                              | 0                             |

Source: Table 14.3.2.1.1.11\\_updated.

Data cut-off date: 15 Feb2021(BOSTON); 01 Sep 2019 (STOMP)

- SAE:adverseevent;SVd:selinexorwithbortezomib anddexamethasone,TEAE:treatment-emergent adverseevent; TRAE:treatment-related adverseeventVd:bortezomiband dexamethasone.
- a All SVd population includes 195 patients from the BOSTON SVd arm + 64 patients from the BOSTON crossover aim (SVdX), including 1 additional patient who crossed over from Vd arm since the primary analysis + 42 patients from the supportive study, STOMP.
- c Based on maximum severity grade of each patient.
- Per ophthalmology examination (OE); onset of new cataracts was seen in 25.3% of the patients on BOSTON SVd alm versus 12.2% on the BOSTON Vd arm (Module 5.3.5.1, KCP-330-023 CSR, Table 14.3.9.1.1\\_updated). Worsening of cataract on studywas noted in 23.1%of thepatients onSVd armversus 7.9%on theVd arm (Module 5.3.5.1, KCP-330-023 CSR, Table 14.3.1.1.13.6.1\\_updated).
- d The number of patients with dose modification(s) was not necessarily equal to the sum of the number of patients who had a modified dose or a drug interruption since the same patient could fall into more than one of these categories.
- Study treatment was selinexor with bortezomib and dexamethasone for SVd Aim, and bortezomib with dexamethasone for Vd arm.

## Hyponatremia

The SMQ of hyponatremia retrieved the PTs of hyponatremia and brain oedema.

<div style=\"page-break-after: always\"></div>

Table 25: Summary of hyponatremia, Safety population - Updated analysis

| Patients with at Least One                                       | All1SVd (N =301) n (%)   | BOSTONSVd Am (N= 195) n (%)   | BOSTONVd Arm (N=204) n (%)   |
|------------------------------------------------------------------|--------------------------|-------------------------------|------------------------------|
| Treatment-Emergent AdverseEvent                                  | 24 ( 8.0)                | 16( 8.2)                      | 3( 1.5)                      |
| Grade 3/4 TEAE [1]                                               | 17( 5.6)                 | 10( 5.1)                      | 1( 0.5)                      |
| Grade 4 TEAE [1]                                                 | 1( 0.3)                  | 1( 0.5)                       | 0                            |
| Serious TEAE                                                     | 1( 0.3)                  | 1( 0.5)                       | 0                            |
| TEAE Leading to Dose Modification in Any Study Treatment [2] [3] | 4( 1.3)                  | 2( 1.0)                       | 1( 0.5)                      |
| TEAE Leading to Dose Reduction in Any Study Treatment            | 3( 1.0)                  | 2( 1.0)                       | 0                            |
| TEAE Leading to Dose Intemuption in Any Study Treatment          | 2( 0.7)                  | 1( 0.5)                       | 1( 0.5)                      |
| TEAE Leading to Study Treatment Discontinuation                  | 0                        | 0                             | 0                            |
| TEAE Leading to Death                                            | 0                        | 0                             | 0                            |
| Treatment-Emergent Treatment-Related Adverse Event [4]           | 20 ( 6.6)                | 13( 6.7)                      | 2( 1.0)                      |
| Grade 3/4 TRAE [1]                                               | 14( 4.7)                 | 8( 4.1)                       | 0                            |
| Grade 4 TRAE [1]                                                 | 0                        | 0                             | 0                            |
| Serious TRAE                                                     | 0                        | 0                             | 0                            |
| TRAE Leading to Dose Modification in Any Study Treatment [2] [3] | 4( 1.3)                  | 2( 1.0)                       | 0                            |
| TRAE Leading to Dose Reduction in Any Study Treatment            | 3 ( 1.0)                 | 2( 1.0)                       | 0                            |
| TRAE Leading to Dose Intermuption in Any Study Treatment         | 2( 0.7)                  | 1( 0.5)                       | 0                            |
| TRAE Leading to Study Treatment Discontinuation                  | 0                        | 0                             | 0                            |
| TRAE Leading to Death                                            | 0                        | 0                             | 0                            |

[1]Based on maximum severity grade of each patient.

(Database CutoffDate:2021-02-15;Source Data:ADAE,ADDENOM)

[2] The number ofpatients with dose modification(s)is not necessarily equal to the sum of the number ofpatients who had a modified dose or a drug intemuption since the same

[3]Study treatment is selinexor with bortezomib and dexamethasone for SVd Am, and bortezomib with dexamethasone for Vd Arm

patient could fallinto more than one of these categories.

[4] An AE is considered treatment-related if it is selinexor-related and/or bortezomib-related and/or dexamethasone-related.

## Nervous system disorders

The CMQ neurological toxicity retrieved following PTs: amnesia, cognitive disorder, confusional state, delirium, depressed level of consciousness, dizziness, encephalopathy, hypersomnia, somnolence, and syncope. Peripheral neuropathy was not included.

The incidence of neurological toxicity (CMQ) was similar in the All SVd population and BOSTON SVd arm and higher than the BOSTON Vd arm (All TEAEs: 24.6%, 24.6%, 7.8%; and Grade 3: 5.0%, 4.1%, and 1.0% respectively); 1 additional patient in the All SVd population and BOSTON SVd arm (and none in the BOSTON Vd arm) reported TEAEs of neurological toxicity (PT: delirium; Grade 3, lasting 36 days and assessed as unrelated to any of the study treatments) since the primary analysis. No Grade 4 events were reported in either arm. The incidence of SAEs and discontinuations of neurological toxicity was low and was comparable across all 3 groups (SAEs: 2.0%, 1.5% and 0.5%, respectively; discontinuation: 3.0%, 2.1% and 1.0% in All SVd population, BOSTON SVd arm and BOSTON Vd arm, respectively); 1 additional patient reported an SAE in All SVd population and BOSTON SVd arm since the primary analysis. There were no new patients with discontinuation of study treatment due to TEAE of neurological toxicity since the primary analysis. There were no deaths due to TEAEs of neurological toxicity

<div style=\"page-break-after: always\"></div>

Table 21: Summary of Neurological Toxicity, Safety Population - Updated Analysis

| PatientsWithAtLeast1                                        | All SVd (N=3011) n (%)   | BOSTON SVd Arm (N=195) n (%)   | BOSTON Vd Arm (N=204) n (%)   |
|-------------------------------------------------------------|--------------------------|--------------------------------|-------------------------------|
| Treatment-emergent adverseevent                             | 74 (24.6)                | 48 (24.6)                      | 16 (7.8)                      |
| Grade 3/4 TEAEb                                             | 15 (5.0)                 | 8 (4.1)                        | 2 (1.0)                       |
| Grade 4 TEAEb                                               | 0                        | 0                              | 0                             |
| Treatment-emergent SAE                                      | 6 (2.0)                  | 3 (1.5)                        | 1 (0.5)                       |
| TEAE leading to dose modification in any study treatmente.d | 24 (8.0)                 | 15 (7.7)                       | 3 (1.5)                       |
| TEAE leading to dose reduction in any study treatment       | 14 (4.7)                 | 9 (4.6)                        | 1 (0.5)                       |
| TEAE leading to dose interruption in any study treatment    | 17 (5.6)                 | 12 (6.2)                       | 3 (1.5)                       |
| TEAE leading to study treatment discontinuation             | 9 (3.0)                  | 4 (2.1)                        | 2 (1.0)                       |
| TEAE leading to death                                       | 0                        | 0                              | 0                             |

Source: Table 14.3.2.1.1.13\\_updated.

Data cut-off date: 15 Feb 2021 (BOSTON); 01 Sep 2019 (STOMP)

- SAE: adverse event; SVd: selinexor with bortezomib and dexamethasone, TEAE: treatment-emergent adverse event; TRAE: treatment-related adverse event Vd: bortezomib and dexamethasone.
- All1 SVd population includes 195 patients from the BOSTON SVd arm + 64 patients from the BOSTON crossover arm (SVdX), including 1 additional patient who crossed over from Vd arm since the primary analysis + 42 patients from the supportive study, STOMP.
- c The number of patients with dose modification(s) was not necessarily equal to the sum of the number of patients who had a modified dose or a drug interruption since the same patient could fall into more than one of these categories.

Based on maximum severity grade of each patient.

- d Study treatment was selinexor with bortezomib and dexamethasone for SVd arm, and bortezomib with dexamethasone for Vd arm.

Table 22: Most Common Treatment-Emergent Neurological Toxicity Adverse Events, Safety Population - Primary Analysis

| MedDRAPreferredTerm                                                             | SVd Arm (N =195) n (%)   | Vd Arm (N=204) n (%)   | Total (N=399) n (%)   |
|---------------------------------------------------------------------------------|--------------------------|------------------------|-----------------------|
| PatientswithAtLeastOneTreatment- EmergentNeurological Toxicity CMQ AdverseEvent | 48 (24.6)                | 16 (7.8)               | 64 (16.0)             |
| Dizziness                                                                       | 24 (12.3)                | 9 (4.4)                | 33 (8.3)              |
| Confusional state                                                               | 16 (8.2)                 | 2 (1.0)                | 18 (4.5)              |
| Syncope                                                                         | 7 (3.6)                  | 3 (1.5)                | 10 (2.5)              |
| Amnesia                                                                         | 6 (3.1)                  | 1 (0.5)                | 7 (1.8)               |
| Cognitive disorder                                                              | 3 (1.5)                  | 3 (1.5)                | 6 (1.5)               |
| Somnolence                                                                      | 4 (2.1)                  | 1 (0.5)                | 5 (1.3)               |
| Delirium                                                                        | 2 (1.0)                  | 1 (0.5)                | 3 (0.8)               |
| Depressed level of consciousness                                                | 0                        | 1 (0.5)                | 1 (0.3)               |
| Encephalopathy                                                                  | 1 (0.5)                  | 0                      | 1 (0.3)               |
| Hypersomnia                                                                     | 1 (0.5)                  | 0                      | 1 (0.3)               |

<div style=\"page-break-after: always\"></div>

## Hepatic events

Table 23: Summary of Hepatobiliary Disorders, Safety Population - Updated Analysis

| Patients with at Least One                                       | AllSVd (N=301) n (%)   | BOSTON SVd Arm (N= 195) n (%)   | BOSTON Vd Aim (N=204) n (%)   |
|------------------------------------------------------------------|------------------------|---------------------------------|-------------------------------|
| Treatment-EmergentAdverseEvent                                   | 28( 9.3)               | 24 (12.3)                       | 18 ( 8.8)                     |
| Grade 3/4 TEAE [1]                                               | 9( 3.0)                | 7( 3.6)                         | 9( 4.4)                       |
| Grade 4 TEAE [1]                                                 | 1( 0.3)                | 1( 0.5)                         | 0                             |
| Serious TEAE                                                     | 1( 0.3)                | 1( 0.5)                         | 1( 0.5)                       |
| TEAE Leading to Dose Modification in Any Study Treatment [2] [3] | 9(3.0)                 | 8( 4.1)                         | 5( 2.5)                       |
| TEAE Leading toDoseReduction in AnyStudy Treatment               | 3( 1.0)                | 3( 1.5)                         | 1( 0.5)                       |
| TEAE Leading to Dose Intenmuption in Any Study Treatment         | 7( 2.3)                | 6( 3.1)                         | 5( 2.5)                       |
| TEAE Leading toStudy Treatment Discontinuation                   | 1( 0.3)                | 1( 0.5)                         | 0                             |
| TEAE Leadingto Death                                             | 0                      | 0                               | 0                             |
| Treatment-Emergent Treatment-Related Adverse Event [4]           | 19( 6.3)               | 16( 8.2)                        | 7( 3.4)                       |
| Grade 3/4 TRAE [1]                                               | 6( 2.0)                | 5( 2.6)                         | 2( 1.0)                       |
| Grade 4 TRAE [1]                                                 | 1( 0.3)                | 1( 0.5)                         | 0                             |
| Serious TRAE                                                     | 0                      | 0                               | 0                             |
| TRAE Leading to Dose Modification in Any Study Treatment [2] [3] | 8 ( 2.7)               | 7( 3.6)                         | 3 ( 1.5)                      |
| TRAE Leading to Dose Reduction in Any Study Treatment            | 3( 1.0)                | 3( 1.5)                         | 1( 0.5)                       |
| TRAE Leading to Dose Intermuption in Any Study Treatment         | 6( 2.0)                | 5( 2.6)                         | 3( 1.5)                       |
| TRAE Leading to Study Treatment Discontinuation                  | 0                      | 0                               | 0                             |
| TRAE Leading to Death                                            | 0                      | 0                               | 0                             |

## Cardiac toxicity

A CMQ of cardiac toxicity retrieved PTs of tachycardia, atrial fibrillation, sinus tachycardia and supraventricular extrasystoles.

<div style=\"page-break-after: always\"></div>

Table 24: Summary of Cardiac Toxicity, Safety Population - Updated Analysis

| Patients With At Least 1                                   | All SVd (N=3012) n (%)   | BOSTON SVd Arm (N=195) n (%)   | BOSTON Vd Arm (N=204) n (%)   |
|------------------------------------------------------------|--------------------------|--------------------------------|-------------------------------|
| Treatment-emergent adverse event                           | 23 (7.6)                 | 21 (10.8)                      | 7 (3.4)                       |
| Grade 3/4 TEAEb                                            | 4 (1.3)                  | 3 (1.5)                        | 1 (0.5)                       |
| Grade 4 TEAEbb                                             | 0                        | 0                              | 0                             |
| Treatment-emergent SAE                                     | 5 (1.7)                  | 5 (2.6)                        | 2 (1.0)                       |
| TEAE leading to dose modification in any study treatment.d | 7 (2.3)                  | 7 (3.6)                        | 2 (1.0)                       |
| TEAEleading to dose reduction in any study treatment       | 1 (0.3)                  | 1 (0.5)                        | 0                             |
| TEAE leading to dose interruption in any study treatment   | 7 (2.3)                  | 7 (3.6)                        | 2 (1.0)                       |
| TEAE leading to study treatment discontinuation            | 1 (0.3)                  | 1 (0.5)                        | 0                             |
| TEAE leading to death                                      | 0                        | 0                              | 0                             |

Source: Table 14.3.2.1.1.15\\_updated.

Data cut-off date: 15 Feb 2021 (BOSTON); 01 Sep 2019 (STOMP)

SAE: adverse event; SVd: selinexor with bortezomib and dexamethasone, TEAE: treatment-emergent adverse event; TRAE:treatment-relatedadverseeventVd:bortezomibanddexamethasone.

- a All SVd population includes 195 patients from the BOSTON SVd arm + 64 patients from the BOSTON crossover aim (SVdX), including 1 additional patient who crossed over from Vd arm since the primary analysis + 42 patients from the supportive study, STOMP.

c The number of patients with dose modification(s) was not necessarily equal to the sum of the number of patients who had a modified dose or a drug interruption since the same patient could fall into more than one of these categories.

Based on maximum severity grade of each patient.

- d Study treatment was selinexor with bortezomib and dexamethasone for SVd arm, and bortezomib with dexamethasone for Vd arm.

## Laboratory findings

## Haematology

## Table 30: Summary of grade shift in haematology by treatment group, Safety Population Updated analysis

|                                     | SVd Arm (N =195) n (%)   | Vd Arm (N =204) n (%)   | Total (N=399) n (%)   |
|-------------------------------------|--------------------------|-------------------------|-----------------------|
| Hemoglobinincreased                 |                          |                         |                       |
| Evaluable Patients [1]              | 195                      | 201                     | 396                   |
| Shift to Any Grade                  | 0                        | 0                       | 0                     |
| Shift from Grade <3 to Grade 3 or 4 | 0                        | 0                       | 0                     |
| Shift fromGrade<3 toGrade 3         | 0                        | 0                       | 0                     |
| Shift from Grade<3 to Grade 4       | 0                        | 0                       | 0                     |
| Anemia                              |                          |                         |                       |
| Evaluable Patients [1]              | 195                      | 201                     | 396                   |
| Shift to Any Grade                  | 141 (72.3)               | 103 (51.2)              | 244 (61.6)            |
| Shift fromGrade<3toGrade3or4        | 34 (17.4)                | 24 (11.9)               | 58 (14.6)             |
| Shift from Grade <3 to Grade 3      | 34 (17.4)                | 24 (11.9)               | 58 (14.6)             |
| Shift from Grade<3 to Grade 4       | 0                        | 0                       | 0                     |
| Leukocytosis                        |                          |                         |                       |
| Evaluable Patients [1]              | 195                      | 201                     | 396                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                     | SVd Arm (N = 195) n(%)   | Vd Arm (N= 204) n (%)   | Total (N=399) n(%)   |
|-------------------------------------|--------------------------|-------------------------|----------------------|
| Shift to Any Grade                  | 0                        | 0                       | 0                    |
| Shif fmm Grade <3 tn Grade3or 4     |                          | 0                       |                      |
| Shift from Grade <3 to Grade 3      | 0                        | 0                       | 0                    |
| Shift from Grade <3 to Grade 4      | 0                        | 0                       | 0                    |
| Leukopenia                          |                          |                         |                      |
| Evaluable Patients [1]              | 195                      | 201                     | 396                  |
| Shift to Any Grade                  | 130 (66.7)               | 67 (33.3)               | 197 (49.7)           |
| Shift from Grade <3 to Grade 3 or 4 | 20 (10.3)                | 5 (2.5)                 | 25 (6.3)             |
| Shift from Grade <3 to Grade 3      | 18 (9.2)                 | 4 (2.0)                 | 22 (5.6)             |
| Shift from Grade <3 to Grade 4      | 2 (1.0)                  | 1 (0.5)                 | 3 (0.8)              |
| Lymphoeytosis                       |                          |                         |                      |
| Evaluable Patients [1]              | 188                      | 195                     | 383                  |
| Shift to Any Grade                  | 2 (1.1)                  | 9 (4.6)                 | 11 (2.9)             |
| Shift from Grade <3 to Grade3 or 4  | 0                        | 0                       | 0                    |
| Shift from Grade <3 to Grade 3      | 0                        | 0                       | 0                    |
| Shift from Grade <3 to Grade 4      | 0                        | 0                       | 0                    |
| Lymphocytopenia                     |                          |                         |                      |
| Evaluable Patients [1]              | 188                      | 195                     | 383                  |
| Shift to Any Grade                  | 147 (78.2)               | 137 (70.3)              | 284 (74.2)           |
| Shift from Grade <3 to Grade 3 or 4 | 76 (40.4)                | 49 (25.1)               | 125 (32.6)           |
| Shift from Grade <3 to Grade 3      | 62 (33.0)                | 41 (21.0)               | 103 (26.9)           |
| Shift from Grade <3 to Grade 4      | 14 (7.4)                 | 8 (4.1)                 | 22 (5.7)             |
| Neutropenia                         |                          |                         |                      |
| Evaluable Patients [1]              | 188                      | 195                     | 383                  |
| Shift to Any Grade                  | 92 (48.9)                | 38 (19.5)               | 130 (33.9)           |
| Shift from Grade<3 to Grade3or 4    | 22 (11.7)                | 13 (6.7)                | 35 (9.1)             |
| Shift from Grade <3 to Grade 3      | 18 (9.6)                 | 8 (4.1)                 | 26 (6.8)             |
| Shift from Grade <3 to Grade 4      | 4 (2.1)                  | 5 (2.6)                 | 9 (2.3)              |
| Thrombocytopenia                    |                          |                         |                      |
| Evaluable Patients [1]              | 195                      | 201                     | 396                  |
| Shift to Any Grade                  | 181 (92.8)               | 103 (51.2)              | 284 (71.7)           |
| Shift from Grade <3 to Grade 3 or 4 | 86 (44.1)                | 40 (19.9)               | 126 (31.8)           |
| Shift from Grade <3 to Grade 3      | 59 (30.3)                | 24 (11.9)               | 83 (21.0)            |
| Shift from Grade <3 to Grade 4      | 27 (13.8)                | 16 (8.0)                | 43 (10.9)            |

<div style=\"page-break-after: always\"></div>

## Clinical chemistry

Table 25: Grade Shifts in Clinical Chemistry Laboratory Parameters from Baseline to Worst On-study Postbaseline Value, Safety Population - Updated analysis

|                                            | SVd Arm (N =195) n (%)                     | Vd Arm (N =204) n(%)                       | Total (N=399) n (%)                        |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| Alanine Aminotransferase(ALT)increased     | Alanine Aminotransferase(ALT)increased     | Alanine Aminotransferase(ALT)increased     | Alanine Aminotransferase(ALT)increased     |
| Evaluable Patients [1]                     | 195                                        | 201                                        | 396                                        |
| Shift to Any Grade                         | 65 (33.3)                                  | 60 (29.9)                                  | 125 (31.6)                                 |
| ShiftfromGrade<3toGrade3or4                | 7 (3.6)                                    | 1 (0.5)                                    | 8 (2.0)                                    |
| ShiftfromGrade<3toGrade3                   | 6 (3.1)                                    | 1 (0.5)                                    | 7 (1.8)                                    |
| ShiftfromGrade<3toGrade4                   | 1 (0.5)                                    | 0                                          | 1 (0.3)                                    |
| Hypoalbuminemia                            | Hypoalbuminemia                            | Hypoalbuminemia                            | Hypoalbuminemia                            |
| Evaluable Patients [1]                     | 194                                        | 200                                        | 394                                        |
| Shift to Any Grade                         | 54 (27.8)                                  | 71 (35.5)                                  | 125 (31.7)                                 |
| ShiftfromGrade<3toGrade3or4                | 1 (0.5)                                    | 1 (0.5)                                    | 2 (0.5)                                    |
| ShiftfromGrade<3toGrade3                   | 1 (0.5)                                    | 1 (0.5)                                    | 2 (0.5)                                    |
| ShiftfromGrade<3toGrade 4                  | 0                                          | 0                                          | 0                                          |
| Alkaline Phosphatase (ALP) increased       | Alkaline Phosphatase (ALP) increased       | Alkaline Phosphatase (ALP) increased       | Alkaline Phosphatase (ALP) increased       |
| Evaluable Patients [1]                     | 195                                        | 201                                        | 396                                        |
| Shift toAny Grade                          | 25 (12.8)                                  | 34 (16.9)                                  | 59 (14.9)                                  |
| ShiftfromGrade<3toGrade3or4                | 0                                          | 1 (0.5)                                    | 1 (0.3)                                    |
| ShiftfromGrade<3toGrade3                   | 0                                          | 1 (0.5)                                    | 1 (0.3)                                    |
| ShiftfromGrade<3toGrade4                   | 0                                          | 0                                          | 0                                          |
| Aspartate Aminotransferase (AST) increased | Aspartate Aminotransferase (AST) increased | Aspartate Aminotransferase (AST) increased | Aspartate Aminotransferase (AST) increased |
| Evaluable Paticnts [1]                     | 194                                        | 201                                        | 395                                        |
| Shift to Any Grade                         | 48 (24.7)                                  | 40 (19.9)                                  | 88 (22.3)                                  |
| ShiftfromGrade<3toGrade3or4                | 4 (2.1)                                    | 1 (0.5)                                    | 5 (1.3)                                    |
| ShiftfromGrade<3toGrade3                   | 4 (2.1)                                    | 1 (0.5)                                    | 5 (1.3)                                    |
| Shift from Grade<3 to Grade 4              | 0                                          | 0                                          | 0                                          |
| Hyperbilirubinaemia                        | Hyperbilirubinaemia                        | Hyperbilirubinaemia                        | Hyperbilirubinaemia                        |
| Evaluable Patients [1]                     | 195                                        | 201                                        | 396                                        |
| Shift to Any Grade                         | 33 (16.9)                                  | 27 (13.4)                                  | 60 (15.2)                                  |
| ShiftfromGrade<3toGrade3or4                | 2 (1.0)                                    | 4 (2.0)                                    | 6 (1.5)                                    |
| Shift from Grade<3 to Grade 3              | 2 (1.0)                                    | 4 (2.0)                                    | 6 (1.5)                                    |
| ShiftfromGrade<3toGrade 4                  | 0                                          | 0                                          | 0                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                     | SVd Arm (N = 195) n (%)   | Vd Arm (N=204) n(%)   | Total (N=399) n(%)   |
|-------------------------------------|---------------------------|-----------------------|----------------------|
| Hypercalcemia                       |                           |                       |                      |
| Evaluable Patients [1]              | 195                       | 200                   | 395                  |
| Shift to Any Grade                  | 18 (9.2)                  | 21 (10.5)             | 39 (9.9)             |
| Shift from Grade <3 to Grade 3 or 4 | 3 (1.5)                   | 0                     | 3 (0.8)              |
| Shift from Grade <3 to Grade 3      | 2 (1.0)                   | 0                     | 2 (0.5)              |
| Shif from Grade <3 to Grade 4       | 1 (0.5)                   | 0                     | 1 (0.3)              |
| Hypocalcemia                        |                           |                       |                      |
| Evaluable Patients [1]              | 195                       | 200                   | 395                  |
| Shift to Any Grade                  | 108 (55.4)                | 95 (47.5)             | 203 (51.4)           |
| Shift from Grade <3 to Grade 3 or 4 | 4 (2.1)                   | 2 (1.0)               | 6 (1.5)              |
| Shift from Grade <3 to Grade 3      | 2 (1.0)                   | 0                     | 2 (0.5)              |
| Shift from Grade <3 to Grade 4      | 2 (1.0)                   | 2 (1.0)               | 4 (1.0)              |
| Blood Urea Nitrogen increased       |                           |                       |                      |
| Evaluable Patients [1]              | 8                         | 88                    | 172                  |
| Shift to Any Grade                  | 33 (39.3)                 | 35 (39.8)             | 68 (39.5)            |
| Shift from Grade <3 to Grade 3 or 4 | 4 (4.8)                   | 3 (3.4)               | 7 (4.1)              |
| Shift from Grade <3 to Grade 3      | 3 (3.6)                   | 3 (3.4)               | 6(3.5)               |
| Shift from Grade <3 to Grade 4      | 1 (1.2)                   | 0                     | 1 (0.6)              |
| Creatine Kinase increased           |                           |                       |                      |
| Evaluable Patients [1]              | 170                       | 172                   | 342                  |
| Shift to Any Grade                  | 19 (11.2)                 | 16 (9.3)              | 35 (10.2)            |
| Shift from Grade <3 to Grade 3 or 4 | 0                         | 1 (0.6)               | 1 (0.3)              |
| Shift from Grade <3 to Grade 3      | 0                         | 1 (0.6)               | 1 (0.3)              |
| Shift from Grade <3 to Grade 4      | 0                         | 0                     | 0                    |
| Creatinine increased                |                           |                       |                      |
| Evaluable Patients [1]              | 195                       | 201                   | 396                  |
| Shift to Any Grade                  | 56 (28.7)                 | 50 (24.9)             | 106 (26.8)           |
| Shift from Grade <3 to Grade 3 or 4 | 7 (3.6)                   | 3(1.5)                | 10 (2.5)             |
| Shift from Grade <3 to Grade 3      | 7 (3.6)                   | 2 (1.0)               | 9 (2.3)              |
| Shift from Grade <3 to Grade 4      | 0                         | 1 (0.5)               | 1 (0.3)              |
| Hyperglycemia                       |                           |                       |                      |
| Evaluable Patients [1]              | 104                       | 103                   | 207                  |
| Shift to Any Grade                  | 66 (63.5)                 | 46 (44.7)             | 112 (54.1)           |
| Shift from Grade <3 to Grade 3 or 4 | 3 (2.9)                   | 3 (2.9)               | 6 (2.9)              |
| Shift from Grade <3 to Grade 3      | 3 (2.9)                   | 3 (2.9)               | 6 (2.9)              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                     | SVd Arm (N =195) n (%)   | Vd Arm (N=204) n (%)   | Total (N=399) n (%)   |
|-------------------------------------|--------------------------|------------------------|-----------------------|
| Shift from Grade <3 to Grade 4      | 0                        | 0                      | 0                     |
| Hypoglyeemia                        |                          |                        |                       |
| Evaluable Patients [1]              | 104                      | 103                    | 207                   |
| Shift to Any Grade                  | 8 (7.7)                  | 18 (17.5)              | 26 (12.6)             |
| Shift from Grade <3 to Grade 3 or 4 | 2 (1.9)                  | 0                      | 2 (1.0)               |
| Shift from Grade <3 to Grade 3      | 1 (1.0)                  | 0                      | 1 (0.5)               |
| Shift from Grade <3 to Grade 4      | 1 (1.0)                  | 0                      | 1 (0.5)               |
| Hypermagnesemia                     |                          |                        |                       |
| Evaluahle Patienis [1]              | 190                      | 195                    | 385                   |
| Shift to Any Grade                  | 14 (7.4)                 | 23 (11.8)              | 37 (9.6)              |
| Shift from Grade <3 to Grade 3 or 4 | 1 (0.5)                  | 2 (1.0)                | 3 (0.8)               |
| Shift from Grade <3 to Grade 3      | 1 (0.5)                  | 2 (1.0)                | 3 (0.8)               |
| Shift from Grade <3 to Grade 4      | 0                        | 0                      | 0                     |
| Hypomagnesemia                      |                          |                        |                       |
| Evaluable Patients [1]              | 190                      | 195                    | 385                   |
| Shift to Any Grade                  | 50 (26.3)                | 47 (24.1)              | 97 (25.2)             |
| Shift from Grade <3 to Grade 3 or 4 | 1 (0.5)                  | 2 (1.0)                | 3 (0.8)               |
| Shift from Grade <3 to Grade 3      | 1 (0.5)                  | 2 (1.0)                | 3 (0.8)               |
| Shift from Grade <3 to Grade 4      | 0                        | 0                      | 0                     |
| Hypophosphatemia                    |                          |                        |                       |
| Evaluable Patients [1]              | 192                      | 192                    | 384                   |
| Shift to Any Grade                  | 119 (62.0)               | 83 (43.2)              | 202 (52.6)            |
| Shift from Grade <3 to Grade 3 or 4 | 47 (24.5)                | 19 (9.9)               | 66 (17.2)             |
| Shift from Grade <3 to Grade 3      | 45 (23.4)                | 19 (9.9)               | 64 (16.7)             |
| Shift from Grade <3 to Grade 4      | 2 (1.0)                  | 0                      | 2 (0.5)               |
| Hyperkalemia                        |                          |                        |                       |
| Evaluable Patients [1]              | 195                      | 10Z                    | 396                   |
| Shift to Any Grade                  | 37 (19.0)                | 43 (21.4)              | 80 (20.2)             |
| Shift from Grade <3 to Grade 3 or 4 | 8 (4.1)                  | 5 (2.5)                | 13 (3.3)              |
| Shift from Grade <3 to Grade 3      | 6 (3.1)                  | 5(2.5)                 | 11 (2.8)              |
| Shift from Grade <3 to Grade 4      | 2 (1.0)                  | 0                      | 2 (0.5)               |
| Hypokalemia                         |                          |                        |                       |
| Evaluable Patients [1]              | 195                      | 201                    | 396                   |
| Shift to Any Grade                  | 55 (28.2)                | 47 (23.4)              | 102 (25.8)            |
| Shift from Grade <3 to Grade 3 or 4 | 13 (6.7)                 | 7 (3.5)                | 20 (5.1)              |

<div style=\"page-break-after: always\"></div>

|                                     | SVdArm (N =195) n(%)   | Vd Arm (N=204) n(%)   | Total (N = 399) n(%)   |
|-------------------------------------|------------------------|-----------------------|------------------------|
| Shift from Grade <3 to Grade 3      | 11 (5.6)               | 7 (3.5)               | 18 (4.5)               |
| Shift from Grade <3 to Grade 4      | 2 (1.0)                | 0                     | 2 (0.5)                |
| Hypematremia                        |                        |                       |                        |
| Evaluable Patients [1]              | 195                    | 201                   | 396                    |
| Shift to Any Grade                  | 13 (6.7)               | 20 (10.0)             | 33 (8.3)               |
| Shift from Grade <3 to Grade 3 or 4 | 0                      | 0                     | 0                      |
| Shift from Grade <3 to Grade 3      | 0                      | 0                     | 0                      |
| Shift from Grade <3 to Grade 4      | 0                      | 0                     | 0                      |
| Hyponatremia                        |                        |                       |                        |
| Evaluable Patients [1]              | 195                    | 201                   | 396                    |
| Shift to Any Grade                  | 115 (59.0)             | 50 (24.9)             | 165 (41.7)             |
| Shift from Grade <3 to Grade 3 or 4 | 27 (13.8)              | 6 (3.0)               | 33 (8.3)               |
| Shift from Grade <3 to Grade 3      | 26 (13.3)              | 6 (3.0)               | 32 (8.1)               |
| Shift from Grade <3 to Grade 4      | 1 (0.5)                | 0                     | 1 (0.3)                |

Source: Table 14.3.4.1.2.2 -updated

[1] Patients with non-missing measurement at baseline and at least one post-baseline measurement.

Note: For patients who cross over, measurements collected after crossover are not included.

Note: The percentage will be based on the number of evaluable patients for each test.

## ECG

In the BOSTON study ECG assessments were performed at baseline on all patients and at end of treatment or as clinically indicated. A total of 148 patients (37.1%) had baseline ECGs that were abnormal but not clinically significant (70 [35.9%] in the SVd arm and 78 [38.2%] in the Vd arm). Three patients (0.8% of total) had baseline ECG results that were abnormal but clinically significant, all in the Vd arm.

Table 2: Electrocardiogram: Summary of Overall Interpretation (Safety Analysis Population) - Updated analysis

|                                         | SVdArm (N =195) n (%)   | Vd Arm (N =204) n(%)   | Total (N = 399) n (%)   |
|-----------------------------------------|-------------------------|------------------------|-------------------------|
| OverallInterpretation                   |                         |                        |                         |
| Baseline                                |                         |                        |                         |
| Normal                                  | 124 (63.6)              | 122 (59.8)             | 246 (61.7)              |
| Abnormal, not clinically significant    | 70 (35.9)               | 78 (38.2)              | 148 (37.1)              |
| Abnormal, clinically significant        | 0                       | 3 (1.5)                | 3 (0.8)                 |
| Missing                                 | 1 (0.5)                 | 1 (0.5)                | 2 (0.5)                 |
| Patients with AnyPost-Baseline ECG      | 88 (45.1)               | 75 (36.8)              | 163 (40.9)              |
| Worst On-Study Post-Baseline Result [1] |                         |                        |                         |
| Normal                                  | 51 (58.0)               | 43 (57.3)              | 94 (57.7)               |
| Abnormal, not clinically significant    | 27 (30.7)               | 30 (40.0)              | 57 (35.0)               |
| Abnormal, clinically significant        | 10 (11.4)               | 2 (2.7)                | 12 (7.4)                |
| Missing                                 | 0                       | 0                      | 0                       |

<div style=\"page-break-after: always\"></div>

Table 26: Summary of Shift in Electrocardiogram QTcF (Safety Population) - Updated analysis

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Age

Table  34:  Summary  of  Adverse  Events  Subgroup  Analysis  by  Age  Group  (&lt;75  vs.  ≥75) Treatment-Emergent Adverse Events By Treatment Arm - All Patients in the Safety Population

<!-- image -->

|                                                                  | SVdArm                 | SVdArm              | SVdArm               | Vd Arm                 | Vd Arm                | Vd Arm               |
|------------------------------------------------------------------|------------------------|---------------------|----------------------|------------------------|-----------------------|----------------------|
| Patients with at Least One                                       | Age <75 (N =161) n (%) | Age>=75 (N=34) n(%) | Total (N = 195) n(%) | Age <75 (N = 159) n(%) | Age>=75 (N= 45) n (%) | Total (N= 204) n (%) |
| Treatment-Emergent Adverse Event                                 | 161 (100.0)            | 33 (97.1)           | 194 (99.5)           | 154 (96.9)             | 44 (97.8)             | 198 (97.1)           |
| Grade 3/4 TEAE [1]                                               | 124 (77.0)             | 29 (85.3)           | 153 (78.5)           | 91 (57.2)              | 24 (53.3)             | 115 (56.4)           |
| Grade 4 TEAE [1]                                                 | 34 (21.1)              | 3(8.8)              | 37 (19.0)            | 19 (11.9)              | 3 (6.7)               | 22 (10.8)            |
| Serious TEAE                                                     | 89 (55.3)              | 17 (50.0)           | 106 (54.4)           | 58 (36.5)              | 21 (46.7)             | 79 (38.7)            |
| TEAE Leading to Dose Modification in Any Study Treatment [2] [3] | 142 (88.2)             | 31 (91.2)           | 173 (88.7)           | 121 (76.1)             | 35 (77.8)             | 156 (76.5)           |
| TEAE Leading to Dose Reduction in Any Study Treatment            | 116 (72.0)             | 25 (73.5)           | 141 (72.3)           | 83 (52.2)              | 23 (51.1)             | 106 (52.0)           |
| TEAE Leading to Dose Interruption in Any Study Treatment         | 137 (85.1)             | 30 (88.2)           | 167 (85.6)           | 107 (67.3)             | 32 (71.1)             | 139 (68.1)           |
| TEAE Leading to Study Treatment Discontinuation                  | 31 (19.3)              | 10 (29.4)           | 41 (21.0)            | 23 (14.5)              | 11 (24.4)             | 34 (16.7)            |
| TEAE Leading to Death                                            | 14 (8.7)               | 0                   | 14 (7.2)             | 6(3.8)                 | 7(15.6)               | 13 (6.4)             |
| Treatment-Emergent Treatment-Related Adverse Event [4]           | 155 (96.3)             | 32 (94.1)           | 187 (95.9)           | 131 (82.4)             | 36 (80.0)             | 167 (81.9)           |
| Grade 3/4 TRAE [1]                                               | 112 (69.6)             | 25 (73.5)           | 137 (70.3)           | 65 (40.9)              | 19 (42.2)             | 84 (41.2)            |
| Grade 4 TRAE [1]                                                 | 25 (15.5)              | 3 (8.8)             | 28 (14.4)            | 15 (9.4)               | 2 (4.4)               | 17 (8.3)             |
| Serious TRAE                                                     | 47 (29.2)              | 11 (32.4)           | 58 (29.7)            | 20 (12.6)              | 4 (8.9)               | 24 (11.8)            |
| TRAE Leading to Dose Modification in Any Study Treatment [2] [3] | 130 (80.7)             | 28 (82.4)           | 158 (81.0)           | 102 (64.2)             | 29 (64.4)             | 131 (64.2)           |
| TRAE Leading to Dose Reduction in Any Study Treatment            | 115 (71.4)             | 24 (70.6)           | 139 (71.3)           | 81 (50.9)              | 21 (46.7)             | 102 (50.0)           |
| TRAE Leading to Dose Interruption in Any Study Treatment         | 118 (73.3)             | 27 (79.4)           | 145 (74.4)           | 74 (46.5)              | 23 (51.1)             | 97 (47.5)            |
| TRAE Leading to Study Treatment Discontinuation                  | 25 (15.5)              | 7 (20.6)            | 32 (16.4)            | 18 (11.3)              | 9 (20.0)              | 27 (13.2)            |
| TRAE Leading to Death                                            | 4 (2.5)                | 0                   | 4 (2.1)              | 1 (0.6)                | 0                     | 1 (0.5)              |

Source: Table 14.3.1.1.13.1.2-updated

Note: For patients who cross over, AEs that occurred after the crossover are not included.

[1]Based on maximum severity grade of each patient.

<div style=\"page-break-after: always\"></div>

Sex

## Table 35: Summary of Adverse Events - Subgroup Analysis by Sex Treatment-Emergent Adverse Events By Treatment Arm - All Patients in the Safety Population

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Patients with at Least One                             | Male (N =115) n(%)   | Female (N=80) n (%)   | Total (N =195) n (%)   | Male (N=113) n (%)   | Female (N=91) n(%)   | Total (N=204) n(%)   |
|--------------------------------------------------------|----------------------|-----------------------|------------------------|----------------------|----------------------|----------------------|
| TRAE Leading to Dose Reduction in AnyStudy Treatment   | 78 (67.8)            | 61 (76.3)             | 139 (71.3)             | 60 (53.1)            | 42 (46.2)            | 102 (50.0)           |
| TRAE Leading to Dose Interruption in AnyStudyTreatment | 79 (68.7)            | 66 (82.5)             | 145 (74.4)             | 58 (51.3)            | 39 (42.9)            | 97 (47.5)            |
| TRAE Leading to StudyTreatment Discontinuation         | 15 (13.0)            | 17 (21.3)             | 32 (16.4)              | 18 (15.9)            | 9 (9.9)              | 27 (13.2)            |
| TRAE Leading to Death                                  | 2 (1.7)              | 2 (2.5)               | 4 (2.1)                | 0                    | 1 (1.1)              | 1 (0.5)              |

Source:Table14.3.1.1.13.1.3-updated

Note: For patients who cross over, AEs that occurred after the crossover are not included.

[1]Based onmaximumseveritygradeofeachpatient.

[2] The number of patients with dose modification(s)is not necessarily equal to the sum ofthe number of patients who had a modified dose or a drug interruption since the same patient could fall into more than one of these categories.

[3]Study treatmentisselinexorwithbortezomiband dexamethasoneforSVdArm.Studytreatmentis bortezomibwith dexamethasoneforVdArm.

- [4]ForpatientsinSVdArm,anAEis consideredtreatment-related ifitisselinexor-relatedand/or bortezomib-related and/ordexamethasone-related.Forpatients inVdArm,anAEis consideredtreatmentrelatedifitisbortezomib-related and/or dexamethasone-related.

Race

Table 36: Summary of Adverse Events - Subgroup Analysis by Race Treatment-Emergent Adverse Events By Treatment Arm All Patients in the Safety Population

|                                                                | SVd Arm              | SVd Arm                            | SVd Arm              | Vd Arm               | Vd Arm                               | Vd Arm                |
|----------------------------------------------------------------|----------------------|------------------------------------|----------------------|----------------------|--------------------------------------|-----------------------|
| Patientswith at Least One                                      | White (N =161) n (%) | Racesother than White (N=34) n (%) | Total (N =195) n (%) | White (N =162) n (%) | Racesother than White (N = 42) n (%) | Total (N = 204) n (%) |
| Treatment-Emergent AdverseEvent                                | 160 (99.4)           | 34 (100.0)                         | 194 (99.5)           | 156 (96.3)           | 42 (100.0)                           | 198 (97.1)            |
| Grade 3/4 TEAE [1]                                             | 128 (79.5)           | 25 (73.5)                          | 153 (78.5)           | 90 (55.6)            | 25 (59.5)                            | 115 (56.4)            |
| Grade 4 TEAE [1]                                               | 33 (20.5)            | 4 (11.8)                           | 37 (19.0)            | 19 (11.7)            | 3 (7.1)                              | 22 (10.8)             |
| Serious TEAE                                                   | 83 (51.6)            | 23 (67.6)                          | 106 (54.4)           | 64 (39.5)            | 15 (35.7)                            | 79 (38.7)             |
| TEAE Lcading to Dose ModificationinAny Study Treatment [2] [3] | 143 (88.8)           | 30 (88.2)                          | 173 (88.7)           | 118 (72.8)           | 38 (90.5)                            | 156 (76.5)            |
| TEAELcadingtoDosc Reduction in AnyStudy Treatment              | 115 (71.4)           | 26 (76.5)                          | 141 (72.3)           | 78 (48.1)            | 28 (66.7)                            | 106 (52.0)            |
| TEAE Leading to Dose Interruption in Any StudyTreatment        | 139 (86.3)           | 28 (82.4)                          | 167 (85.6)           | 107 (66.0)           | 32 (76.2)                            | 139 (68.1)            |

<div style=\"page-break-after: always\"></div>

| TEAE Leading to Study Treatment Discontinuation                 | 35 (21.7)   | 6 (17.6)   | 41 (21.0)   | 25 (15.4)   | 9 (21.4)   | 34 (16.7)   |
|-----------------------------------------------------------------|-------------|------------|-------------|-------------|------------|-------------|
| TEAE Leading to Dcath                                           | 10 (6.2)    | 4 (11.8)   | 14 (7.2)    | 11 (6.8)    | 2 (4.8)    | 13 (6.4)    |
| Treatment-Emergent Treatment-Related Adverse Event [4]          | 153 (95.0)  | 34 (100.0) | 187 (95.9)  | 127 (78.4)  | 40 (95.2)  | 167 (81.9)  |
| Grade 3/4 TRAE [1]                                              | 116 (72.0)  | 21 (61.8)  | 137 (70.3)  | 68 (42.0)   | 16 (38.1)  | 84 (41.2)   |
| Grade 4 TRAE [1]                                                | 25 (15.5)   | 3 (8.8)    | 28 (14.4)   | 15 (9.3)    | 2 (4.8)    | 17 (8.3)    |
| Serious TRAE                                                    | 39 (24.2)   | 19 (55.9)  | 58 (29.7)   | 21 (13.0)   | 3 (7.1)    | 24 (11.8)   |
| TRAE Lcading toDose Modification in Any Study Treatment [2] [3] | 130 (80.7)  | 28 (82.4)  | 158 (81.0)  | 98 (60.5)   | 33 (78.6)  | 131 (64.2)  |
| TRAE Leading to Dose Reduction in Any Study Treatment           | 113 (70.2)  | 26 (76.5)  | 139 (71.3)  | 75 (46.3)   | 27 (64.3)  | 102 (50.0)  |
| TRAE Lcading to Dose Interruption in Any Study Treatment        | 121 (75.2)  | 24 (70.6)  | 145 (74.4)  | 76 (46.9)   | 21 (50.0)  | 97 (47.5)   |
| TRAE Leading to Study Treatment Discontinuation                 | 27 (16.8)   | 5 (14.7)   | 32 (16.4)   | 20 (12.3)   | 7 (16.7)   | 27 (13.2)   |
| TRAE Leading to Death                                           | 2 (1.2)     | 2 (5.9)    | 4 (2.1)     | 1 (0.6)     | 0          | 1 (0.5)     |

Source:Table14.3.1.1.13.1.4-updated

Note: For patients who cross over, AEs that occurred after the crossover are not included.

[1]Basedonmaximumseveritygradeofeachpatient.

[2] The number of patients with dose modification(s) is not necessarily equal to the sum of the number of patients who had a modified dose or a drug interruption since the same patient could fall into more than one

of these categories.

- [3]Studytreatment isselinexorwithbortezomibanddexamethasoneforSVdArm.Studytreatment is bortezomibwithdexamethasoneforVdArm.
- [4] For patients in SVd Arm, an AE is considered treatment-related ifit is selinexor-related and/or bortezomib-relatedand/ordexamethasone-related.ForpatientsinVdArm,anAEis considered treatmentrelatedifitisbortezomib-relatedand/ordexamethasone-related.

<div style=\"page-break-after: always\"></div>

## Renal impairment

## Table 37: Summary of Adverse Events - Subgroup Analysis by Baseline Creatinine Clearance Treatment-Emergent Adverse Events By Treatment Arm - All Patients in the Safety Population

<!-- image -->

|                                                                  | SVd Arm                                    | SVd Arm                                        | SVd Arm                                       | SVd Arm               | Vd Arm                                      | Vd Arm                                         | Vd Arm                                         | Vd Arm              |
|------------------------------------------------------------------|--------------------------------------------|------------------------------------------------|-----------------------------------------------|-----------------------|---------------------------------------------|------------------------------------------------|------------------------------------------------|---------------------|
| Patients with at Least One                                       | Creatinine Clearance <30 mL/min (N=3) n(%) | Creatinine Clearance 30-60 mL/min (N=53) n (%) | Creatinine Clearance >60 mL/min (N=139) n (%) | Total (N = 195) n (%) | Creatinine Clearance <30 mL/min (6=N) n (%) | Creatinine Clearance 30-60 mL/min (N=58) n (%) | Creatinine Clearance 09< mL/min (N= 137) n (%) | Total (N=204) n (%) |
| Treatment- Emergent Adverse Event                                | 3 (100.0)                                  | 53 (100.0)                                     | 138 (99.3)                                    | 194 (99.5)            | 8 (88.9)                                    | 57 (98.3)                                      | 133 (97.1)                                     | 198 (97.1)          |
| Grade 3/4 TEAE [1]                                               | 2 (66.7)                                   | 41 (77.4)                                      | 110 (79.1)                                    | 153 (78.5)            | 4 (44.4)                                    | 33 (56.9)                                      | 78 (56.9)                                      | 115 (56.4)          |
| Grade 4TEAE [1]                                                  | 0                                          | 11 (20.8)                                      | 26 (18.7)                                     | 37 (19.0)             | 0                                           | 7 (12.1)                                       | 15 (10.9)                                      | 22 (10.8)           |
| Serious TEAE                                                     | 3 (100.0)                                  | 28 (52.8)                                      | 75 (54.0)                                     | 106 (54.4)            | 5 (55.6)                                    | 26 (44.8)                                      | 48 (35.0)                                      | 79 (38.7)           |
| TEAE Leading to Dose Modification in Any Study Treatment [2] [3] | 3 (100.0)                                  | 48 (90.6)                                      | 122 (87.8)                                    | 173 (88.7)            | 6 (66.7)                                    | 48 (82.8)                                      | 102 (74.5)                                     | 156 (76.5)          |
| TEAE Leading to Dose Reductionin Any Study Treatment             | 3 (100.0)                                  | 35 (66.0)                                      | 103 (74.1)                                    | 141 (72.3)            | 4 (44.4)                                    | 30 (51.7)                                      | 72 (52.6)                                      | 106 (52.0)          |
| TEAE Leading to Dose Interruption in Any Study Treatment         | 3 (100.0)                                  | 47 (88.7)                                      | 117 (84.2)                                    | 167 (85.6)            | 6(66.7)                                     | 43 (74.1)                                      | 90 (65.7)                                      | 139 (68.1)          |
| TEAE Leading to Study Treatment Discontinuation                  | 0                                          | 11 (20.8)                                      | 30 (21.6)                                     | 41 (21.0)             | 1 (11.1)                                    | 13 (22.4)                                      | 20 (14.6)                                      | 34 (16.7)           |
| TEAE Leading to Deah                                             | 1 (33.3)                                   | 2 (3.8)                                        | 11 (7.9)                                      | 14 (7.2)              | 2 (22.2)                                    | 6 (10.3)                                       | 5 (3.6)                                        | 13 (6.4)            |
| Treatment- Emergent Treatment- Related Adverse Event [4]         | 3 (100.0)                                  | 49 (92.5)                                      | 135 (97.1)                                    | 187 (95.9)            | 6 (66.7)                                    | 48 (82.8)                                      | 113 (82.5)                                     | 167 (81.9)          |
| Grade 3/4 TRAE [1]                                               | 3 (100.0)                                  | 35 (66.0)                                      | 99 (71.2)                                     | 137 (70.3)            | 3 (33.3)                                    | 28 (48.3)                                      | 53 (38.7)                                      | 84 (41.2)           |
| Grade 4 TRAE [1]                                                 | 0                                          | 8 (15.1)                                       | 20 (14.4)                                     | 28 (14.4)             | 0                                           | 5 (8.6)                                        | 12 (8.8)                                       | 17 (8.3)            |
| Serious TRAE                                                     | 2 (66.7)                                   | 20 (37.7)                                      | 36 (25.9)                                     | 58 (29.7)             | 2 (22.2)                                    | 6 (10.3)                                       | 16 (11.7)                                      | 24 (11.8)           |

<div style=\"page-break-after: always\"></div>

| TRAE Leading to Dose Modification in Any Study Treatment [2] [3]   | 3 (100.0)   | 41 (77.4)   | 114 (82.0)   | 158 (81.0)   | 5 (55.6)   | 38 (65.5)   | 88 (64.2)   | 131 (64.2)   |
|--------------------------------------------------------------------|-------------|-------------|--------------|--------------|------------|-------------|-------------|--------------|
| TRAE Leading to Dose Reduction in Any Study Treatment              | 3 (100.0)   | 34 (64.2)   | 102 (73.4)   | 139 (71.3)   | 4 (44.4)   | 28 (48.3)   | 70 (51.1)   | 102 (50.0)   |
| TRAELeading to Dose Interruption in Any Study Treatment            | 3 (100.0)   | 40 (75.5)   | 102 (73.4)   | 145 (74.4)   | 3 (33.3)   | 31 (53.4)   | 63 (46.0)   | 97 (47.5)    |
| TRAE Leading to Study Treatment Discontinuation                    | 0           | 7 (13.2)    | 25 (18.0)    | 32 (16.4)    | 1 (11.1)   | (0'61)11    | 15 (10.9)   | 27 (13.2)    |
| TRAE Leading to Death                                              | 0           | 1 (1.9)     | 3 (2.2)      | 4 (2.1)      | 0          | 0           | 1 (0.7)     | 1 (0.5)      |

Note: For patients who cross over,AEs that occurred after the crossover are not included.

Source: Table 14.3.1.1.13.1.5-updated

[1]Based onmaximumseveritygradeof eachpatient.

[2]The number ofpatientswith dosemodification(s) is not necessarily equal to the sum ofthe number of

[3]Study treatment is selinexorwith bortezomib and dexamethasone forSVd Arm.Study treatment is bortezomibwithdexamethasoneforVdArm.

patients whohad a modified dose or a drug interruption since the same patient could fall into more than one ofthesecategories.

[4]For patients inSVdArm,an AE is considered treatment-related ifit is selinexor-relatedand/or bortezomib-related and/or dexamethasone-related.For patients inVd Arm, an AE is considered treatmentrelatedifitisbortezomib-relatedand/ordexamethasone-related.

Hepatic impairment

Table: Summary of TEAEs by Baseline Hepatic Function and Treatment Arm (All Patients in the Safety Population)

|                                                        | SVd Arm(N=195)                        | SVd Arm(N=195)                        | Vd Arm (N=204)                        | Vd Arm (N=204)                                  |
|--------------------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|-------------------------------------------------|
| Patientswith atLeastOne                                | Normal Hepatic Function (N=167) n (%) | Mild Hepatic Impairment (N=25)a n (%) | Normal Hepatic Function (N=188) n (%) | Mild/ Moderate Hepatic Impairment (N=16) n (%)b |
| TEAE                                                   | 166 (99.4)                            | 25 (100.0)                            | 183 (97.3)                            | 15 (93.8)                                       |
| Grade3/4 TEAEc                                         | 129 (77.2)                            | 21 (84.0)                             | 107 (56.9)                            | 8 (50.0)                                        |
| Grade 4 TEAEc                                          | 32 (19.2)                             | 5 (20.0)                              | 21 (11.2)                             | 1 (6.3)                                         |
| SAE                                                    | 87 (52.1)                             | 18 (72.0)                             | 72 (38.3)                             | 7 (43.8)                                        |
| TEAELeading toDoseModification in Any Study Treatmentd | 148 (88.6)                            | 24 (96.0)                             | 142 (75.5)                            | 14 (87.5)                                       |
| TEAELeadingtoDoseReduction                             | 122 (73.1)                            | 18 (72.0)                             | 96 (51.1)                             | 10 (62.5)                                       |
| TEAELeadingtoDoseInterruption                          | 142 (85.0)                            | 24 (96.0)                             | 127 (67.6)                            | 12 (75.0)                                       |
| TEAELeadingtoStudyTreatment Discontinuation            | 36 (21.6)                             | 5 (20.0)                              | 31 (16.5)                             | 3 (18.8)                                        |
| TEAE LeadingtoDeath                                    | 11 (6.6)                              | 3 (12.0)                              | 12 (6.4)                              | 1 (6.3)                                         |

SAE = serious adverse event; SVd=selinexor plus bortezomib plus low-dose dexamethasone; TEAE = treatmentemergent adverse event;Vd=bortezomibpluslow-dose dexamethasone.

Source:Table 14.4.3.2.1,Table 14.4.3.2.4

Data cut-off date:15Feb2021.

a There were no patients with moderate or severe hepatic impairment in the SVd arm and 3 patients had missing baselinehepaticfunction assessment in theSVd arm.

b Of the 16 patients with mild/moderate hepatic impairment in the Vd arm, 12 patients had mild hepatic impairment and 4 patients had moderate hepatic impairment.No patient had severe hepatic impairment.

d The number of patients with dose modification(s)is not necessarily equal to the sum of the number of patients who had a modified dose or a drug interruption since the same patient could fall into more than one of these categories.

cBased on maximum severitygrade of each patient.

## Safety related to drug-drug interactions and other interactions

See PK/PD section

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

As of the updated analysis, TEAEs leading to discontinuation of study treatment were reported in 67 (22.3%) patients in the All SVd population and 41 (21.0%) patients in the BOSTON SVd arm compared with 34 (16.7%) patients in the BOSTON Vd arm (Table 29). No additional patients discontinued study treatment due to TEAEs in the BOSTON SVd arm since the primary analysis. Of the total 34 patients in the BOSTON Vd arm who discontinued treatment due to TEAEs, 2 discontinued (1 due to PN and 1 due to corona virus infection) after the primary analysis.

PN remained the most common cause of treatment discontinuation across all 3 groups, with a higher incidence in the BOSTON Vd arm (7.8%) compared with the All SVd (4.0%) and BOSTON SVd arm (4.6%).

Table 38: Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation Occurring in ≥1% of Patients in the All SVd Population, Safety Population - Updated Analysis

| MedDRA System Organ Class MedDRAPreferredTerm              | All SVd (N=301) n (%)   | BOSTONSVd Arm (N=195) n (%)   | BOSTONVd Arm (N=204) n (%)   |
|------------------------------------------------------------|-------------------------|-------------------------------|------------------------------|
| PatientswithatleastlTEAEleadingto treatmentdiscontinuation | 67 (22.3)               | 41 (21.0)                     | 34 (16.7)                    |
| Blood and lymphatic system disorders                       | 9 (3.0)                 | 5 (2.6)                       | 1 (0.5)                      |
| Thrombocytopenia                                           | 8 (2.7)                 | 4 (2.1)                       | 1 (0.5)                      |
| Anaemia                                                    | 4 (1.3)                 | 2 (1.0)                       | 0                            |
| Gastrointestinaldisorders                                  | 12 (4.0)                | 9 (4.6)                       | 3 (1.5)                      |
| Nausea                                                     | 9 (3.0)                 | 6 (3.1)                       | 0                            |
| Vomiting                                                   | 4 (1.3)                 | 4 (2.1)                       | 0                            |
| General disorders and administration site conditions       | 18 (6.0)                | 13 (6.7)                      | 3 (1.5)                      |
| Fatigue                                                    | 10 (3.3)                | 7 (3.6)                       | 1 (0.5)                      |
| Infections and infestations                                | 4 (1.3)                 | 2 (1.0)                       | 5 (2.5)                      |
| Pneumonia                                                  | 3 (1.0)                 | 1 (0.5)                       | 0                            |
| Investigations                                             | 5 (1.7)                 | 3 (1.5)                       | 1 (0.5)                      |
| Weight decreased                                           | 3 (1.0)                 | 2 (1.0)                       | 1 (0.5)                      |
| Metabolism and nutrition disorders                         | 9 (3.0)                 | 6 (3.1)                       | 2 (1.0)                      |
| Decreased appetite                                         | 6 (2.0)                 | 4 (2.1)                       | 1 (0.5)                      |
| Nervous system disorders                                   | 21 (7.0)                | 12 (6.2)                      | 20 (9.8)                     |
| Neuropathy peripheral                                      | 12 (4.0)                | 9 (4.6)                       | 16 (7.8)                     |
| Cognitive disorder                                         | 4 (1.3)                 | 1 (0.5)                       | 2 (1.0)                      |
| Psychiatric disorders                                      | 12 (4.0)                | 6 (3.1)                       | 1 (0.5)                      |
| Confusional state                                          | 3 (1.0)                 | 2 (1.0)                       | 0                            |
| Depression                                                 | 3 (1.0)                 | 0                             | 0                            |

Source: Table 14.3.1.7.1.1\\_updated and 14.3.1.7.1.2\\_updated.

Datacut-off date:15Feb2021(BOSTON);01Sep2019(STOMP)

Note: This table uses MedDRA version 22.0. System Organ Classes were recoded to aggregate medically similar SOCs. Preferred Terms were recoded to aggregate medically similar PTs.

MedDRA: Medical Dictionary for RegulatoryActivities;SVd:selinexor with bortezomib and dexamethasone;

TEAE: treatment-emergent adverse event;Vd: bortezomib and dexamethasone.

a All SVd population includes 195 patients from the BOSTON SVd arm + 64 patients from the BOSTON crossover arm (SVdX), including 1 additional patient who crossed over from the Vd arm since the primary analysis + 42 patients from the supportive study, STOMP.

## Adverse events leading to dose reduction

<div style=\"page-break-after: always\"></div>

Overall, 253 (63.4%) patients in the Safety Population experienced dose reduction due to any cause. The frequency dose reduction was higher in the SVd arm compared with the Vd arm (73.3% versus 53.9%, respectively).

Table 39: TreatmentEmergent Adverse Events Leading to Dose Reduction in ≥4 P atients in Either Arm (Safety Population) - Updated analysis

| MedDRAPreferredTerm   | SVd Arm (N =195) n(%)   | Vd Arm (N = 204) n(%)   | Total (N =399) n (%)   |
|-----------------------|-------------------------|-------------------------|------------------------|
| Neuropathy peripheral | 39 (20.0)               | 58 (28.4)               | 97 (24.3)              |
| Thrombocytopenia      | 65 (33.3)               | 9 (4.4)                 | 74 (18.5)              |
| Fatigue               | 21 (10.8)               | 5 (2.5)                 | 26 (6.5)               |
| Asthenia              | 14 (7.2)                | 5 (2.5)                 | 19 (4.8)               |
| Insomnia              | 10 (5.1)                | 8 (3.9)                 | 18 (4.5)               |
| Weight decreased      | 14 (7.2)                | 4 (2.0)                 | 18 (4.5)               |
| Decreased appetite    | 17 (8.7)                | 0                       | 17 (4.3)               |
| Nausea                | 14 (7.2)                | 0                       | 14 (3.5)               |
| Diarrhoea             | 4 (2.1)                 | 7 (3.4)                 | 11 (2.8)               |
| Oedema peripheral     | 5 (2.6)                 | 5 (2.5)                 | 10 (2.5)               |
| Neutropenia           | 8 (4.1)                 | 0                       | 8 (2.0)                |
| Dyspnoea              | 4 (2.1)                 | 3 (1.5)                 | 7 (1.8)                |
| Vomiting              | 6 (3.1)                 | 1 (0.5)                 | 7 (1.8)                |
| Cataract              | 5 (2.6)                 | 1 (0.5)                 | 6 (1.5)                |
| Pneumonia             | 5 (2.6)                 | 1 (0.5)                 | 6 (1.5)                |
| Anaemia               | 5 (2.6)                 | 0                       | 5 (1.3)                |
| Confusional state     | 5 (2.6)                 | 0                       | 5 (1.3)                |
| Hyperglycaemia        | 4 (2.1)                 | 1 (0.5)                 | 5 (1.3)                |

Source:Table14.4.3.4.4

Note: For patients who cross over, AEs that occur after the crossover are not included.

Note: This table uses MedDRA version 22.0. Preferred Terms are recorded to aggregate medically similar PTs.

In the updated analysis, TEAEs leading to dose reduction were reported in 141 (72.3%) patients in the SVd arm and 106 (52.0%) patients in the Vd arm. No additional patients required dose reduction due to TEAEs in the SVd arm since the primary analysis. Of the 106 patients with dose reductions due to TEAEs in the Vd arm, 2 patients had at least 1 TEAE leading to dose reduction after the primary analysis.

The proportion of patients with dose reductions due to TEAEs was higher in the SVd arm compared with the Vd arm (72.3% versus 52.0%). The most common AEs leading to dose reduction were PN (SVd, 20.0%; Vd, 28.4%), thrombocytopenia (SVd, 33.3%; Vd, 4.4%), and fatigue (SVd, 10.8%; Vd, 2.5%).

## Adverse events leading to dose interruption

Overall, 328 (82.2%) patients in the Safety Population experienced dose delay or interruption due to any cause. The frequency of dose delay or interruption was higher in the SVd arm compared with the Vd arm (88.7% versus 76.0%, respectively).

The most frequently reported TEAEs leading to dose interruption in patients receiving SVd were thrombocytopenia (34.9%), asthenia (13.8%), fatigue (13.8%) and pneumonia (10.8%) In patients

<div style=\"page-break-after: always\"></div>

receiving Vd, the most frequently reported were PN (18.1%), pneumonia (10.8%), upper respiratory tract infection (9.8%), asthenia (7.8%), and thrombocytopenia (7.8%).

Table 40: Treatmentemergent Adverse Events Leading to Dose Interruption in ≥4 Patients in Either Arm (Safety Population) - Updated analysis

| MedDRAPreferredTerm               | SVd Arm (N =195) n (%)   | VdArm (N =204) n(%)   | Total (N=399) n (%)   |
|-----------------------------------|--------------------------|-----------------------|-----------------------|
| Thrombocytopenia                  | 69 (35.4)                | 16 (7.8)              | 85 (21.3)             |
| Neuropathy peripheral             | 16 (8.2)                 | 37 (18.1)             | 53 (13.3)             |
| Pneumonia                         | 22 (11.3)                | 23 (11.3)             | 45 (11.3)             |
| Asthenia                          | 28 (14.4)                | 16 (7.8)              | 44 (11.0)             |
| Upper respiratory tract infection | 24 (12.3)                | 20 (9.8)              | 44 (11.0)             |
| Fatigue                           | 28 (14.4)                | 4 (2.0)               | 32 (8.0)              |
| Pyrexia                           | 16 (8.2)                 | 14 (6.9)              | 30 (7.5)              |
| Bronchitis                        | 15 (7.7)                 | 14 (6.9)              | 29 (7.3)              |
| Diarrhoea                         | 15 (7.7)                 | 12 (5.9)              | 27 (6.8)              |
| Decreased appetite                | 18 (9.2)                 | 2 (1.0)               | 20 (5.0)              |
| Neutropenia                       | 17 (8.7)                 | 2 (1.0)               | 19 (4.8)              |
| Cough                             | 11 (5.6)                 | 7 (3.4)               | 18 (4.5)              |
| Anaemia                           | 12 (6.2)                 | 5 (2.5)               | 17 (4.3)              |
| Lower respiratory tract infection | 9 (4.6)                  | 8 (3.9)               | 17 (4.3)              |
| Dyspnoea                          | 6 (3.1)                  | 8 (3.9)               | 14 (3.5)              |
| Influenza                         | 10 (5.1)                 | 4 (2.0)               | 14 (3.5)              |
| Nausea                            | 14 (7.2)                 | 0                     | 14 (3.5)              |
| Weight decreased                  | 12 (6.2)                 | 2 (1.0)               | 14 (3.5)              |
| Urinary tract infection           | 7 (3.6)                  | 2 (1.0)               | 9 (2.3)               |
| Cataract                          | 8 (4.1)                  | 0                     | 8 (2.0)               |
| Infection                         | 5 (2.6)                  | 3 (1.5)               | 8 (2.0)               |
| Herpes zoster                     | 3 (1.5)                  | 4 (2.0)               | 7 (1.8)               |
| Oedema peripheral                 | 2 (1.0)                  | 5 (2.5)               | 7 (1.8)               |
| Vomiting                          | 6 (3.1)                  | 0                     | 6 (1.5)               |
| Acute kidney injury               | 5 (2.6)                  | 0                     | 5 (1.3)               |
| C-reactive protein increased      | 1 (0.5)                  | 4 (2.0)               | 5 (1.3)               |
| Confusionalstate                  | 5 (2.6)                  | 0                     | 5 (1.3)               |
| Oropharyngeal pain                | 4 (2.1)                  | 1 (0.5)               | 5 (1.3)               |
| Epistaxis                         | 4 (2.1)                  | 0                     | 4 (1.0)               |
| Gastroenteritis                   | 4 (2.1)                  | 0                     | 4 (1.0)               |
| Insomnia                          | 0                        | 4 (2.0)               | 4 (1.0)               |
| Overdose                          | 4 (2.1)                  | 0                     | 4 (1.0)               |

Source:Table14.4.3.4.5

Note: For patients who cross over, AEs that occur after the crossover are not included.

Note: This table uses MedDRA version 22.0. Preferred Terms are recorded to aggregate medically similar PTs.

In the updated analysis, the proportion of patients with dose delay or interruption due to at least 1 TEAE remained unchanged from the primary analysis and was higher in the SVd arm compared with the Vd arm (85.6% versus 68.1%).

<div style=\"page-break-after: always\"></div>

## 2.5.1. Post marketing experience

As of 15 Feb 2021, approximately 2659 patients were treated with XPOVIO (selinexor). Adverse event reports (n=1397) from the commercial use of selinexor have been received through 15 Feb 2021 and are in line with the expected side effect profile based on the package insert for RRMM. Majority of the events were non-serious (84.2%) and 15.8% events were serious. There have been 222 fatal reports among the approximately 2659 patients who received selinexor since its commercial availability. According to the MAH, the postmarketing safety data with selinexor is consistent with what was observed during the clinical studies and no new safety signals were identified.

Table 27: Commercial use of XPOVIO through 15 February 2021

|                             | Total           |
|-----------------------------|-----------------|
| ApproximateNumberofPatients | 2659            |
| NumberofReports             | 1397 Cases      |
| Expedited Cases             | 1074Submissions |
| Fatal Reports               | 222             |
| NumberofEvents;n            | 7367            |
| NonseriousEvents;n(%)       | 6203 (84.2%)    |
| SeriousEvents; n (%)        | 1164 (15.8%)    |

Source: Patient exposure calculated using actual sales and patient experience collected from Karyopharm Safety Database

Table 28: Adverse events from postmarketing experience

| Preferred Term      | N   |
|---------------------|-----|
| Nausea              | 670 |
| Fatigue             | 512 |
| Decreased appetite  | 485 |
| Diarrhoea           | 353 |
| Vomiting            | 274 |
| Thrombocytopenia    | 274 |
| Weight decreased    | 229 |
| Asthenia            | 214 |
| Anaemia             | 201 |
| Death               | 195 |
| Plasma cell myeloma | 178 |
| Constipation        | 131 |
| Dizziness           | 120 |
| Dehydration         | 117 |
| Confusional state   | t8  |
| Leukopenia          | 73  |
| Hyponatraemia       | 70  |
| Dyspnoea            | 69  |
| Fall                | 63  |
| Drug ineffective    | 61  |

Source: Karyopharm Safety Database

<div style=\"page-break-after: always\"></div>

## 2.5.2. Discussion on clinical safety

Through the current variation application, the MAH is seeking an extension of the indication for selinexor in combination with bortezomib and dexamethasone for the treatment of adult patients with RRMM who had received 1 to 3 prior regimens.

Safety data of this application is mainly based on results from the BOSTON study (KCP-330-023), a Phase 3 randomised, open-label, multicenter study in which selinexor in combination with bortezomib and dexamethasone (SVd; n=195 ) was compared with bortezomib plus dexamethasone (Vd; n=204). In addition, safety data of 42 patients included in Arm 2 of the study STOMP (KCP-330-017) have been provided which is considered supportive, since not all of these patients received the recommended dosing regimen for SVd. Pooled safety data of the BOSTON and STOMP studies as well as data of the 64 patients who crossed over from the Vd arm to the SVd arm in the BOSTON study have been submitted (n=301).

Safety data discussed below are based on the last data cut-off ( 15 Feb 2021 ) from the BOSTON study.

In the BOSTON study selinexor was administered at a dose of 100 mg PO plus bortezomib 1.3 mg/m2 SC plus dexamethasone 40 mg (20 mg dose 2 days per week) in 35-days cycles. It should be noted that the recommended dose of selinexor in combination with bortezomib and dexamethasone differs from the one currently authorised (i.e. 80 mg on days 1 and 3 in combination with dexamethasone). As per protocol, a selinexor dose escalation (i.e. increase selinexor to a fixed 60 mg dose BIW during Weeks 1 through  5  of  each  cycle  and  dexamethasone  20  mg  BIW  on  the  same  days  as  selinexor)  may  be considered for patients who do not achieve at least a PR within the first 2 cycles, were tolerating SVd and do not have any AEs related to study treatment Grade &gt;2 at the time of dose escalation.

At the time of the data cut-off 37 (9.3%) patients were still on treatment (21 in the SVd arm and 16 in the Vd arm). Disease progression was the main cause for treatment discontinuation in both treatment arms (76 [39%] patient SVd and 118 [57.8%] patients Vd). A higher number of patients in the SVd arm withdrawn consent compared with Vd (37 [19.0%] vs. 21 [10.3%], respectively). The main reasons for patient withdrawal consent were related to AEs, logistical reasons and poor health/entered hospice care. Further, even though numbers are low, double of the patients discontinued treatment in the SVd arm due to physician decision (10 [5.1%] vs. 5 [2.5%]), being the main reason 'patient not benefitting from treatment/PD not approved by IRC' (3 patients in each treatment arm). Other causes in the SVd arm included adverse events, poor health and logistical reasons. Somehow, these data reflect the increased toxicity of the combination with the addition of selinexor.

Median treatment duration was similar between treatment arms (30 weeks in the SVd arm and 32 weeks in the Vd arm), with a treatment exposure of at least 48 weeks (i.e. around 11 months) in 35.9% and 32.4% of patients, respectively. Dose modifications were more frequent in the SVd group compared with the Vd group (91.8% vs. 82.4%). As previously observed in the STORM study (i.e. in RRMM patients), dose delay/interruption (86.7%) and dose reduction (65.6%) to selinexor were frequent. It is important to note that doses of bortezomib and dexamethasone were lower in the experimental arm than in the control arm. However, dose delay/interruption to bortezomib (82.1% vs. 74.0%) and dexamethasone (80.0%  vs.  72.5%)  were  higher  in  the  SVd  arm.  According  to  the  MAH,  the  higher  rate  of  dose delay/interruptions to bortezomib and dexamethasone may be due to concomitant discontinuation of selinexor, since in most cases the three drugs were interrupted or delayed for most TEAEs. There were 51 (26.2%) patients with dose escalation in the SVd arm and 17 (8.3%) in the Vd arm. The MAH clarified that the majority of these dose increases were dose readjustments after a preceding dose reduction in selinexor and only 16 patients in the SVd arm had a dose escalation to selinexor 60 mg BIW. Besides, dose escalation in the Vd arm referred to dose increases of either bortezomib or dexamethasone after a previous dose reduction.

<div style=\"page-break-after: always\"></div>

Patients included in the study had a median age of 67 (range: 38, 90) years. There were 79 patient who were ≥75 years, with a higher rate in the Vd arm (34 [17.4%] vs. 45 [22.1%]). Most of patients had an ECOG performance status of 0 or 1. There were 20 (10.3%) patients in the SVd arm and 15 (7.4%) in the Vd arm with ECOG 2. All patients had received prior antineoplastic therapy, with a median of 1 and 2 prior lines of anti-MM therapy in the SVd and Vd arms (range: 1, 3), respectively. According to the protocol patients must have received at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens. A BSA &lt;1.4 m 2  at baseline was an exclusion criterion and according to the protocol, in no case may the selinexor dose exceed 70 mg/m 2  per dose for any patient. In the SVd arm baseline median BSA was 1.85 (range: 1.4, 2.4). The MAH was requested to clarify what was the recommendation for those patients (if any) that due to body weight fluctuations reached a BSA &lt;1.4 m 2  during the study and justify whether any dose restriction according to BSA should be included in the SmPC. According to the MAH only 2 patients reached a BSA &lt;1.4 m 2  during the study. In both cases, the dose of selinexor had been previously reduced due to toxicity and was lower than the stipulated limit. Bearing in mind that a higher exposure may be translated into higher toxicity and considering the already known safety profile of selinexor a restriction not to exceed the 70 mg/m 2  per dose has been included in the SmPC.

Most patients (99.5%) received at least 1 concomitant medication. In the SVd arm, most commonly treatments received were antiemetics, mainly serotonin (5-HT3) antagonists (88.2%).

Patients  with  symptomatic  ischemia,  uncontrolled  clinically  significant  conduction  abnormalities, congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction &lt;40%, or myocardial infarction within 3 months prior to C1D1 were excluded from the study.

Almost all patients reported at least one adverse event (&gt;97%) in both treatment arms. The most commonly reported adverse events (AEs) (≥20%) in the SVd arm were th rombocytopenia (62.1% SVd  vs.  27.5%  Vd),  nausea  (50.3%  vs.  10.3%),  fatigue  (42.1%  vs.  18.1%),  anaemia  (37.4%  vs. 23.5%), decreased appetite (35.4% vs. 5.4%), diarrhoea (33.3% vs. 25.5%), peripheral neuropathy (33.3% vs. 48.5%), weight decreased (26.2% vs. 12.3%), vomiting (20.5% vs. 4.9%), cataract (23.6% vs. 7.4%) and asthenia (25.1% vs. 13.2%).

There were other less frequent AEs with a higher incidence in the SVd arm compared with the Vd arm, such  as  visual  impairment  (7.2%  vs.  2.0%),  upper  respiratory  tract  infection  (20.5%  vs.  14.7%), nasopharyngitis  (11.8%  vs.  4.9%),  septic  shock  (2.1%  vs.  0),  hyponatraemia  (7.7%  vs.  1.5%), hypophosphatemia  (8.7%  vs.  3.4%),  dizziness  (12.3%  vs.  4.4%),  dysgeusia  (6.7%  vs.  0.5%), confusional state (8.2% vs. 1.0%), depression (3.6% vs. 0) and oropharyngeal pain (7.2% vs. 2%). Cardiac AEs were also more frequent in the SVd arm (17.4% vs. 7.8%), although it does not appear to be driven by any particular PT.

A higher proportion of patients reported TEAEs of haemorrhage in the SVd arm compared with the Vd arm (34 [17.4%] vs. 15 (7.4%)]), although most of these events were of grade 1 or 2. The most common TEAEs of haemorrhage in the SVd arm were epistaxis (5.6%) and contusion (3.1%). The incidence of TEAEs of Grade 3-4 and Grade 5 were comparable between treatment arms. However, SAEs were more frequent in the SVd arm (7 [3.6%] vs. 1 [0.5%]) and there were 8 (4.1%) patients that discontinued treatment due to a TEAE (while none in the control arm). SAEs included two fatal TEAEs (1 cerebral haemorrhage and 1 haemorrhagic shock). The event of cerebral haemorrhage occurred after only one dose of selinexor and in the context of PD; thus it appears unlikely to be related to selinexor treatment. However, contribution of selinexor to the haemorrhagic shock fatal TEAE cannot be ruled out, since it occurred in a patient with thrombocytopenia, which is a known ADR of selinexor. Other SAEs were epistaxis (3), haematuria (1) and lower gastrointestinal haemorrhage. The events of epistaxis occurred in patients with thrombocytopenia, which is a known ADR of selinexor, therefore, they can be considered related to selinexor (even if in some of them other confounding factors were also present). Moreover, in one  of  these  patients  an  event  of  melena  was  also  reported.  Regarding  the  events  of  lower

<div style=\"page-break-after: always\"></div>

gastrointestinal haemorrhage and haematuria, a causal relationship with selinexor cannot be established. Information on the risk of thrombocytopenia as well as significant bleeding in patients treated with selinexor is already included in the SmPC.

There were 10 (5.1%) patients in the SVd arm with an event of overdose (7 were due to selinexor overdose). Five of these patients had a TEAE. In most of the cases of selinexor overdose the patient had took an extra dose of selinexor. There was also one patient that erroneously took 320 mg of selinexor who suffer a SAE of pulmonary embolism that resolved. No other SAEs were reported. Medication errors is included as an important potential risk in the RMP.

AEs of Grade 3/4 were more frequently reported in the SVd arm compared with the Vd arm (78.5% vs. 56.4%). The most frequently reported (≥10%) in the SVd arm were thrombocytopenia (40.5% vs. 17.6%), anaemia (16.4% vs. 9.8%), fatigue (13.3% vs. 1%) and cataract (11.3% vs. 2%).

Of  note,  the  indicende  of  Grade ≥ 2  peripheral  neuropathy  events  was  a  secondary  endpoint  in  the BOSTON study. A lower rate of Grade ≥ 2 peripheral neuropathy events was reported in the SVd arm compared with the Vd arm (42 [21.5%] vs. 73 [35.8%] Vd), which is not unexpected taking into account the lower dose of bortezomib in the experimental arm.

Up to the data cut-off, 147 patients had died in the BOSTON study (68 [34.9%] SVd and 79 [38.7%] Vd). According to the MAH most of these deaths were due to disease progression (33/68 [48.5%]) SVd and 35/80 [43.8%] Vd). There were 34 patients who died while on treatment or withing 30 days of the last dose of study treatment (16 [8.2%] and 18 [8.8%] patients in the SVd and Vd groups, respectively), the majority of these deaths were related to an AE (13 [6.7%] and 14 [6.9%]). In the SVd arm the most common AEs leading to death were pneumonia (3 [1.5%] SVd vs. 4 [2.0%] Vd) and septic shock (3 [1.5%] vs 0). According to the MAH, the 3 fatal AEs of septic shock occurred in India (see further comments below). Moreover, there were 10 deaths due to AEs reported in patients who crossed over from the Vd arm to SVdX (9 events) and SdX (1 event). Of the 9 AEs leading to death in the SVdX arm, 4 patients died within 30 days of the last dose of Vd and within 7 days of SVdX treatment.

Serious adverse events ( SAEs ) were more frequent in the SVd arm compared with the Vd arm (54.4% vs. 38.7%). In the SVd arm more than a half of these SAEs were considered treatment related (29.7% vs. 11.8%). The most commonly reported SAEs (regardless of causality) were pneumonia (14.9% SVd vs. 13.2% Vd), cataract (4.6% vs. 0) and sepsis (4.1% vs. 1.0%).

There were 41 (21%) patients in the SVd arm and 34 (16.7%) in the Vd arm that required treatment discontinuation due to AEs. The main AEs leading to discontinuation was peripheral neuropathy (9 [4.6%] SVd vs. 16 [7.8%] Vd) which is related to bortezomib treatment. Other AEs that led to treatment discontinuation in the SVd arm were fatigue (7 [3.6%]), nausea (6 [3.1%]), thrombocytopenia, vomiting and decreased appetite (2.1% each), all of them considered ADRs of selinexor.

Dose modifications due to AEs were also frequent. In the SVd arm 72.3% of patients required any dose reduction compared with 52% of patients in the Vd arm. The main AEs that led to dose reductions in the SVd arm were thrombocytopenia (33.3% SVd vs. 4.4% Vd), peripheral neuropathy (20% vs. 28.4%) and fatigue (10.8% vs. 2.5%). Further, 85.6% in the SVd arm and 68.1% in the Vd required dose interruption  during  the  study.  The  main  AEs  that  led  to  dose  interruption  in  the  Sd  arm  were thrombocytopenia  (35.4%),  asthenia  (14.4%),  fatigue  (14.4%),  upper  respiratory  tract  infection (12.3%), and pneumonia (11.3%).

## Adverse events of special interest (AESIs)

According to the protocol of the BOSTON study, AESIs for selinexor include cataracts and acute cerebellar syndrome (ACS). Further, the MAH has provided brief summaries of other significant adverse events, called AEs of clinical interest, which include cytopenias (thrombocytopenia, neutropenia), gastrointestinal

<div style=\"page-break-after: always\"></div>

events  (nausea,  vomiting),  decreased  appetite/weight  decreased,  infections  (pneumonia,  sepsis, opportunistic infections), eye disorders (blurred vision, cataract), hyponatremia, neurological and cardiac toxicity and hepatobiliary disorders. According to the MAH, these AEs were selected based on identified and potential risks of selinexor.

Thrombocytopenia is a known ADR of selinexor. In the BOSTON study 62.1% of patients reported an event of thrombocytopenia, with 40.5% of events of Grade 3/4 and 3 SAEs. No fatal adverse events were reported.  According  to  the  MAH  events  were  managed  with  dose  modifications  (40%  SVd  vs. 17.6%), thrombopoietin (TPO) receptor agonists (29.3% SVd vs. 4.5% Vd) and platelet growth factors and platelet transfusions. Among patients with Grade ≥3 AEs of thrombocytopenia bleeding events were reported in 4 (5.1%) patients in the SVd arm and 2 (5.6%) patients in the Vd arm, thus despite the higher rate of thrombocytopenia in the SVd arm, it does not seem to be associated with an increased risk of bleeding events.

Neutropenia was reported in 31 (15.9%) patients in the SVd arm and 14 (6.9%) patients in the Vd arm. The majority of events were of Grade 1 or 2. AEs of Grade 3/4 were reported in 9.7% and 3.9% of patients respectively. Febrile neutropenia was reported in 1 patient in each treatment arm. According to the MAH, neutropenia events were managed with dose modifications ang G-CSF treatment.

Gastrointestinal adverse events, including vomiting and nausea, are among the most frequently reported AEs in patients treated with selinexor. Other characteristic AEs of selinexor are decreased appetite and weight decreased. As previously discussed at the time of the MAA, these AEs (including fatigue) have been reported with other XPO-1 inhibitors and are considered a class effect. While the exact mechanism associated to these AEs is unknown, it is considered they might be mediated by CNS toxicity. According to the MAH in most cases several of these AEs were concurrent. Although it is acknowledged that most of these events were mild, they led to treatment discontinuation in several patients despite treatment measures. As per protocol, all patients should receive 5-HT3 antagonists (or alternative treatment if the patient does not tolerate 5-HT3 antagonists), starting on C1D1 before the first dose of study treatment. It  is  important  to  implement  early  measures  (i.e.  dose  modifications  and  supportive  treatments)  in patients treated with selinexor, particularly taking into account the inherent risk of these patients to suffer from this type of AEs.

In the BOSTON study 8 (4.1%) patients reported AEs of sepsis in the SVd arm compared with 2 (1.0%). According to the MAH, disbalances between treatment arms are mainly driven by 4 cases reported in India, of which 3 were fatal, in 23 patients treated with SVd. The MAH argues that the higher rate of sepsis  in  India  may  be  due  to  an  inadequate  management  of  these  patients,  in  addition  to  prior treatments received and the presence of other conditions such as asthma. Further, the MAH states that 2 of these 4 patients had significant weight loss, an important identified risk of selinexor. According to the MAH, additional measures were implemented and since then no new cases were identified and even SAEs were reduced. Safety data from the 23 patients treated with SVd in India have been provided. SAEs were more frequent in patients from India compared with other countries (65.2% vs. 50%), mainly vomiting (3 [13%] vs. 4 [2.3%]) and septic shock (3 [13%] vs. 1 [0.6%]). Treatment discontinuation was also more frequent in patients from India (17.4% vs. 4.7).

The incidence of opportunistic infections was almost double in the SVd arm compared with Vd arm (8.2% vs. 4.4%), although SAEs were similar (3 [1.5%] vs. 2 [1%]) and no fatal AEs were reported. The most frequent opportunistic infections were candida infections, herpes zoster, herpes virus and to a lesser extent respiratory syncytial virus infection. SAEs of opportunistic infections reported in the SVd arm were respiratory syncytial virus (2 events) and meningitis tuberculous (1 event).

Blurred vision and cataract, respectively, are considered very common and common ADRs of selinexor. In the BOSTON study 27 (13.8%) patients reported AE of blurred vision, most of them mild/moderate

<div style=\"page-break-after: always\"></div>

and no SAEs were observed. Regarding cataract, a higher rate of AEs of cataract was reported in the SVd arm compared with the Vd arm (23.6% vs. 7.4%). Of these, 11 (11.3%) were of Grade 3/4 in the SVd arm while only 4 (2.0%) in the Vd arm. Further, there were 9 (4.6%) patients with SAEs in the SVd and none in the Vd arm. According to the MAH, the higher risk of cataract in the SVd arm vs Vd arm may be related to selinexor increasing the risk of glucocorticoid-associated cataract. Ophthalmology examination (OE) during screening was performed in approximately 97% of patients. Of these, 120 (61.5%) in the SVd and 130 (63.7%) in the Vd had cataract at baseline. A warning regarding cataract has been included in section 4.4. of the SmPC.

Neurological toxicity was reported in 48 (24.6%) patients in the SVd arm while 16 (7.8%) in the Vd arm. Of  these,  8  (4.1%)  and  3  (1.5%)  patients,  reported  AEs  of  Grade  3  and  SAEs  in  the  SVd  group, respectively. The most frequently reported AEs were dizziness and confusional state, which are already included as ADRs in the SmPC. Considering the All SVd population (i.e. including patients who crossed over  from  the  Vd  to  the  SVd  arm  and  patients  from  STOMP  study),  a  total  of  6  patients  reported neurological SAEs, including 2 delirium, 2 syncope, 1 encephalopathy and 1 cognitive disorder/confusional  state  and  most  of  them  were  considered  related  to  selinexor  treatment  by  the investigator.

A higher incidence of cardiac events was reported in the SVd arm compared with the Vd arm (10.8% vs 3.4%). There were 3 (1.5%) vs. 1 (0.5%) AEs of Grade 3 and 5 (2.6%) vs 2 (1.0%) SAEs, in the SVd and Vd groups, respectively. No fatal AEs were reported. Tachycardia and atrial fibrillation were the most commonly reported. In fact, most of SAEs were atrial fibrillation. Tachycardia is currently included as ADR of selinexor. Regarding atrial fibrillation the incidence was slightly higher in the SVd arm (7 [3.6%] vs. 3 [1.5%]) and at least in 4 patients the event was considered serious. However, in many of these cases,  other  risk  factors  were  present  and  therefore  a  clear  relationship  with  selinexor  cannot  be established at this stage. The MAH is encouraged to closely monitor it through routine pharmacovigilance activities.

No events of tumour lysis syndrome (TLS) were reported in the SVd arm of the BOSTON study. TLS is included as an ADR in the SmPC (sections 4.4. and 4.8). According to the MAH, there were no cases of ACS in the BOSTON study (neither in the STOMP study).

## Laboratory findings

Overall, laboratory findings are reflecting the safety profile of selinexor. Shifts to a worst post-baseline value (i.e. from Grade&lt;3 to Grade 3 or 4) observed in clinical parameters in a higher rate in the SVd arm  compared  with  the  Vd  arm  were  leukopenia  (10.3%  vs.  2.5%),  lymphocytopenia  (38.3%  vs. 25.1%), thrombocytopenia (42.6% vs. 19.4%), hypophosphatemia (23.4% vs. 9.9%) and hyponatremia (13.8% vs 3.0%).

ECG assessments were performed at baseline on all patients and at end of treatment or as clinically indicated. Of the 72 and 52 patients in the SVd and Vd arm, respectively, with any post-baseline ECG, in the SVd group there were 2 (2.8%) patients with a QTcF≥500 and 7 (9.7%) w ith an increase from baseline &gt;60 while no QTcF values ≥500 were reported in the Vd arm and only 1 (1.9%) patient had an increase &gt;60. According to the MAH, most of these patients had history of cardiac events and no cases of Torsade de Pointes nor any other ventricular arrhythmia were reported.

## Subgroups of special interest

Safety data have been presented according to age, sex, race and renal function.

With regards to age, a higher rate of SAEs (56.0% vs. 46.5% vs.) and discontinuations (27.5% vs. 12.8%) due to AEs is observed in the subgroup of elderly patients (≥65 years) compared with younger patients (&lt;65). In the subgroup of patients ≥75 years (n=34) the incidence of Grade 3/4 AEs was

<div style=\"page-break-after: always\"></div>

increased. However, a similar pattern is also observed in the control arm. By PT, fatigue, dizziness and confusional state were more frequent in elderly patients. It is however surprising that cataract, whose incidence increase with age, was more frequent in patients &lt;65 (15.6% vs. 29.1%). According to the MAH a definitive mechanism for the imbalance in the cataract rates could not be identified and it is considered that several factors may have contributed (i.e. longer duration of exposure to study treatment in younger patients, a higher median number of prior lines received, a higher total dexamethasone dose received and a higher median duration of the most recent prior therapy).

The safety profile of SVd appears to be worse in female patients, according to the higher rates of Grade 4 AEs (21.3% female vs. 14.8% male), SAEs (61.3% vs. 45.2%), dose reductions (78.8% vs. 67.8%), dose interruptions (91.3% vs. 81.7%) and study treatment discontinuations (26.3% vs. 17.4%). AEs more  frequently  reported  in  women  than  men  were  nausea,  fatigue,  diarrhoea,  weigh  decreased, vomiting,  upper  respiratory  tract  infection,  neutropenia,  oedema  peripheral  and  hypokalaemia. According to the MAH, the higher incidence of some TEAEs in female patients compared with male patient may be due to the (expected) lower body weight and therefore higher selinexor exposure in female patients. Overall, TEAEs reported in a higher frequency in female patients are already known ADRs of selinexor.

A total of 25 patients in the SVd arm had mild hepatic impairment while none of them had moderate hepatic impairment. Acknowledging the limited sample size, a higher rate of TEAEs of Grade 3/4, SAEs, dose interruptions (all patients except one required a dose interruption) and deaths were reported in patients with mild hepatic impairment treated with SVd compared with patients with normal hepatic function. However, the number of patients with mild hepatic impairment was low and differences do not appear to be driven by any particular TEAE.

## Additional expert consultations

NA

## Assessment of paediatric data on clinical safety

NA

## 2.5.3. Conclusions on clinical safety

The addition of selinexor to Vd involves an increase in toxicity, with higher rates of Grade 3/4 AEs, SAEs, dose modifications and treatment discontinuations.

The most commonly reported AEs (SVd vs Vd) were thrombocytopenia (62.1% vs. 27.5%), nausea (50.3% vs. 10.3%), fatigue (42.1% vs. 18.1%), anaemia (37.4% vs. 23.5%), decreased appetite (35.4% vs. 5.4%), diarrhoea (33.3% vs. 25.5%), peripheral neuropathy (33.3% vs. 48.5%), weight decreased (26.2% vs. 12.3%), vomiting (20.5% vs. 4.9%), cataract (23.6% vs. 7.4%) and asthenia (25.1% vs. 13.2%). Most of these AEs are considered ADRs of selinexor, except for peripheral neuropathy, which is a known ADR of bortezomib. Of note, the incidence of peripheral neuropathy was lower in the SVd arm due to the lower dose of bortezomib. Overall, the safety profile of the combination was consistent with the already known safety profile of its components.

## 2.5.4. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Significance of paediatric studies

Not applicable

## 3. Risk management plan

The MAH submitted an updated RMP version 2.0, date of final sign off 07 July 2021 with this application. The (main) proposed RMP changes were the following:

Completion of KCP-330-023/ BOSTON study to fulfil the specific obligation. Update in the safety data to reflect the safety information captured during the KCP-330-023 study and update in the exposure data. Proposed additional product indication and dosing regimen.

## Part II - Safety Specification

## Part II- Module SIII Clinical trial exposure

This section was updated with information of the KCP-330-023 study.

PRAC Rapporteurs assessment comment:

The changes to this section are acceptable.

## Part II- Module SV post authorisation exposure

This section was updated with the proposed indication and the post authorisation exposure up to 31 Mar 2020.

PRAC Rapporteurs assessment comment:

The changes to this section are acceptable.

## Part II- Module SVII.2 New safety concerns and reclassification with a submission of an updated RMP

No new safety concers were included within this updated version of the RMP.

## Part II- Module SVII.3.1. Presentation of important identified risks and important potential risks

Throughout this section safety data of the Boston study was added.

## Part II- Module SVII - Summary of the safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                     |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Thrombocytopenia and Bleeding Severe infections due to Neutropenia Fatigue Decreased appetite Weight decreased Hyponatraemia Confusional state |

<div style=\"page-break-after: always\"></div>

| Important potential risks   | Tumor lysis syndrome Acute cerebellar syndrome Medication error                             |
|-----------------------------|---------------------------------------------------------------------------------------------|
| Missing information         | Use in patients with severe renal impairment Use in patients with severe hepatic impairment |

## Part III - Pharmacovigilance plan

The MAH proposed no changes to this section of the RMP. There are no routine pharmacovigilance activities beyond adverse reaction reporting and signal detection. No additional PV activities are ongoing or planned.

PRAC Rapporteurs assessment comment:

As no new safety concerns have been identified, routine pharmacovigilance activities are considered sufficient to monitor the risks of selinexor in the new indication.

## Part IV - Plans for post-authorisation efficacy studies

The MAH removed study KCP330 2023 from the pharmacovigilance plan. With this removal there are no remaining plans for post-authorisation efficacy studies.

PRAC Rapporteurs assessment comment:

As study KCP330-2023 has been finalised it is accepted that this study is removed from the PhV plan.

## Part V - Risk minimisation measures

This section of the RMP was updated in line with the proposed wordings in the SmPC and routine risk minimisation measures for the new identified risk of cataract were described.

The MAH proposed no additional risk minimisation measures.

PRAC Rapporteurs assessment comment:

As no new safety concerns have been identified, routine risk minimisation measures are considered sufficient to minimise the risks of selinexor in the new indication.

## Part VI: Summary of the risk management plan

The summary of the risk management plan was updated in line with the changes outlined above.

PRAC Rapporteurs assessment comment:

This section should be updated according to the comments above.

## 3.1. Overall conclusion on the RMP

The changes to the RMP are acceptable.

## 4. Changes to the Product Information

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

<div style=\"page-break-after: always\"></div>

## 4.1.1. User consultation

No justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH. However, the changes to the package leaflet are minimal and do not require user consultation with target patient groups.

## 5. Benefit-Risk Balance

## 5.1. Therapeutic Context

Nexpovio (selinexor) received a conditional marketing authorisation (CMA) valid throughout the EU on 26 March 2021, for its use in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

To fulfil the Specific Obligation (SOB) of the initial CMA the MAH was requested to submit the results of the phase 3, KCP-330-023/BOSTON study comparing the efficacy and safety of selinexor plus bortezomib plus low-dose dexamethasone versus bortezomib plus low dose dexamethasone in adult patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior anti-MM regimens. The present application incorporates both the primary analysis of the BOSTON study as well as updated data using a later data cut-off (15 Feb 2021).

With the current application, the MAH is submitting a Grouped Type II /Type IB variation of selinexor (Nexpovio):

- The Type II variation is aimed at extending the indication for Nexpovio to be used ' in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ' and to fulfil the SOB in the context of the initial CMA, as mentioned above.
- The Type IB variation relates to the introduction of a new pack size (8 tablets per pack) for added convenience to patients for dose modification in the new intended treatment setting.

## 5.1.1. Disease or condition

Multiple myeloma (MM) is a clonal plasma cells disorder, that represents approximately a 0.8% of all cancers  worldwide  (Ferlay  2015).  The  proliferation  of  the  malignant  clonal  plasma  cells  leads  to subsequent replacement of normal bone marrow haematopoietic precursors and overproduction of Mproteins with progressive morbidity and eventual mortality.

Characteristic  MM  hallmarks  include  osteolytic  lesions,  anaemia  (due  to  bone  marrow  dysfunction), increased susceptibility to infections (due to immunosuppression), hypercalcemia, renal insufficiency/failure, and neurological complications (Palumbo 2011).

## 5.1.2. Available therapies and unmet medical need

Nowadays, different classes of drugs are available for multiple myeloma patients (alkylators, steroids, proteasome inhibitors [PIs], immunomodulatory agents [IMiDs], histone deacetylase inhibitors [HDACIs] and monoclonal antibodies). Among these treatment options, lenalidomide (an IMiD) and bortezomib (a PI) have a prominent role. Both are used as frontline treatment of MM and in combination with other drugs at relapse.

<div style=\"page-break-after: always\"></div>

The  International  Myeloma  Working  Group  (IMWG)  recommends  treating  relapsed  MM  patients considering patient-specific factors, tumour characteristics and prior therapy (both type of therapy and the  response  to  the  therapy;  Ludwig  2014).  With  disease  progression,  a  change  in  drug  classes  is recommended.

## 5.1.3. Main clinical studies

This  application  is  based  on  the  efficacy  results  from  the  pivotal  ongoing Phase  3  KCP-330-023 (BOSTON) study and supported by the Phase 1b/2 KCP-330-017 (STOMP) study .

Results  presented  below  are  based  on  the  primary  analysis  (DCO:  18  Feb  2020),  unless  otherwise specified.

## 5.2. Favourable effects

- Treatment with selinexor plus bortezomib plus low-dose dexamethasone (SVd) resulted in a statistically significant improvement in PFS in the SVd arm (13.93 months) compared with bortezomib plus low-dose dexamethasone (Vd) (9.46 months); HR=0.70 (95% CI: 0.5279, 0.9335) p=0.0075; at a median overall follow-up of 13.17 and 16.53 months for the SVd and Vd arms, respectively. These results were generally consistent across multiple sensitivity analyses and pre-specified subgroups.
- A higher ORR was observed for the SVd group (76.4%) compared with the Vd group (62.3%). The estimate of odds ratio was 1.96 with 95% CI (1.26, 3.05); p =0.0012.
- The rate of ≥VGPR (sCR + CR + VGPR) was higher for the SVd group (44.6%) compared with the Vd group (32.4%); p=0.0082
- Median OS was not reached for SVd at a median follow-up of 17.3 months. The probability of survival was higher for the SVd arm throughout the study. The median OS for patients in the Vd arm was 24.97 months (95% CI: 23.49, NE).
- The median DOR in patients with confirmed PR or better was of 20.3 (95% CI: 12.55, NE) months in the SVd arm and 12.9 (95% CI: 9.26, 15.77) months in the Vd arm.
- The median TTNT in the SVd arm was 16.1 months (95% CI: 13.9, NE) compared to 10.8 months (95% CI: 9.8, 13.4) in the Vd arm.

The results from the updated analysis of the BOSTON study (DCO 15 Feb 2021) were overall consistent with the results of the primary analysis.

Further, updated OS data with a median follow-up of 33.61 months in the SVd arm and 33.84 monhts in the Vd arm (DCO 22 March 2022) showed a HR of 0.93 (95% CI: 0.67, 1.27).

## 5.3. Uncertainties and limitations about favourable effects

Although  the  control  arm  in  the  BOSTON  study  is  an  accepted  standard  of  care,  the  room  for improvement of response of a patient previously exposed to bortezomib, alone or in combination in a previous first line, appears limited with the proposed combination and in fact Vd is usually considered as an option in later lines of treatment. In this context, the control arm in the BOSTON study (Vd) could be considered, at present, as a suboptimal treatment option in the intended treatment setting. This said, it is acknowledged that the treatment landscape for MM patients is evolving quickly and demonstration of superiority vs. the proposed control arm should in principle suffice for regulatory approval.

<div style=\"page-break-after: always\"></div>

## 5.4. Unfavourable effects

In the BOSTON study almost all patients, reported at least one adverse event (&gt;97%) in both treatment arms. The most commonly  repor ted adverse events (AEs) (≥20%)  in the SVd arm were thrombocytopenia (62.1% SVd vs. 27.5% Vd), nausea (50.3% vs. 10.3%), fatigue (42.1% vs. 18.1%), anaemia (37.4% vs. 23.5%), decreased appetite (35.4% vs. 5.4%), diarrhoea (33.3% vs. 25.5%), peripheral neuropathy (33.3% vs. 48.5%), weight decreased (26.2% vs. 12.3%), vomiting (20.5% vs. 4.9%), cataract (23.6% vs. 7.4%) and asthenia (25.1% vs. 13.2%).

AEs of Grade 3/4 were reported in 78.5% of patients in the SVd arm and 56.4% in the Vd arm. The most frequent ly  reported  AEs  of  Grade  3/4  (≥10%)  in  the  SVd  arm  were  thrombocytopenia  (40.5%  vs. 17.6%), anaemia (16.4% vs. 9.8%), fatigue (13.3% vs. 1%) and cataract (11.3% vs. 2%).

Up to the data cut-off, 147 patients had died in the BOSTON study (68 [34.9%] SVd and 79 [38.7%] Vd), most of them due to disease progression. There were 34 patients who died while on treatment or withing 30 days of the last dose of study treatment (16 [8.2%] SVd and 18 [8.8%] Vd groups) and the majority of these deaths were related to an AE (13 [6.7%] SVd and 14 [6.9%] Vd). In the SVd arm the most common AEs leading to death were pneumonia (3 [1.5%] SVd vs. 4 [2.0%] Vd) and septic shock (3 [1.5%] vs 0).

Serious adverse events (SAEs) were more frequent in the SVd arm compared with the Vd arm (54.4% vs. 38.7%). In the SVd arm more than a half of these SAEs were considered treatment related (29.7% vs. 11.8%). The most commonly reported SAEs (regardless of causality) were pneumonia (14.9% SVd vs. 13.2% Vd), cataract (4.6% vs. 0) and sepsis (4.1% vs. 1.0%).

There were 41 (21%) patients in the SVd arm and 34 (16.7%) in the Vd arm that required treatment discontinuation due to AEs. The main AEs leading to discontinuation was peripheral neuropathy (9 [4.6%] SVd  vs.  16  [7.8%]  Vd)  which  is  related  to  bortezomib  treatment.  Other  AEs  that  led  to  treatment discontinuation in the SVd arm were fatigue (7 [3.6%]), nausea (6 [3.1%]), thrombocytopenia, vomiting and decreased appetite (2.1% each).

In the SVd arm 72.3% of patients required any dose reduction compared with 52% of patients in the Vd arm. The main AEs that led to dose reductions in the SVd arm were thrombocytopenia (33.3% SVd vs. 4.4% Vd), peripheral neuropathy (20% vs. 28.4%) and fatigue (10.8% vs. 2.5%). Further, 85.6% in the SVd arm and 68.1% in the Vd required dose interruption during the study. The main AEs that led to dose interruption in the Sd arm were thrombocytopenia (35.4%), asthenia (14.4%), fatigue (14.4%), upper respiratory tract infection (12.3%), and pneumonia (11.3%).

Other AEs reported in patients treated with SVd and which are known ADRs of selinexor or considered significant  AEs  of  selinexor  were  thrombocytopenia,  neutropenia,  nausea,  vomiting,  decreased appetite/weight  decreased,  infections  (pneumonia,  sepsis,  opportunistic  infections),  eye  disorders (blurred vision, cataract), hyponatremia, neurological and cardiac toxicity and hepatobiliary disorders.

## 5.5. Uncertainties and limitations about unfavourable effects

There were no uncertainties in the knowledge about the unfavourable effects.

## 5.6. Effects Table

## Effects table for trial KCP-330-023/BOSTON (eudract: 2016-003957-14):

## selinexor,  bortezomib,  and  dexamethasone  (SVd)  versus  bortezomib  and  dexamethasone

(Vd) in patients with relapsed or refractory multiple myeloma (RRMM) data cut-off date: 18feb-2020

<div style=\"page-break-after: always\"></div>

| Effect                      | Short description                                                    | SVd n=195                                                     | Vd n=207                                                    | Uncertain ties / Strength of evidence   | References   |
|-----------------------------|----------------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|-----------------------------------------|--------------|
| Favourable effects          | Favourable effects                                                   |                                                               |                                                             |                                         |              |
| PFS                         | Progression Free Survival Hazard Ratio (95% CI) One-sided p- value   | 0.71 (0.54, 0.93) 0.0075                                      | 0.71 (0.54, 0.93) 0.0075                                    |                                         |              |
|                             | Median PFS in months (95% CI)                                        | 13.2 (11.7, Not Reached)                                      | 9.5 (8.1, 10.8)                                             |                                         |              |
| ORR                         | Overall Response rate n (%) 95% CI One-sided p- value sCR CR VGPR PR | 150 (76.9) (70.4, 82.6) 0.0012 19 (10) 14 (7) 54 (28) 63 (32) | 131 (63.3) (56.3, 69.9) 0.0012 13 (6) 9 (4) 45 (22) 64 (31) |                                         |              |
| Unfavourable effects        | Unfavourable effects                                                 |                                                               |                                                             |                                         |              |
|                             |                                                                      | SVd n=195                                                     | Vd n=204                                                    |                                         |              |
| Grade 3/4 AEs               | AEs of grade 3 or 4 regardless or causality, n (%)                   | 153 (78.5)                                                    | 115 (56.4)                                                  |                                         |              |
| SAEs                        | SAEs regardless of causality, n (%)                                  | 106 (54.4)                                                    | 79 (38.7)                                                   |                                         |              |
| Discontinuations due to AEs | Discontinuation due to AEs regardless of causality, n(%)             | 41 (21.0)                                                     | 34 (16.7)                                                   |                                         |              |
| Thrombocytopenia            | AEs occurring in                                                     | 121 (62.1)                                                    | 56 (27.5)                                                   |                                         |              |
| Nausea                      | ≥20% of                                                              | 98 (50.3)                                                     | 21 (10.3)                                                   |                                         |              |
| Fatigue                     | patients; n (%)                                                      | 82 (42.1)                                                     | 37 (18.1)                                                   |                                         |              |
| Anaemia                     |                                                                      | 73 (37.4) 69 (35.4)                                           | 48 (23.5) 11 (5.4)                                          |                                         |              |
| Decreased appetite          |                                                                      | 65 (33.3)                                                     | 52 (25.5)                                                   |                                         |              |
| Diarrhoea                   |                                                                      |                                                               |                                                             |                                         |              |
| Weight decreased            |                                                                      | 51 (26.2)                                                     | 25 (12.3)                                                   |                                         |              |
| Neuropathy peripheral       |                                                                      | 65 (33.3)                                                     | 99 (48.5)                                                   |                                         |              |
| Vomiting                    |                                                                      | 40 (20.5)                                                     | 10 (4.9)                                                    |                                         |              |
| Cataract                    |                                                                      | 46 (23.6)                                                     | 15 (7.4)                                                    |                                         |              |
| Asthenia                    |                                                                      | 49 (25.1)                                                     | 27 (13.2)                                                   |                                         |              |
| AEs leading to death        |                                                                      | 14 (7.2)                                                      | 13 (6.4)                                                    |                                         |              |

<div style=\"page-break-after: always\"></div>

AEs=Adverse  events;  HR=hazard  ratio;  PFS=progression-free  survival;  IRC=independent  review  committee; SVd=selinexor plus bortezomib plus low-dose dexamethasone; Vd=bortezomib plus low-dose dexamethasone.

Note:  Progression-free  survival  is  calculated  from  date  of  randomization  until  the  first  date  of  IRC-confirmed progressive disease per International Myeloma Working Group response criteria, or death due to any cause, whichever occurred first.

a The Investigator reported 1 patient in All SVd and 1 patient in Vd died due to PD and TEAE. To be conservative, the Sponsor counted these as TEAEs leading to death. Safety data are based on the data cut-off date 15 Feb 2021

## 5.7. Benefit-risk assessment and discussion

## 5.7.1. Importance of favourable and unfavourable effects

Treatment with the (once weekly) combination of selinexor with bortezomib and dexamethasone tested in the BOSTON study (SVd) leads to a significant improvement in median PFS compared to the standard (BIW) Vd regimen in the targeted patient population, i.e. adult patients with multiple myeloma who have received at  least  one prior  therapy.  This  benefit  in  terms  of  PFS  is  supported  by  several  secondary endpoints. Moreover, no evidence of detrimental effects on survival has been observed also considering that cross over to either SVd or Sd was allowed in the trial.

From the safety point of view, the addition of selinexor to Vd treatment involves a remarkable increase in  toxicity,  with  a  higher  rate  of  Grade  3/4  AEs,  SAEs  and  treatment  discontinuations.  The  most commonly  reported  AEs  were  thrombocytopenia,  nausea,  fatigue,  anaemia,  decreased  appetite, diarrhoea, peripheral neuropathy, weight decreased, vomiting, cataract and asthenia. Of note, since doses of bortezomib in the SVd arm were lower than in the Vd arm, a lower incidence of peripheral neuropathy was reported in patients treated with SVd.

## 5.7.2. Balance of benefits and risks

Selinexor in combination with bortezomib and dexamethasone has demonstrated an improvement in PFS compared to the standard (BIW) Vd regimen in the target patient population (i.e. adult patients with MM who have received at least one prior therapy), which is supported by several secondary endpoints. Despite the toxicity of this combination, it is considered that the benefits of the proposed combination outweigh its risks.

## 5.7.3. Additional considerations on the benefit-risk balance

The results from the pivotal BOSTON study in support of this application were intended to fulfil the Specific Obligation (SOB) in the context of the Conditional Marketing Authorisation (CMA) of Nexpovio (selinexor) which was granted on 26 March 2021. The SOB is now considered fulfilled. The data from the BOSTON study confirms a positive B/R balance for selinexor in the sought indication and constitute a comprehensive data package supporting granting of a marketing authorisation no longer subject to specific obligations.

## 5.8. Conclusions

The overall benefit/risk balance of selinexor in the claimed indication is positive.

## 4. Recommendations

Based on the review of the submitted data, this application regarding the following changes:

<div style=\"page-break-after: always\"></div>

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |
| B.II.z                 | B.II.z - Quality change - Finished product - Other variation                                                                   | Type IB | I, IIIA and IIIB   |

- Extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and,
- Addition of a new pack size (8 tablets) to align with the dose modification guidance for the new indication.

Accordingly, Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 6.5 of the SmPC are updated to reflect the new indication and the new pack size.

- Fulfilment of the Specific Obligation agreed in the context of the CMA of Nexpovio via the submission of results from the confirmatory Phase 3 study, KCP-330-023, thereby supporting the granting of a marketing authorisation not subject to specific obligations. Annex II is updated to reflect the completion of the Specific Obligation. The Labelling and Package Leaflet are amended accordingly. The RMP (v 2.0) is amended consequently.

## is recommended for approval.

In addition, the CHMP, having considered the application as set out in the appended assessment report and having reviewed the data submitted by the marketing authorisation holder including the evidence concerning compliance with specific obligations, is of the opinion that the risk-benefit balance of the above mentioned medicinal product remains favourable, that all specific obligations laid down in Annex II have been fulfilled and that comprehensive data supports a favourable benefit-risk balance of the above mentioned medicinal product. Therefore, pursuant to Article 14-a(8) of Regulation (EC) No 726/2004, the CHMP recommends by consensus the granting of a marketing authorisation in accordance with Article 14(1) of Regulation (EC) No 726/2004 for the above mentioned medicinal product for which the draft Summary of Product Characteristics is set out in Annex I.

## Amendments to the marketing authorisation

In view of the data submitted with the group of variations, amendments to Annex(es) I, IIIA and IIIB, Annex A and to the Risk Management Plan are recommended.

In addition, the following obligation has been fulfilled, and therefore it is recommended that it be deleted from the Annex II to the Opinion:

| In order to confirm the efficacy and safety of selinexor in combination with dexamethasone in the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti- CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy, the MAH should submit the   | May 2021   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|

<div style=\"page-break-after: always\"></div>

| results of the phase 3, KCP-330- 023/BOSTON study (data cut off Feb 2021), comparing the efficacy and safety of selinexor plus bortezomib plus low-dose dexamethasone versus bortezomib plus low dose dexamethasone in adult patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior anti-MM regimens.   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Similarity with authorised orphan medicinal products

The CHMP is of the opinion that Polivy is not similar to Imnovid, Farydak, Ninlaro, Darzalex, Kyprolis, Blenrep, Abecma and CARVYKTI within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## 5. EPAR changes

The table in Module 8b of the EPAR will be updated as follows:

## Scope

Please refer to the Recommendations section above

## Summary

Please refer to Scientific Discussion 'Nexpovio-H-C-5127-II-0001/G'